Glycoprotein hormone receptor mutations

ABSTRACT

A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity. Methods, kits and uses employing the mutant TSHR or fragment thereof according to the invention are also provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/317,687 filed Dec. 9, 2016 entitled “Glycoprotein Hormone Receptor Mutations,” which is a filing under 35 U.S.C. 371 of International Application No. PCT/GB2015/000171 filed Jun. 11, 2015, entitled “Glycoprotein Hormone Receptor Mutations,” which claims priority to Great Britain Patent Application No. 1410409.5 filed Jun. 11, 2014, which applications are incorporated by reference herein in their entirety.

REFERENCE TO SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML file, created on Jun. 16, 2023, is named 4263-00601.xml and is 124,616 bytes in size.

FIELD OF THE INVENTION

The present invention relates generally to glycoprotein hormone receptors, particularly but not exclusively to the thyroid stimulating hormone (TSH) receptor (TSHR). The invention relates to mutations, especially single point mutations, that improve the thermostability of such receptor, particularly TSHR, preparations. Further, the invention relates to single point mutations combined together to even further improve the stability of such preparations. The invention also relates to methods using thermostable glycoprotein hormone receptor, including TSHR, preparations to detect the presence of autoantibodies, such as TSHR autoantibodies (TRAbs), for diagnosis, monitoring and prediction of diseases associated with autoimmunity, especially TSHR autoimmunity.

BACKGROUND The TSH Receptor

The TSHR is a member of the G-protein coupled receptor (GPCR) family and consists of three domains: the extracellular leucine-rich repeat domain (LRD), the hinge region and a transmembrane domain (TMD) with an intracellular C-terminus (Núñez Miguel R et al (2004) Thyroid 14: 991-1011). TSHR260 is a subdomain of TSHR consisting of residues 22-260 and encompassing most of the LRD (Sanders J et al (2007) Thyroid 17:395-410). The TSHR260 shows similar binding to TRAbs as the full-length TSHR (Rees Smith B et al (2009) Hormone and Metabolic Research 41: 448-455 and WO 2010/073012).

In the thyroid, the TSHR is present on the basal membrane of thyroid follicular epithelial cells. Binding of TSH to the TSHR starts activation of the TSHR signalling cascade which involves binding of G-proteins to the TSHR followed by stimulation of the cyclic AMP pathway and synthesis of thyroid hormones (thyroxine; T4 and triiodothyronine; T3) (Sanders J et al (1997) Ballibre's Clinical Endocrinology and Metabolism. Ed T F Davies 11: 451-479; pub Ballière Tindall, London and Latif R et al (2009) Endocrinology and Metabolism Clinics of North America 38: 319-341).

Autoimmune Thyroid Disease

Autoimmune thyroid disease is one of the most common autoimmune conditions with a prevalence rate of 600 to 1000 per 100,000 (Jacobson D L et al (1997) Clinical Immunology and Immunopathology 84: 223-243 and Cooper G S et al (2009) Journal of Autoimmunity 33: 197-207). The major thyroid autoantigens targeted by the autoimmune system are thyroid peroxidase (TPO), thyroglobulin (Tg) and the TSHR. TPO autoantibodies (TPOAbs) and thyroglobulin autoantibodies (TgAbs) are serological markers of thyroid autoimmunity in different forms of AITD including, Hashimoto's thyroiditis, Graves' disease and post-partum thyroiditis (PPT) (Rees Smith B et al (2007) Thyroid 17: 923-938). TRAbs are markers of TSHR autoimmunity, in particular, Graves' disease. Furthermore TRAbs are responsible for the pathology of Graves' disease. There are two main types of TRAbs; stimulating type and blocking type (Rees Smith B et al (2007) supra and Rees Smith B et al (2009) supra).

Thyroid stimulating autoantibodies bind to the TSHR and mimic the actions of TSH thereby stimulating the thyroid to produce high levels of T4 and T3; these autoantibodies are also described as TRAbs with stimulating activity or TSH agonist activity (Rees Smith B et al (2007) supra). The feedback control mechanism of thyroid function is no longer effective in the presence of thyroid stimulating autoantibodies and the patients present with clinical symptoms of a hyperactive thyroid characterised by excess of thyroid hormones in serum and their metabolic consequences. This condition is known as Graves' disease. TRAbs with stimulating activity may also interact with the TSHRs in retro-orbital tissue and contribute to the development of the eye signs of Graves' disease (Seethalakshimi, I and Bahn R (2012) Best Pract Res Clin Endocrinol Metab 26:281-289 and Rees Smith B, Sanders J and Furmaniak J (2008) Biomarkers Med 2: 567-576). A human monoclonal autoantibody which acts as a powerful thyroid stimulator (hMAb TSHR1; also referred to as M22) has been described in detail in EP 1565493B1. The structure of the complex of M22 Fab bound to TSHR260 has been solved by X-ray crystallography at 2.55 Å resolution as described in WO 2008/025991A1. Analysis of the structure of the TSHR260-M22 complex provides detailed information about the receptor and the stimulating autoantibody residues involved in interactions with each other.

A further human monoclonal autoantibody with potent thyroid stimulating activity (K1-18) is described in WO 2010/073012.

Blocking type TRAbs occur less frequently in patients with AITD than stimulating autoantibodies. Blocking type autoantibodies bind to the TSHR, prevent TSH from binding to the receptor but have no ability to stimulate TSHR activity. Consequently, formation and secretion of thyroid hormones (T4 and T3) is greatly reduced and the patients with this type of TRAb present with clinical symptoms of under-active thyroid (hypothyroidism). Blocking type autoantibodies are known as TRAbs with blocking activity or TSH antagonist activity (Rees Smith B et al (1988) Endocrine Reviews 9: 106-121 and Rees Smith B et al (2007) supra). A human autoantibody to the TSHR with TSH antagonist activity (5C9) has been described in detail in WO 2008/099185A1 and a further human monoclonal autoantibody with powerful TSHR blocking activity (K1-70) has been described in WO 2010/073012. The structure of K1-70 Fab in complex with TSHR260 has been solved by X-ray crystallography as described in Sanders P et al (2011) Journal of Molecular Endocrinology 46: 81-99. The TSHR260-K1-70 structure shows the binding arrangements between the TSHR and the TSHR blocking autoantibody at the molecular level. Comparison of the TSHR260-M22 and TSHR260-K1-70 structures provides a unique insight into the similarities and differences in the interactions of a stimulating and a blocking autoantibody with the TSHR (Nunez Miguel R et al (2012) Journal of Molecular Endocrinology 49: 137-151). TSHR-R255 emerged as a key amino acid residue forming strong interactions with M22 but not K1-70 consistent with the reported importance of R255 for the stimulating activity of various human and animal TSHR antibodies and stimulating antibodies in patient sera (Sanders J et al (2006) Thyroid 16: 1195-1206 and WO 2006/016121).

Methods to Detect TSHR Antibodies

It is well documented in the art that patient TRAbs with stimulating or blocking activity bind to regions on the TSHR LRD overlapping with each other and with the TSH binding site. However, there are subtle differences in the TSHR residues in contact with autoantibodies present in different sera (Rees Smith B et al (2007) supra). It is also documented that human monoclonal autoantibodies M22 and K1-70 are representative of TRAbs in patients with AITD (Sanders J et al (2007) supra, Rees Smith B et al (2009) supra, Evans M et al (2010) Clinical Endocrinology 73: 404-412, Nunez Miguel et al (2012) supra). The principles of TSHR interaction with TSH and TRAbs have been employed in different assays to detect patient TSHR autoantibodies.

Measurements of TRAbs are important in the diagnosis and management of Graves' disease and other thyroid disorders. Currently four types of assay are used to measure TRAbs:—

-   -   a) competitive binding assays which measure the ability of         patient serum TRAbs to inhibit the binding of TSH or human         monoclonal TRAbs to preparations of TSH receptor;     -   b) bioassays which measure the ability of TRAbs to stimulate         cells expressing the TSH receptor in culture;     -   c) immunoprecipitation of labelled TSH receptor preparations         with TRAbs; and     -   d) Bridge type assays in which divalent TRAbs bind to TSHR         coated onto ELISA plate wells with one arm and to liquid phase         TSHR260-alkaline phosphatase fusion protein (TSHR260-AP) with         the other arm to form a bridge.

Measurement of TSH receptor autoantibodies using such assays are described in references:—

-   Sanders J et al (1997) supra. -   Sanders J et al (1999) Journal of Clinical Endocrinology and     Metabolism 84: 3797-3802. -   Rees Smith B et al (2004) Thyroid 14: 830-835 -   Rees Smith B et al (2009) supra.

Strategies to Improve TSHR Stability

We have appreciated that proteins such as TSHR and TSHR260 have poor stability and are denatured during purification. Accordingly, more thermostable proteins, for example more thermostable TSHR260 and full length TSHR, would have a number of applications including:

-   -   a) Enabling production of highly purified TSHR260 and full         length TSHR.     -   b) Designing improved assays for detection of TRAbs.     -   c) Enabling crystallisation of highly purified TSHR260 free from         stabilising antibodies.     -   d) Designing drugs whereby crystals of ligand-free TSHR260 are         soaked into fragment libraries followed by X-ray crystallography         to identify novel drug scaffolds.     -   e) Designing strategies to obtain increased thermostability of         regions of full length TSHR outside TSHR260.

Natural proteins are stable enough in their native environment to function, but are often not optimally thermostable under the range of conditions required for industrial uses. Protein engineering methods, particularly mutagenesis, have been used to improve the thermostability of both soluble proteins and membrane proteins. Previous strategies for improving the thermostability of proteins by mutagenesis have involved one of two approaches (i) testing a small number of rationally-designed mutations, or (ii) testing a large number of mutations produced either randomly or systematically (Dodevski I and Plückthun A (2011) Journal of Molecular Biology 408: 519-655; Serrano-Vega M J et al (2008) Proceedings of the National Academy of Sciences of the USA 105: 877-882) for thermostabilising effects on the protein.

The present invention describes mutations introduced particularly into TSHR, and especially into TSHR260, following the work of the present inventors to identify mutations that are most likely to improve the thermostability (Table 1):

-   -   In β-sheets, the position and environment of amino acid residues         plays an important role in the formation and stability of         β-sheets with periodicity of polar and nonpolar residues         important for determining secondary structure (Xiong H et         al (1995) Proceedings of the National Academy of Sciences of the         USA 92: 6349-6353). The preferred residue periodicity for         β-strands is 0+0−0+0—where “0” is a non-polar residue such as         Ile or Thr, “+” is a positive residue, preferably Arg and “−” is         a negative residue, preferably Asp.     -   The leucine rich domain (LRD) has a general consensus sequence         of the leucine rich repeat (LRR) motif,         LxxLxLxxNxLxxLpxxoFxxLxx, where “L” is Leu, Ile, Val or Phe, “N”         is Asn, Thr, Ser or Cys, “o” is non-polar and “x” is a         non-conserved residue (Matsushima N et al (2010) BMC         Microbiology 10: 235-245). Residues can be mutated to conform to         this motif.     -   Amino acids which tend to stabilise or destabilise proteins have         been identified either computationally, by comparing the         sequences of homologous proteins in mesophilic and thermophilic         organisms or the amino acid composition of their proteomes, or         experimentally, by measuring the thermodynamic properties of         mutants. Different residues have different stabilising effects         depending on whether they are at the surface or the core of the         protein (Yokota K et al (2006) Science and Technology of         Advanced Materials 7: 255-262) or their position in secondary         structure elements (Xiong H, et al (1995) supra; Vogt G et         al (1997) Journal of Molecular Biology 269: 631-643; Minor D L         and Kim P S (1994) Nature 367: 660-663 and Minor D L and Kim P         S (1994) Nature 371: 264). Stabilising residues include Glu,         Lys, Arg and Tyr residues on the surface and Ala in the core;         while Gln, Met, Cys and Ser and Asn tend to be destabilising         (Cambillau C and Claverie J-M (2000) Journal of Biological         Chemistry 275: 32383-32386; Kim C A and Berg J M (1993) Nature         362:267-270; Kumar S et al (2000) Journal of Biomolecular         Structure & Dynamics 17 Suppl 1: 79-85; Minor D and Kim P S         1994a+b supra; Montanucci L et al (2008) Bioinformatics 24:         i190-i195; Pack S P and Yoo Y J (2004) Journal of Biotechnology         111: 269-277; Smith C K et al (1994) Biochemistry 33: 5510-5517;         Szilágy A and Závodsky P (2000) Structure 8: 493-504; Vogt G et         al (1997) supra; Yokota K et al (2006) supra).     -   Thermophilic organisms tend to have more charged residues and         less polar uncharged residues compared to mesophilic organisms         (Cambillau C and Claverie J-M (2000) supra). The number and         arrangement of ion pairs plays a large role in improving the         thermostability of proteins (Vetriani CDL et al (1998)         Proceedings of the National Academy of Sciences of USA 95:         12300-12305; Kumar S et al (2000) supra; Montanucci et al (2008)         supra; Szilágy A and Závodsky P (2000) supra). This probably         explains the high frequency of Glu and Lys in thermophilic         proteins.     -   Mutation of residues to the consensus sequence of homologues of         a protein in different organisms can be used to identify         possible thermostabilising mutations. This has been used to         produce more thermostable mutants of a wide range of proteins         including immunoglobulin domains, GroEL minichaperones, p53 and         phytase with increases in apparent melting point (T_(m)) of         5° C. to 36° C. (reviewed in Lehmann M and Wyss M (2001) Current         Opinion in Biotechnology 12: 371-375).     -   Residues with the appropriate backbone torsion angles can be         mutated to either Pro, to improve the rigidity and therefore         stability of the protein, or to Gly, to reduce the strained         torsion angles in residues in the left-hand helical conformation         (Vielle C and Ziekus G J (2001) Microbiology and Molecular         Biology Reviews 65:1-43).     -   Computational modelling can be used to predict the effect of         mutations on the thermostability of the protein, although the         results obtained are variable.

The novel strategy to improve the thermostability of particularly TSHR and fragments thereof such as TSHR260 described in this invention used rational-scanning mutagenesis of the polypeptide TSHR260 (amino acid residues M22-L260), where every residue was mutated to another amino acid determined by a combination of rational approaches (listed above), coupled to a thermostability assay. The novel strategy described involved four steps: (i) site-directed mutagenesis by PCR to obtain the mutants, (ii) expression of the TSHR260 mutants by transient transfection of CHO-K1 cells, (iii) assessment of protein expression and thermostability, (iv) analysis of thermostability curves of the most stable mutants identified in (iii).

The most thermostabilising single mutations were combined to make double, triple, quadruple, quintuple and hextuple mutants of TSHR260, which increase the thermostability of TSHR260 even further.

The single and combined mutations that increased the thermostability of TSHR260 were also found to increase the thermostability of full length TSHR as well.

Similarly, thermostabilising mutations were identified in the transmembrane domain (TMD) of the TSHR. The 6 mutations from the most stable hextuple TSHR260 mutant were expressed as full length TSHR in combination with the thermostabilising TMD mutations. The thermostability of these full-length TSHR mutants was tested using analysis of thermostability curves and the most thermostabilising mutations in the TMD were combined to further increase the thermostability of the full length TSHR.

Full-length TSHR mutants and fragments thereof with improved thermostability can be used in assays to detect TSHR autoantibodies in patient sera and can be purified in an active form.

Related Previous Patent Applications

The invention described in EP 1565493B1 provides details about the properties of a human monoclonal autoantibody (M22 or hMAb TSHR1) with powerful stimulating activity and its interaction with the TSHR. The interactions between M22 Fab and the TSHR LRD have been solved at the molecular level from the X-ray diffraction analysis (2.55 Å resolution) of the complex between the two molecules as described in WO 2008/025991A1.

WO 2006/016121A1 discloses a mutated TSHR preparation including at least one point mutation which can be used in the differential screening and identification of patient serum stimulating TSHR autoantibodies, patient serum blocking TSHR autoantibodies and TSH in a sample of body fluid from a patient being screened.

Generation and characterisation of a mouse MAb (9D33) with TSHR blocking activity is described in WO 2004/050708A2. 9D33 binds to the TSHR with high affinity (2×10¹⁰ L/mol) and is an effective antagonist of TSH, hMAb TSHR1 (M22) and patient serum TRAbs with stimulating or blocking activities.

WO 2008/099185A1 discloses the isolation and characterisation of a human MAb (5C9) to the TSHR that is an effective antagonist of TSH and of stimulating TRAbs in patient sera. 5C9 has been found unexpectedly to inhibit TSHR constitutive activity, that is to say the production of cyclic AMP by the TSHR in a test system in the absence of thyroid stimulating hormone or M22. Furthermore, 5C9 has been found to inhibit increases in TSHR basal activity (i.e. activity in the absence of TSH) associated with TSHR activating mutations.

WO 2010/073012 discloses the isolation and characterisation of a further human monoclonal autoantibody (K1-18) with powerful stimulating activity and a human monoclonal autoantibody (K1-70) that is a potent TSHR antagonist from the peripheral blood lymphocytes of a patient. K1-18 and K1-70 have the characteristics of TRAbs with stimulating and blocking activities respectively found in patients' sera. The invention provides the first evidence that TRAbs with opposing activities (stimulation and blocking) can be present at the same time in a single patient's serum. Further the invention described in WO 2010/073012 describes a novel assay to measure TRAbs based on the bridging principle whereby divalent antibodies bind to the TSHR coated onto an ELISA plate well with one arm and to liquid phase TSHR260-alkaline phosphatase with the other arm to form a bridge.

SUMMARY OF THE INVENTION

The invention relates generally but not exclusively to the TSHR, and particularly but not exclusively to the TSHR sequence between the residues 22-260 (TSHR260) (FIGS. 3 and 4 ; SEQ ID Nos 3 and 4). A further aspect of the invention relates in particular to amino acid mutations in TSHR260, in particular to designing amino acid mutations using a novel rational-scanning mutagenesis approach, where every residue is mutated to another amino acid determined by a combination of rational approaches. Further, the invention relates to high-throughput methods to generate and test numerous mutants. One aspect of the invention relates to producing particularly but not exclusively TSHR260 containing single amino acid mutations characterised by greater thermostability relative to the wild type TSHR260 (TSHR260-WT).

Another aspect of the invention relates to designing, producing and testing the combinations of two single amino acid mutations to generate TSHR260 containing double mutations. One aspect of the invention relates to particularly but not exclusively TSHR260 containing double mutations characterised by greater thermostability relative to TSHR260 containing a single mutation and to TSHR260-WT.

Another aspect of the invention relates to designing, producing and testing of particularly but not exclusively TSHR260 containing triple, quadruple, quintuple and hextuple combinations of single amino acid mutations. These aspects of the invention relate to generating particularly but not exclusively mutated TSHR260 characterised by increased thermostability relative to TSHR260 containing a lower number of mutations and to TSHR260-WT.

In one aspect the invention describes a successful approach to identify stabilising mutations in the TSHR sequence that would not have been discovered had only a small number of residues been selected by rational approaches or computational modelling.

In one aspect the invention relates to the important biological activity of TSHR260. The biological activity relates to the ability to bind TSHR autoantibodies, in particular the TSHR stimulating human monoclonal autoantibody M22. The invention describes specific and novel single, double, triple, quadruple, quintuple and hextuple mutations that increase the thermostability of the TSHR260 measured by way of the ability of TSHR260 to bind M22. These aspects of the invention relate to novel mutated TSHR260 preparations which have increased thermostability and retain the ability to bind M22 and other TSHR autoantibodies.

In another aspect of the invention the novel single and combined mutations that increased the thermostability of TSHR260 were also, surprisingly, found to increase the thermostability of full length TSHR (FIGS. 1 and 2 ; SEQ ID Nos 1 and 2). The mutations in full length TSHR while increasing the thermostability of the TSHR did not affect its biological activity (i.e. ability of ligands to stimulate the TSHR) or its ability to bind TRAbs.

Further aspects of the invention relate to design and development of improved methods for detection of TSHR autoantibodies. In one aspect of the invention, particularly but not exclusively TSHR260 preparations stable in aqueous solution are employed to bind TSHR autoantibodies present in body fluids in an assay kit format. In another aspect of the invention, stable preparations of the full-length TSHR containing the stabilising mutations are employed to bind TSHR autoantibodies present in body fluids in an assay kit format. In a further aspect, stable full-length TSHRs provide improved means to detect TSHR bioactivity in response to binding to TSH or TSHR stimulating antibodies. This bioactivity could be, but is not limited to, stimulation of cyclic AMP production in cell lines expressing stable TSHR.

Further applications of the stable preparations of the TSHR could relate to new opportunities to neutralise TSHR autoantibodies present in the body fluids of patients with AITD. These applications could be, but are not limited to, contacting the body fluids with, for example, the stable TSHR260 preparations or, for example, the stable full-length TSHR preparations in vitro or in vivo. In addition, TSHR preparations containing fewer amino acids than TSHR260 can be stabilised by the same mutations as could TSHR preparations containing sequences intermediate to TSHR260 and full length TSHR. Although preparations of human TSHR are usually preferred, TSHR preparations of other species can be stabilised in the same way. Even further aspects of the invention open new opportunities to improve the stability of other similar proteins, in particular the other glycoprotein hormone receptors (FSHR and LHR (FIG. 11 ; SEQ ID Nos 57 and 58 respectively).

DESCRIPTION OF THE INVENTION

According to one aspect of the present invention, there is provided a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprising one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The mutations are preferably point mutations. In the following, where used, the word “mutant” refers to both full length TSHR and any fragment thereof, such as the fragment TSHR260 (FIGS. 3 and 4 ; SEQ ID Nos 3 and 4). Thermostability is discussed and defined further below.

Suitably, a TSHR fragment is one which is an antigenic fragment, and in particular is one which retains the ability to bind TSHR autoantibodies, in particular the TSHR stimulating human monoclonal autoantibody M22. Suitable fragments include TSHR260, as well as sequences of smaller lengths and those of intermediate length between TSHR260 and full length TSHR. TSHR418 (residues 22 to 418) is another example of such a fragment.

In one aspect of the invention, the mutant TSHR or fragment thereof is a full-length TSHR or comprises at least 70% or more, at least 80% or more, or at least 90% or more, of the length of full-length TSHR as measured by the number of amino acids present in the mutant compared to full-length TSHR.

Preferably, the one or more mutation is within the extracellular leucine-rich repeat domain (LRD) of the TSHR or fragment thereof. More preferably, the one or more mutation is within residues 22 to 260 (TSHR260) of the TSHR or fragment thereof.

In a preferred aspect, a mutant TSHR or fragment thereof according to the invention is from a mammalian species, particularly one which is from, or is derived from, human TSHR (SEQ ID Nos 1 and 2). However, any other suitable species may be used, and other such species include monkey, porcine, bovine, cat, dog, mouse, rat, sheep or horse TSHR (SEQ ID Nos 47-56 respectively).

Preferably a mutant TSHR or fragment thereof according to the invention binds TSHR autoantibodies, particularly the TSHR autoantibody M22, K1-70 or K1-18.

In one aspect, the invention provides a mutant TSHR or fragment thereof wherein the thermostability (as further defined herein) of the mutant as determined by its half-life at 42° C. is 1.5 times greater or more than the half-life of the equivalent wild type TSHR or fragment. Preferably, the thermostability of the mutant as determined by the half-life at 42° C. is 1.7, or 2, or 3, or 3.5, or 5 times greater or more than the half-life of the equivalent wild type TSHR or fragment. The figures above apply in particular, but not exclusively, to mutants comprising only one single point mutation.

The half-life of the mutant TSHR or fragment thereof (such as TSHR260), as compared to the half-life of the equivalent wild type TSHR or fragment thereof, is suitably measured in a binding assay which determines the amount of mutant TSHR or fragment thereof (or equivalent wild type protein) that retains the ability to bind an antibody or autoantibody to the TSHR at the test temperature.

A mutant TSHR or fragment thereof according to the invention may comprise any number of single point mutations, but we prefer to use from one to six single point mutations. In a preferred aspect of the invention the mutant contains one, two, three, four, five, or six point mutations selected from any one of the following mutations: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, I167F, P168Y, V169R, N170W, T179C, I253R and R255Y (FIGS. 5 and 6 ; SEQ ID Nos 11-25, 27-43, 45 and 46 respectively). However, it will be understood that different point mutations from those above could be selected if desired, and one aspect of the present invention is the provision of a binding assay which enables the thermostability of any particular point mutation, or combination of point mutations, to be determined. In one aspect of the invention, the mutant contains only one single point mutation.

In another aspect, a mutant TSHR or fragment thereof according to the invention contains a double point mutation (that is, two single point mutations only). Preferably, the thermostability of such double point mutants as determined by the half-life at 42° C. is 3.5, or 5, or 7, or 9 times greater or more than the half-life of the equivalent wild type TSHR or fragment. Alternatively, the thermostability of such double point mutants as determined by its half-life at 50° C. is 3, or 5, or 6, or 8 or 10 times greater or more than the half-life of the equivalent wild type TSHR or fragment.

In a further aspect, a mutant TSHR or fragment thereof according to the invention contains a triple point mutation (that is, three single point mutations only). Preferably, the thermostability of such triple point mutations as determined by the half-life at 50° C. is 9, or 12, or 15 times greater or more than the half-life of the TSHR260 mutant comprising the single point mutation I253R (SEQ ID No 45). The TSHR260 mutant comprising the single point mutation I253R can be compared to wild type TSHR260 (TSHR260-WT), so as to enable a comparison between the more thermostable mutations (often comprising three of more single point mutations) and wild type TSHR260 (for which meaningful measurements of half-life at higher temperatures are difficult). TSHR260-I253R improved the thermostability 3.0±0.4 times over TSHR260-WT at 42° C., i.e. increased the half-life of TSHR260 at 42° C. by 53±6 minutes (See, for example the data in Tables 3 and 7). It also improved the thermostability at 50° C. by 2.85±0.13 times over TSHR260-WT.

In a further aspect, a mutant TSHR or fragment thereof according to the invention contains a quadruple point mutation (that is, four single point mutations only). Preferably, the thermostability of such quadruple point mutants as determined by the half-life at 50° C. is 20, or 30, or 50 times greater or more than the half-life of the TSHR260 mutant comprising the single point mutation I253R. Alternatively, the thermostability of such quadruple point mutants as determined by its half-life at 55° C. is 12, or 20, or 30 times greater or more than the half-life of the TSHR260 mutant comprising the single point mutation I253R.

In a further aspect, a mutant TSHR or fragment thereof according to the invention contains a quintuple point mutation (that is, five single point mutations only). Preferably, the thermostability of such quintuple point mutants as determined by the half-life at 55° C. is 40, or 70, or 100 times greater or more than the half-life of the TSHR260 mutant comprising the single point mutation I253R.

In a further aspect, a mutant TSHR or fragment thereof according to the invention contains a hextuple point mutation. Preferably, the thermostability of such hextuple point mutants as determined by the half-life at 55° C. is 500, or 750, or 900 times greater or more than the half-life of the TSHR260 mutant comprising the single point mutation I253R. Alternatively, the thermostability of such hextuple mutants as determined by its half-life at 60° C. is 3 times greater or more than the half-life of the TSHR260 mutant comprising the quadruple point mutation I253R+D143P+R112P+D151E (herein referred to as JMG45 (SEQ ID Nos 45, 36, 34 and 37 respectively), which has a predicted thermostability at 60° C. of 174 times that of TSHR260-WT) or at 55° C. is 1.2 times greater or more than the half-life of the TSHR260 mutant comprising the quadruple point mutation I253R+D143P+R112P+D151E. Full length TSHR mutants may be used if desired, in any aspect of the invention. Human, mouse or porcine full length TSHR mutants are particularly preferred, and have been shown to have good thermostability. In a further aspect, a mutant TSHR according to the invention is a full-length TSHR mutant, wherein the thermostability of the mutant as determined by its half-life at 50° C. is 3, or 5, times greater or more than the half-life of the equivalent wild type full length TSHR.

In a preferred aspect, a full length TSHR mutant comprises three or more point mutations within residues 22 to 260 (TSHR260) of the TSHR.

In a particularly preferred aspect of the invention, a mutant TSHR or fragment thereof consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. Consisting essentially of in this context means that suitably there is at least 80% sequence identity to TSHR260, preferably 90% sequence identity, more preferably 95% sequence identity.

In one aspect, a mutant TSHR or fragment thereof of the invention preferably contains a single point mutation from any of: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, I167F, P168Y, V169R, N170W, T179C, I253R and R255Y. As will be understood by those in the art, “P28E” refers to mutation of the amino acid proline (P) to glutamic acid (E) at sequence position 28 of the TSHR, and so forth.

In another aspect, a mutant TSHR or fragment thereof according to the invention contains two point mutations, one of which is I253R (SEQ ID No 45) and the second of which is: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, I167F, P168Y, V169R, N170W, T179C, or R255Y.

In another aspect, a mutant TSHR or fragment thereof according to the invention contains three point mutations, one of which is I253R (SEQ ID No 45), the second of which is D143P (SEQ ID No 36) and the third of which is one of P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D151E, S166T, P168Y, V169R and N170W.

In another aspect, a mutant TSHR or fragment thereof according to the invention contains four point mutations, one of which is I253R, the second of which is D143P and the third of which is R112P (SEQ ID No 34), and a fourth of which is one of L59F, H63C, D151E, S166T, V169R and N170W.

In another aspect, a mutant TSHR or fragment thereof according to the invention contains five point mutations, one of which is I253R, the second of which is D143P, the third of which is R112P, a fourth of which is D151E (SEQ ID No 37) or H63C (SEQ ID No 32) and a fifth of which is one of L59F, (H63C or D151E), S166T and V169R (SEQ ID Nos 30, 32, 37, 38 and 41 respectively).

In another aspect, a mutant TSHR or fragment thereof according to the invention contains six mutations, one of which is I253R, the second of which is D143P, the third of which is R112P, a fourth of which is D151E, a fifth of which is H63C and a sixth of which is either S166T or V169R.

In another aspect, a mutant TSHR or fragment thereof according to the invention may contain from one, two, three, four, five, or six point mutations selected from any of: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, 1167F, P168Y, V169R, N170W, T179C, I253R and R255Y.

In one preferred aspect, the mutant TSHR or fragment thereof consists of TSHR260 and the equivalent wild type consists of wild type TSHR260.

A particularly preferred feature of the mutants of the invention is that the binding of monoclonal TSHR antibodies, particularly autoantibodies, to the mutant is unaffected, or substantially unaffected, when compared with the binding of the same monoclonal TSHR antibodies or autoantibodies to the equivalent wild type TSHR or fragment.

The invention also provides a mutant TSHR or fragment thereof according to the invention for use in medicine. There are potentially a number of medical and therapeutic uses of the mutants of the invention. For example, the invention provides a mutant TSHR or fragment thereof according to the invention for use in the detection of TSHR monoclonal autoantibodies and patient TRAbs. Also provided is a mutant TSHR or fragment thereof according to the invention for use in a therapeutically effective amount for absorbing circulating patient TRAbs.

The invention also provides the use of a mutant TSHR or fragment thereof according to the invention for small-molecule fragment screening to identify new scaffolds for small molecule drugs.

The invention also provides an in vitro method of treating an autoimmune disease associated with an immune reaction to the TSH receptor in a subject, which method comprises passing a sample of the subject's blood through a solid phase column having bound thereto a mutant TSHR or fragment thereof according to the invention, and absorbing the circulating TRAbs in the said blood onto the said mutant TSHR or fragment thereof.

The invention also provides a mutant TSHR or fragment thereof according to the invention wherein the mutant comprises a detectable label. The label may, for example, be selected from the group consisting of enzymatic labels, isotopic labels, chemiluminescent labels, fluorescent labels and dyes. Such labels may be added in any suitable way, for example, via gene fusion using an appropriate construct (as described further below) or by chemical labelling. Those skilled in the art will be familiar with the relevant techniques needed, and the identity of suitable labels.

In a preferred aspect, the label comprises an alkaline phosphatase (AP) label or a biotin label. Most preferably, an alkaline phosphatase label is employed.

In a preferred aspect, the labelled mutant consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. Certain preferred mutants are those consisting of the subdomain TSHR260 of the TSHR receptor and an alkaline phosphatase (AP) label, denoted herein as TSHR260-AP-X, wherein “X” indicates the one or more amino acid mutations in the mutant.

The labelled mutant or fragment thereof may comprise any one or more of the amino acid point mutations described herein. The mutations may be introduced into the wild type TSHR or fragment thereof either before or after the labelling, as will be understood by those skilled in the art.

The invention also provides a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprising one or more mutations within the transmembrane domain (TMD), wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment.

Preferably, mutant TSHR or fragment thereof is a full-length TSHR or comprises at least 70% or more, or at least 80% or more, or at least 90% or more, of the length of full-length TSHR as measured by the number of amino acids present in the mutant compared to full-length TSHR.

In a preferred aspect, mutant TSHR or fragment with the one or more TMD mutations further comprises one or more further mutations which are not in the transmembrane domain, which one or more further mutations are according to the invention as described herein. The one or more further mutations may, for example, be in the TSHR260 subdomain accordingly to aspects of the invention described herein. Preferably, the further mutations comprise at least two or more further mutations which are not in the transmembrane domain. Preferably, such mutations are in the TSHR260 subdomain.

In one aspect, the said further mutations comprise the hextuple point mutation H63C+R112P+D143P+D151E+V169R+I253R (TSHR-JMG55) (SEQ ID Nos 32, 34, 36, 37, 41 and 45 respectively).

Preferably, the invention provides a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof wherein the one or more mutations within the transmembrane domain (TMD) provide increased thermostability with respect to the equivalent mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof which comprises only the said further mutations which are not in the transmembrane domain. The “equivalent” mutant thyroid stimulating hormone receptor (TSHR) here would thus be identical to the mutant in question, and thus comprise the same mutations except that it would lack any of the further mutations in the transmembrane domain. The term “equivalent” as used throughout the specification in similar contexts has the same meaning, mutatis mutandis.

In one aspect, the invention provides a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprising one or more mutations within the transmembrane domain (TMD) wherein the thermostability of the mutant as determined by its half-life at 33° C. is 1.2 times greater or more, or 1.3 times greater or more, than the half-life of the equivalent TSHR or fragment which comprises only the said further mutations which are not in the transmembrane domain.

In another aspect, the invention provides a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprising one or more mutations within the transmembrane domain (TMD) wherein the thermostability of the mutant as determined by its half-life at 33° C. is 1.2 times greater or more, or 1.3 times greater or more, than the half-life of the TSHR mutant comprising the hextuple mutation H63C+R112P+D143P+D151E+V169R+I253R (TSHR-JMG55).

Preferably, in the above aspects, the thermostability of the mutant as determined by its half-life at 33° C. is 2 times greater or more, or 3 times greater or more, or 5 times greater or more. Thermostability is defined generally below, but may for example be measured by stability assay A, B, or C shown in FIGS. 14 b, c and d respectively.

Preferably, a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof according to the invention contains two point mutations in the transmembrane domain (TMD), wherein the thermostability of the mutant as determined by its half-life at 33° C. as measured by stability assay C shown in FIG. 14 d is 1.1 times greater or more than the half-life of the equivalent TSHR or fragment which comprises only a single point mutation in the transmembrane domain (TMD) selected from T477I (SEQ ID No 97), V595I (SEQ ID No 100) or I648L (SEQ ID No 103).

In another preferred aspect, a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof according to the invention contains two point mutations in the transmembrane domain (TMD), wherein the thermostability of the mutant as determined by its half-life at 55° C. as measured by stability assay A or stability assay B shown in FIGS. 14 b and 14 c respectively is 1.5 times greater or more than the half-life of the equivalent TSHR or fragment which comprises only a single point mutation in the transmembrane domain (TMD) selected from T477I, V595I or I648L.

Preferably, a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof according to the invention is such that at least one of the said two point mutations in the TMD is selected from T477I, V595I, and I648L.

Preferably, a mutant TSHR or fragment thereof according to the invention having a mutation within the transmembrane domain (TMD) contains a single point mutation from any of: E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, V595I, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L, Y678A (SEQ ID Nos 89-108 respectively). Two or more of these mutations may also be combined.

Preferably, a mutant TSHR or fragment thereof according to the invention having a mutation within the transmembrane domain (TMD) contains two point mutations, one of which is T477I or V595I or I648L and the second of which is a different mutation selected from E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, V595I, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L, Y678A.

In another aspect, the invention also provides a method of purifying a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprising one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment, which method comprises:

-   -   i) purifying a composition comprising the mutant or fragment         thereof by column chromatography; ii) collecting the purified         mutant or fragment thereof.

The composition may be any suitable composition or formulation containing mutant protein to be purified. For example, it may comprise an aqueous solution. It may comprise culture supernatant—for example, supernatant derived from cell cultures used to produce the mutant proteins.

The mutant TSHR or fragment thereof to be purified may be, for example, any one of the mutant TSHR or fragment thereof proteins according to the invention described herein. Preferably, the mutant consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor and preferably may also comprise one of the following set of mutations:

-   -   1) I253R (FIGS. 5 and 6 ; SEQ ID Nos 27 and 45)     -   2) D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 18, 27, 36 and 45)     -   3) R112P+D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16, 18, 27, 34,         36 and 45) 4) R112P+D143P+D151E+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 16, 18, 19, 27, 34, 36, 37 and 45)     -   5) R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16,         18, 19, 23, 27, 34, 36, 37, 41 and 45)     -   6) H63C+R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 14, 16, 18, 19, 23, 27, 32, 34, 36, 37, 41 and 45)     -   7) H63C+R112P+D143P+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 23, 27, 32, 34, 36, 41 and 45)     -   8) H63C+R112P+D143P+S166T+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 20, 27, 32, 34, 36, 38 and 45).

Preferably, the column chromatography comprises an ion-exchange chromatography such as a cation-exchange or anion-exchange chromatography. Standard chromatography equipment and processes may be used, and such will be clear to those skilled in the art. Surprisingly, we have found that mutant proteins according to the present invention and described herein can, in fact, owing to their increased thermostability, be purified in the above way, unlike their wild type equivalents. This forms an aspect of the present invention.

Preferably, the purification method of the invention further comprises, either before or after step i), purifying a composition comprising the mutant or fragment thereof by affinity chromatography. Any suitable affinity chromatography may be used, but in a preferred aspect the affinity chromatography comprises antibody affinity chromatography and/or metal-ion affinity chromatography. One or both may be used.

In a particularly preferred aspect, the purification method of the invention described above comprises:

-   -   i) purifying a composition comprising the mutant or fragment         thereof by cation-exchange or anion-exchange column         chromatography;     -   ii) further purifying the mutant or fragment thereof by antibody         affinity chromatography;     -   iii) optionally further purifying the mutant or fragment thereof         by metal-ion affinity chromatography;     -   iv) collecting the purified mutant or fragment thereof.

Preferably, the antibody in step (ii) is an antibody, preferably a monoclonal antibody, which binds a conformational epitope within the TSHR extracellular domain. Any suitable antibody may be used. 14C4 is one preferred mouse monoclonal antibody.

In a preferred aspect, step (iii) above comprises using nickel-affinity chromatography, although other suitable metal-ion affinity chromatography columns may be used.

In another preferred aspect, a method of purification according to the invention wherein the affinity chromatography is antibody affinity chromatography and also comprises elution with elution buffer at pH 4.5+/−0.2, optionally preceded by elution with elution buffer at pH 5.0+/−0.2.

Preferably, in the purification method of the invention, the mutant consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. Preferably the mutant comprises the following set of mutations:

H63C+R112P+D143P+D151E+V169R+I253R.

In a further aspect, according to the present invention purification of the mutant TSHR or fragment thereof does not require antibody bound to, or in complex with, the mutant or fragment thereof. The invention provides mutants of increased stability such that functional, active protein may be produced via purification without the need to stabilise the mutant of fragment thereof during purification with antibody bound or complexed to it.

In one aspect of the invention, particularly but not exclusively TSHR260 preparations, especially TSHR260-JMG55 preparations, which are stable in aqueous solution, are purified to obtain a preparation with high activity in the TSHR260 binding ELISA (shown in FIG. 12 a ).

The increased thermostability of the mutant TSHR proteins according to the invention allows for their purification, for example by the purification methods described herein. Such purification of active protein has hitherto been unachievable. Accordingly, the invention provides TSHR proteins, including TSHR260 proteins, at a level of purity and activity not previously achievable. These are novel products. “Purified” mutant TSHR or a fragment thereof as used herein is intended to refer to a mutant TSHR or fragment thereof which has been subjected to at least one purification step. The purification step or steps may be any suitable purification for purifying protein, and such will be clear to those skilled in this field. For example, the purification steps described and claimed herein may be used, but other suitable purifications are not excluded and may be used if desired.

According to another aspect of the present invention, there is provided purified mutant TSHR or fragment thereof according to the invention described herein obtained by the purification method of the invention described herein. The mutant TSHR of fragments thereof are also obtainable by the purification method of the invention. It is possible that other methods of purification may be used to produce the purified mutants of the present invention.

In a related aspect, therefore, the invention also provides a purified mutant TSHR or fragment thereof according to the invention described herein characterised in that the activity of the said purified mutant in a TSHR activity assay is greater than the activity of the unpurified mutant from culture supernatant as measured in the same TSHR activity assay. The supernatant will preferably be from a suitable cell culture used to express and secrete the mutant protein (as for example described herein). The TSHR activity assay may be any suitable assay which is capable of giving a measure of the activity of the mutant being tested, provided that exactly the same assay using the same conditions (i.e an identical assay) is used for both the unpurified and purified samples. Examples of a number of suitable assays are given herein, as will be clear to those skilled in the art. Particularly suitable assays are those shown in FIGS. 12 a, 12 d , and 13 c.

The activity in the TSHR activity assay may be expressed in any suitable way, for example as the amount of activity per volume of sample—for example units per ml. Suitably, the activity is the specific activity of the mutant as measured in units of activity per quantity of protein—for example, units per mg.

In a preferred aspect, the invention provides a purified mutant TSHR or fragment thereof according to the invention described herein characterised in that the activity of the said purified mutant in a TSHR activity assay is 500 fold or greater compared to the activity of the unpurified mutant from culture supernatant as measured in the same TSHR activity assay. The activity may in fact be higher, for example the activity may be 1000 fold or greater, or 5000 fold or greater, compared to the activity of the unpurified mutant from culture supernatant as measured in the same TSHR activity assay. Preferably, the activity is expressed or measured as specific activity in units per mg of protein.

Preferably, the activity of the unpurified mutant is measured from the culture supernatant harvested directly from the culture, without any dilution or concentration of the supernatant, although it will be understood this may be done if desired—such will not affect the activity measured when expressed in terms of specific activity in units per mg of protein.

Preferably, the TSHR activity assay measures the ability of the said mutant to bind TSHR antibody or autoantibody. Any suitable antibody or autoantibody may be used, and suitable TSHR autoantibodies include M22, K1-70 or K1-18 (as described herein).

Preferably, the TSHR activity assay comprises mutant to be tested bound directly or indirectly to an ELISA plate. Preferably, the mutant to be tested is bound or coated indirectly on to an ELISA plate. For example, this may be achieved using antibody which binds TSHR but does not interfere with normal binding of the TSHR itself. Preferably, the antibody is a monoclonal antibody, which binds a conformational epitope within the TSHR extracellular domain. Any suitable antibody may be used. 14C4 is one preferred mouse monoclonal antibody, but others may be used, as will be understood.

In a preferred aspect, the TSHR activity assay comprises an assay as shown in FIG. 12 a or FIG. 13 c . If the mutant whose activity is to be tested is capable of being bound directly to an ELISA plate, then an assay of the type shown in FIG. 12 d may be used. Preferably, purified mutant TSHR or fragment thereof according to the invention consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor and comprises one of the following set of mutations:

-   -   1) I253R (FIGS. 5 and 6 ; SEQ ID Nos 27 and 45)     -   2) D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 18, 27, 36 and 45)     -   3) R112P+D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16, 18, 27, 34,         36 and 45)     -   4) R112P+D143P+D151E+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16, 18,         19, 27, 34, 36, 37 and 45)     -   5) R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16,         18, 19, 23, 27, 34, 36, 37, 41 and 45)     -   6) H63C+R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 14, 16, 18, 19, 23, 27, 32, 34, 36, 37, 41 and 45)     -   7) H63C+R112P+D143P+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 23, 27, 32, 34, 36, 41 and 45)     -   8) H63C+R112P+D143P+S166T+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 20, 27, 32, 34, 36, 38 and 45).

In a particularly preferred aspect, the invention provides a purified mutant TSHR or fragment thereof according to the invention as described herein wherein the mutant comprises the set of mutations: H63C+R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14, 16, 18, 19, 23, 27, 32, 34, 36, 37 41 and 45).

The purified mutant TSHR or fragment thereof according to the invention may also comprise a detectable label as described herein.

Also provided is a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof according to the invention described herein, wherein the mutant or fragment thereof is deglycosylated and retains activity, for example as measured in a TSHR activity assay. Examples of such assays are described herein, and also above in relation to the activity of purified mutants. Any suitable TSHR activity assay may be used For example, the assays shown in FIG. 12 a or 13 c may be used to measure activity. The activity is preferably at least 70% or more, at least 80% or more, or at least 90% or more, the activity of the non-deglycosylated mutant or fragment thereof. In some cases, the activity may be hardly diminished at all, or may be the same as, or essentially the same as, the activity of the non-deglycosylated mutant or fragment thereof.

In principle, deglycosylation may be applied to any one of the mutant thyroid stimulating hormone receptor (TSHR) or fragments thereof described and claimed herein, although we prefer that the mutant comprises at least a double point mutation. A certain level of stability is required, and testing of the kind described herein will be able to determine the activity of the mutant protein after deglycosylation in each case. We expect mutants having at least a double point mutation, or in some cases at least a triple point mutation, to be capable of being deglycosylated, whilst retaining sufficient activity. As will be understood, deglycosylation removes the sugar residues from the protein, and enables more ready crystallisation. Any suitable deglycosylation process may be used, and one suitable technique is described in detail below.

A deglycosylated mutant according to the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor and comprises one of the following set of mutations:

-   -   1) I253R (FIGS. 5 and 6 ; SEQ ID Nos 27 and 45)     -   2) D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 18, 27, 36 and 45)     -   3) R112P+D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16, 18, 27, 34,         36 and 45)     -   4) R112P+D143P+D151E+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16, 18,         19, 27, 34, 36, 37 and 45)     -   5) R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16,         18, 19, 23, 27, 34, 36, 37, 41 and 45)     -   6) H63C+R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 14, 16, 18, 19, 23, 27, 32, 34, 36, 37, 41 and 45)     -   7) H63C+R112P+D143P+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 23, 27, 32, 34, 36, 41 and 45)     -   8) H63C+R112P+D143P+S166T+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 20, 27, 32, 34, 36, 38 and 45),         although as stated above deglycosylation can in principle be         applied to any one of the mutants described and claimed herein.

There is also provided a method, including a diagnostic method, for detecting analyte autoantibodies to the TSHR, the method comprising contacting a sample of analyte autoantibody with a mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof according to the invention described herein. Use of TSHR260 mutants, especially those labelled with alkaline phosphatase, are particularly preferred. TSHR260 comprising the point mutations H63C+R112P+D143P+D151E+V169R+I253R (JMG55) is especially preferred.

The analyte antibodies may come from any suitable source. Preferably, the sample of analyte autoantibodies has been isolated from a subject believed to contain such analyte autoantibodies. The sample may be from any species, including human—for example, human patient sera. Suitably, the sample comprises human or animal patient sera.

The invention also provides a method, including a diagnostic method, for detecting analyte autoantibodies to the TSHR, which method comprises:

-   -   a) providing a sample, for example a sample of body fluid, from         a subject;     -   b) providing one or more first sources of TSHR or a fragment         thereof,     -   c) providing one or more second sources of TSHR wherein the         second source is a mutant thyroid stimulating hormone receptor         (TSHR) or a fragment thereof according to the invention;     -   d) contacting said first and second sources of TSHR         simultaneously or successively with said sample, for example a         sample of body fluid, whereby said antibodies to the TSHR form         one or more complexes comprising [TSHR of first source]-[TSHR         antibody]-[TSHR of second source];     -   e) prior to, or concurrent with or subsequent to step (d),         providing immobilising means whereby said first source of TSHR         as present in a complex as formed in step (d) is immobilised to         a solid support prior to, or concurrent with, or subsequent to         step (d);     -   f) prior to, or concurrent with or subsequent to step (d)         providing direct or indirect detectable labelling means whereby         said second source of TSHR as present in the complex as formed         in step (d) is provided with such direct or indirect labelling         means prior to, or concurrent with or subsequent to step (d);         and     -   g) detecting the presence of complexes formed in (d) according         to (e) so as to provide an indication of the presence of TSHR         antibodies in said sample of body fluid.

The first source of TSHR may be any suitable form of TSHR (wild type or mutated), including full-length TSHR, or fragments, including TSHR260, although preferably the first source of TSHR provided in (b) is full length TSHR, including one or more epitopes of a TSH receptor or a polypeptide comprising one or more epitopes of a TSH receptor. If desired, the first source of TSHR provided in (b) is a mutant TSHR or a fragment thereof according to the invention described herein. Both the first and second sources of TSHR in the methods of the invention may therefore, if desired, be a mutant TSHR or a fragment thereof according to the invention as described and claimed herein.

In a preferred aspect, the mutant TSHR or fragment thereof consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor, although may in principle be any of the mutant TSHRs or fragments thereof disclosed herein.

The labelling means may comprise any suitable means of labelling the second source of TSHR, and suitable means and their methods of application and use will be known to those in the art. The label may, for example, be selected from the group consisting of enzymatic labels, isotopic labels, chemiluminescent labels, fluorescent labels and dyes. Such labels may be added in any suitable way, for example, via gene fusion using an appropriate construct (as described further below) or by chemical labelling. Those skilled in the art will be familiar with the relevant techniques needed, and the identity of suitable labels.

In a preferred aspect, the label comprises an alkaline phosphatase (AP) label or a biotin label. Most preferably, an alkaline phosphatase label is employed.

In a preferred aspect, the labelled mutant consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. Certain preferred mutants are those consisting of the subdomain TSHR260 of the TSHR receptor and an alkaline phosphatase (AP) label, denoted herein as TSHR260-AP-X, wherein “X” indicates the one or more amino acid mutations in the mutant.

Preferably, the labelling means comprises an alkaline phosphatase (AP) label.

Preferably, the mutant is directly labelled with the labelling means—for example, a TSHR260 directly chemically labelled with alkaline phosphatase (AP) label or a biotin.

In a preferred aspect, the immobilising means whereby said first source of TSHR is immobilised to a solid support, comprises a monoclonal antibody, recombinant antibody, synthetic antibody or fragment thereof. An example is the antibody 4E31 (described herein), but any suitable antibody may be used.

The solid support may be any suitable support, but is preferably a plate, for example an ELISA plate, or an ELISA plate well.

The invention also provides a kit for detecting analyte autoantibodies to the TSHR, which kit comprises:

-   -   a) one or more first sources of TSHR or a fragment thereof,     -   b) one or more second sources of TSHR wherein the second source         is a mutant thyroid stimulating hormone receptor (TSHR) or a         fragment thereof according to the invention described herein;     -   c) means for contacting said first and second sources of TSHR         simultaneously or successively with a sample believed to contain         analyte autoantibodies to the TSHR whereby said antibodies to         the TSHR form one or more complexes comprising [TSHR of first         source]-[TSHR antibody]-[TSHR of second source];     -   d) immobilising means for immobilising said first source of TSHR         as present in a complex as formed in (c) to a solid support         prior to, or concurrent with, or subsequent to (c);     -   e) detectable labelling means for directly or indirectly         labelling said second source of TSHR as present in the complex         as formed in (c) labelled prior to, or concurrent with, or         subsequent to, formation of said complex; and     -   f) means for detecting the presence of complexes formed in (c)         so as to provide an indication of the presence of TSHR         antibodies in said sample.

The kit may, for example, comprise any one or more of the features described above in relation to the corresponding method.

In particular, if desired, the first source of TSHR provided in (a) is a mutant TSHR or a fragment thereof according to the invention described herein. Both the first and second sources of TSHR in kits according to the invention may therefore, if desired, be a mutant TSHR or a fragment thereof according to the invention as described and claimed herein. The invention also provides a solid support having directly or indirectly bound thereto a mutant thyroid stimulating hormone receptor (TSHR) or a fragment thereof according to the invention described herein.

Preferably, the solid support according to the invention has bound thereto a mutant thyroid stimulating hormone receptor (TSHR) or a fragment thereof which consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor.

In a preferred aspect, a solid support according to the invention has bound thereto a mutant thyroid stimulating hormone receptor (TSHR) or a fragment thereof comprising one of the following set of mutations:

-   -   1) I253R (FIGS. 5 and 6 ; SEQ ID Nos 27 and 45)     -   2) D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 18, 27, 36 and 45)     -   3) R112P+D143P+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16, 18, 27, 34,         36 and 45) 4) R112P+D143P+D151E+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 16, 18, 19, 27, 34, 36, 37 and 45)     -   5) R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 16,         18, 19, 23, 27, 34, 36, 37, 41 and 45)     -   6) H63C+R112P+D143P+D151E+V169R+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 14, 16, 18, 19, 23, 27, 32, 34, 36, 37, 41 and 45)     -   7) H63C+R112P+D143P+V169R+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 23, 27, 32, 34, 36, 41 and 45)     -   8) H63C+R112P+D143P+S166T+I253R (FIGS. 5 and 6 ; SEQ ID Nos 14,         16, 18, 20, 27, 32, 34, 36, 38 and 45).

The invention thus provides the use, in particular, of stable purified mutants of TSHR260, especially TSHR260-JMG55, directly coated onto ELISA plate wells for detection of TSHR monoclonal autoantibodies and patient serum TRAbs. Such mutants may comprise a detectable label such as an alkaline phosphatase (AP) label, if desired.

Suitably, the mutant thyroid stimulating hormone receptor (TSHR) or a fragment thereof is directly bound to the said solid support.

In a preferred aspect, the support is an ELISA plate comprising one or more wells.

The invention also provides a kit comprising a solid support according to the invention.

The invention also provides the use of a solid support according to the invention or a kit according to the invention comprising the solid support, for detecting TSHR monoclonal autoantibodies or patient TRAbs.

DESCRIPTION OF THE DRAWINGS

TSHR molecules and methods in accordance with the invention will now be described, by way of example only, with reference to the accompanying drawings, FIGS. 1 to 30 , in which:

FIG. 1 shows the DNA sequence of the human (wild type) TSHR (SEQ ID No 1).

FIG. 2 shows the amino acid sequence of the human (wild type) TSHR (SEQ ID No 2).

FIG. 3 shows the DNA sequence of the human (wild type) TSHR260 fragment (SEQ ID No 3).

FIG. 4 shows the amino acid sequence of the human (wild type) TSHR260 fragment (SEQ ID No 4).

FIG. 5 shows the DNA sequence of thermostabilising TSHR single mutations (SEQ ID Nos 11-28).

FIG. 6 shows the amino acid sequence of thermostabilising TSHR single mutations (SEQ ID Nos 29-46).

FIGS. 7A-7E show representative examples of the results of a TSHR260 thermostability assay for TSHR260 mutants heated at (a) 42° C., (b) 50° C., (c) 50° C., (d) 55° C. and (e) 60° C.

FIG. 8 shows the thermostability of full-length TSHR mutants by heating on a 14C4 Fab₂ plate at 50° C.

FIG. 9 illustrates the TSHR260 domain in cartoon format and shows the position of native residues of the most thermostabilising mutations in stick conformation.

FIGS. 10A-10C show the alignment of TSHR amino acid sequences from human, grivet monkey, rhesus monkey, porcine, bovine, cat, dog, mouse, rat, sheep, horse (SEQ ID Nos 2, 47-56 respectively).

FIGS. 11A-11B show the alignment of the human TSHR amino acid sequence with human FSHR and human LHR (SEQ ID Nos 2, 57 and 58 respectively).

FIGS. 12A-12D show diagrams of assays involving TSHR260: (a) TSHR260-binding assay; (b) TSHR260 thermostability assay; (c) inhibition of M22-POD binding to TSHR260 and (d) TSHR260-JMG55 coated ELISA plate well assay.

FIGS. 13A-13C show diagrams of assays involving TSHR260-AP: (a) TSHR260-AP bridge ELISA; (b) TSHR260-AP thermostability assay and (c) TSHR260-AP bridge inhibition ELISA.

FIGS. 14A-14E show diagrams of assays involving TSHR: (a) TSHR-binding assay; (b) TSHR stability assay A; (c) TSHR stability assay B; (d) TSHR stability assay C and (e) inhibition of M22-POD binding to TSHR.

FIG. 15 shows the DNA sequence of TSHR260-AP (SEQ ID No 59)

FIG. 16 shows the amino acid sequence of TSHR260-AP (SEQ ID No 60)

FIG. 17 shows the DNA sequence of porcine (wild type) TSHR (SEQ ID No 61).

FIG. 18 shows the amino acid sequence of porcine (wild type) TSHR (SEQ ID No 62).

FIG. 19 shows the DNA sequence of mouse (wild type) TSHR (SEQ ID No 63).

FIG. 20 shows the amino acid sequence of mouse (wild type) TSHR (SEQ ID No 64).

FIG. 21 shows the DNA sequence of porcine (mutated) TSHR (SEQ ID No 65).

FIG. 22 shows the amino acid sequence of porcine (mutated) TSHR (SEQ ID No 66).

FIG. 23 shows the DNA sequence of mouse (mutated) TSHR (SEQ ID No 67).

FIG. 24 shows the amino acid sequence of mouse (mutated) TSHR (SEQ ID No 68).

FIGS. 25A-25H show the activity as measured by the bridge inhibition ELISA assay illustrated in FIG. 13(c) of the load and elution pools for purification of (a) TSHR260 (wild type), (b) TSHR260 (wild type) in complex with 14C4 IgG, (c) TSHR260 (wild type) in complex with 25E1 IgG, (d) TSHR260 (wild type) in complex with 2H11 IgG, (e) TSHR260 (wild type) in complex with 23H4 IgG, (f) TSHR260 (wild type) in complex with 36F11 IgG, (g) TSHR260 (wild type) in complex with 9B7 IgG and (h) TSHR260-JMG55 on either streamline DEAE or streamline HST matrices.

FIG. 26 shows the distribution of TSHR260-JMG55 activity in the elution fractions after 14C4-affinity chromatography of streamline HST purified TSHR260-JMG55.

FIG. 27 shows a stained 12% non-reduced SDS-PAGE gel of purified TSHR260-JMG55-5.0 (low specific activity) and purified TSHR260-JMG55-4.5 (high specific activity) after 3 rounds of column purification (streamline HST, 14C4-affinity and nickel-affinity chromatography). Lane 1: Molecular Weight Markers; lane 2: TSHR260 (wild type) culture supernatant control; lane 3: Insect cell culture media control; lane 4: purified TSHR260-JMG55-5.0 (2.4 μg) and lane 5: purified TSHR260-JMG55-4.5 (3.0 μg).

FIGS. 28A-28B show deglycosylation of purified TSHR260-JMG55-4.5 using Endoglycosidase F3 at different concentrations (stained 12% non-reduced SDS-PAGE gel). (A) Lane 1: Molecular Weight Markers; Lane 2: Insect cell culture media negative control; Lane 3: Nickel-affinity purified TSHR260-JMG55-4.5 (untreated); Lanes 4-6: 40 mU Endoglycosidase F3/mg of TSHR260-JMG55-4.5 after 24 h, 72 h and 120 h incubation respectively; Lanes 7-9: 0 mU Endoglycosidase F3/mg of TSHR260-JMG55-4.5 after 24 h, 72 h and 120 h incubation respectively. (B) Lane 1: Molecular Weight Markers; Lane 2: Insect cell culture media negative control; Lane 3: Nickel-affinity purified TSHR260-JMG55-4.5 (untreated); Lanes 4-6: 60 mU Endoglycosidase F3/mg of TSHR260-JMG55-4.5 after 24 h, 72 h and 120 h incubation respectively; lanes 7-9: 80 mU Endoglycosidase F3/mg of TSHR260-JMG55-4.5 after 24 h, 72 h and 120 h incubation respectively.

FIG. 29 shows the DNA sequence of thermostabilising single amino acid mutations made in the TMD of TSHR-JMG55 (SEQ ID Nos 69-88).

FIG. 30 shows the amino acid sequence of thermostabilising single amino acid mutations made in the TMD of TSHR-JMG55 (SEQ ID Nos 89-108).

METHODS Computational Modelling of TSHR260 Mutations

Computational modelling was performed with Discovery studios v3.5 (Accelrys Software Inc, Accelrys Ltd, Cambridge, CB4 OWN, UK) using the Calculate Mutation Energy Stability protocol. The crystal structure of TSHR260-M22 Fab complex (PDB code: 3G04; Available from the RCSB Protein Databank at www.rcsb.org/pdb/explore/explore.do?structureld=3go4) was used as the initial model for all mutations to ensure that mutations which do not disturb the binding of M22 to TSHR260 were chosen. Each residue in the TSHR260 structure was mutated to each of the other 19 possible amino acids and the mutation energy data collected and compared.

The computational modelling data was used in conjunction with other predictions of stabilising mutations to estimate which target residue is most likely to be stabilising for each position. These other predictions were based on a number of factors:

-   -   1. Torsion angles of the residues predicting favourable         conformations for Pro or Gly amino acids.     -   2. Consensus sequence of TSHR from other organisms and other         glycoproteins     -   3. Position of the residue in the LRR and/or β-sheets.     -   4. Position of the residue in the surface or core of the         protein.

Primer Design

Primers were designed to introduce point mutations into TSHR260 using the PrimerX website (www.bioinformatics.org/primerx/index.htm). The protein-based primer design option was used, using the QuikChange SDM protocol, and choosing primer pairs such that their overhang was between two and ten residues. Primers had melting temperatures between 73° C. and 84° C. (ideally greater than 76° C.), were between 27 and 49 base pairs in length and had a GC content between 33% and 70% (ideally greater than 40%). Primers were ordered in 96-well format, in 10 μM aqueous solution from Sigma Genosys, Haverhill, CB9 8QP, UK.

Mutagenesis, Plasmid DNA Preparation and Purification

The TSHR260-6His template construct (coding amino acids 1-260 of the human TSHR; see FIGS. 3 (SEQ ID No 3) and 4 (SEQ ID No 4) for the nucleotide sequence and amino acid sequence respectively of the wild type TSHR 260) was previously amplified using full-length human TSHR as template (Oda Y et al (1998) Journal of Molecular Endocrinology 20: 233-244) with the addition of a six His tag at the C terminus. Residues 1-260 of TSHR were amplified from the full-length TSHR with two primers 5′-cactgcaggatccaaatgaggccggcggacttg-3′ (SEQ ID No 5) and 5′-cagtcctctagattatcagtgatggtggtggtgatggttaagagtccaggtgttcttgctat-3′ (SEQ ID No 6) which add a BamHI restriction site at the N terminus, and a one amino acid linker (Asn), a six His tag, a stop codon and an XbaI restriction site to the C terminus of human TSHR amino acids 1-260. The PCR product was cloned into pcDNA3.1+ using BamHI and XbaI restriction sites.

Mutations in the TSHR260 sequence (FIG. 5 ; SEQ ID Nos 11 to 28 and FIG. 6 ; SEQ ID No 29 to 46) were generated by site-directed mutagenesis using the polymerase chain-reaction (PCR) with the QuikChange II methodology (Agilent Technologies UK Ltd, Stockport, SK8 3GR). Mutagenesis was performed in 96-well plate format using KOD hot start polymerase kit (Novagen from VWR International, Lutterworth, LE17 4XN, UK). Using TSHR260-6His as the template, or the appropriate TSHR260 mutants in the vector pcDNA3.1+, 50 μL PCR reactions were set up so that the final concentration in each reaction was: 1×KOD buffer, 0.2 mM dNTPs, 1.5 mM MgSO₄, 0.02 U/μL KOD hot start polymerase, 9% v/v DMSO (Sigma Aldrich, Poole, BH12 4QH), 0.2 ng/μL template DNA, 0.3 μM forward primer and 0.3 μM reverse primer. The following PCR program was run: 2 minutes denaturation at 94° C.; 18 cycles of 15 s denaturation at 94° C., 1 minute annealing at 68° C., 8 minutes elongation at 68° C.; followed by a final step of elongation at 68° C. for 7 minutes. The template was digested by incubation with 2 μL DpnI (Fisher Scientific, Loughborough, LE11 5RG) at 37° C. for at least 3 h.

1 μL of the PCR reaction was added to 30 μL XL1 blue competent cells in 1.5 mL microtubes or 96-well cell culture cluster round bottom plates (Nunc A/S, Roskilde, Denmark) and incubated on ice for 30 minutes. Cells were heat-shocked at 42° C. for 90 s, transferred to ice and 200 μL Luria Broth (LB) media added. Cells were incubated at 37° C. for 1 hour before being spread on LB agar plates containing ampicillin (100 μg/mL). When more than 30 transformations were performed simultaneously, LB agar containing ampicillin (100 μg/mL) poured into Q-tray plates with 48 divisions (Molecular Dimensions, Newmarket, CB8 7SQ, UK) were used. Plates were incubated at 37° C. overnight to allow colonies to grow.

Two colonies from each transformation were picked and grown at 37° C. overnight in 7 mL LB media with 100 μg/mL ampicillin in 15 mL Falcon tubes or 24-well deep-well blocks (Promega UK Ltd, Southampton, SO16 7NS, UK). Plasmid DNA was extracted from the cell pellet of the overnight cultures using the Qiagen PlasmidPlus 96 Miniprep Kit (Qiagen Ltd, Manchester, M15 6SH, UK) or Wizard PlusMiniprep DNA purification System (Promega) and the mutated TSHR260 cDNA was sequenced by Source Bioscience (Cambridge, CB4 0WU, UK) to confirm the presence of the desired mutations. Stocks of E. coli strains containing the mutant TSHR260-6His were maintained at −70° C. after addition of glycerol (14% final concentration) to an aliquot of the overnight culture.

Introduction of Specific Amino Acid Mutations into the Full Length Human TSHR Sequence Using PCR

The TSHR full length nucleotide sequence (Oda Y et al (1998) supra) was cloned into pcDNA5.1/FRT vector (Invitrogen) using BamHI and XhoI restriction sites following standard cloning procedures. Mutations in the full length sequence were generated by site directed mutagenesis using the PCR with the QuikChange II methodology as described above for the TSHR260 mutations, except mutagenesis was performed in 0.2 mL PCR tubes instead of a 96 well plate format. The PCR reaction was transformed, expanded and the mutations verified by sequencing as described above for TSHR260 PCR products. See FIGS. 1 (SEQ ID No 1) and 2 (SEQ ID No 2) for the nucleotide sequence and amino acid sequence respectively of full length wild type TSHR.

Transient Transfections of TSHR260 Mutants into CHO-KJ Cells Using Freestyle Max Reagent

One day prior to transfection, 1.5×10⁵ CHO-K1 cells/well were plated out into 24-well cell culture plates (Nunc). For each well to be transfected, 5 μL TSHR260-6His mutant in pcDNA3.1+(0.2 μg/μL) was mixed with 20 μL Optipro SFM (Life Technologies, Paisley, PA4 9RF, UK). 2.5 μL Freestyle Max reagent (Life Technologies) diluted in 22.5 μL Optipro SFM was added to each DNA/Optipro SFM mixture and incubated at room temperature for 10-20 minutes. 40 μL DNA/Freestyle Max mix was added to CHO-K1 cells in a 24-well plate and incubated at 37° C. for 40-48 h. Thereafter expressed TSHR protein secreted into the media was harvested by centrifugation at 13000 rpm for 2 minutes to remove the cell debris and the supernatant stored at −70° C.

The TSHR260-WT standard was made by transfecting an 80 cm² flask containing 90% confluent CHO-K1 cells with TSHR260-6His in pcDNA3.1+. 20 μL TSHR260-6His in pcDNA3.1+(1 μg/μL) was added to 480 μL Optipro SFM (Life Technologies). 50 μL Freestyle Max reagent (Life Technologies) diluted in 450 μL Optipro SFM was added to the DNA/Optipro SFM mixture and incubated at room temperature for 10-20 minutes. 1 mL DNA/Freestyle Max mix was added to the 80 cm² flask of CHO-K1 cells and incubated at 37° C. for 40-48 h. Thereafter expressed TSHR260-6His protein secreted into the media was harvested by centrifugation at 3000 rpm for 30 minutes to remove the cell debris and the supernatant stored at −70° C. This was defined as 100 U/mL. Further TSHR260-WT standard samples were diluted to be the same concentration as the first TSHR260-WT standard, as detected in the TSHR260-binding assay (see below).

Transfection of Full Length TSHR Constructs into CHO Cells Using the Flp-In System

A confluent flask of Flp-In-CHO cells (Invitrogen, Paisley, PA4 9RF, UK; O'Gorman, S., Fox, D. T., and Wahl, G. M. (1991) Science 251: 1351-1355) was used to seed 24 well plate wells at 1×10⁵-1.5×10⁵ cells/well in DMEM (Invitrogen), 10% foetal calf serum (FCS) (Invitrogen), 1×L-Glutamine (Invitrogen) and 1× non-essential amino acids (NEAA) (Invitrogen) with no antibiotics. The cells were incubated overnight at 37° C., 5% CO₂ and >95% humidity.

The pcDNA5.1/FRT TSHR DNA (described above) and pOG44 DNA (Invitrogen) were diluted to give 0.01 μg/mL and 0.1 μg/mL solutions, respectively in sterile water. The pOG44 DNA and the TSHR DNA were mixed at 3 different concentrations: (1) 9 μL of pOG44, 10 μL TSHR DNA and 31 μL optimem I (Invitrogen); (2) 8 μL pOG44, 20 μL TSHR DNA and 22 μL optimem I; (3) 9.5 μL pOG44, 5 μL TSHR DNA and 35.5 μL Optimem I and incubated at room temp for 5 min. 50 μL of 1:25 diluted lipofectamine (Invitrogen) in optimem I was added to each tube (1-3 above) and incubated for 20 min at room temp. Each incubation mixture was then added to 1 well (in a 24 well plate) of 95% confluent Flp-In-CHO cells and incubated overnight under conditions described above. The culture media was then removed and changed for DMEM, 10% FCS, 1×L-glutamine, 1×NEAA and 1× penicillin (100 u/mL)/streptomycin (100 μg/mL) (Invitrogen) and incubation continued overnight. The cells were then detached from the well using 1× trypsin/EDTA solution (Invitrogen) and split into 4 new wells and grown in the media as above with addition of 600 μg/mL of hygromycin (Invitrogen).

The cells transfected with both, the pOG44 plasmid DNA and pcDNA5.1/FRT TSHR are capable of inserting the TSHR into the Flp-In-CHO cell genome and conferring hygromycin resistance on the cell so it will be able to grow in hygromycin selection media. The Flp-In system from Invitrogen is so designed that the TSHR in our constructs will be inserted into the FRT site in the Flp-In-CHO cells by the pOG44. The Flp-In-CHO cells contain one Flp-In site per cell therefore the TSHR DNAs will be inserted in the same place in the genome in each experiment and it will be present as one copy per cell. This system has the advantage that screening colonies of cells for those with optimum expression levels (followed by cell cloning to find a stable cell line) is not necessary. Consequently, cells expressing mutated TSHR that grows in the hygromycin selection media can be expanded quickly and used in different assays.

Antibodies Used in TSHR260 Binding Assay

14C4

The 14C4 TSHR mouse monoclonal antibody used in the TSHR260-binding assay was prepared by cDNA immunisation. Briefly, six- to eight-week old NMRI (out bred) mice were injected intramuscularly with 100 μL of 10 μM cardiotoxin five days before intramuscular immunisation with 100 μg of full-length TSHR cDNA (pRC/CMVhTSHR; Oda et al (1998) supra). TSHR DNA immunisation was repeated at three week intervals for a total of five injections (Hasan et al (1999) J. Immunol. Methods 229:1-22). The mouse bleeds were tested for the presence of TSHR antibodies by inhibition of ¹²⁵I-labelled TSH binding to the TSHR (assay manufactured by RSR Ltd, Cardiff, UK). Monoclonal antibodies were produced using the spleen cells from the mouse with the highest TSHR antibody titres in the serum. Isolated spleen cells were mixed in a 1:2 ratio with a mouse myeloma cell line (X63_Ag8.653; ECACC Porton Down, UK) and fused using 10% DMSO and 50% PEG (Sigma Aldrich, Poole, UK) according to previously described methods (de St Groth, S. F., & Scheidegger, D. (1980). Journal of immunological methods 35, 1-21.). Cells were cultured in DMEM (supplemented with 20% fetal calf serum containing HAT to select for hybrids) and plated into 48-well plates. To obtain 14C4, supernatants from the cell cultures were screened for TSHR antibodies by immunoprecipitation of ¹²⁵I-TSH labelled TSHR complexes. In these assays the full-length TSHR is labelled using ¹²⁵I-TSH to form a ¹²⁵I-TSH-TSHR complex. The ¹²⁵I-TSH-TSHR complex is bound by antibodies which are capable of binding to the TSHR at the same time as TSH. The complex can then be precipitated using standard PEG precipitation techniques and the radioactivity in the pellet measured. The cells from the positive wells were recloned two times by limiting dilution to obtain clones expressing the required monoclonal antibody. 14C4 IgG binds to a conformational epitope on the convex surface of the TSHR allowing TSH or patient TRAb to bind to the concave surface of the TSHR at the same time. 14C4 is available from RSR Ltd, Cardiff, UK (www.rsrltd.com).

M22 Protein Data Bank (PDB) Accession Number 3G04

(www.rcsb.org/pdb/explore/explore.do?structureld=3go4)

M22 (hMAb TSHR1) is a human thyroid stimulating monoclonal autoantibody which was obtained from peripheral blood lymphocytes from a patient with Graves' disease (Sanders et al (2003) Lancet 362: 126-128). Briefly, lymphocytes were isolated from 20 mL of peripheral blood of a 19-year old man with hyperthyroidism and high levels of TSHR autoantibodies (due to Graves' disease). The lymphocytes were infected with Epstein Barr virus and fused with a mouse/human hybrid cell line (K6H6/B5; ECACC, Porton Down, UK) using standard techniques (Hayakawa N et al (2002) Autoimmunity 35: 343-55). The cells were plated out in 48-well plates and the supernatants screened by the inhibition of ¹²⁵I-TSH binding to TSHR coated tubes (assay RSR Ltd, Cardiff, UK). Positive wells were then recloned by limiting dilution until a single colony producing high concentrations of TSHR autoantibody M22 was isolated. M22 (hMAb TSHR1) is well known in the art as the WHO 2^(nd) International Standard for Thyroid Stimulating Antibody NIBSC code: 08/204 (Burns C et al (2010) WHO International Collaborative Study of the proposed 2^(nd) International Standard for Thyroid Stimulating Antibody, Expert Committee on Biological Standardization, Geneva 18 to 22 Oct. 2010, WHO/BS/10.214, Available at: www.who.int/biologicals/expert_committee/BS_2142 Thyroid_Stimulating_Autoantibody.pdf). M22 (hMAb TSHR1) is available to purchase from RSR Ltd, Cardiff, UK (Supra).

Thermostability

In the context of the present invention, thermostability is, generally speaking, the ability of the mutant TSHR or fragment thereof (such as a TSHR260 mutant) to retain its normal biological activity after being exposed to a given temperature for a defined time period. Suitably, it can be determined by the percentage of active mutant protein remaining after the temperature exposure. One suitable measure of the amount of active mutant protein is the percentage of mutant protein that retains the ability to bind an antibody or autoantibody to the TSHR in a binding assay. The amount of active mutant protein remaining after exposure to a given temperature can thus be measured as a function of time and a thermostability curve at that temperature obtained—for example as shown in FIG. 7 . The half-life of the mutant protein—that is, the time taken for the amount of active protein to fall to 50% of its initial value (i.e. 50% is inactive or denatured)—can thus be derived. The half-life of the mutant protein gives a convenient quantitative measure of the thermostability of the protein, and this can be compared with the half-life of the equivalent non-mutated TSHR or fragment thereof (i.e. wild type TSHR or fragments thereof such as wild type TSHR260) in order to assess whether there has been an increase or decrease in thermostability.

A suitable binding assay may, for example, comprise a plate having bound thereto a mutant TSHR or fragment thereof to be tested, and a labelled antibody or autoantibody to TSHR, and such an assay forms part of the present invention. The mutant to be tested is suitably bound to the plate in such a way so as not to interfere with binding of the antibody to the mutant protein. The mutant may, for example, be bound to the plate using any suitable antibody, and one such antibody is 14C4 as described above. The amount of labelled antibody bound can be used to indicate the amount of active mutant protein, as will be clear to those skilled in the art. Preferably, a labelled monoclonal autoantibody to TSHR is employed, such as M22 (as described above), to bind to the mutant protein being assayed. The principle of such an assay is, for example, shown in FIGS. 12 a and 12 b , FIGS. 13 a and 13 b , and FIGS. 14 a, b, c and d. Whilst the specific details of the assays shown in the above Figures vary, the thermostability of the mutant protein in each case can be derived by comparing mutant protein and wild type by measuring the amount of protein that retains the ability to bind an antibody or autoantibody (such as M22) to the TSHR.

In the present invention, the terms “thermostability” and “thermostable” (and all related terms such as “increased thermostability”) are to be understood in a quantitative sense as referring to the half-life of the mutant TSHR or fragment thereof (such TSHR260), as compared to the half-life of the equivalent wild type TSHR or fragment thereof, as measured under identical conditions in a binding assay which determines the amount of mutant TSHR or fragment thereof (or equivalent wild type protein) that retains the ability to bind an antibody or autoantibody to the TSHR at the test temperature. Preferably, the autoantibody used to test this binding ability of the mutant is M22, K1-70 or K1-18.

Any suitable binding assay which allows a determination of the half-life of the mutant TSHR or fragment thereof as described above may be used. For the purposes of the present invention, we have employed specific binding assays of this type and these are described fully below. These binding assays can in principle be employed to determine the thermostability of any mutant TSHR or fragment (whether full-length, TSHR260, or a sequence length shorter or longer than TSHR260).

For fragments of the TSHR, such as TSHR260 mutants, we have employed the thermostability protocol and TSHR260-binding assay described below to determine thermostability. Whilst the invention has been described primarily with respect to TSHR260 mutants, it will be understood that the thermostability protocol and binding assay can be used in the same way with other TSHR fragments of varying sequence lengths.

With respect to full-length TSHR and full-length mutants, we have employed a similar, but modified, binding assay as described under “Thermostability of full-length TSHR and mutants coated on 14C4-Fab₂ ELISA plates” and “Thermostability of full-length TSHR mutants” below. In this assay, the main difference is that the full-length sample is bound to the plate before heating to the test temperature.

TSHR260-Binding Assay

Maxisorp 96-well ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 14C4 Fab₂ (Jeffreys J et al (2002) Thyroid 12: 1051-1061 and Sanders J et al (2007) supra) in coating buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, 1.5 mM NaN₃, 0.01 g/L Phenol Red, pH9.2), incubated at room temperature for 3 h and then at 4° C. overnight. Wells were washed three times with wash buffer (50 mM NaCl; 20 mM Tris pH 7.8; 1% v/v Triton X-100) and 150 μL test sample (TSHR260-6His harvested from transiently transfected CHO-K1 cells) was applied to each well and incubated at room temperature for 1 h to allow the TSHR260 to bind to 14C4-Fab₂. The wells were then washed and incubated with 75 μL of assay buffer (50 mM NaCl, 20 mM Tris pH7.8, 1% v/v Triton X-100, 1 g/L BSA, 50 mg/L normal mouse IgG) and 75 μL of healthy blood donor serum pool (NPS) for 1 h at room temperature at 500 shakes per minute on an ELISA plate shaker. Thereafter the contents of the wells were emptied, the wells washed and 100 μL of M22 Fab-peroxidase conjugate (M22-POD, RSR Ltd, Cardiff, CF23 8HE, UK) added to each well. After 25 minutes incubation at room temperature without shaking the plate wells were washed again followed by addition of 100 μL of tetramethylbenzidine and a further incubation of 25 minutes at room temperature without shaking. The reaction was stopped by addition of 50 μL of 0.5 M H₂SO₄ and the absorbance of each well read at 450 nm on an ELISA plate reader (FIG. 12 a ).

Binding and Stability Screen

TSHR260-6His samples harvested from transiently transfected CHO-K1 cells were diluted 1/4 in CHO-K1 media ((−)DMEM, 10% FBS, 2× Glutathione, 1×Pen/Strep, 1×NEAA). For each sample, a 100 μL aliquot was heated at 42° C. for 30 min, while a second identical sample was kept on ice. Samples were then diluted 1/5 in TAT buffer (50 mM NaCl, 10 mM Tris pH7.8, 1% v/v Triton X-100, 1 g/L BSA, 0.2 g/L sodium azide) and 150 μL aliquots were applied in duplicate to the TSHR260-binding assay (FIG. 12 a ), which was performed as above. The amount of TSHR protein detected (see TSHR260 binding assay above) was expressed as i) a percentage of the TSHR260-WT standard and ii) the fraction of active TSHR protein remaining after heating. This was compared to the fraction of TSHR260-WT standard remaining after heating to give the mutant stability as a percentage of TSHR260-WT standard stability. Where the amount of active TSHR protein detected was too high or too low to be accurately determined, the binding assay was repeated at different dilutions of TSHR260 mutant.

Thermostability of TSHR260 Mutants

TSHR260 mutants transiently expressed in CHO-K1 cells and harvested from the supernatant as above, were diluted to 25% TSHR260-WT standard (see above) in CHO-K1 media. 100 μL aliquots were heated for between 0 and 30 days at 37° C. or between 0 and 3 hours at 42° C., 50° C., 55° C. or 60° C. Samples were then diluted 1/5 in TAT buffer (87.5 μL sample+350 μL TAT buffer) and 150 μL aliquots were applied in duplicate to the TSHR260-binding assay described above (FIG. 12 b ). Assay data were plotted against time and fitted to an exponential curve and the half-life (t_(1/2)) of the mutants calculated and compared to TSHR260-WT, TSHR260-I253R or TSHR260-JMG45 (defined in Table 5).

Dot Blot Assay to Determine the Total Amount (Active Plus Inactive) of TSHR Expressed

The expression levels of TSHR260 mutants were determined by Dot Blot assays using the Bio-Dot Microfiltration Apparatus (Bio-Rad Laboratories Ltd, Hemel Hempstead, HP2 7DX, UK). 50 μL aliquots of TSHR260-6His preparations harvested from transfected cell cultures as described above were applied to the Bio-Dot apparatus and allowed to enter the nitrocellulose membrane by gravity-flow. The samples were followed with 50 μL phosphate buffered saline (PBS, 8 g/L NaCl, 1.15 g/L disodium hydrogen phosphate, 0.2 g/L potassium dihydrogen phosphate, 0.2 g/L potassium chloride, pH7.4) by gravity flow. The samples on the membrane were then washed with 400 μL wash buffer (0.5% (v/v) Tween in PBS), applying vacuum to pull the wash buffer through the membrane. The membrane was then removed from the Bio-Dot apparatus and blocked by incubation with 0.1 mg/L polyvinyl acetate in PBS for 1 minute, with gentle shaking. The membrane was washed with wash buffer (3× three minutes, room temperature, with shaking) and incubated with the primary antibody, a TSHR monoclonal antibody, 18C5-IgG (0.01 mg/mL) or 8E2-IgG (0.02 mg/mL) (Jeffreys J et al (2002) supra) diluted in antibody buffer (180 g/L D-glucose, 10% (v/v) Foetal calf serum, 10% (v/v)˜87% glycerol, 0.5% (v/v) Tween in PBS) for 1 h with shaking at room temperature. The membrane was again washed with wash buffer (3× three minutes, room temperature, with shaking), after which it was incubated with a secondary antibody, Goat anti-mouse HRP (0.04 μg/mL, Sigma) in PBS for 1 hour with shaking at room temperature. After washing the membrane again with wash buffer (3× three minutes, room temperature, with shaking), the membrane was incubated with chemiluminesence substrate, Super Signal West Pico Stable Peroxide (ThermoScientific) and Super Signal West Pico Luminal Enhancer (ThermoScientific).

18C5-IgG and 8E2-IgG bind to linear epitopes of TSHR260 therefore their binding is not affected by unfolding of the TSHR protein. The 18C5-IgG recognises the linear epitope formed by TSHR residues 246-260, while the 8E2-IgG binds to a linear epitope on the N-terminus of TSHR260, residues 36-42. Using the two antibodies in combination enables the detection of TSHR260 on the blots irrespective of potential changes in TSHR protein folding following mutagenesis (i.e. detection of active plus inactive TSHR).

Thermostability of Full-Length TSHR and Mutants Coated on 14C4-Fab₂ ELISA Plates.

For testing ‘on-plate’ stability of full length wild type TSHR and mutated TSHR (JMG37, JMG45 and JMG52) 96-well Maxisorp ELISA plates (Nunc) were coated as follows. 14C4 Fab₂ was diluted to 1 μg/mL in coating buffer and 150 μL was aliquoted into each well of the 96-well ELISA plate. This was incubated for 3 h at room temperature followed by an overnight incubation at 4° C. ELISA plate wells were washed three times with wash buffer to remove any unbound antibody. Wild type and mutated TSHR samples were removed from −80° C., allowed to thaw at room temperature and placed on ice (0° C.). The TSHR samples were then diluted in TAT buffer. 150 μL of each dilution was pipetted into four ELISA plate wells and incubated overnight at 4° C. Plates were washed three times with wash buffer to remove any TSHR that had not bound to the 14C4 Fab₂. TAT buffer was added to each well (150 μL) and an adhesive plate cover was then applied to seal the wells. Each plate was then placed in an incubator set at 42° C. or 50° C. One strip (8 wells) of the 96-well plate was removed from each plate after 5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 minutes and inserted in to a spare ELISA plate rack, which was then kept on ice. After the 180-minute time course was complete the receptor dilution buffer was aspirated from the ELISA wells.

Assay buffer was then added to each well (75 μL) followed by healthy blood donor serum pool (75 μL) and incubated for 1 hour at room temperature (20-25° C.) at 500 shakes per minute on an ELISA plate shaker. Well contents were discarded and washed once with wash buffer and 100 μL of M22-POD (RSR Ltd) was added to each well. After a 25-minute incubation at room temperature without shaking, plate wells were washed twice with wash buffer then once with water. 100 μL tetramethylbenzidine was then added to each well and incubated for 25 minutes. The reaction was stopped with 50 μl 0.5 M H₂SO₄ and the absorbance of each well was read at 450 nm on an ELISA plate reader (Stability assay A, FIG. 14 b ).

M22-POD, K1-18-POD and K1-70-POD Binding to TSHR260 and Full-Length TSHR Mutants

Maxisorp ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 14C4 Fab₂ in coating buffer, incubated at room temperature for 3 hours and then at 4° C. overnight. TSHR260 mutants were diluted in CHO-K1 media and then diluted 1/5 in TAT buffer. Alternatively, full-length TSHR mutants were diluted in TAT buffer. Wells were washed and 150 μL TSHR260 or full-length TSHR test sample was applied to each well and incubated at room temperature for 1 hour to allow the TSHR260 or full-length TSHR to bind to 14C4-Fab₂. The wells were then washed and incubated with 75 μL of assay buffer and 75 μL of healthy blood donor serum for 1 hour at room temperature at 500 shakes per minute on an ELISA plate shaker. Thereafter the contents of the wells were emptied, the wells washed and incubated with 100 μL of M22-POD (RSR Ltd), K1-18 peroxidase conjugate (K1-18-POD; RSR Ltd) or K1-70 peroxidase conjugate (K1-70-POD; RSR Ltd) at a range of concentrations between 10 μg/mL and 1 ng/mL. After 25 minutes incubation at room temperature without shaking, the plate wells were washed again followed by addition of 100 μL of tetramethylbenzidine and a further incubation of 25 minutes at room temperature without shaking. The reaction was stopped by addition of 50 μL of 0.5 M H₂SO₄ and the absorbance of each well read at 450 nm on an ELISA plate reader. For non-specific binding, CHO-K1 media was diluted in TAT buffer and applied as negative controls to the wells as for the TSHR260 mutants or the full-length TSHR mutants and treated in the same way, including incubation with varying concentrations of M22-POD, K1-18 POD or K1-170 POD. GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA) was used to plot the binding curves for M22-POD, K1-18-POD and K1-70-POD, correcting for non-specific binding by subtracting the OD450 of the negative CHO-K1 controls from the OD450 of the TSHR260 or TSHR samples incubated with the matching concentrations of M22-POD, K1-18 POD or K1-70 POD. Non-linear regression (one-site specific binding saturation curve) was used to calculate the equilibrium binding constant (K_(d)), which is the concentration of ligand (M22-POD, K1-18-POD or K1-70-POD) at which half of the receptor (full length TSHR or TSHR260 mutants) is bound to ligand. K_(d) is equivalent to 1/K_(a), where K_(a) is the affinity constant (FIG. 12 a and FIG. 14 a ).

M22 IgG, K1-18IgG, K1-70IgG and TRAb Positive Patient Sera Inhibition of M22-POD Binding to TSHR260 Mutants in the TSHR260-Binding Assay.

ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 14C4 Fab₂ in coating buffer, incubated at room temperature for 3 h and then at 4° C. overnight. TSHR260-WT, TSHR-JMG37, TSHR-JMG45, TSHR-JMG52 and TSHR-JMG55 were diluted in media, followed by 1/5 dilution in TAT buffer. Wells were washed and 150 μL full length TSHR test sample was applied to each well and incubated at room temperature for 1 h to allow the TSHR260 to bind to 14C4-Fab₂. The wells were then washed and incubated with 75 μL of assay buffer and 75 μL of TRAb positive patient sera or M22 IgG, K1-18 IgG or K1-70 IgG diluted in NPS (1000 ng/mL to 0.1 ng/mL) for 1 h at room temperature at 500 shakes per minute on an ELISA plate shaker. Thereafter the contents of the wells were emptied, the wells washed and 100 μL of 89.5 ng/mL M22-POD (RSR Ltd) added to each well. After 25 minutes incubation at room temperature without shaking, the plate wells were washed again followed by addition of 100 μL of tetramethylbenzidine and a further incubation of 25 minutes at room temperature without shaking. The reaction was stopped by addition of 50 μL of 0.5 M H₂SO₄ and the absorbance of each well read at 450 nm on an ELISA plate reader (FIG. 12 c ).

M22IgG, K1-18 IgG, K1-70 IgG and TRAb Positive Patient Sera Inhibition of M22-POD Binding to Full-Length TSHR Mutants.

ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 14C4 Fab₂ in coating buffer, incubated at room temperature for 3 h and then at 4° C. overnight. Full-length TSHR-WT, TSHR-JMG37, TSHR-JMG45 and TSHR-JMG52 were diluted in TAT buffer. Wells were washed and 150 μL full length TSHR test sample was applied to each well and incubated at 4° C. overnight to allow the full-length TSHR mutants to bind to 14C4-Fab₂. The wells were then washed and incubated with 75 μL of assay buffer and 75 μL of TRAb positive patient sera or M22 IgG, K1-18 IgG or K1-70 IgG diluted in NPS (1000 ng/mL to 0.1 ng/mL) for 1 h at room temperature at 500 shakes per minute on an ELISA plate shaker. Thereafter the contents of the wells were emptied, the wells washed and 100 μL of 89.5 ng/mL M22-POD (RSR Ltd) added to each well. After 25 minutes incubation at room temperature without shaking, the plate wells were washed again followed by addition of 100 μL of tetramethylbenzidine and a further incubation of 25 minutes at room temperature without shaking. The reaction was stopped by addition of 50 μL of 0.5 M H₂SO₄ and the absorbance of each well read at 450 nm on an ELISA plate reader (FIG. 14 e ).

Analysis of TSHR Stimulation

Transfection of mutated TSHR constructs into Chinese hamster ovary (CHO) cells using the Flp-In system is described in WO2006/016121A.

The ability of TSH, monoclonal TRAbs (M22 and K1-18) and patient sera to stimulate production of cyclic AMP in CHO cells transfected with the human TSHR was tested as described in WO2004/050708A2. CHO cells expressing the TSHR mutants were seeded into 96-well plates at 2-3×10⁵ cells per well and grown for 48 hours until 100% confluent. The test samples (TSH, M22-Fab, K1-18 IgG or patient sera) were added (100 μL diluted in cyclic AMP assay buffer i.e. NaCl free Hank's Buffered Salts solution containing 1 g/L glucose, 20 mM HEPES, 222 mM sucrose, 15 g/L bovine serum albumin and 0.5 mM 3-isobutyl-1-methylxanthine, pH 7.4) and incubated for 1 hour at 37° C. After removal of test solutions, cells were lysed by incubation with 200 μL lysis buffer (0.37% HCl, 1% (v/v) Triton X-100) for 30 minutes with shaking at room temperature and cyclic AMP concentration in the lysates assayed using Direct cyclic AMP Elisa kits from Enzo Life Sciences. Results are expressed as pmol/mL of cyclic AMP in the cell lysate (200 μL). These experiments were compared to similar experiments carried out using CHO cells expressing wild type TSHR. Each assay was performed at least twice. GraphPad Prism was used to fit a dose-response curve to the TSH, M22 and K1-18 data using non-linear regression. This enabled calculation of the EC50 of each agonist (TSH or monoclonal TRAb), i.e. the concentration of agonist which gives a response halfway between the maximum and baseline cyclic AMP concentration.

Alignment of the Human TSHR Protein Sequence to TSHR Protein Sequences from Other Organisms and with the Human FSHR and the Human LHR Sequences

The protein sequences for TSHR from grivet monkey, rhesus monkey, porcine, bovine, cat, dog, mouse, rat, sheep and horse (FIG. 10 ; SEQ ID Nos 47-56) and the protein sequences from human FSHR (FIG. 11 ; SEQ ID No 57) and human LHR (FIG. 11 ; SEQ ID No 58) were obtained from the Uniprot database and aligned to the protein sequence of human TSHR (FIG. 2 ; SEQ ID No 2) using DNAStar MegAlign (v. 9.1, DNAStar, Madison, WI, USA).

Production of TSHR260-Alkaline Phosphatase (TSHR260-AP) Construct

One example of a labelled mutant according to the invention (TSHR260 comprising an alkaline phosphatase label) is described below, although it will be understood that different labels and different length mutant TSHRs (including full-length TSHR) may be used if desired. Other labels may, for example, be selected from the group consisting of enzymatic labels, isotopic labels, chemiluminescent labels, fluorescent labels and dyes, and such are known in the art. Such labels may be added in any suitable way, for example, via gene fusion using an appropriate construct (as described further below) or by chemical labelling. Those skilled in the art will be familiar with the relevant techniques needed for any particular label. Biotin labelling, involving any suitable biotinylation process, may be used.

The methods used to produce a TSHR260-alkaline phosphate (AP) construct have been described in WO2010/073012A2 to which reference can be made for further details.

The TSHR260 construct (coding amino acids 1-260 of the human TSHR; amino acids 1-21 being the leader sequence) (FIGS. 3 and 4 ; SEQ ID Nos 3 and 4 for the nucleotide and amino acid sequences respectively of the wild type TSHR260) was amplified using full-length human TSHR as the template (Oda Y, et al 1998. Journal of Molecular Endocrinology 20: 233-244) and joined to the coding sequence of a secreted alkaline phosphatase (excluding the 17 amino acid alkaline phosphatase leader sequence) using the cloning vector pSEAP2-basic (Clontech) as the template. Two PCR reactions were carried out, the first used the full-length TSHR amplified with specific primers (Primer 1—cactgcgaat tcaaaatgag gccggcggac ttgctg (SEQ ID No 7); Primer 2—gttctcctcc tcaactggga tgatgttaag agtccaggtg tttcttgc (SEQ ID No 8) (Sigma Genosys) which added an EcoRI restriction site at the N-terminus, and a 1 amino acid linker (Asparagine) and the first 8 amino acids (excluding the 17 amino acid leader sequence) of the secreted alkaline phosphatase at the C-terminus. The second PCR was carried out using the cloning vector pSEAP2-basic amplified with the primers (Primer 3—gcaagaaaca cctggactct taacatcatc ccagttgagg aggagaac (SEQ ID No 9); Primer 4—taatacgact cactataggg (SEQ ID No 10)) which adds amino acids 254-260 of the TSHR and a 1 amino acid linker (Asparagine) to the N-terminus of the secreted alkaline phosphatase and a 6 histidine tag, a stop codon and an XhoI restriction site at the C-terminus of the secreted alkaline phosphatase gene. The PCR reactions were carried out for 30 cycles of 1 minute at 94° C., 1 minute at 40° C. and 1 minute at 72° C. followed by 7 minutes at 72° C. The PCR products were run on 1% agarose gels and the DNA extracted using a Geneclean II kit (Anachem Ltd, Luton) following the manufacturer's instructions. Purified PCR products 1 and 2 were then used to set up a third PCR to construct the whole TSHR260-alkaline phosphatase gene. The PCR 3 reaction contained 200 ng of PCR 1 product and 200 ng of PCR 2 product and PCR 3 was carried out for 7 cycles at 94° C. for 1.5 minutes, 65° C. for 1.5 minutes and 72° C. for 1.5 minutes. The temperature was then increased to 94° C. again for 2 minutes and primer 1 and primer 4 added followed by 30 cycles of 94° C. for 1 minute, 52° C. for 1 minute and 72° C. for 2 minutes. The PCR 3 product was cloned into pFastBac1 using EcoRI and XhoI restriction sites and the presence of the mutation was verified using sequencing by the Sanger-Coulson method (Sanger F et al 1997. Proceedings of the National Academy of Sciences of the USA 74: 5463-5467). Recombinant DNA was made using the Bac to Bac Baculovirus expression system (Invitrogen, UK) and transfected into Sf-9 cells to obtain and amplify recombinant baculovirus stock as described in WO2008/025991A1. TSHR260-AP was expressed in insect cells as described in WO2008/025991A1.

Production of TSHR260-AP Construct Containing Stabilising Amino Acid Mutations

The methods used to introduce specific mutations into the TSHR sequence of the TSHR260-AP construct (FIGS. 15 and 16 ; SEQ ID Nos 59 and 60) are as described above for the TSHR260 mutations. TSHR mutations (FIGS. 5 and 6 ; SEQ ID Nos 14, 16, 18, 19, 20, 23, 27, 32, 34, 36, 37, 38, 41 and 45) were introduced sequentially into the TSHR260-AP construct resulting in eight separate constructs (TSHR260-AP-I253R, TSHR260-AP-JMG22, TSHR260-AP-JMG37, TSHR260-AP-JMG45, TSHR260-AP-JMG52, TSHR260-AP-JMG55, TSHR-AP-JMG57 and TSHR260-AP-JMG58) detailed below. Amino acid residue numbering refers to the position that the amino acid is found in the native wild type TSHR sequence:

-   -   TSHR260-AP-I253R=TSHR260-AP+I253R (FIGS. 5 and 6 ; SEQ ID Nos 27         and 45)     -   TSHR260-AP-JMG22=TSHR260-AP+D143P+I253R (FIGS. 5 and 6 ; SEQ ID         Nos 18, 27, 36 and 45)     -   TSHR260-AP-JMG37=TSHR260-AP+R112P+D143P+I253R (FIGS. 5 and 6 ;         SEQ ID Nos 16, 18, 27, 34, 36 and 45)     -   TSHR260-AP-JMG45=TSHR260-AP+R112P+D143P+D151E+I253R (FIGS. 5 and         6 ; SEQ ID Nos 16, 18, 19, 27, 34, 36, 37 and 45)     -   TSHR260-AP-JMG52=TSHR260-AP+R112P+D143P+D151E+V169R+I253R (FIGS.         5 and 6 ; SEQ ID Nos 16, 18, 19, 23, 27, 34, 36, 37, 41 and 45)     -   TSHR260-AP-JMG55=TSHR260-AP+H63C+R112P+D143P+D151E+V169R+I253R         (FIGS. 5 and 6 ; SEQ ID Nos 14, 16, 18, 19, 23, 27, 32, 34, 36,         37, 41 and 45)     -   TSHR260-AP-JMG57=TSHR260-AP+H63C+R112P+D143P+V169R+I253R (FIGS.         5 and 6 ; SEQ ID Nos 14, 16, 18, 23, 27, 32, 34, 36, 41 and 45)     -   TSHR260-AP-JMG58=TSHR260-AP+H63C+R112P+D143P+S166T+I253R (FIGS.         5 and 6 ; SEQ ID Nos 14, 16, 18, 20, 27, 32, 34, 36, 38 and 45).

Antibodies Used in the TSHR260-AP Bridge ELISA

4E31

The 4E31 antibody is a mouse monoclonal antibody to residues 603-764 of the C-terminus of the TSHR (C-TSHR) which can be used to immobilise the full-length TSHR onto ELISA plate wells (EP 1021721B1, Bolton et al., (1999) supra). For the immunisation of mice, C-TSHR was expressed in Escherichia coli as a fusion protein with glutathione S-transferase (GST) using standard protocols (Oda Y et al., (1998) supra). The 3′ end of cDNA (1809 to 2295 bp) coding for the last 162 amino acids was cloned in frame with the GST fusion protein in pGEX2T vector (Pharmacia Biotech, St. Albans ALI 3AW UK). An overnight culture of E. coli (strain UT580) transformed with pGEX-2T/C-TSHR plasmid was diluted 1/5 into 2×YTG medium (16 g/L Tryptone, 10 g/L yeast extract, 5 g/L NaCl, 20 g/L glucose, pH 7.0), incubated for 3 hours at 30° C. Thereafter, isopropyl-3-D-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM in order to induce C-TSHR/GST fusion protein expression, followed by incubation for a further three hours. The bacterial pellets were resuspended in PBS (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na₂HPO₄, 0.24 g/L KH₂PO₄ pH 7.4) containing 1% (v/v) Triton X-100 and sonicated three times for one minute on ice. The inclusion bodies were pelleted, washed in 4M urea, solubilised in 8M urea and separated on 9% polyacrylamide gels (SDS-polyacrylamide electrophoresis, SDS-PAGE) under reducing conditions. The C-TSHR/GST fusion protein (MW 44 kDa) was electroeluted from polyacrylamide gel slices in 0.1 M NaHCO₃ and 0.1% SDS pH 7.8, dialysed against 50 mM Tris-HCl pH 8.0 and stored in aliquots at −70° C.

The 4E31 antibody was prepared by immunisation with electroeluted C-TSHR/GST fusion protein. Briefly, BALB C mice were immunised with 50 μg C-TSHR/GST per mouse per injection until the titre of TSHR antibody was high. The mouse bleeds were tested using an immunoprecipitation assay based on ³⁵S-labelled TSHR produced in an in vitro transcription/translation system (Prentice et al., (1997) Journal of Clinical Endocrinology and Metabolism, 84:1288-1292). Mouse spleen cells were fused with mouse myeloma cell line (X63 Ag8.653; ECACC Porton Down, UK) and cloned to produce a stable hybridoma secreting the monoclonal antibody using standard techniques (Oda et al., (1998) supra). 4E31 is available for purchase from RSR Ltd, Cardiff, UK (supra).

K1-70

K1-70 is a blocking type human monoclonal autoantibody to the TSHR which was obtained from the peripheral blood lymphocytes of a patient with hypothyroidism (Evans et al, (2010) Clinical Endocrinology 73: 404-412; EP2367850). Briefly, lymphocytes were isolated from 20 mL of peripheral blood of a 54 year old patient with hypothyroidism and high levels of TSHR antibodies. The lymphocytes were infected with Epstein Barr virus and fused with a mouse/human hybrid cell line (K6H6/B5; ECACC, Porton Down, UK) using standard techniques (Hayakawa N et al., (2002) supra). The cells were plated out in 48-well plates and the supernatants screened using an assay based on inhibition of ¹²⁵I-TSH binding to TSHR coated tubes (assay kit available from RSR Ltd, Cardiff, UK). Positive wells were then recloned by limiting dilution until a single colony producing high concentrations of TSHR autoantibody K1-70 was isolated. K1-70 is available for purchase from RSR Ltd, Cardiff, UK (supra)

M22

As detailed above in “Antibodies used in TSHR260 binding assay”

Bridge ELISA Based on TSHR260-AP

A bridge ELISA was used based on the method described previously (FIG. 13 a , Rees Smith, B et al (2009) supra, WO2010/073012A2). This ELISA was based on the ability of divalent TSHR antibodies to bind with one antigen binding site to TSHR coated onto an ELISA plate well and with the other antigen binding site to TSHR260-AP in liquid phase i.e. forming a bridge. TSHR in the form of full-length detergent-solubilised receptor expressed in CHO cells was coated onto ELISA plate wells via 4E31, a C-terminal antibody as described previously (Bolton, J et al (1999) supra). In the assay 75 μL of start buffer (50 mM NaCl; 20 mM Tris pH 7.8; 1 g/L BSA; 50 mg/L normal mouse IgG; 1% Triton X-100 pH 7.8) and 75 μL of test sample (patient sera or monoclonal antibodies diluted in a pool of healthy blood donor serum or diluted in assay buffer [50 mM NaCl, 20 mM Tris pH 7.8, 1% Triton X-100, 1 g/L BSA]) were added to the ELISA plate wells coated with the full-length detergent solubilised TSHR and incubated for 2 hours at room temperature with shaking (500 rpm). Then the contents of the wells were removed, the wells washed 3 times with wash buffer (50 mM NaCl, 20 mM Tris pH 7.8, 1% Triton X-100) followed by addition of 100 μL of TSHR260-AP (diluted in wash buffer containing 0.2 g/L MgCl₂-6H₂O and 2 g/L BSA). After incubation for 1 hour at room temperature with shaking (500 rpm) the wells were emptied, washed (3 times) and 100 μL of p-nitrophenyl phosphate (pNpp) substrate (Europa Bioproducts Ltd, Ely, Cambridge UK) added and the plate incubated in the dark for 45 minutes. Thereafter 100 μL of stop solution (1 M NaOH) was added and the absorbance read at 405 nm in an ELISA plate reader. The results were expressed as OD_(450 nm) absorbance values and concentration of TRAb in each sample calculated using a standard curve prepared with the human monoclonal TSHR autoantibody K1-70.

Thermostability of TSHR260-AP Mutants

TSHR260-AP mutants (see “Production of TSHR260-AP construct containing stabilising amino acid mutations” for SEQ ID Nos) expressed in insect cells and harvested from the supernatant as above, were diluted in wash buffer containing 0.2 g/L MgCl₂-6H₂O and 2 g/L BSA to give an appropriate absorbance in the TSHR260-AP bridge ELISA (FIG. 13 b ). 150 μL aliquots were heated for between 0 and 3 hours at 50° C., 60° C. or 65° C. 100 μL of sample was applied in duplicate to the TSHR260-AP bridge ELISA described above (FIG. 13 b ). Assay data were plotted against time and fitted to an exponential curve and half-life (t_(1/2)) of the mutants calculated and compared to TSHR260-AP WT (FIGS. 15 and 16 ; SEQ ID Nos 59 and 60), TSHR260-AP-JMG22 or TSHR260-AP-JMG45 (defined above in “Production of TSHR260-AP construct containing stabilising amino acid mutations”).

TSHR260 Bridge Inhibition ELISA

The TSHR260 bridge ELISA described above can be modified to form an inhibition ELISA for the detection of uncomplexed TSHR260 and TSHR260-Mab complexes (FIG. 13 c ). In the assay 75 μL of start buffer (as described for TRAb ELISA; Bolton J, et al (1999) supra) and 75 μL of 1 μg/mL M22 IgG or 1 μg/mL K1-70 IgG were added to the ELISA plate wells coated with full-length detergent-solubilised TSHR and incubated for 30 minutes at room temperature with shaking (500 rpm). Then the contents of the wells were removed, the wells washed with wash buffer (50 mM NaCl, 20 mM Tris pH 7.8, 1% Triton X-100) followed by addition of 100 μL of test sample (i.e. unlabelled TSHR260 or TSHR260-Mab complexes) per well. After incubation for 1 hour at room temperature with shaking (500 rpm) the contents of the wells were removed and the wells washed with wash buffer and 100 μL of TSHR260-AP (diluted in wash buffer containing 0.2 g/L MgCl₂-6H₂O and 2 g/L BSA) was added. After incubation for 30 minutes at room temperature with shaking (500 rpm) the wells were emptied, washed (3 times) and 100 μL of p-nitrophenyl phosphate (pNpp) substrate (Europa Bioproducts Ltd, Ely, Cambridge UK) added and the plate incubated for 45 minutes. Thereafter 50 μL of stop solution (1 M NaOH) was added and the absorbance read at 405 nm in an ELISA plate reader. The inhibition of labelled TSHR260 (i.e. TSHR260-AP) binding by test sample containing unlabelled TSHR260 was expressed as: 100× (1-ratio of absorbance 405 nm of test sample to absorbance 405 nm of buffer alone).

For ease of comparison of the TSHR260 activity in the different volumes of the initial starting material and the eluted TSHR260 pools after purification on either anion or cation exchange chromatography the activity of each test sample was expressed as a dilution factor relative to the undiluted elution material.

Production of Monoclonal Antibodies to the Convex Surface of Human TSHR

The 2H11, 25E1, 23H4, 9B7 and 36F11 TSHR mouse monoclonal antibodies to the convex surface of the TSHR used in the partial purification of TSHR260 were prepared by cDNA immunisation. Briefly, six- to eight-week old OF1 (out bred) mice were injected intramuscularly with 100 μl of 10 □M cardiotoxin five days before intramuscular immunisation with 100 μg of full-length TSHR cDNA (pRC/CMVhTSHR; Oda et al (1998) supra). TSHR DNA immunisation was repeated at three week intervals for a total of five injections (Hasan et al (1999) J. Immunol. Methods 229:1-22). The mouse bleeds were tested for the presence of antibodies to the convex surface of the TSHR by inhibition of Biotin-labelled 14C4 IgG binding to the TSHR (assay manufactured by RSR Ltd, Cardiff, UK). Monoclonal antibodies were produced using the spleen cells from the mouse with the highest TSHR antibody titres in the serum. Isolated spleen cells were fused with a mouse myeloma cell line (Sp2/O-Ag14) using standard procedures (de St Groth, S. F., & Scheidegger, D. (1980). Journal of Immunological Methods 35, 1-21.). Cells were cultured in DMEM (supplemented with 15% foetal calf serum containing HAT to select for hybrids) and plated into 96-well plates. To obtain antibodies to the convex surface of the TSHR, supernatants from the cell cultures were screened by inhibition of Biotin labelled 14C4 IgG binding to the TSHR coated onto ELISA plate wells. In these assays the full-length TSHR is bound to an ELISA plate well using 4E31 (an antibody to the C terminus of the TSHR), the TSHR antibodies in the culture supernatant bind to the immobilised TSHR and wells that contain antibodies to the convex surface of the TSHR (i.e. overlapping with the 14C4 binding site) inhibit binding of biotin labelled 14C4 to the TSHR. The cells from the positive wells were recloned two times by limiting dilution to obtain clones expressing the required monoclonal antibody.

Preparation of TSHR260 and TSHR260-JMG55

High-Five™ insect cells (BTI-TN-5B1-4 from Invitrogen) were maintained in Insect Xpress media (Lonza). 2 L or 0.2 L shake-flasks were seeded at a cell density of approximately 1.00×10⁶ cells/mL and incubated overnight at 27° C. at 110 rpm (after which time the temperature was reduced to 23° C.). Cells were infected using the Bac to Bac system (Invitrogen) with baculovirus stock at a multiplicity of infection (MOI) of 0.012 pfu/mL. Culture supernatants containing either TSHR260 (FIG. 4 ; SEQ ID No 4) or TSHR260-JMG55 were harvested 120 hours post infection by centrifugation at 500 g for 10 minutes at 4° C. One tablet of Complete protease inhibitors (Roche Diagnostics, Lewes, UK) was added per 200 mL of supernatant, before storing at −70° C. until purification.

Preparation of TSHR260 in the Presence of Different Monoclonal Antibodies

High-Five™ insect cells were cultured and infected as above for TSHR260 except that 2 mg/L of TSHR monoclonal antibody (14C4, 2H11, 25E1, 36F11, 9B7 or 23H4 IgG) was added to the culture media after approximately 96 hours. Culture supernatants containing TSHR260-TSHR Mab complexes were harvested 120 hours post infection by centrifugation at 500 g for 10 minutes at 4° C. One tablet of Complete protease inhibitors (Roche Diagnostics, Lewes, UK) was added per 200 mL of supernatant, before storing at −70° C. until purification by either anion or cation exchange chromatography depending on the PI of the individual complex.

Purification of TSHR260

Culture supernatant containing TSHR260 (100 mL) was diluted 1:1 with HPLC grade water and adjusted to pH 9.0 using 2M Tris and loaded onto 15 mL of Streamline DEAE matrix for purification by anion exchange chromatography. The column was washed with 10 mM Tris-HCl (pH 9.0), 50 mM NaCl, followed by elution with 500 mM NaCl and 10 mM Tris-HCl (pH 9.0). The eluted material was dialysed into 50 mM NaCl, 10 mM Tris-HCl pH 8.0. The presence of the TSHR260 in the elution fractions was confirmed by Western blotting analysis using a mouse monoclonal antibody (10 μg/mL) reactive with a TSHR epitope within amino acids 246-260 (TSHR MAb 18C5, Jeffreys J et al (2002) supra) and the activity measured in the TSHR260 bridge inhibition ELISA (FIG. 13 c ).

Purification of TSHR260 in the Presence of 14C4, 2H11, 25E1, 23H4, 36F11 or 9B7 TSHR Monoclonal Antibodies

Culture supernatant containing TSHR260-14C4-IgG complex (200 mL) was diluted 1:1 with HPLC grade water, adjusted to pH 9.0 using 2M Tris and loaded onto 15 mL of Streamline DEAE matrix and purified by anion exchange chromatography as above for uncomplexed TSHR260.

Culture supernatant containing TSHR260-2H11-IgG, TSHR260-25E1-IgG, TSHR260-23H4-IgG, TSHR260-36F11-IgG or TSHR260-9B7-IgG complex (600 mL) was adjusted to pH 6.3 with 500 mM NaH₂PO₄ and loaded onto 10 mL of Streamline Direct HST matrix for purification by cation exchange chromatography. The column was washed with 50 mM NaH₂PO₄ (pH 6.0), 50 mM NaCl followed by 50 mM NaH₂PO₄ (pH 7.0), 50 mM NaCl then eluted in 50 mM NaH₂PO₄ (pH 8.0), 50 mM NaCl. The presence of TSHR260 in the elution fractions was confirmed by Western blotting analysis using a mouse monoclonal antibody 18C5 (10 μg/mL) reactive with a TSHR epitope within amino acids 246-260 (TSHR-MAb 18C5, Jeffreys J et al (2002) supra) and the activity measured in the TSHR260 bridge inhibition ELISA (FIG. 13 c ).

Purification of TSHR260-JMG55

An equivalent purification to that described below may be used for other mutants according to the invention. TSHR260-JMG55 was purified by three rounds of column chromatography using: a) Cation exchange chromatography on Streamline Direct HST matrix; b) Monoclonal antibody affinity chromatography on 14C4 coupled to sepharose and c) Nickel-affinity chromatography. Culture supernatant containing TSHR260-JMG55 (12 L) was adjusted to pH 6.0 with 500 mM sodium phosphate (NaH₂PO₄). Tween 80 was added to a final concentration of 0.015% v/v and the culture supernatant was loaded onto 75 mL of Streamline Direct HST matrix in a Streamline 25 expanded bed chromatography system (GE Healthcare). Two further batches of 12 L were processed in the same way in separate experiments.

The column was washed with 50 mM NaH₂PO₄ (pH 6.0), 50 mM NaCl containing 0.015% v/v Tween 80, followed by 100 mM NaCl, 50 mM Tris-HCl (pH 7.0) containing 0.015% v/v Tween 80 then eluted with 100 mM NaCl, 50 mM Tris-HCl (pH 8.0) containing 0.015% v/v Tween 80. The presence of the TSHR260-JMG55 in the elution fractions was confirmed by Western blotting analysis using a mouse monoclonal antibody 8E2 (10 g/mL) reactive with a TSHR epitope within amino acids 36-42 (TSHR-MAb 8E2, Jeffreys J et al (2002) supra) and the activity measured in the TSHR260-binding assay (FIG. 12 a ). Samples were also analysed in the TSHR260 bridge inhibition ELISA for comparison with the streamline purifications of the TSHR260 and TSHR260-IgG complexes (FIG. 13 c ).

TSHR260-JMG55 was purified further by affinity chromatography using a mouse monoclonal antibody 14C4 that binds to a conformational epitope within amino acids 22-261 of the TSHR extracellular domain (Jeffreys J et al (2002) supra), coupled to CNBr-activated sepharose 4B (Sigma). In particular, TSHR260-JMG55 pooled from the three Streamline column elutions was loaded onto a 7 mL 14C4-affinity column, washed with 100 mM NaCl, 50 mM Tris-HCL (pH 8.0) containing 0.015% v/v Tween 80. The 14C4-affinity column was sequentially eluted with elution buffer (100 mM NaCl, 100 mM citrate, 0.015% v/v Tween 80) at pH 5.0 followed by elution buffer at pH 4.5. Elution fractions were collected into an equal volume of neutralisation buffer (0.5 mM Tris-HCl, pH 8.0, 0.015% v/v Tween 80) followed by dialysis into 100 mM NaCl, 50 mM Tris-HCl, pH 8.0 containing 0.015% v/v Tween 80. Fractions eluted at pH 5.0 (TSHR260-JMG55-5.0) and fractions eluted at pH 4.5 (TSHR260-JMG55-4.5) were pooled and dialysed separately. The presence of the TSHR260-JMG55 in the elution fractions was confirmed by Western blotting analysis using a mouse monoclonal antibody 8E2 (10 g/mL) and the activity measured using the TSHR260-binding assay (FIG. 12 a ).

Dialysed TSHR260-JMG55-4.5 was further purified using nickel-affinity chromatography. The TSHR260-JMG55 was adjusted to a final concentration of 10 mM imidazole, pH 8.0 and loaded onto a NiNTA-HiTrap 1 mL Immobilised Metal Affinity Column (IMAC) HP column (GE Healthcare) using an Äkta 10 platform (GE Healthcare), washed with 10 mM imidazole (pH 8.0) in wash buffer (100 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.015% v/v Tween 80) and eluted with 150 mM imidazole (pH 8.0) in wash buffer. The eluted TSHR260-JMG55-4.5 was pooled and dialysed into 100 mM NaCl, 50 mM Tris-HCL (pH 8.0) containing 0.015% v/v Tween 80 and stored at −70° C. The presence of TSHR260-JMG55 in the elution fractions was confirmed by Western blotting analysis using a mouse monoclonal antibody 8E2 (10 g/mL) and the activity analysed in the TSHR260-binding assay (FIG. 12 a ). The concentration of purified TSHR260-JMG55-4.5 was calculated from the absorbance at 280 nm on the basis that 1 absorbance unit is equivalent to 1.43 mg/mL of TSHR260-JMG55 (this extinction coefficient was obtained using DNASTAR Protean V.9.1.0). The concentration was confirmed by densitometric analysis using Image Lab software (Bio-Rad) of material run on a 12% non-reduced SDS-PAGE gel stained with SimplyBlue SafeStain (Invitrogen).

Dialysed TSHR260-JMG55-5.0 was also further purified using IMAC nickel-affinity chromatography. The TSHR260-JMG55-5.0 was loaded onto a NiNTA HiTrap column (GE Healthcare) using an Äkta 10 platform (GE Healthcare), washed with wash buffer then eluted with 150 mM imidazole (pH 8.0) in wash buffer. The eluted TSHR260 JMG55-5.0 was then dialysed into 100 mM NaCl, 50 mM Tris-HCL (pH 8.0) and 0.015% v/v Tween 80. The presence of the TSHR260-JMG55 in the elution fractions was confirmed by Western blotting analysis using a mouse monoclonal antibody 8E2 (10 g/mL) and the activity analysed in the TSHR260-binding assay (FIG. 12 a ). The concentration of purified TSHR260-JMG55-5.0 was calculated from the absorbance at 280 nm on the basis that 1 absorbance unit is equivalent to 1.43 mg/mL of TSHR260-JMG55 (this extinction coefficient was obtained using DNASTAR Protean V.9.1.0). The concentration was confirmed by densitometric analysis using Image Lab software (Bio-Rad) of material run on a 12% non-reduced SDS-PAGE gel stained with SimplyBlue SafeStain (Invitrogen).

TSHR260-JMG55-4.5 Coated ELISA Plate Well Assay

Maxisorp 96-well ELISA plate (Nunc) wells were coated with 150 μL aliquots of 4 μg/mL or 0.4 μg/mL purified JMG55-TSHR260-4.5 in coating buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, 1.5 mM NaN₃, 0.01 g/L Phenol Red, pH9.2 containing 5 μg/mL BSA), and incubated at 4° C. overnight. Wells were washed three times with wash buffer (50 mM NaCl; 20 mM Tris pH 7.8; 1% v/v Triton X-100) followed by 1 hour incubation with 250 μL post-coat buffer (154 mM NaCl, 58 mM sucrose, 3 g/L BSA, 0.2 g/L sodium azide). Wells were washed three times with wash buffer, and incubated with 75 μL of assay buffer (50 mM NaCl, 20 mM Tris pH7.8, 1% v/v Triton X-100, 1 g/L BSA) and 75 μL of healthy blood donor serum pool (NPS) for 1 h at room temperature at 500 shakes per minute on an ELISA plate shaker. Thereafter the contents of the wells were emptied, the wells washed and 100 μL of either M22 Fab-peroxidase conjugate (M22-POD, RSR Ltd, Cardiff, CF23 8HE, UK), K1-70 IgG-peroxidase conjugate (K1-70-POD) or K1-18 IgG-peroxidase conjugate (K1-18-POD) at a range of concentrations (0.25 to 7.5 μg/mL) added to each well. After 25 minutes incubation at room temperature without shaking, the plate wells were washed again followed by addition of 100 μL of tetramethylbenzidine and a further incubation of 25 minutes at room temperature without shaking. The reaction was stopped by addition of 50 μL of 0.5 M H₂SO₄ and the absorbance of each well read at 450 nm on an ELISA plate reader (FIG. 12 d ).

Deglycosylation of TSHR260-JMG55-4.5

Deglycosylation may be applied as described below to other mutants according to the invention. Deglycosylation reactions were performed using Endoglycosidase F3 (Endo F3, Sigma) and 5 g of TSHR260-JMG55-4.5 at 0 mU/mg, 40 mU/mg, 60 mU/mg and 80 mU/mg (Endo F3:TSHR260-JMG55-4.5 ratio) in 50 mM sodium acetate buffer (pH 4.5) at 20° C. for 24 h, 72 h and 120 h. The reactions were analysed on 12% non-reduced SDS-PAGE by staining with SimplyBlue SafeStain (Invitrogen) and western blotting using the TSHR mouse monoclonal antibody 8E2. Any change in the molecular weight of the TSHR260-JMG55-4.5 was determined using Mark12 molecular weight markers (Invitrogen). The activity of TSHR260-JMG55-4.5 was determined by TSHR260-binding assay (FIG. 12 a ) after deglycosylation.

Introduction of Specific Amino Acid Mutations into Full-Length Mouse and Porcine TSHR Sequences Using PCR

The porcine TSHR full-length nucleotide sequence (FIG. 17 ; SEQ ID No 61) was cloned from a porcine thyroid cDNA library (EP 1021721B1). Briefly total RNA was prepared from 2.5 g of porcine thyroid tissue using the acid phenol guanidine method (P Chomczynski, N Sacchi; Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction; Analytical Biochemistry 1987; 162: 156-159). mRNA was prepared using a Dynal bead mRNA purification kit (Dynal Biotec Ltd; Wirral, CH62 3QL, UK). This mRNA was used to make a cDNA library using ZapExpress cDNA Gigapack Cloning Kit III (Stratagene Ltd., Cambridge CB4 4DF UK). Four degenerate oligonucleotides were made to known TSHR sequences (mouse, rat, human, dog and bovine) and two fragments of porcine TSHR amplified using PCR. These were sequenced to verify their homology with TSHR cDNA and used to screen the cDNA library for full-length porcine TSHR clones. Three full-length clones were obtained and fully sequenced. The coding sequence of the porcine TSHR cDNA was cloned into the BamHI and NotI restriction sites of the pcDNA5.1/FRT vector (Invitrogen) using standard cloning procedures. Amino acid sequence see FIG. 18 (SEQ ID No 62).

The mouse TSHR full-length nucleotide sequence (FIG. 19 ; SEQ ID No 63) was synthesised with a BamHI restriction site at the 5′ terminus and a NotI restriction site at the 3′ terminus (Geneart, Life Technologies, Paisley, UK) and cloned into pcDNA5.1/FRT vector (Invitrogen) using standard cloning procedures. Amino acid sequence see FIG. 20 (SEQ ID No 64).

Mutations in full-length mouse and porcine TSHR sequences were generated by site-directed mutagenesis using PCR with QuikChange II methodology as described for human TSHR260 above. See FIGS. 21 and 22 (SEQ ID Nos 65 and 66) for the nucleotide and amino acid sequences, respectively of mutated porcine TSHR and FIGS. 23 and 24 (SEQ ID Nos 67 and 68) for the nucleotide and amino acid sequences, respectively of mutated mouse TSHR. See Table 54 for the JMG55 equivalent amino acid mutations in the porcine and mouse TSHRs.

Stable transfections of the full-length TSHR constructs into Flp-In CHO cells were carried out as detailed above in “Transfection of full-length TSHR constructs into CHO cells using the Flp-In system”.

Thermostability of Full-Length Mouse and Porcine TSHR (Wild Type and Mutants)

The thermostability of full-length mouse and porcine TSHR wild type and mutants was tested in stability assay B (FIG. 14 c ), involving TSHR bound to 4E31-coated plates heated at 55° C., as described below in “Thermostability of full-length TSHR mutants” (FIG. 14 c ).

Analysis of Mouse and Porcine Wild Type and Mutated TSHR in Response to Stimulation by TSH and by M22

Transfection of wild type and mutated TSHR constructs into Chinese hamster ovary (CHO) cells using the Flp-In system is described in WO2006/016121A.

The ability of TSH and the thyroid stimulating monoclonal antibody M22 to stimulate production of cyclic AMP in CHO cells expressing the wild type and mutated mouse and porcine TSHR was tested as described above in “Analysis of TSHR stimulation” for the human TSHR.

Preparation of Detergent Solubilised Full-Length Wild Type and Mutated TSHR

CHO cells expressing full-length wild type or mutated TSHR (human, porcine or mouse) were grown to confluence, detached from 175 cm² cell culture flasks and the cell pellet washed with 50 mM NaCl, 10 mM Tris-HCl, pH7.5 containing 1 mM phenylmethylsulfonylfluoride (PMSF), then homogenised in the same buffer. The cell membranes after centrifugation at 12000 g for 30 min at 4° C. were solubilised in the same buffer (4 mL of buffer for approximately 4×10⁸ cells) as used for homogenisation except for addition of 1% Triton X-100. The solubilised receptor preparations were centrifuged at 90000 g for two hours at 4° C. and the supernatant stored at −70° C.

Analysis of TSH Binding to Full-Length Wild Type and Mutated TSHR

Maxisorp assay tubes (Nunc) were coated with 200 μL aliquots of 10 μg/mL 4E31-Fab₂ in coating buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, 1.5 mM NaN₃, 0.01 g/L Phenol Red, pH 9.2), incubated at 37° C. for 90 min and then overnight at 4° C. Wells were washed 3 times with assay buffer (50 mM NaCl; 20 mM Tris-HCl pH 7.8, 1% Triton-X-100). Full-length TSHR preparations were diluted in assay buffer and 200 μL aliquots incubated in the 4E31-coated tubes overnight at 4° C. Wells were washed 3 times with assay buffer. Unlabelled TSH in 50 μL in assay buffer, 50 μL of ¹²⁵I-labelled TSH (30,000 cpm in assay buffer) and 50 μL of start buffer (50 mM NaCl; 20 mM Tris-HCl pH 7.8, 1% Triton-X-100, 1 g/L BSA, 50 mg/L normal mouse IgG) were applied to the coated tubes and incubated for 2 hours at room temperature with gentle shaking, washed twice with 1 mL of assay buffer and counted in a gamma counter. The concentration of TSH bound vs. bound/free was plotted (G Scatchard (1949) Annals of the New York Academy of Sciences 51: 660-672) to derive the association constants.

Thermostabilising Mutations in the TMD of the TSHR-JMG55

Further to the thermostabilising mutations identified in the LRD of the TSHR, the sequence of the TMD of TSHR-JMG55 was examined to determine whether further thermostabilising mutations may be identified in this domain of the TSHR. Three principles were used to predict possible thermostabilising mutations in the TMD of the TSHR: i) the consensus sequence of TSHR homologues in other organisms was used to identify possible thermostabilising mutations; ii) mutations that cause lower basal cAMP signalling activity of TSHR (retrieved from the SSFA database (www.ssfa-gphr.de); Kreuchwig A et al (2013) Mol Endocrinol. 8: 1357-63) were examined as these may stabilise the inactive conformation of TSHR which, for GPCRs, is more thermostable than the active conformation; and iii) mutations that have been identified as thermostabilising in other GPCRs, namely β₁-adrenoceptor (β₁AR, Serrano-Vega et al (2008) PNAS 105: 877-82; Miller J L and Tate C G (2011) J. Mol. Bio. 413: 628-38), A2A adenosine receptor (A_(2A)R; Doré A S et al (2011) Structure 19: 1283-93), NTS₁ neurotensin receptor (NTS₁R; Egloff P et al (2014) PNAS 111: E655-62; Shibata Y et al (2009) J. Mol. Bio. 390: 262-277) and corticotrophin-releasing factor receptor-1 (CRF₁R; Hollenstein K et al (2013) Nature 499: 438-443), were transferred to TSHR. In total 56 possible thermostabilising mutations were identified: 10 TSHR consensus mutations, 19 TSHR inactivating mutations, 26 GPCR thermostabilising mutations and one mutation, Y601A, that is both inactivating in TSHR and thermostabilising in the β₁-adrenoceptor (Table 59).

The TSHR-JMG55 full-length nucleotide sequence was cloned into pcDNA3.1(+) vector (Invitrogen) using BamHI and XhoI restriction sites following standard cloning procedures. Mutations in the full-length TSHR-JMG55 sequence were generated by site directed mutagenesis using PCR with the QuikChange II methodology as described above for the TSHR260 mutations. The PCR reaction was transformed, expanded and the mutations verified by sequencing as described above for TSHR260 PCR products. Larger quantities of plasmid DNA were obtained by growing 50 mL cultures in LB media with ampicillin (100 μg/mL). Plasmid DNA was extracted from the cell pellet of the overnight cultures using the Qiagen Plasmid Plus Midi Kit (Qiagen Ltd, Manchester, M15 6SH, UK).

Transient Transfections of Full-Length TSHR Mutants into CHO-KJ Cells Using Freestyle Max Reagent

One day prior to transfection, 2.2×10⁵ CHO-K1 cells/well were plated out into 90 mm cell culture dishes (Nunc). For each 90 mm dish to be transfected, 30 μg TSHR-JMG55 mutant in pcDNA3.1(+) was mixed with 600 μL Optipro SFM (Life Technologies, Paisley, PA4 9RF, UK). 60 μL Freestyle Max reagent (Life Technologies) diluted in 540 μL Optipro SFM was added to each DNA/Optipro SFM mixture and incubated at room temperature for 10-20 minutes. 1200 μL DNA/Freestyle Max mix was added to CHO-K1 cells in a 90 mm dish and incubated at 37° C. for 40-48 h. CHO-K1 cells expressing TSHR-TMD mutants were harvested by rinsing the cell mono-layer with 4 mL PBS, and then harvesting the cells in 1 mL PBS using scraping to dislodge the cells. The cells were centrifuged in 1.5 mL vials at 13 000 rpm for 1 minute, the supernatant discarded and the cell pellet stored at −70° C. When required, each cell pellet was solubilised by suspension in 1 mL solubilisation buffer (50 mM NaCl, 10 mM Tris pH 7.8, 1% v/v Triton X-100, Complete protease inhibitors (Roche)), and incubated on ice for at least 30 minutes. This material was then used immediately or stored at −70° C.

The TSHR-JMG55 standard was made by transfecting 80 cm² flasks containing 90% confluent CHO-K1 cells with TSHR-JMG55 in pcDNA3.1+. For each 80 cm² flask, 40 μg TSHR-JMG55 in pcDNA3.1 was mixed with 800 μL Optipro SFM (Life Technologies), then 80 μL Freestyle Max reagent (Life Technologies) diluted in 720 μL Optipro SFM was added to the DNA/Optipro SFM mixture and incubated at room temperature for 10-20 minutes. 1.6 mL DNA/Freestyle Max mix was added to each 80 cm² flask of CHO-K1 cells and incubated at 37° C. for 40-48 h. CHO-K1 cells expressing TSHR-JMG55 standard were harvested from each 80 cm² flask by rinsing the cell mono-layer with 10 mL PBS, and then harvesting the cells in 2 mL PBS using scraping to dislodge the cells. Cells from all the flasks were pooled and aliquoted in 1 mL aliquots in 1.5 mL vials. The cells were centrifuged at 13 000 rpm for 1 minute, the supernatant discarded and the cell pellet stored at −70° C. When required, each cell pellet was solubilised by suspension in 500 μL solubilisation buffer (50 mM NaCl, 10 mM Tris pH 7.8, 1% v/v Triton X-100, Complete protease inhibitors (Roche)), and incubated on ice for at least 30 minutes. This material was then used immediately or stored at −70° C. TSHR-JMG55 standard was diluted so that it gave the same activity in TSHR-binding assays (described below in “TSHR-binding assay”, FIG. 14 a ) with 14C4-coated ELISA plate wells as TSHR260-WT standard gave in TSHR260-binding assays (FIG. 12 a ) with 14C4-coated ELISA plate wells as defined in “Transient transfections of TSHR260 mutants into CHO-K1 cells using Freestyle Max reagent”. This was defined as having a 14C4-activity of 100 U/mL. Similarly, the same sample assayed in the TSHR binding assay to 4E31-coated ELISA plate wells (FIG. 14 a ) was used to define a 4E31-activity of 100 U/mL. Further TSHR-JMG55 standard samples were diluted to the same concentration as the first TSHR-JMG55 standard, as detected in the TSHR-binding assays with 14C4- and 4E31-coated ELISA plate wells, respectively.

Antibodies Used in the TSHR-Binding Assay

4E31

As detailed above in “Antibodies used in the TSHR260-AP Bridge ELISA”

14C4

As detailed above in “Antibodies used in TSHR260 binding assay”

M22

As detailed above in “Antibodies used in TSHR260 binding assay”

TSHR-Binding Assay

Maxisorp 96-well ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 14C4-Fab₂ (Jeffreys J et al (2002) supra and Sanders J et al (2007) supra) or 1 μg/mL 4E31-Fab₂ (EP 1021721B1, Bolton et al (1999) supra) in coating buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, 1.5 mM NaN₃, 0.01 g/L Phenol Red, pH9.2), incubated at room temperature for 3 h and then at 4° C. overnight. Wells were washed three times with wash buffer (50 mM NaCl; 20 mM Tris pH 7.8; 1% v/v Triton X-100) and 150 μL test sample (TSHR harvested from transiently transfected CHO-K1 cells), diluted in TAT buffer (50 mM NaCl, 10 mM Tris pH7.8, 1% v/v Triton X-100, 1 g/L BSA, 0.2 g/L sodium azide) was applied to each well and incubated at room temperature for 1 h or at 4° C. overnight to allow the TSHR to bind to 14C4-Fab₂ or 4E31-Fab₂ coated plates.

The wells were then washed and incubated with 75 μL of assay buffer (50 mM NaCl, 20 mM Tris pH7.8, 1% v/v Triton X-100, 1 g/L BSA, 50 mg/L normal mouse IgG) and 75 μL of healthy blood donor serum pool (NPS) for 1 h at room temperature at 500 shakes per minute on an ELISA plate shaker. Thereafter the contents of the wells were emptied, the wells washed and 100 μL of M22 Fab-peroxidase conjugate (M22-POD, RSR Ltd, Cardiff, CF23 8HE, UK) added to each well. After 25 minutes incubation at room temperature without shaking the plate wells were washed again followed by addition of 100 μL of tetramethylbenzidine and a further incubation of 25 minutes at room temperature without shaking. The reaction was stopped by addition of 50 μL of 0.5 M H₂SO₄ and the absorbance of each well read at 450 nm on an ELISA plate reader (FIG. 14 a ).

For each mutant, their activity in assays bound to both 14C4-coated plates and 4E31-coated plates was measured and compared to a TSHR-JMG55 standard diluted to have the same activity bound to the 14C4-coated plates as the TSHR260-WT standard bound to the 14C4-coated plates in the TSHR260-binding assay (100 U/mL) as defined in “Transient transfections of TSHR260 mutants into CHO-K1 cells using Freestyle Max reagent” and “Transient transfections of full-length TSHR mutants into CHO-K1 cells using Freestyle Max reagent”.

Thermostability of Full-Length TSHR Mutants

The thermostability of TSHR mutants was measured in three different ways: A) Heating TSHR mutants bound to 14C4-coated ELISA plate wells (FIG. 14 b ); B) Heating TSHR mutants bound to 4E31-coated ELISA plate wells (FIG. 14 c ); and C) Heating TSHR mutants in solution and then binding them to 4E31-coated ELISA plate wells for the assay (FIG. 14 d ).

Thermostability assays A and B: Maxisorp 96-well ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 14C4-Fab₂ (thermostability assay A) or 1 μg/mL 4E31-Fab₂ (thermostability assay B) in coating buffer, incubated at room temperature for 3 h and then at 4° C. overnight. Wells were washed three times with wash buffer and 150 μL test sample (TSHR harvested from transiently transfected CHO-K1 cells), diluted in TAT buffer was applied to each well and incubated at 4° C. overnight to allow the TSHR to bind to 14C4- or 4E31-coated ELISA plate wells. Plates were washed three times with wash buffer to remove any TSHR that had not bound to the 14C4-Fab₂ or 4E31-Fab₂. TAT buffer was added to each well (150 μL) and an adhesive plate cover was then applied to seal the wells. Each plate was then placed in a water bath set at 45° C. or 55° C. One strip (8 wells) of the 96-well plate was removed from each plate after periods of up to 180 minutes and inserted in to a spare ELISA plate rack, which was then kept on ice. After the 180-minute time course was complete the receptor dilution buffer was aspirated from the ELISA plate wells and the TSHR-binding assay (FIG. 14 a ) described above was continued. Assay data were plotted against time and fitted to an exponential curve and the half-life (t_(1/2)) of the mutants calculated and compared to TSHR-JMG55 or another TSHR mutant.

Thermostability assay C: Maxisorp 96-well ELISA plate (Nunc) wells were coated with 150 μL aliquots of 1 μg/mL 4E31-Fab₂ in coating buffer, incubated at room temperature for 3 h and then at 4° C. overnight. TSHR mutants transiently expressed in CHO-K1 cells were diluted in solubilisation buffer. 100 μL aliquots were heated between 0 and 2 hours at 33° C. or 40° C. Samples were then diluted 1/4 in TAT buffer (83.3 μL sample+250 μL TAT buffer) and 150 μL aliquots were applied in duplicate to 4E31-coated ELISA plate wells that had been washed three times with wash buffer and the TSHR-binding assay (FIG. 14 a ) was carried out as described above. Assay data were plotted against time and fitted to a two-phase exponential decay equation. The percentage of active TSHR mutant remaining after heating for 10, 30 and 120 min was calculated and compared to TSHR-JMG55 or another TSHR mutant to give a survival ratio at 10, 30 and 120 min.

Results Single Mutations

In our experiments, 239 single mutants of TSHR260 have been prepared and expressed. In particular, each residue from Met22 to Leu260 was mutated to the amino acid estimated to be the most thermostabilising for each position (Table 1). These mutants have been screened for binding and stability in the TSHR260-binding assay (FIG. 12 a, b , Table 2). The half-life at 42° C. of the 64 best candidates identified in the screen were determined and compared to wild-type TSHR260 (TSHR260-WT, average t_(1/2)=30.7±1.1 minutes), to give the difference in half-life between the mutant and TSHR260-WT (Δt_(1/2)) and the stability ratio between the half-life of the mutant and the half-life of TSHR260-WT (Table 3). These thermostability curves identified 17 mutations (P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, 1167F, P168Y, V169R, N170W, T179C, I253R and R255Y) (FIGS. 5 and 6 ; SEQ ID Nos 11-25, 27-43, 45 and 46) that significantly improve the thermostability of the TSHR260-WT by at least 60%, which gives a 17-minute increase in the half-life of the protein at 42° C. (Table 3). The best single mutant, I253R (SEQ ID No 45), improved the thermostability 3.0±0.4 times over TSHR260-WT at 42° C., i.e. increased the half-life of TSHR260 at 42° C. by 53±6 minutes (FIG. 7 a ). It also improved the thermostability at 50° C. by 2.85±0.13 times over TSHR260-WT.

Surprisingly, the 17 mutations that had the best thermostabilising effect are distributed throughout the TSHR260 structure (FIG. 9 ), although most are on the convex surface or edges between the convex and concave surfaces of the LRD. Seven are on the convex surface, (P142I, D143P, S166T, 1167F, P168Y, V169R, and N170W), six are on the edges of the LRD (T62V, H63C, L64Y, R112P, T179C, R255Y); only three are on the concave surface (L59F, D151E and I253R) and P28E is not visible in the crystal structure. Leu59 and Ile253 are on the concave side but do not interact with M22-Fab in the crystal structure (PDB code 3G04; Sanders J et al (2007) supra). Of these thermostabilising mutants, Asp151 is the only residue that interacts directly with M22-Fab forming a salt-bridge as shown in the crystal structure. Consequently, Asp151 was mutated to another negative amino acid, Glu, to maintain the salt-bridge interactions.

Dot Blot Results (to Determine Total Amount of TSHR Expressed, i.e. Active Plus Inactive TSHR)

The amount of TSHR260 detected in the TSHR260-binding assay varied for different mutants (between 0% and 1000% of TSHR260-WT) and consequently the total amount of each mutant expressed was measured using a Dot Blot assay. The results of Dot Blot assays are shown in Table 4. The level of expression measured by the Dot Blot assay was defined relative to TSHR260-WT and compared to the results of the TSHR260-binding assay, which was also defined relative to TSHR260-WT. The ratio between the TSHR260-binding assay results and the Dot Blot results was calculated (TSHR260-binding÷Dot Blot) to determine when there was a large discrepancy between the total amount of TSHR260 detected in the Dot Blot assay and the amount of active TSHR260 detected in the TSHR260-binding assay.

Double Mutants

Double mutants of TSHR260 have been made by adding the mutations P142I (SEQ ID No 35) and I253R (SEQ ID No 45) to the best stabilising mutations as shown in Table 5; Mutants JMG1-JMG15 and JMG31 are double mutants with P142I. Mutants JMG15-JMG29 are double mutants with I253R. Although P142I had a large thermostabilising impact, improving the thermostability of TSHR260 5-fold, it was expressed at very low levels. This low expression level was also observed in the case of the double mutants which included P142I. Therefore further mutagenesis and thermostability assays were continued with I253R mutants only.

Similar to P142I, the single mutants, T62V, L64Y, P142I, I167F, P168Y, N170W and T179C had low expression levels (Table 4) which were also observed in the double and triple mutants containing these mutations. As a practical matter, these were not used for further mutant combinations.

The stability of the double mutations was measured at both 42° C. (Table 6) and at 50° C. (Table 7). All of the double mutations tested improved the thermostability relative to TSHR260-WT and the single mutant TSHR260-I253R. The most thermostable double mutant was JMG22 (I253R+D143P) (SEQ ID Nos 45 and 36 respectively), which improved the thermostability of TSHR260-WT 9.3±0.5 times at 42° C. and 15.1±0.7 times at 50° C. to give a half-life of 261±45 min and 23.8±0.7 minutes, respectively (FIG. 7 a, b ).

Triple Mutants

Mutants JMG30-JMG42 are triple mutants of TSHR260 with the mutation D143P (SEQ ID No 36) added to the most stabilising double mutations (Table 5). Two triple mutants, 1167F+D143P+I253R and T179C+D143P+I253R, were not made because their respective double mutants JMG25 (1167F+I253R) and JMG29 (T179C+I253R) showed poor expression levels.

Thermostability curves were established for the triple mutants at 50° C. and compared to the thermostability of I253R at 50° C. (Table 8). The most thermostable triple mutant was JMG37 (I253R+D143P+R112P) (SEQ ID Nos 45, 36 and 34 respectively), which had a half-life of 69±3 minutes at 50° C. and was 16.6±0.5 times more thermostable than TSHR260-I253R (FIG. 7 b, c ).

Quadruple Mutants

Mutants JMG43-JMG48 are quadruple mutants of TSHR260 with the mutation R112P (SEQ ID No 34) added to the most thermostabilising triple mutants (Table 5). Thermostability curves were determined for the quadruple mutants at 50° C. and 55° C. and compared to the thermostability of I253R at these temperatures (Table 8 and Table 9). The most thermostable quadruple mutant was JMG45 (I253R+D143P+R112P+D151E) (SEQ ID Nos 45, 36, 34 and 37 respectively), which had a half-life of 226±31 minutes at 50° C., and was 58±6 times more thermostable than TSHR260-I253R (FIG. 7 c ). At 55° C. it had a half-life of 27±3 minutes and was 54±7 times more thermostable than TSHR260-I253R (FIG. 7 d ). At 60° C. it had a half life of 2.40±0.16 minutes.

Quintuple Mutants

Mutants JMG49-JMG52 are quintuple mutants of TSHR260 in which D151E (SEQ ID No 37) was added on to the quadruple mutants (Table 5). The most thermostable quintuple mutant was JMG52 (I253R+D143P+R112P+D151E+V169R) (SEQ ID Nos 45, 36, 34, 37 and 41 respectively) (Table 9 and Table 10). It had a half-life of 66±12 minutes at 55° C. and was 125.1±0.6 times more thermostable than TSHR260-I253R (FIG. 7 d ). At 60° C. it had a half-life of 7.1±0.6 minutes and was 3.0±0.2 times more thermostable than TSHR260-JMG45 (FIG. 7 e ).

Hextuple Mutants

The hextuple mutations were made by adding an S166T (SEQ ID No 38) or V169R (SEQ ID No 41) mutation on to the quintuple mutant JMG50 to give JMG54 (I253R+D143P+R112P+D151E+H63C+S166T) (SEQ ID Nos 45, 36, 34, 37, 32 and 38 respectively) and JMG55 (I253R+D143P+R112P+D151E+H63C+V169R) (SEQ ID Nos 45, 36, 34, 37, 32 and 41 respectively) (Table 5 and Table 10). They were too thermostable at 55° C. to be accurately measured and so thermostability was measured at 60° C. (FIG. 7 e ). JMG54 had a half-life of 9.6±1.5 minutes at 60° C. and was 4.0±0.4 times more thermostable than TSHR260-JMG45. JMG55 had a half-life of 13±3 minutes at 60° C. and was 5.2±0.9 times more thermostable than TSHR260-JMG45. JMG55 is 5.2 times more thermostable than TSHR260-JMG45, which is 56 times more thermostable than TSHR260-I253R, which in turn is 3.1 times more thermostable than TSHR260-WT. Comparison of other thermostability ratios suggests that component stability ratios can be multiplied to obtain the overall thermostability ratio (Table 12). Therefore JMG55 is approximately 900 times more thermostable than TSHR260-WT.

Thermostability at 37° C.

The thermostability of the most stable single, double, triple, quadruple, quintuple and hextuple TSHR260 mutants (I253R, JMG22 (I253R+D143P), JMG37 (I253R+D143P+R112P), JMG45 (I253R+D143P+R112P+D151E), JMG52 (I253R+D143P+R112P+D151E+V169R) and JMG55 (I253R+D143P+R112P+D151E+V169R+H63C)) was measured at 37° C. relative to TSHR260-WT. The half-life of the mutants was calculated from the thermostability curves at 37° C. and is shown in Table 11. Table 11 also shows the stability ratios for each mutant compared to TSHR260-WT. These are consistent with the stability ratios observed at other temperatures (Table 12).

Comparing the Thermostability of the Most Thermostable Mutants at a Range of Temperatures

The stability ratios of mutants compared to TSHR260-WT do not change greatly at different temperatures i.e. 42° C. and 50° C. Above 50° C. TSHR260-WT is so unstable it cannot be used as a reference preparation. Consequently a more suitable mutant was chosen instead. The stability ratios obtained with this more stable mutant as reference were then multiplied by the stability ratio of the stable reference mutant compared to TSHR260-WT (Table 12). For example, JMG37 is 12.0±0.9 times more thermostable than I253R at 55° C., which is 3.1 times more thermostable than TSHR260-WT. Therefore JMG37 is calculated to be 12.0×3.1=37±3 times more thermostable than TSHR260-WT at 55° C., which corresponds well to the measured thermostability ratio relative to TSHR260-WT at 37° C. (34±5 times).

Thermostability of Full-Length TSHR and Mutants Coated on 14C4 Plates.

The thermostability of full-length TSHR-WT (SEQ ID No 2), TSHR-JMG37 (SEQ ID Nos 45, 36, 34), TSHR-JMG45 (SEQ ID Nos 45, 36, 34, 37), TSHR-JMG52 (SEQ ID Nos 45, 36, 34, 37, 41) and TSHR-JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41) bound to ELISA plates coated with 14C4-Fab₂ was determined by heating the plates at 42° C. or 50° C. Unexpectedly, the full-length TSHR mutants, TSHR-JMG37, TSHR-JMG45, TSHR-JMG52 and TSHR-JMG55 were considerably more thermostable than TSHR-WT (Table 13, Table 14). At 50° C., TSHR-WT has a half-life of 33 minutes, TSHR-JMG37 has a half-life of 110 minutes and is 3.4 times more thermostable than TSHR-WT, TSHR-JMG45 has a half-life of 173 minutes and is 5.3 times more thermostable that TSHR-WT, TSHR-JMG52 has a half-life of 175 minutes and is 5.4 times more thermostable that TSHR-WT and TSHR-JMG55 is 6.9 times more thermostable than TSHR-WT with a half-life of 226 minutes (FIG. 8 )

M22-POD, K1-18-POD and K1-70-POD Binding to TSHR260 and Full-Length TSHR Mutants

M22-POD, K1-18 POD and K1-70 POD binding to TSHR260 mutants and full-length TSHR has been tested by varying the concentration of TRAb-peroxidase conjugate (i.e. M22-POD, K1-18 POD or K1-70 POD) binding to ELISA plates coated with TSHR260 mutants or full-length TSHR mutants and detecting the binding of TRAb-peroxidase conjugate by incubation with the substrate tetramethylbenzidine. The binding constant (K_(d)), which is the concentration of ligand (TRAb-peroxidase) at which half of the receptor (TSHR or TSHR260 mutants) is bound to ligand, was determined relative to the binding constant of TSHR260-WT or full-length TSHR-WT as appropriate. The mutations tested did not affect the binding of full-length TSHR or TSHR260 to any of M22-POD, K1-18-POD or K1-70-POD (Table 15 to Table 21).

K1-18 IgG and K1-70 IgG Inhibition of M22-POD Binding to TSHR260 Mutants and Full-Length TSHR Mutants

Incubating the receptor (TSHR260 mutants and full-length TSHR mutants), with varying concentration of K1-18 IgG and K1-70 IgG, which bind to the same site as M22, before incubation with M22-POD, measures inhibition of M22-POD binding and indicates whether the receptor-antibody interactions have been affected by the thermostabilising mutations. K1-18 IgG and K1-70 IgG inhibit the binding of M22-POD to the TSHR260 mutants and the full-length TSHR mutants to a similar extent as to TSHR260-WT and full-length TSHR-WT respectively. These results show that the mutations have not affected binding of the monoclonal TSHR antibodies to TSHR260 or full-length TSHR (Table 22 to Table 25).

Inhibition of M22-POD Binding to TSHR260 and Full-Length TSHR Mutants by TRAb Positive Patient Sera

To determine whether the thermostabilised mutants of TSHR260 and full-length TSHR are suitable for use in assays to detect TRAbs in patient sera, the ability of patient sera to inhibit the binding of M22-POD to TSHR260-WT, TSHR260-JMG52, TSHR260-JMG55 full-length TSHR-WT, TSHR-JMG45 and TSHR-JMG52 was measured (FIG. 12 c , FIG. 14 e ). The patient sera inhibited the binding of M22-POD to TSHR260-JMG52 and TSHR260-JMG55 similarly to TSHR260-WT (Table 27, Table 29). Furthermore, the patient sera inhibited the binding of M22-POD to full-length TSHR-JMG45 and full-length TSHR-JMG52 similarly to full-length TSHR-WT (Table 28, Table 29). Therefore, the thermostable TSHR260 or full length TSHR mutants are suitable for use in assays to detect TRAb in patient sera.

Analysis of TSHR Stimulation

The stimulation of full-length TSHR and full-length TSHR mutants (expressed in FlpIn CHO cells) by TSH, M22 Fab and K1-18 IgG, was determined by measuring the amount of cyclic AMP produced using a range of different concentrations of TSH, M22-Fab or K1-18 IgG. In each assay, the stimulation of the TSHR mutants was compared to the stimulation of TSHR-WT detected in the same assay. The EC50, i.e. the concentration of agonist (TSH, M22-Fab, or K1-18 IgG) which produces 50% of the maximum stimulation response, was calculated for each mutant and compared to TSHR-WT (Table 30 to Table 39). Surprisingly, the mutations did not have a marked effect on cyclic AMP production in response to stimulation by TSH, M22 or K1-18, although there was a small increase in EC50 of M22 for the quadruple mutant TSHR-JMG45 (I253R+D143P+R112P+D151E), the quintuple mutant TSHR-JMG52 (I253R+D143P+R112P+D151E+V169R) and the hextuple mutant TSHR-JMG55 (I253R+D143P+R112P+D151E+V169R+H63C), relative to TSHR-WT (Table 38).

Stimulation of full-length TSHR-WT, TSHR-JMG45 and TSHR-JMG52 by TRAb positive patient sera was also measured and compared to the effects of healthy blood donor sera. The stimulation of the mutated full-length TSHRs by patient sera was very similar to the stimulation of TSHR-WT (Table 40 and Table 41).

Transferability of Thermostabilising Human TSHR Mutations to TSHR from Other Species and Other Glycoprotein Hormone Receptors.

There is a high sequence homology (86-97.5% sequence identity) between the TSHR sequences currently available from different mammalian species. This suggests that most of the thermostabilising mutations identified in the human TSHR (hTSHR), will be thermostabilising in these homologues. Table 42 shows that most of the amino acids mutated in the human TSHR to improve thermostability are conserved across species. Pro28, Leu59, Thr62, Leu64, Arg 112, Pro142, Asp143, Asp151, Ser166, Pro168, Asn170, Thr179 and Ile253 are conserved across all species (Table 42). In the case of thermostabilising mutation H63C, position 63 is Gln in dog TSHR and Arg in both Rhesus monkey and Grivet monkey rather than His. As these residues are quite different to both His and Cys, it is difficult to predict whether mutation to Cys may still be thermostabilising. Regarding thermostabilising mutation I167F, in mouse, rat and sheep, position 167 is Val rather than Ile. As Ile and Val are both similar aliphatic amino acids, it is likely that mutation to Phe may still be thermostabilising. In the case of thermostabilising mutation V169R, position 169 is Ala in porcine, bovine, cat, dog, sheep and horse TSHR sequences, which is similar to the aliphatic Val present in human, therefore it is expected that mutation to Arg will also be thermostabilising in these TSHRs. In contrast, in mouse and rat, the residue 169 is Glu, which is a charged residue like Arg, therefore mutation to Arg may not have as dramatic a stabilising effect as in the human TSHR. Regarding thermostabilising mutation R255Y, mouse and rat have Lys at position 255, rather than Arg present in the other TSHR sequences, which are both positively charged amino acids. Therefore mutation to Tyr may still be thermostabilising at position 255.

There is lower sequence identity between hTSHR (SEQ ID No 2) and the other glycoproteins hFSHR (SEQ ID No 57) (50% sequence identity) and hLHR (SEQ ID No 58) (53.3% sequence identity). However, sequence alignment (FIG. 11 ) indicates that many of the thermostabilising mutated residues in hTSHR correspond to the same or similar residues in the hFSHR and hLHR. Consequently, many thermostabilising mutations are likely to be transferable (Table 43). In the FSHR it is expected that T56V, L58Y, N106P, P136I, D137P, Q145E, I160F, N163W, S172C and R247Y will be thermostabilising. In the LHR, the corresponding mutations P33E, L56F, V61Y, K109P, P139I, D140P, I164F, P165Y, N167W, S176C and I249R are predicted to be thermostabilising.

Further Thermostabilising TSHR260-Mutants

Two more thermostable quintuple TSHR260 mutants have been made and tested for thermostability: TSHR260-JMG57 (I253R+D143P+R112P+V169R+H63C) (SEQ ID Nos 45, 36, 34, 41 and 32 respectively) and TSHR260-JMG58 (I253R+D143P+R112P+S166T+H63C) (SEQ ID Nos 45, 36, 34, 38 and 32 respectively) have a half-life at 55° C. of 40±2 min and 31.4±0.4 min respectively and are 1.64±0.07 and 1.28±0.05 times more thermostable than the quadruple mutant TSHR260-JMG45. TSHR260-JMG57 and TSHR260-JMG58 also maintain the ability to detect patient sera in inhibition of M22-POD binding assays (FIG. 12 c , Table 44).

M22IgG, K1-70 IgG and K1-18IgG Binding to Alkaline Phosphatase Labelled TSHR260 Mutants in the Bridge ELISA

The assay (FIG. 13 a ) relies on the bivalent properties of human monoclonal stimulating type TSHR autoantibodies (M22 IgG and K1-18 IgG) and the human monoclonal blocking type TSHR autoantibody (K1-70 IgG) to form a bridge between immobilised full-length wild type TSHR and alkaline phosphatase labelled TSHR260 mutants (TSHR260-AP-I253R, TSHR260-AP-JMG22, TSHR260-AP-JMG37, TSHR260-AP-JMG45, TSHR260-AP-JMG52, TSHR260-AP-JMG55, TSHR260-AP-JMG57 and TSHR260-AP-JMG58) (see “Production of TSHR260-AP construct containing stabilising amino acid mutations” for SEQ ID Nos). When diluted in a pool of healthy blood donor serum, M22 IgG, K1-70 IgG and K1-18 IgG all bound to the TSHR260-AP mutants and to wild type TSHR260-AP in a similar dose dependent manner (Table 45 a-c; e-g). Furthermore, when diluted in assay buffer, M22 IgG, K1-70 IgG and K1-18 IgG all bound to the TSHR260-AP mutants and to wild type TSHR260-AP in a similar dose dependent manner (Table 46a-c; e-g). A negative control human monoclonal autoantibody to GAD (5B3 IgG) diluted in healthy blood donor serum or assay buffer was tested for binding (Table 45d and Table 46d). No binding was seen between 5B3 IgG (negative control antibody) and either the wild type TSHR260-AP or TSHR260-AP mutants, (absorbance values of 0.0016-0.033 for dilutions in healthy blood donor serum and 0.001-0.034 for dilutions in assay buffer). These experiments demonstrated the ability of human monoclonal TSHR autoantibodies with either stimulating or blocking activity to bind to alkaline phosphatase labelled TSHR260 mutants.

TRAb Positive and TRAb Negative Sera Binding to Alkaline Phosphatase Labelled TSHR260 Mutants in the Bridge ELISA

Twelve TRAb positive patient sera (G1-G12) and eleven TRAb negative patient sera (N1-N11) were tested for their ability to bind bivalently and form a bridge between immobilised full-length TSHR and alkaline phosphatase labelled TSHR260 (TSHR260-AP) mutants (TSHR260-AP-I253R, TSHR260-AP-JMG22, TSHR260-AP-JMG37, TSHR260-AP-JMG45, TSHR260-AP-JMG52, TSHR260-AP-JMG55, TSHR260-AP-JMG57 and TSHR260-AP-JMG58) (FIG. 13 a ). Binding of TRAb positive and TRAb negative sera was similar for both the wild type and mutant TSHR260-AP (Table 47a). Using the K1-70 IgG standard curve to calculate TRAb concentrations for each patient serum showed that TRAb concentrations calculated for the mutant TSHR260-AP constructs compared well to the average of the wild type TSHR260-AP assays (Table 47b). Performing Pearson correlation of assay results obtained with each TSHR260-AP mutant compared to the average TRAb concentration determined with wild type TSHR260-AP gave good r-values (Table 47c), demonstrating that patient sera TRAb bind to wild type TSHR260-AP and the TSHR260-AP mutants in a similar way.

Thermostability of TSHR260-AP Mutants

TSHR260-AP mutant half-lives (t_(1/2)) were calculated by fitting an exponential curve to the time course data (0 h-3 h) for each TSHR260-AP construct at each temperature, using duplicate measurements (FIG. 13 b ). The half-life of each construct at each temperature tested is shown in Table 48. The half-life for each TSHR260-AP mutant was compared to the half-life for TSHR260-AP-JMG45 (65° C.), TSHR260-AP-JMG22 (60° C.) or TSHR260-AP-WT (50° C.). From this a predicted stability ratio could be calculated to show the overall stability of each TSHR260-AP mutant compared to TSHR260-AP-WT. TSHR260-AP-JMG22, TSHR260-AP-JMG45 and TSHR260-AP-JMG55 had half-lives of approximately 11-fold, 66-fold and 165-fold greater than TSHR260-AP-WT, respectively. Although the increase in stability between TSHR260-AP-WT and the TSHR260-AP mutants was reduced compared to TSHR260 without the alkaline phosphatase fusion protein, the thermostability of the TSHR260-AP constructs were greater than the equivalent constructs without alkaline phosphatase. The half-life of TSHR260-AP-WT at 50° C. was 2.9-fold greater than the half-life of wild type TSHR260 (without alkaline phosphatase). Similarly, at 60° C. TSHR260-AP-JMG45 and TSHR260-AP-JMG55 had half-lives of 3.2-fold and 1.5-fold greater, respectively, than the equivalent TSHR260 constructs without alkaline phosphatase.

Purification of Wild Type TSHR260

After purification using anion exchange chromatography the eluted wild type TSHR260 pool contained approximately 80-fold less activity in the TSHR260 bridge inhibition ELISA than the initial material loaded onto the anion exchange column (FIG. 25 a ). These results confirm that the wild type TSHR260 is inherently unstable during purification with an 80-fold loss of activity after only one round of anion exchange chromatography purification.

Purification of Wild Type TSHR260 in Complex with TSHR Monoclonal Antibodies (14C4, 2H11, 25E1, 23H4, 36F11 or 9B7)

Previously we have shown that TSHR260 (wild type) can be stabilised, purified and crystallised when in complex with the human monoclonal thyroid stimulating autoantibody M22 (WO 2008/025991A1). However M22 binds to the TSHR260 fragment with high affinity (5×10¹⁰ L/mol), is not easily dissociated and inhibits binding of patient serum autoantibodies to the TSHR260 fragment (EP 1565493B1, Nakatake et al. (2006) Thyroid, 16: 1077-1084). Therefore the formation and purification of a complex of TSHR260-M22 cannot be used as a purification method for uncomplexed TSHR260 for use in assay systems to detect binding of patient autoantibodies to the TSHR or for other purposes.

Purification of the wild type TSHR260 in complex with 14C4 IgG, 25E1 IgG, 2H11 IgG, 36F11 IgG or 9B7 IgG (TSHR monoclonal antibodies to the convex surface of the TSHR which do not compete with M22 for binding to TSHR) by ion exchange chromatography showed similar activity (less than 2-fold decrease) in the eluted material relative to the load material after analysis in the TSHR260-AP bridge inhibition ELISA (FIG. 13 c , FIGS. 25 b, c, d, f and g respectively). However 23H4 IgG (a further monoclonal antibody to the convex surface of the TSHR) was less effective at stabilising the wild type TSHR260 with the eluted material following cation exchange chromatography containing approximately 15-fold less activity than the initial material loaded onto the column, measured in the TSHR260 bridge inhibition ELISA (FIG. 25 e ). These experiments show that purification of the wild type TSHR260 in complex with different TSHR mouse monoclonal antibodies (14C4, 2H11, 25E1 or 23H4, 36F11 IgG or 9B7 IgG; which bind to the convex surface of the TSHR away from the binding sites of patient serum autoantibodies) was able to stabilise the wild type TSHR260 during one round of ion exchange chromatography.

Purification of TSHR260-JMG55

Initial purification by cation exchange chromatography of 36 Litres of insect cell culture supernatant containing TSHR260-JMG55 showed a 529-fold increase in the specific activity of the TSHR260-JMG55 from 30 U/mg to 15,872 U/mg measured in the TSHR260 binding assay (FIG. 12 a , Table 49). Units of TSHR260-JMG55 are defined relative to TSHR260 standard as described in “Transient transfections of TSHR260 mutants into CHO-K1 cells using Freestyle Max reagent”.

Analysis of the initial load material and the eluted pool from the streamline column in the TSHR260 bridge inhibition ELISA (FIG. 13 c ) showed similar activity (approximately 3-4 fold decrease in total activity) in the eluted pool relative to the load material (FIG. 25 h ).

Further purification of TSHR260-JMG55 using a TSHR MAb 14C4 affinity column resulted in the purification of two different forms of TSHR260-JMG55 (FIG. 26 ). Elution of the 14C4-affinity column at pH 5.0 gave purified TSHR260-JMG55-5.0 which had a low specific activity of 12,041 U/mg while elution at pH 4.5 gave purified TSHR260-JMG55-4.5 which had a high specific activity of 11,443,46 U/mg (Table 49). A final purification of the high activity TSHR260-JMG55-4.5 using nickel affinity chromatography increased the specific activity of the purified protein to 6,414,000 U/mg giving an overall purification level of 213,708 compared to the initial culture supernatant (Table 49 and Table 50a). In contrast, final purification of the low activity TSHR260-JMG55-5.0 using nickel affinity chromatography gave a specific activity of 20,361 U/mg for the purified protein giving an overall purification level of 679 compared to the initial culture supernatant (Table 49 and Table 50b).

The two forms of the purified TSHR260-JMG55 ran as single bands of approximately 34 kDa on a 12% non-reduced SDS PAGE (FIG. 27 ). After the final purifications 0.665 mg of high specific activity TSHR260-JMG55-4.5 (6,414,000 U/mg) and 0.927 mg of low specific activity TSHR260-JMG55-5.0 (20,361 U/mg) were obtained.

K1-18-POD, K1-70-POD and M22-POD bound to purified JMG55-TSHR260-4.5 coated ELISA plate wells in a dose dependant manner (Table 51).

Deglycosylation of TSHR260-JMG55-4.5

Incubation of purified TSHR260-JMG55-4.5 in deglycosylation buffer without Endo F3 for 1, 3 and 5 days at 20° C. showed no reduction in the molecular weight (FIG. 28A). In contrast deglycosylation of TSHR260-JMG55-4.5 with Endo F3 at 40 mU/mg, 60 mU/mg or 80 mU/mg resulted in a maximum reduction in molecular weight of approximately 2 kDa at 120 h, 72 h and 24 h respectively (FIGS. 28A and 28B). Analysis of the activity of the deglycosylated TSHR260-JMG55-4.5 after 120 h incubation at 20° C. was determined in the TSHR260-binding assay (FIG. 12 a ) and compared to the activity of the untreated purified TSHR260-JMG55-4.5 material stored at −70° C. (Table 52). Incubation of TSHR260-JMG55-4.5 with no enzyme (0 mU/mg), 40 mU/mg, 60 mU/mg or 80 mU/mg gave 111%, 100%, 104% and 104% of the activity of the untreated purified TSHR260-JMG55-4.5 material respectively.

The purified TSHR260-JMG55-4.5 protein retained its activity and was stable after three rounds of column chromatography (streamline HST, 14C4 affinity and nickel affinity chromatography) and removal of approximately 2 kDa of sugar residues by deglycosylation with Endo F3.

In contrast to the wild type TSHR260, the TSHR260-JMG55 mutated TSHR can be successfully purified by three rounds of column chromatography (streamline HST, 14C4 affinity followed by nickel affinity chromatography) without the addition of a TSHR monoclonal antibody to form a stable complex. Two different forms of active TSHR260-JMG55 have been purified from the culture supernatant, a high specific activity form (TSHR260-JMG55-4.5) which had a specific activity of 6,414,000 U/mg and a low specific activity form which had a specific activity of 20,361 U/mg (315-fold lower). The observation that deglycosylated, purified TSHR260-JMG55-4.5 was active in the TSHR260-binding assay further confirmed the increased stability of the mutated TSHR fragment.

Transferability of Thermostable Human TSHR Mutations to Mouse and Porcine TSHR

The equivalent mutations of the most thermostable human TSHR mutant, JMG55 (I253R+D143P+R112P+D151E+V169R+H63C), were transferred to mouse TSHR (I253R+D143P+R112P+D151E+E169R+H63C) (FIG. 23 ; SEQ ID No 67 for nucleotide sequence and FIG. 24 ; SEQ ID No 68 for amino acid sequence) and porcine TSHR (I253R+D143P+R112P+D151E+A169R+H63C) (FIG. 21 ; SEQ ID No 65 for nucleotide sequence and FIG. 22 ; SEQ ID No 66 for amino acid sequence) (Table 54). Five of the six mutated residues are identical in human, mouse and porcine TSHR, Only residue 169 differs between species: in human TSHR it is valine, in mouse TSHR it is glutamic acid and in porcine TSHR it is alanine. For both mouse and porcine TSHR residue 169 was mutated to arginine as in human TSHR-JMG55. The full-length mutant mouse TSHR and porcine TSHR were compared to the respective full-length wild type TSHR with respects to thermostability, binding affinities for ¹²⁵I-TSH and responsiveness to stimulation when transfected into CHO cells

Thermostability of Full-Length Wild Type and Mutated Mouse, Porcine and Human TSHR

The thermostability of full-length wild type and mutated mouse, porcine and human TSHR was measured in stability assay B at 45° C. (FIG. 14 c ). Stability assay B involves binding TSHR mutants to 4E31-coated plates overnight and then heating the plates at 45° C. in a water bath for up to three hours. The percentage of active TSHR remaining after heating is measured in the TSHR-binding assay (FIG. 14 a , Table 55).

The mutations increased the thermostability of mouse TSHR 6.3 times, (from a half-life of 2.15 min to 13.6 min). There was a similar increase in the thermostability of porcine TSHR (from a half-life of 3.6 min to 12.1 min to give a 3.34-fold improvement in thermostability). Mutated human TSHR (TSHR-JMG55, half-life of 184 min) was 39 times more thermostable than wild type human TSHR (half-life of 4.8 min). This shows that the thermostabilising mutations found in human TSHR are transferable to TSHR from other species and improve their thermostability, however the improvement in thermostability is not as great as the improvement in thermostability observed for human TSHR-JMG55.

Stimulation of Mouse and Porcine Wild Type and Mutated TSHR Expressed in CHO Cells

Stimulation of full-length wild type mouse and porcine TSHRs and full-length mouse and porcine TSHR-JMG55 equivalent mutants (Table 54) (expressed in Flp-In CHO cells) by TSH and M22 Fab, was assessed by measuring the amount of cyclic AMP produced with a range of different concentrations of the two TSHR agonists (TSH or M22-Fab). In each assay, the stimulation of the TSHR mutant was compared to stimulation of TSHR-WT (measured in the same assay). The EC50, i.e. the concentration of agonist which produces 50% of the maximum stimulation response, was calculated for each mutant and compared to TSHR-WT (Table 56 and Table 57). Similar to the full-length human TSHR-WT and full-length human TSHR-JMG55 mutation, the JMG55 equivalent mutations did not have a marked effect on cyclic AMP production in response to stimulation by TSH or M22 compared to the equivalent mouse or porcine TSHR-WT.

Binding Affinity of 125I-TSH to Solubilised Full-Length Human, Mouse and Porcine TSHR, Wild Type and Mutated

¹²⁵I-TSH binding to human, mouse and porcine wild type TSHRs (expressed in CHO cells and detergent solubilised) gave similar affinity constants of 1.80×10⁹ L/mol, 1.58×10⁹ L/mol and 1.99×10⁹ L/mol respectively (Table 58). ¹²⁵I-TSH binding to detergent solubilised full-length mutated human (JMG55), mouse and porcine TSHR (JMG55 equivalent; Table 54) also showed similar affinity constants (0.98×10⁹ L/mol, 0.87×10⁹ L/mol and 1.25×10⁹ L/mol respectively) to the wild type TSHRs. This indicated that the binding of TSH to the full-length TSHR was unaffected by the JMG55 equivalent TSHR mutations in different TSHR species.

Thermostability Effects of Single Mutations to the Transmembrane Domain (TMD) of TSHR-JMG55

In total 56 possible thermostabilising mutations in the transmembrane domain of TSHR were identified: 10 TSHR consensus mutations, 19 TSHR inactivating mutations, 26 GPCR thermostabilising mutations and one mutation (Y601A) that is both inactivating in the TSHR and thermostabilising in the β₁-adrenoceptor (Table 59). These single mutations were added to full-length TSHR-JMG55, which already contains six thermostabilising mutations (I253R, D143P, R112P, D151E, H63C and V169R) (SEQ ID Nos 45, 36, 34, 37, 32 and 41) located in the LRD,

The mutants showed different relative levels of activity in the assays when bound to 14C4-coated plates or 4E31-coated plates (FIG. 14 a ). This suggests that some of the mutations affect binding of the TSHR to these antibodies. For this reason the activity of the mutants in both forms of the assay were tested and the samples were diluted appropriately to give similar OD450 readings (between 2.0 and 2.5 OD450) in each assay. D460A and S505A did not have high enough activity to determine their thermostability. Due to low activity in the 14C4 thermostability assay (A), the thermostability of C600R could only be determined in the 4E31 thermostability assays (B and C).

The thermostability of full-length TSHR-JMG55 and mutants bound to ELISA plates coated with 14C4-Fab₂ or 4E31-Fab₂ was measured in three different ways. Stability assay A involves binding TSHR mutants to 14C4-coated ELISA plate wells by overnight incubation at 4° C. and then heating the wells at 55° C. in a water bath for up to two hours (FIG. 14 b ). Similarly, stability assay B involves binding TSHR mutants to 4E31-coated ELISA plate wells by incubation overnight at 4° C. and then heating the wells at 55° C. in a water bath for up to two hours (FIG. 14 c ). In contrast, stability assay C involves heating the TSHR mutants in solution at 33° C. for up to two hours followed by binding to a 4E31-coated ELISA plate wells (FIG. 14 d ). In all cases the percentage of active TSHR remaining after heating is measured in the TSHR-binding assay (FIG. 14 a ).

TSHR260 wild type and TSHR260 mutants are small, globular domains of the TSHR. In this relatively simple case the inactivation of the protein by heat over time accurately fits a single-phase exponential decay curve from which the half-life (t_(1/2)) is calculated. However, the full-length TSHR is a multi-domain protein and therefore there exist transition states between the folded and unfolded state of the protein. Therefore, in stability assay C where the protein is heated in solution (FIG. 14 d ), the TSHR unfolding is better modelled as two-phase decay, i.e. the decay of the protein is the sum of two decay processes, one fast and one slow, giving rise to two parameters “half-life(slow)” and “half-life(fast)” that describe the unfolding process and a third parameter, “PercentFast”, what percentage of the decay process is described by the fast decay process. It is more complicated to directly compare three parameters, and therefore the comparisons have been made on the percentage of active TSHR remaining after heating for 10, 30 and 120 minutes. Alternatively, an apparent half-life is estimated by determining the time point at which the TSHR has lost 50% of its activity. In the case of stability assays A and B (FIG. 14 a and FIG. 14 b ), one of the TSHR domains is tethered to the plate by the antibodies 14C4 or 4E31. This leads to a heat-inactivation process which more closely resembles single-phase exponential decay and thus a half-life for TSHR mutants in these assays can be determined and compared. For all assays the thermostability of TSHR-JMG55 is measured in the same experiment and used to determine the half-life ratio of each TSHR mutant.

Surprisingly, most of the mutations tested were thermostabilising in at least one of the stability assays (half-life ratio ≥1.3). Only two of the 54 mutations assayed, C599S and I622A were neutral or destabilising in all three thermostability assays (Table 60). The twenty most thermostabilising mutations of TSHR-JMG55 are E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, V595I, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L and Y678A (FIG. 29, 30 , SEQ IDs 69 to 88 (DNA) and 89 to 108 (protein)). They increase the stability of TSHR-JMG55 up to 4.5-fold in stability assay A, up to 1.6-fold in stability assay B, and up to 15-fold in stability assay C.

Thermostability of Double Mutations in the TMD of TSHR-JMG55

Three of the single TSHR-JMG55 TMD mutants, T477I, V595I and I648L (FIG. 30 ; SEQ ID Nos 97, 100 and 103 respectively), were selected for further mutagenesis as they increased the thermostability considerably in all three thermostability assays. These three mutations were combined with each other and with the other most thermostabilising single mutations (n=17) to form double mutants of TSHR-JMG55 (Table 61 and FIGS. 29 and 30 ; SEQ ID Nos 69-88 and SEQ ID Nos 89-108, respectively). Mutants JMG59 to JMG73 are combinations with T477I, mutants JMG74 to JMG92 are combinations with V595I and JMG93 to JMG111 are combinations with I648L. JMG66 and JMG82 are identical (JMG55+T477I+V595I), JMG68 and JMG101 are identical (JMG55+T477I+I648L) and JMG87 and JMG104 are identical (JMG55+V595I+I648L). The construct JMG85 (JMG55+V595I+C600R) was not made as the mutations V595I and C600R are too close together and would be likely to interfere with each other.

All of these double mutants, JMG59 to JMG111 were assayed in thermostability assay C format (FIG. 14 d ) and compared to the thermostability of single mutants T477I, V595I or I648L in the same assay (Table 62). Five out of the fifteen T477I double mutants (JMG59 to JMG73) were thermostabilising relative to T477I (defined as a half-life ratio ≥1.1). Twelve out of the eighteen V595I double mutants (JMG74 to JMG92) were thermostabilising relative to V595I and twelve of nineteen I648L double mutants (JMG93 to JMG111) were thermostabilising relative to I648L (JMG111 was not active enough to be tested in the thermostability assays). JMG87 [JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41)+V595I (SEQ ID No 100)+I648L (SEQ ID No 103)], JMG90 [JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41)+V595I (SEQ ID No 100)+S671A (SEQ ID No 106)] and JMG91 [JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41)+V595I (SEQ ID No 100)+Y678L (SEQ ID No 107)] were the most thermostabilising V595I mutants in thermostability assay C.

Because the V595I double mutants (JMG74 to JMG92) were the most thermostabilising and did not have as great a difference in activities in the 14C4 and 4E31 assays as those observed for the T477I double mutants, the JMG74 to JMG92 mutants were further analysed in stability assays A and B (FIG. 14 b, c ; Table 63). All of these mutants were thermostabilising in at least one of these thermostability assays relative to V595I. The half-life in stability assay A increased from 27 min at 55° C. for TSHR-JMG55-V595I to 59 min for JMG82 (JMG55+V595I+T477I) [JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41)+V595I (SEQ ID No 100)+T477I (SEQ ID No 97)]. The most thermostable mutant in stability assay B was JMG84 (JMG55+V595I+K565L) [JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41)+V595I (SEQ ID No 100)+K565L (SEQ ID No 99)] with a half-life at 55° C. of 38 min, a 2.4-fold improvement on the 18 min half-life of TSHR-JMG55-V595I. However, JMG91 (JMG55+V595I+Y678L) and JMG84 (JMG55+V595I+K565L) were selected as the mutants with the best all-round thermostability in all three thermostability assays. In stability assay A, JMG91 has a half-life of 48 min at 55° C., a 1.8 times improvement of TSHR-JMG55-V595I, in stability assay B it has a half-life of 30 min at 55° C. which is a 1.7 times improvement of TSHR-JMG55-V595I and in stability assay C, it has a half-life of 108 min at 33° C. which is a 2.1 times improvement over TSHR-JMG55-V595I. This is equivalent to survival of 80%, 64% and 49% after 10, 30 and 120 min respectively at 33° C., which is an increase in stability of 1.3, 1.1 and 1.3 times respectively. In stability assay A, JMG84 has a half-life of 44 min at 55° C., a 1.6 times improvement of TSHR-JMG55-V595I, in stability assay B it has a half-life of 38 min at 55° C. which is a 2.4 times improvement of TSHR-JMG55-V595I and in stability assay C, it has a half-life of 102 min at 33° C. which is a 1.6 times improvement over TSHR-JMG55-V595I. This is equivalent to survival of 72%, 60% and 48% after 10, 30 and 120 min respectively at 33° C., which is an increase in stability of 1.1, 1.1 and 1.4 times respectively.

Thermostability of Triple Mutations in the TMD of TSHR-JMG55

TSHR-JMG91 and TSHR-JMG84 were combined with 15 single mutations that were thermostabilising in the double TSHR mutant thermostability assays (Table 61). Due to the increased thermostability of these mutants, in stability assay C, the solubilised TSHR mutants were heated at 40° C. instead of 33° C. used previously. While some of the triple mutants are thermostabilising relative to the double mutants TSHR-JMG91 (JMG55+V595I+Y678L) or TSHR-JMG84 (JMG55+V595I+K565L) in stability assays A and B, only the triple TMD mutants of full length TSHR-JMG55 built on TSHR-JMG84 (JMG127 to JMG142) are thermostabilising in thermostability assay C at 40° C. (Table 64). The overall most thermostabilising of the triple mutants of TSHR-JMG55 is TSHR-JMG131 (JMG55+V595I+K565L+N455A) [JMG55 (SEQ ID Nos 45, 36, 34, 37, 32, 41)+V595I (SEQ ID No 100)+K565L (SEQ ID No 99)+N455A (SEQ ID No 93)]. In stability assay A, TSHR-JMG131 has a half-life at 55° C. of 60 minutes, which is a 1.5-fold improvement of the 38±4 minute half-life of TSHR-JMG84. In stability assay B at 55° C., TSHR-JMG131 has a 32 minute half-life, which is a 1.1 times improvement of the 23±7 minute half-life of TSHR-JMG84. In stability assay C at 40° C., TSHR-JMG131 has a half-life of 47 minutes which is a 3.5-fold increase in thermostability over TSHR-JMG84, which has a half-life of 14±3 minutes at 40° C.

M22-POD, K1-70-POD and K1-18-POD Binding to TSHR TMD Mutants

M22-POD, K1-18-POD and K1-70-POD binding to full-length TSHR mutants, TSHR-JMG55, TSHR-JMG55-V595I, TSHR-JMG84 (JMG55+V595I+K565L) and TSHR-JMG91 (JMG55+V595I+Y678L), has been tested by varying the concentration of TRAb-peroxidase conjugate (i.e. M22-POD, K1-18 POD or K1-70 POD) binding to ELISA plates coated with TSHR mutants and detecting the binding of TRAb-peroxidase conjugate by incubation with the substrate tetramethylbenzidine (FIG. 14 a ). The binding constant (K_(d)), i.e. the concentration of ligand (TRAb-peroxidase) at which half of the receptor is bound to ligand, was determined (Table 65). The mutations tested did not affect the binding of TSHR mutants to any of M22-POD, K1-18-POD or K1-70-POD relative to TSHR-JMG55 (Table 65 to Table 67).

Inhibition of M22-POD Binding to Full-Length TSHR-JMG55 Mutants by M22 IgG, K1-18 IgG, K1-70 IgG or TRAb Positive Patient Sera

Inhibition of M22-POD binding to full-length TSHR-JMG55 mutants TSHR-JMG55, TSHR-JMG55-V595I, TSHR-JMG84 (JMG55+V595I+K565L) and TSHR-JMG91 (JMG55+V595I+Y678L) was determined by incubating the TSHR mutants with M22 IgG, K1-18 IgG, K1-70 IgG or TRAb positive patient sera before incubation with M22-POD (FIG. 14 e ). M22 IgG, K1-18 IgG, K1-70 IgG and TRAb positive patient sera inhibit the binding of M22-POD to the full-length TSHR mutants to a similar extent as to TSHR-JMG55. These results show that the mutations have not affected binding of the monoclonal TSHR antibodies to full-length TSHR (Table 68 to Table 70). Similarly, the TRAb positive patient sera show similar inhibition of M22-POD binding to the TSHR-JMG55 mutants as to TSHR-JMG55 (Table 71). Therefore, these full-length TSHR mutants are suitable for use in assays to detect TRAb in patient sera.

Transferability of Thermostabilising Human TSHR Mutations in the TMD Region to TSHR from Other Species and Other Glycoprotein Hormone Receptors.

Table 72 shows that most of the amino acids located in the TMD that have been mutated in the human TSHR to improve thermostability are conserved across human, mouse and porcine TSHR. Glu409, Asp410, His443, Leu452, Asn455, Met463, Tyr466, Leu467, Thr477, Gln489, Lys565, Cys600, Tyr601, Lys660, Tyr667, Ser671 and Tyr678 are conserved across all species. Residue 595 is Val in human and mouse, but Thr in porcine. Mutation of Thr595 to Ile in porcine TSHR is likely to be thermostabilising. Residue 648 is Ile in human but Leu in mouse and porcine. Therefore mouse and porcine TSHR already have the target residue of the I648L thermostabilising mutation in hTSHR. Mutation to Val, another aliphatic residue may alter the thermostability.

The sequence alignment of human TSHR (SEQ ID No 2), FSHR (SEQ ID No 57) and LHR (SEQ ID No 58) (FIG. 11 ) indicates that many of the thermostabilising mutated residues in hTSHR correspond to the same or similar residues in the hFSHR and hLHR. Consequently, most of the thermostabilising mutations located in the TMD of TSHR are likely to be thermostabilising when transferred to the equivalent residues of FSHR and LHR (Table 73). The only differences are: His443, which is Gln391 in FSHR and Arg388 in LHR; Met463, which is Ile411 in FSHR; Ile648, which is Ser596 in FSHR and Ala593 in LHR; and Tyr667 which is His615 in FSHR and Tyr612 in LHR. Some of these equivalent mutations may still be thermostabilising.

SUMMARY AND CONCLUSIONS

This invention presents a novel approach to improving the thermostability of glycoprotein hormone receptor proteins such as the TSHR based on rational-scanning mutagenesis. Here, the approach of rationally designing a few stabilising mutations has been combined with the power of the scanning mutagenesis approach of mutating every residue in a protein to alanine to identify thermostabilising positions in the TSHR sequence. In the rational-scanning mutagenesis approach, for each position in the TSHR protein the most probable stabilising mutation (predicted by the present inventors by a combination of computational and rational methods) has been produced and tested for thermostabilising properties. In this invention high-throughput methods have enabled us to generate and screen many mutants to identify the most thermostabilising mutations. This has enabled the identification of more thermostabilising mutations in the TSHR sequence than would have been possible otherwise. The methods described in the invention could also be applied to improve thermostability of other proteins. The method of the invention has in particular enabled the identification of 17 greatly thermostabilising mutations of TSHR260 (P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, I167F, P168Y, V169R, N170W, T179C, I253R and R255Y) (FIGS. 5 and 6 ; SEQ ID Nos 11-25, 27-43, 45 and 46) that have been successfully combined to produce more thermostable TSHR260 mutants which improve the thermostability of TSHR260 up to 900 times. These mutants still bind TSHR stimulating human autoantibody M22 in a similar manner to TSHR260-WT. The thermostability of the most stable single (TSHR260-I253R) (SEQ ID No 45), double (TSHR260-JMG22: I253R (SEQ ID No 45)+D143P (SEQ ID No 36)), triple (TSHR260-JMG37: I253R (SEQ ID No 45)+D143P (SEQ ID No 36)+R112P (SEQ ID No 34)), quadruple (TSHR260-JMG45: I253R (SEQ ID No 45)+D143P (SEQ ID No 36)+R112P (SEQ ID No 34)+D151E (SEQ ID No 37)), quintuple (TSHR260-JMG52: I253R (SEQ ID No 45)+D143P (SEQ ID No 36)+R112P (SEQ ID No 34)+D151E (SEQ ID No 37)+V169R (SEQ ID No 41)) and hextuple (TSHR260-JMG55: I253R (SEQ ID No 45)+D143P (SEQ ID No 36)+R112P (SEQ ID No 34)+D151E (SEQ ID No 37)+V169R (SEQ ID No 41)+H63C (SEQ ID No 32)) TSHR260 mutants improve the thermostability of the TSHR260 by approximately 3.1, 13, 42, 174, 450, 700 and 900 times respectively. Furthermore, in the case of full-length TSHR, the triple (TSHR-JMG37: I253R+D143P+R112P), quadruple (TSHR-JMG45: I253R+D143P+R112P+D151E), quintuple (TSHR-JMG52 I253R+D143P+R112P+D151E+V169R) and hextuple (TSHR260-JMG55: I253R+D143P+R112P+D151E+V169R+H63C) TSHR mutants improve the thermostability relative to full-length wild-type TSHR.

The mutations do not affect binding of the monoclonal TSHR antibodies (M22, K1-18 and K1-70) to TSHR260 or full length TSHR. Further, TRAb positive patient sera inhibit the binding of M22-POD to the TSHR260 mutants and full-length TSHR mutants to the same extent as to wild-type TSHR260 and full-length TSHR respectively. Even further, M22-Fab, K1-18 IgG and TSH stimulate the production of cyclic AMP in full length TSHR mutants expressed in Flp-In CHO cells in a similar way to that seen for the wild-type TSHR.

Increasing the thermostability of TSHR preparations, especially TSHR260, has enabled purification of the mutants, in particular the most thermostable mutant of TSHR260, TSHR260-JMG55 (I253R+D143P+R112P+D151E+V169R+H63C; SEQ ID Nos 45, 36, 34, 37, 41 and 32 respectively), to homogeneity while retaining its activity without the need for an antibody bound to it to maintain the folded state of TSHR260. This is the first time conformationally active TSHR260 has been purified without antibodies bound to it. After deglycosylation of the purified material using Endoglycosidase F3, the TSHR260-JMG55 was still active. Both the purified and the deglycosylated TSHR260-JMG55 material can be used in improved assays to detect TSHR autoantibodies in patient sera.

These thermostabilising mutations were also transferable, for example to the fusion protein TSHR260-AP, which consists of the detectable label alkaline phosphatase joined to TSHR260 for use in assays. The thermostabilising TSHR260-AP mutants, TSHR260-AP-JMG22 (I253R+D143P; SEQ ID Nos 45 and 36), TSHR260-AP-JMG45 (I253R+D143P+R112P+D151E; SEQ ID Nos 45, 36, 34 and 37) and TSHR260-AP-JMG55 (I253R+D143P+R112P+D151E+V169R+H63C; SEQ ID Nos 45, 36, 34, 37, 41 and 42) improve the thermostability of TSHR260-AP approximately 11-, 66-, or 165-fold respectively. These TSHR260-AP mutants are still able to bind TRAb antibodies (M22, K1-18, K1-70 and TRAb positive patient sera) to the same extent as wild-type TSHR260-AP. These constructs are valuable for use in the TSHR260-AP bridge ELISA for detecting TSHR autoantibodies in patient sera. Other detectable labels may also be used and it is expected that the thermostabilising mutations identified for TSHR260 and full-length TSHR will also increase the thermostability of these labelled constructs and therefore enable their use in a wide range of applications.

Many of the thermostabilising mutations disclosed in this invention are surprising and would not have been predicted by computational modelling or examination of the structure alone.

The experiments described as part of the present invention have highlighted the limited usefulness of using modelling software. The computationally predicted thermostabilities of mutants were mainly used in two situations. Firstly, when there was more than one option for rational mutagenesis, Discovery Studios was used to predict which mutation was likely to be most thermostabilising in a specific position. Secondly, when there was no clear rational mutation for a single residue, Discovery Studios software was used to predict the most thermostabilising, or, if all the mutations were destabilising, the least destabilising mutation. The software has been of some use in identifying many thermostabilising mutations that may not have been tested otherwise (e.g. H63C, S84F, P142I, D143P, P168Y, N170W and R255Y). However, for some residues, mutagenesis to any other amino acid was predicted to be destabilising. In these cases the least destabilising prediction out of many destabilising mutations was chosen. Surprisingly, some of these were found to be some of the most stabilising mutations (e.g. T62V, L64Y, P142I and I167F). There are also many cases of mutations that were predicted to be stabilising that were actually destabilising, illustrating the limitations of computational modelling and the requirement for experimental studies, which has now been possible using the methods disclosed in the present invention.

One of the most successful strategies of the invention has been the removal and introduction of proline residues into the structure. In total, 5/23 (22%) of the mutations to or from proline (i.e. P28E, R112P, P142I, D143P and P168Y) stabilise TSHR260 considerably, however it can also be very disruptive to the structure with 8/23 mutants (35%) expressed at very low levels or not at all. Proline, with its five-membered ring, has a very rigid structure with the backbone dihedral angle φ constrained to −63°±15° and the torsion angles of the residue preceding the proline residue constrained too. This decreased flexibility of the protein backbone gives it the lowest conformational entropy so that where the geometry is favourable, replacing an amino acid with proline produces a more thermostable TSHR. However, where the geometry is unfavourable, a proline residue can introduce strain into the structure by confining the torsion angles. Substituting such a proline residue with another more flexible amino acid, releases the strain producing a more thermostable residue.

A second successful strategy of the invention has been the mutation of surface residues to charged residues. P28E, D151E, V169R and I253R have all involved the introduction or change of a charged residue to the surface of the protein. In particular, V169R and I253R, involve the mutation of aliphatic surface residues to the analogous residue in hFSHR, which in both cases is Arg.

Further stabilising mutations of full-length TSHR were identified in the transmembrane domain (TMD) of TSHR. The twenty most thermostabilising mutations identified in the TMD region of TSHR are: E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, V595I, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L and Y678A (FIGS. 29 and 30 ; SEQ ID Nos 69-88 (DNA) and SEQ ID Nos 89-108 (protein)). They increase the stability of TSHR-JMG55 up to 4.5-fold in stability assay A, up to 1.6-fold in stability assay B, and up to 15-fold in stability assay C. They have been combined to form double (e.g. TSHR-JMG91 (JGM55 (SEQ ID Nos 45, 36, 34, 37, 32 and 41)+V595I (SEQ ID No 100)+Y678L (SEQ ID No 107)) and TSHR-JGM84 (JGM55 (SEQ ID Nos 45, 36, 34, 37, 32 and 41)+V595I (SEQ ID No 100)+K565L (SEQ ID No 99)) and triple mutants (e.g. TSHR-JMG131 (JMG55 (SEQ ID Nos 45, 36, 34, 37, 32 and 41)+V595I (SEQ ID No 100)+K565L (SEQ ID No 99)+N455A (SEQ ID No 93)) with mutations located in the TMD which further increase the thermostability of full-length TSHR.

An immediate and key outcome of the invention is production for the first time of thermostable TSHR preparations. This opens up new opportunities to apply the effect of the mutations to the stability of the full-length TSHR and other TSHR preparations consisting of shorter sequences. Such TSHR preparations will be useful for the production of improved, manual and automated assay systems (for detection of patient TRAbs) which can be run at higher temperatures. Furthermore, thermostable TSHR preparations can be purified and the availability of such pure preparations will have important implications for studies on the structure of the TSHR and development of new therapeutics.

Tables

TABLE 1 Single amino acid mutations in TSHR260 Mutation Reason for mutation Mutation Reason for mutation G21D surface L64Y DS M22K consensus sequence R65K consensus sequence G23R consensus sequence T66V DS C24E surface I67L DS S25P consensus sequence P68Q consensus sequence S26D surface S69P torsion angles P27T natural variant - H70R consensus sequence hypothyroid P28E surface A71C DS C29E surface F72Y DS E30D surface S73E surface C31I β-sheet N74H DS H32I DS L75W DS Q33E β-sheet, surface P76E surface E34W DS N77E surface E35D consensus sequence I78V core D36E surface S79L DS F37R surface R80W DS R38I DS I81L DS V39I β-sheet Y82F DS T40D β-sheet V83L consensus sequence C41I β-sheet S84F DS K42R surface I85Y DS D43E surface D86N DS I44L DS V87D surface Q45H consensus sequence T88E surface R46I DS L89A core I47F DS Q90E surface P48I DS Q91D DS S49C DS L92W DS L50I DS E93D surface P51R DS S94E surface P52T natural variant H95G torsion angles S53I DS S96A surface T54I DS F97Y surface Q55W DS Y98W surface T56I DS N99G torsion angles L57I β-sheet L100I LRR K58F DS S101I DS L59F consensus sequence K102R surface I60E surface V103L LRR E61W DS T104I DS T62V DS H105F DS H63C DS I106W DS E107Q DS F153T β-sheet I108W DS F154Y DS R109Y DS I155F DS N110W DS L156F LRR T111I β-sheet E157Q DS R112P torsion angles I158L LRR N113S consensus sequence T159R β-sheet L114W DS D160E β-sheet T115L consensus sequence N161I DS Y116F consensus sequence P162E surface I117L LRR Y163E surface D118E surface M164I LRR P119E surface T165S LRR D120E surface S166T β-sheet A121Y DS I167F LRR L122F LRR P168Y DS K123R surface V169R surface E124D surface N170W DS L125I LRR A171S consensus sequence P126W DS F172W DS L127C DS Q173E surface L128W DS G174I DS K129R surface L175F LRR F130T surface C176V LRR L131I LRR N177E surface G132W DS E178D surface I133F LRR T179C surface F134Y DS L180I LRR N135F DS T181I DS T136Y DS L182I LRR G137N DS K183R natural variant, β-sheet L138F LRR L184I LRR K139R consensus sequence Y185F DS M140V consensus sequence N186L DS F141Y DS N187Q DS P142I DS G188D DS D143P DS F189Y DS L144I LRR T190I DS T145F DS S191E β-sheet K146V DS V192I consensus sequence V147I consensus sequence Q193H DS Y148W DS G194P torsion angles S149Q DS Y195H consensus sequence T150I DS A196R DS D151E surface F197W DS I152V consensus sequence N198P torsion angles G199Q surface L230F DS T200Q DS L231I LRR K201W DS D232N DS L202I LRR V233I LRR D203E β-sheet S234M DS A204I β-sheet Q235Y consensus sequence V205I LRR T236N LRR Y206F DS S237I DS L207I LRR V238L LRR N208R DS T239C disulphide, DS K209Y DS A240S surface N210I DS L241I LRR K211R surface P242L DS Y212I DS S243P DS L213F DS, LRR K244W DS T214I DS G245L DS V215E surface L246F LRR I216F LRR E247C DS D217P LRR H248S consensus sequence K218N consensus sequence L249E surface D219W DS K250C DS A220F DS E251C DS F221W DS L252I LRR, β-sheet G222D DS I253R surface G223P DS A254L LRR, DS V224I LRR R255Y DS Y225H consensus sequence N256Y DS S226W DS T257N LRR G227A torsion angles W258I LRR, β-sheet P228L LRR T259S LRR S229T β-sheet L260C disulphide Reasons for carrying out the particular mutations are as follows: Torsion angles—mutations of residues with the correct backbone structure for mutation to Pro or Gly determined by examination of the torsion angles of the backbone of the TSHR260 crystal structure; Consensus—mutations to the consensus sequence of either TSHR across different species, or the three glycoprotein hormone receptors. Also, one naturally occurring TSHR variant P27T that is reported to cause hypothyroidism; β-sheet—mutagenesis of β-strand residues so that the alternating polar, non-polar periodicity is maintained, core residues mutated to Ile, surface residues mutated to Thr, Asp or Arg. LRR—mutations to conform to the general consensus sequence of the leucine rich repeat motif, LxxLxLxxNxLxxLpxxoFxxLxx, where “L” is Leu, Ile, Val or Phe, “N” is Asn, Thr, Ser or Cys, “o” is non-polar and “x” is a non-conserved residue (Matsushima, Miyashita, Mikami, & Kuroki, 2010); Surface -surface residues mutated to Glu (or Asp if already Glu), nature of charged residues are maintained by mutating Arg to Lys and Lys to Arg; Core—mutations of core residues, Ile and Ala to Val, Gly to Gln, other residues to Ala. DS—mutations that were predicted to be stabilising by molecular modelling with Discovery Studios software.

TABLE 2 Effect of single mutations on the stability of TSHR260 as assessed in an assay based on binding of M22-peroxidase to TSHR260 (TSHR260-binding assay) Binding in Binding in TSHR 260 assay Stability screen TSHR260 assay Stability screen Mutation (% WT std) (% WT stability) Mutation (% WT std) (% WT stability) WT 100 100 E61W 69 77 M22K 72 135 T62V 16 123 G23R 307 78 H63C 153 143 C24E 71 82 L64Y 20 142 S25P 86 140 R65K 5 97 S26D 59 142 T66V 33 87 P27T 124 129 I67L 57 79 P28E 24 216 P68Q 26 40 C29E 62 90 S69P 243 82 E30D 40 152 H70R 43 81 C31I 195 138 A71C 42 69 H32I 175 104 F72Y 45 35 Q33E 241 83 S73E 196 64 E34W 49 140 N74H 31 71 E35D 246 129 L75W 13 0 D36E 226 103 P76E 79 91 F37R 33 46 N77E 48 81 R38I 164 135 I78V 37 0 V39I 110 121 S79L 19 0 T40D 25 93 R80W 12 0 C41I 8 250 I81L 23 0 K42R 61 172 Y82F 85 102 D43E 22 0 V83L 80 102 I44L 14 89 S84F 154 108 Q45H 0 — I85Y 397 145 R46I 0 — D86N 25 154 I47F 5 79 V87D 40 141 P48I 9 34 T88E 59 110 S49C 0 — L89A 35 109 L50I 9 0 Q90E 244 73 P51R 0 — Q91D 44 96 P52T 10 171 L92W 9 0 S53I 35 118 E93D 98 83 T54I 82 82 S94E 83 96 Q55W 41 74 H95G 23 57 T56I 172 126 S96A 70 85 L57I 102 92 F97Y 14 66 K58F 78 136 Y98W 52 104 L59F 200 209 N99G 56 75 I60E 54 118 L100I 7 205 S101I 116 130 L144I 42 96 K102R 88 244 T145F 0 — V103L 271 159 K146V 0 — T104I 94 162 V147I 284 66 H105F 38 0 Y148W 129 50 I106W 6 223 S149Q 0 — E107Q 54 92 T150I 140 76 I108W 7 54 D151E 426 153 R109Y 21 47 I152V 242 90 N110W 45 78 F153T 75 101 T111I 41 122 F154Y 0 — R112P 351 167 1155F 0 — N113S 149 146 L156F 0 — L114W 9 170 E157Q 44 0 T115L 37 90 I158L 47 0 Y116F 96 129 T159R 23 60 I117L 60 54 D160E 0 — D118E 79 68 N161I 0 — P119E 57 49 P162E 16 130 D120E 128 55 Y163E 23 0 A121Y 20 0 M164I 449 136 L122F 332 49 T165S 87 58 K123R 228 59 S166T 690 170 E124D 365 62 I167F 16 189 L125I 31 0 P168Y 21 248 P126W 6 0 V169R 696 212 L127C 187 66 N170W 44 205 L128W 0 — A171S 0 — K129R 205 71 F172W 0 — F130T 16 81 Q173E 0 — L131I 0 — G174I 0 — G132W 0 — L175F 0 — I133F 122 34 C176V 0 — F134Y 205 76 N177E 34 96 N135F 2 0 E178D 37 0 T136Y 0 — T179C 10 208 G137N 0 — L180I 193 90 L138F 1 0 T181I 0 — K139R 216 203 L182I 13 95 M140V 5 0 K183R 77 66 F141Y 0 — L184I 10 117 P142I 5 201 Y185F 42 33 D143P 562 214 N186L 0 — N187Q 0 — V224I 36 59 G188D 0 — Y225H 243 115 F189Y 0 — S226W 21 33 T190I 59 61 G227A 0 — S191E 271 159 P228L 0 — V192I 241 102 S229T 0 — Q193H 70 77 L230F 280 128 G194P 238 156 L231I 12 55 Y195H 32 99 D232N 0 — A196R 0 — V233I 0 — F197W 0 — S234M 3 0 N198P 0 — Q235Y 123 109 G199Q 0 — T236N 0 — T200Q 0 — S237I 6 0 K201W 0 — V238L 225 141 L202I 0 — T239C 10 80 D203E 77 60 A240S 160 161 A204I 9 0 L241I 141 81 V205I 2 — P242L 0 — Y206F 31 0 S243P 9 0 L207I 0 — K244W 0 — N208R 0 — G245L 0 0 K209Y 0 — L246F 0 — N210I 5 — E247C 5 0 K211R 124 76 H248S 58 66 Y212I 0 — L249E 0 — L213F PCR 0 K250C 24 91 T214I 0 — E251C 165 144 V215E 164 111 L252I 144 142 1216F 19 0 I253R 978 178 D217P 4 0 A254L 54 84 K218N 132 105 R255Y 188 177 D219W 5 0 N256Y 11 59 A220F 0 — T257N 74 71 F221W 4 0 W258I 123 89 G222D 106 56 T259S 104 67 G223P 2 0 L260C 20 22 For each TSHR260 mutation expressed in CHO-K1 cells, M22-binding in the TSHR260 assay (FIG. 12a) is expressed as a percentage of TSHR260-WT and the stability, determined by the proportion of active protein remaining after heating at 42° C. for 30 min (FIG. 12b), is expressed as a percentage of the TSHR260-WT stability (% WT). The stability screen results of mutations which increase the stability are in bold. These mutations were tested in the thermostability assay to determine the half-life of the mutant (FIG. 12b). M22 is a human monoclonal autoantibody to the TSHR.

TABLE 3 Half-life of TSHR260 mutants at 42° C. determined in the TSHR260-binding assay Stability ratio relative to Mutation t_(1/2) at 42° C. (min) Δt_(1/2) relative to WT (min) WT at 42° C. n WT 30.9 ± 1.1 0.0 ± 1.1 1 ± 0 24  M22K 27 ± 4 −3 ± 9  1.0 ± 0.3 2 G23R 25.8 ± 0.8 −10.3 ± 1.1  0.72 ± 0.02 3 S25P 25 ± 4 1 ± 2 1.05 ± 0.10 2 S26D 31.3 ± 1.2 7.8 ± 0.6 1.34 ± 0.05 2 P27T 33 ± 2 2 ± 2 1.11 ± 0.11 3 P28E 58.9 ± 0.2 30 ± 4 2.1 ± 0.3 2 E30D 39 ± 4 5.2 ± 1.2 1.16 ± 0.06 2 C31I 31.1 ± 1.8 3 ± 5 1.14 ± 0.20 2 Q33E 27.9 −11 0.72  1^(a) E35D 25 ± 4 −5 ± 4  0.85 ± 0.10 2 R38I 33.7 ± 0.8 2 ± 2 1.07 ± 0.08 2 K42R 28 3 1.11  1^(a) 147F 24 −3.7 0.87  1^(a) P52T 27.1 2 1.08  1^(a) S53I 36.5 ± 0.8 3 ± 6 1.11 ± 0.19 2 T56I 26.8 −4 0.86  1^(a) K58F 29.4 ± 1.2 2 ± 5 1.08 ± 0.18 2 L59F 47 ± 5 18 ± 4  1.61 ± 0.12 5 T62V  74 ± 14 49 ± 13 2.9 ± 0.4 2 H63C 70 ± 7 37 ± 7  2.2 ± 0.2 4 L64Y 113 ± 7  80 ± 13 3.7 ± 0.9 2 T66V 30 ± 6 −3 ± 6  0.92 ± 0.19 2 S69P 32 ± 3 −1.6 ± 1.8  0.95 ± 0.06 3 H70R 27.8 −7 0.81  1^(a) P76E 25.9 −7 0.79  1^(a) S84F 44 ± 5 10 ± 6  1.30 ± 0.18 5 I85Y 38 ± 2 2.8 ± 1.8 1.08 ± 0.05 5 D86N 39.7 15 1.59  1^(a) V87D 41 17 1.7  1^(a) Q90E 32 ± 4 −4 ± 5  0.92 ± 0.16 3 S101I 38 ± 4 2 ± 3 1.06 ± 0.09 3 K102R 30.3 ± 1.4 −4.6 ± 1.8  0.87 ± 0.04 2 V103L 34 ± 4 −1 ± 6  0.99 ± 0.16 2 T104I 31.5 ± 1.6 −6 ± 3  0.84 ± 0.07 3 R112P 62 ± 7 27 ± 7  1.8 ± 0.2 4 N113S 21.5 −20 0.52  1^(a) Y116F 24.3 −10.6 0.7  1^(a) K139R 30.6 6 1.23  1^(a) P142I 134 ± 20 109 ± 19  5.5 ± 0.8 2 D143P 80 ± 9 55 ± 9  3.2 ± 0.4 2 D151E 53.2 ± 1.4 27.9 ± 1.8  2.11 ± 0.09 2 1152V 34.1 4 1.14  1^(a) P162E 13.4 −14 0.48  1^(a) M164I 34 6 1.22  1^(a) S166T 49 ± 2 23 ± 3  1.85 ± 0.15 2 I167F 72 ± 8 44 ± 8  2.6 ± 0.3 2 P168Y  74 ± 18 49 ± 17 2.9 ± 0.5 3 V169R 56 ± 9 32 ± 9  2.3 ± 0.4 2 N170W 70 ± 13 47 ± 14 3.1 ± 0.7 2 T179C 60 ± 7 35 ± 7  2.4 ± 0.3 3 S191E 42.5 ± 1.6 14 ± 3  1.52 ± 0.15 2 G194P 42 ± 2 13.7 ± 0.6  1.49 ± 0.01 2 V205I 12 −12.2 0.49  1^(a) V215E 32.8 ± 0.2 3 ± 3 1.11 ± 0.13 2 K218N 24.3 −7 0.78  1^(a) Y225H 34.2 ± 0.5 5.4 ± 1.6 1.19 ± 0.07 2 L230F 31 ± 3 3.8 ± 0.5 1.14 ± 0.03 2 Q235Y 26.1 −5 0.85  1^(a) V238L   38 ± 0.6 8 ± 2 1.3 ± 0.1 2 A240S 32 ± 2 7.73 ± 0.11 1.32 ± 0.03 2 E251C 30.2 −2 0.94  1^(a) L252I 30 ± 4 2.04 ± 0.04 1.07 ± 0.01 2 I253R 81 ± 3 53 ± 6  3.0 ± 0.4 3 R255Y 42 ± 3 17.8 ± 1.1  1.73 ± 0.02 2 The half-life of each mutant is determined by heating aliquots at 42° C. assaying at intervals over a period of two hours (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. In each experiment, the thermostability (half-life, t_(1/2)) of TSHR260-WT was measured and used to determine the difference in half-life (Δt_(1/2)) and half-life ratio compared to the half-life of TSHR260-WT in the same experiment. In bold are the most thermostabilising mutants, which were used to make double mutants. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± standard error of the mean (SEM) for experiments repeated at least twice. ^(a)Experiments that have only been performed a single time (assayed in duplicate) do not have SEM associated with them.

TABLE 4 Analysis of the levels of expression of TSHR260 mutants relative to TSHR260-WT, as measured by the Dot Blot assay (total amount of TSHR mutant, i.e. active plus inactive), and their activity in the TSHR260-binding assay relative to TSHR260-WT Stability ratio at 42° C. (WT ratio) Dot Blot TSHR260-binding TSHR260-binding/ or * stability Mutation (% WT) assay (% WT) Dot Blot (Ratio) Classification screen data (% WT) WT 100 100 1.00 a 1.00 Neg 2 0 0.00 — — M22K 30 88 2.97 b 0.87 G23R 370 345 0.93 a 0.71 C24E 43 37 0.86 a *82 S25P 173 65 0.38 c 1.02 S26D 270 73 0.27 c 1.33 P27T 201 133 0.66 a 1.04 P28E 121 25 0.20 c 1.97 C29E 142 62 0.44 a *90 E30D 132 38 0.29 c 1.14 C31I 32 195 6.10 b 1.04 H32I 199 175 0.88 a *104 Q33E 403 24 0.60 a 0.72 E34W 55 49 0.89 a *140 E35D 358 246 0.69 a 0.82 D36E 420 226 0.54 a *103 F37R 65 33 0.51 a *46 R38I >420 164 <0.39 c 1.03 V39I 141 110 0.78 a *121 T40D 85 24 0.29 c *93 C41I 4 8 2.21 — *250 K42R 35 61 1.76 a 1.11 D43E 58 22 0.38 c *0 I44L 288 14 0.05 c *89 Q45H 232 0 0.00 c — R46I 0 0 0.00 — — I47F nd 5 nd — 0.87 P48I 18 11 0.62 — *34 S49C 93 0 0.00 c — L50I 72 9 0.12 c *0 P51R 9 0 0.00 — — P52T 49 7 0.14 c 1.08 S53I 28 40 1.43 a 1.06 T54I 116 82 0.71 a *82 Q55W 13 41 3.13 b *74 T56I 220 172 0.78 c 0.86 L57I 155 102 0.66 a *92 K58F nd 78 nd — 1.07 L59F 87 171 1.96 a 1.58 I60E >420 54 <0.13 c *118 E61W 67 69 1.02 a *77 T62V 5 9 1.78 — 2.91 H63C 34 172 5.04 b 1.99 L64Y 3 10 3.50 — 3.28 R65K 10 5 0.49 — *97 T66V nd 33 nd — 0.91 I67L 46 57 1.22 a *79 P68Q 48 26 0.55 a *40 S69P 44 234 5.30 b 0.96 H70R 69 43 0.63 a 0.81 A71C 26 42 1.60 a *69 F72Y 4 45 10.93 b *35 S73E 86 196 2.28 a *64 N74H 82 31 0.38 c *71 L75W 8 13 1.60 — *0 P76E 75 79 1.06 a 0.79 N77E 35 48 1.37 a *81 I78V 46 39 0.84 a *0 S79L 20 19 0.93 a *0 R80W 36 12 0.32 a *0 I81L 13 23 1.83 a *0 Y82F 112 85 0.76 a *102 V83L 118 80 0.68 a *102 S84F 159 191 1.20 a 1.13 I85Y 359 309 0.86 a 1.06 D86N 7 30 4.46 b 1.59 V87D 195 45 0.23 c 1.66 T88E 200 59 0.29 c *110 L89A 14 35 2.46 a *109 Q90E 98 244 2.49 a 0.90 Q91D 12 44 3.63 b *96 L92W 6 9 1.53 — *0 E93D 133 98 0.74 a *83 S94E 85 83 0.98 a *96 H95G 20 23 1.15 a *57 S96A 104 70 0.68 a *85 F97Y 4 14 4.04 — *66 Y98W 33 52 1.60 a *104 N99G 14 56 3.93 b *75 L100I 2 10 5.44 — *205 S101I 12 116 9.79 b 1.00 S101L 8 109 13.16 b 1.21 K102R 68 88 1.29 a 0.88 K102L 8 13 1.60 — *81 V103L 109 271 2.49 b 0.95 T104I 59 94 1.61 a 0.83 H105F 24 38 1.59 a *0 I106W 3 6 1.97 — *223 E107Q 18 54 2.98 b *92 I108W 1 7 5.03 — *54 R109Y 8 21 2.55 a *47 N110W 15 45 2.95 b *78 T111I 10 41 4.10 b *122 R112P 123 351 2.86 b 1.65 N113S 94 149 1.59 a 0.52 L114W 2 9 4.54 — *170 T115L 50 37 0.75 a *90 Y116F 137 96 0.70 a 0.70 I117L >420 60 <0.14 c *54 D118E 144 79 0.55 a *68 P119E >420 57 <0.14 c *49 D120E >420 128 <0.30 c *55 A121Y 15 20 1.31 — *0 L122F >420 332 <0.79 a *49 K123R >420 228 <0.54 a *59 E124D >420 365 <0.87 a *62 L125I 180 31 0.17 c *0 P126W 5 6 1.38 — *0 L127C 210 187 0.89 a *66 L128W 4 0 0.00 — — K129R 131 205 1.56 a *71 F130T 159 16 0.10 c *81 L131I 30 0 0.00 c — G132W 9 0 0.00 — — I133F 210 122 0.58 a *34 F134Y 198 205 1.04 a *76 N135F 12 2 0.14 — *0 T136Y 1 0 0.00 — — G137N 6 0 0.00 — — L138F 1 1 0.58 — — K139R 187 166 0.89 a 1.23 M140V 20 7 0.36 — *0 F141Y 2 0 0.00 — — P142I 3 8 2.42 — 5.49 D143P 43 576 13.36 b 3.12 L144I 154 42 0.27 c *96 T145F 4 0 0.00 — — K146V 2 0 0.00 — — V147I 210 284 1.35 a *66 Y148W 204 129 0.63 a *50 S149Q 0 0 0.00 — — T150I 91 140 1.54 a *76 D151E 298 476 1.59 a 2.11 I152V 210 343 1.63 a 1.14 F153T 201 75 0.37 c *101 F154Y 3 0 0.00 — — I155F 18 0 0.00 — — L156F 2 0 0.00 — — E157Q >210 44 <0.21 c *0 I158L >210 47 <0.22 c *0 T159R 145 23 0.16 c *60 D160E 9 0 0.00 — — N161I 8 0 0.00 — — P162E 38 11 0.29 c 0.48 Y163E 98 23 0.24 c *0 M164I >210 523 <2.49 a 1.22 T165S >210 87 <0.41 c *58 S166T 266 682 2.56 b 1.87 I167F 4 18 5.23 — 2.50 P168Y 1 14 10.01 — 2.60 V169R 157 720 4.59 b 2.22 N170W 5 61 12.65 b 2.93 A171S 27 0 0.00 c — F172W 3 0 0.00 — — Q173E 5 0 0.00 — — G174I 4 0 0.00 — — L175F 4 0 0.00 — — C176V 20 0 0.00 c — N177E 22 34 1.56 a *96 E178D 85 37 0.44 a *0 T179C 2 8 4.68 — 2.37 L180I 132 193 1.46 a *90 T181I 44 0 0.00 c — L182I 69 13 0.18 c *95 K183R 143 77 0.54 a *66 L184I 17 10 0.57 — *117 Y185F 112 42 0.37 c *33 N186L 9 0 0.00 — — N187Q 5 0 0.00 — — G188D 13 0 0.00 — — F189Y 19 0 0.00 — — T190I 85 59 0.70 a *61 S191E 301 392 1.30 a 1.48 V192I 151 0 0.00 c — Q193H 183 59 0.32 c *77 G194P 293 329 1.12 a 1.49 Y195H 204 32 0.15 c *99 A196R 39 0 0.00 c — F197W 4 0 0.00 — — N198P 7 0 0.00 — — G199Q 28 0 0.00 c — T200Q 5 0 0.00 — — K201W 16 0 0.00 — — L202I 13 0 0.00 — — D203E 87 77 0.88 a *60 A204I 3 9 2.63 — *0 V205I 3 4 1.22 — 0.49 Y206F 133 31 0.23 c *0 L207I 17 0 0.00 — — N208R 25 0 0.00 c — K209Y 36 0 0.00 c — K209R 224 196 0.87 a 0.93 N210I 1 0 0.00 — — K211R 31 124 4.01 b *76 Y212I 18 0 0.00 a — L213F nd nd — — nd T214I 10 0 0.00 — — V215E 97 150 1.56 a 1.12 I216F 95 19 0.20 c *0 D217P 14 4 0.26 — *0 K218N >420 163 <0.39 c 0.78 D219W 20 5 0.22 a *0 A220F 8 0 0.00 — — F221W 3 4 1.14 — *0 G222D >420 106 <0.25 c *56 G222L 138 289 2.09 a 1.00 G223P 1 2 1.48 — *0 V224I 96 36 0.37 c *59 Y225H >420 279 <0.66 a 1.19 S226W 58 21 0.37 c *33 G227A 2 0 0.00 — — P228L 5 0 0.00 — — S229T 3 0 0.00 — — L230F >420 338 <0.81 a 1.13 L231I 50 12 0.24 c *55 D232N 42 0 0.00 c — V233I 20 0 0.00 c — S234M 26 3 0.11 c *0 Q235Y 71 142 2.00 a 0.85 T236N 22 0 0.00 c — S237I 7 6 0.86 — *0 V238L 286 264 0.92 a 1.32 T239C 3 16 5.18 — *80 A240S 78 136 1.75 a 1.33 L241I 84 141 1.68 a *81 P242L 8 0 0.00 — — S243P 61 9 0.15 c *0 K244W 5 0 0.00 — — G245L 0 0 — — — L246F 0 0 — — — E247C 18 7 0.40 a *0 H248S 64 58 0.90 a *66 L249E 0 0 — — — K250C 0 24 103.88 b *91 E251C 74 199 2.69 b 0.94 L252I 104 175 1.69 a 1.07 I253R 381 902 2.37 a 2.93 A254L 25 54 2.11 a *84 R255Y 31 175 5.70 b 1.74 N256Y 21 11 0.50 a *59 T257N 58 74 1.27 a *71 W258I 70 123 1.76 a *89 T259S 61 104 1.72 a *67 L260C 17 20 1.19 a *22 nd = not determined. The results of the Dot blot and the TSHR260-binding assay (FIG. 12a) were expressed as relative to the TSHR260-WT (% WT), respectively. Mutants are classified by the ratio between the TSHR260-binding assay and the dot Blot assay (total TSHR mutant protein) as follows: a little or no difference between the TSHR260-binding data and the Dot Blot expression data; b TSHR260-binding is considerably greater than the Dot Blot expression (TSHR260-binding/Dot Blot > 2.5); or c Dot Blot expression is considerably greater than the TSHR260-binding (TSHR260-binding/Dot Blot < 0.4). Where both the TSHR260-binding assay results and the Dot Blot results are low (less than 20% WT), these are not classified. Stability ratio is based on the half-life of the mutants, but where this was not measured, the stability screen data (as a percentage of TSHR260-WT (% WT)), where the mutants were heated at 42° C. for 30 minutes, is listed*.

TABLE 5 Combination of single TSHR260 mutations to produce double, triple, quadruple, quintuple and hextuple TSHR260 mutants Mutant name Mutation 1 Mutation 2 Mutation 3 Mutation 4 Mutation 5 Mutation 6 Double JMG1 P142I P28E Mutants JMG2 P142I L59F JMG3 P142I T62V JMG4 P142I H63C JMG5 P142I L64Y JMG6 P142I R112P JMG7 P142I D143P JMG8 P142I D151E JMG9 P142I S166T JMG10 P142I I167F JMG11 P142I P168Y JMG12 P142I V169R JMG13 P142I N170W JMG14 P142I T179C JMG15 P142I I253R JMG31 P142I R255Y JMG16 I253R P28E JMG17 I253R L59F JMG18 I253R T62V JMG19 I253R H63C JMG20 I253R L64Y JMG21 I253R R112P JMG22 I253R D143P JMG23 I253R D151E JMG24 I253R S166T JMG25 I253R I167F JMG26 I253R P168Y JMG27 I253R V169R JMG28 I253R N170W JMG29 I253R T179C Triple JMG30 I253R P142I D143P Mutants JMG32 I253R D143P P28E JMG33 I253R D143P L59F JMG34 I253R D143P T62V JMG35 I253R D143P H63C JMG36 I253R D143P L64Y JMG37 I253R D143P R112P JMG38 I253R D143P D151E JMG39 I253R D143P S166T JMG40 I253R D143P P168Y JMG41 I253R D143P V169R JMG42 I253R D143P N170W Quadruple JMG43 I253R D143P R112P L59F Mutants JMG44 I253R D143P R112P H63C JMG45 I253R D143P R112P D151E JMG46 I253R D143P R112P S166T JMG47 I253R D143P R112P V169R JMG48 I253R D143P R112P N170W Quintuple JMG49 I253R D143P R112P D151E L59F mutants JMG50 I253R D143P R112P D151E H63C JMG51 I253R D143P R112P D151E S166T JMG52 I253R D143P R112P D151E V169R JMG57 I253R D143P R112P H63C V169R JMG58 I253R D143P R112P H63C S166T Hextuple JMG53 I253R D143P R112P D151E H63C L59F mutants JMG54 I253R D143P R112P D151E H63C S166T JMG55 I253R D143P R112P D151E H63C V169R Corresponding mutations in full length TSHR are defined as TSHR-JMGx where x is the respective mutation number in TSHR260.

TABLE 6 Thermostability of the TSHR260 double mutants measured at 42° C. TSHR260- binding t_(1/2) at Δ t_(1/2) Stability Δ t_(1/2) Stability Mutant Mutation Mutation levels 42° C. (min) ratio (min) ratio name 1 2 (% WT) (min) Relative to WT Relative to I253R n WT std 100 28 ± 2  0 ± 2 1.0 ± 0.0 −60 ± 4  0.32 ± 0.01 10  I253R I253R 836 88 ± 7 59 ± 5 3.8 ± 0.1 0 ± 0 1.0 ± 0.0 8 JMG2 P142I L59F 29  253 ± 133  221 ± 128 8 ± 3 159 ± 126 2.6 ± 1.2 2 JMG4 P142I H63C 14 275 ± 94 245 ± 87 9.2 ± 1.0 180 ± 87  2.9 ± 0.8 2 JMG7 P142I D143P 15 70 48 3.2 −18 0.8  1^(a) JMG9 P142I S166T 11 197 171 7.4 109 2.2  1^(a) JMG15 P142I I253R 7 343 316 14 273 4.9  1^(a) JMG16 I253R P28E 35 212 ± 60 174 ± 59 5.6 ± 1.4 102 ± 50  1.9 ± 0.4 2 JMG17 I253R L59F 1007 144 ± 26 118 ± 20 5.5 ± 0.1 71 ± 13 1.96 ± 0.01 2 JMG19 I253R H63C 433 231 ± 10 205 ± 5  9.1 ± 1.4 157 ± 3  3.2 ± 0.4 2 JMG20 I253R L64Y 63 159 ± 17 132 ± 16 6.3 ± 0.9 74 ± 32 2.0 ± 0.5 2 JMG21 I253R R112P 1041 — — — — — 0 JMG22 I253R D143P 1031 261 ± 45 233 ± 42 9.3 ± 0.5 183 ± 37  3.3 ± 0.2 2 JMG23 I253R D151E 1200 126 ± 1  103 ± 1  5.6 ± 0.4 55 ± 9  1.8 ± 0.2 2 JMG24 I253R S166T 1357 141 ± 6  115 ± 7  5.5 ± 0.5 59 ± 7  1.7 ± 0.1 2 JMG26 I253R P168Y 40  329 ± 209  296 ± 203 9 ± 5 227 ± 191 3.0 ± 1.5 2 JMG27 I253R V169R 1194 142 ± 11 117 ± 12 5.6 ± 0.7 60 ± 12 1.7 ± 0.2 2 JMG28 I253R N170W 20  271 ± 111  238 ± 104 7.9 ± 1.8 161 ± 101 2.4 ± 0.8 2 JMG30 I253R PD142IP 91 24 −2 0.92 −76 0.24  1^(a) JMG1, JMG3, JMG5, JMG6, JMG8, JMG10, JMG11, JMG12, JMG13, JMG14, JMG18, JMG25, JMG29 and JMG31 showed too low binding in the TSHR260-binding assays so that determination of thermostability was not possible. The thermostability of JMG21 was not measured at 42° C. JMG30 is a triple mutant that was studied at only 42° C. The half-life of each mutant is determined by heating aliquots at 42° C. assaying at intervals over a period of three hours (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. In each experiment, the thermostability of TSHR260-WT and TSHR260-I253R were measured and used to determine the difference in half-life (Δ t_(1/2)) and half-life ratio compared to the half-life of TSHR260-WT and TSHR260-I253R in the same experiment. The most thermostabilising mutant with a good level of binding in the TSHR260-binding assays is in bold. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± SEM for experiments repeated at least twice. ^(a)Experiments that have only been performed a single time (assayed in duplicate) do not have SEM associated with them.

TABLE 7 Thermostability of the TSHR260 double mutants measured at 50° C. TSHR260- binding Δ t_(1/2) Stability Δ t_(1/2) Stability Mutant Mutation Mutation levels t_(1/2) (min) ratio (min) ratio name 1 2 (% WT) (min) Relative to WT Relative to I253R n WT std 100 1.43 ± 0.05   0 ± 0.05 1 ± 0 −2.61 ± 0.12  0.35 ± 0.02 9 I253R I253R 827 4.18 ± 0.10 3.1 ± 0.2 2.85 ± 0.13 0 ± 0 1 ± 0 19  JMG2 P142I L59F 9 42 41 29 39 11  1^(a) JMG4 P142I H63C 7 23 ± 3  22 ± 3  16 ± 3  23 ± 2  6.9 ± 1.5 2 JMG9 P142I S166T 7 4.82 ± 0.02 3.55 ± 0.03 3.80 ± 0.05 1.1 ± 0.3 1.30 ± 0.10 2 JMG16 I253R P28E 16 9.1 ± 1.5 7.7 ± 1.6 6.3 ± 1.4 4.7 ± 1.2 2.03 ± 0.19 2 JMG17 I253R L59F 833 6.03 ± 0.05 4.81 ± 0.09 5.0 ± 0.2 2.07 ± 0.12 1.52 ± 0.04 2 JMG19 I253R H63C 387 7.3 ± 1.0 6 ± 1 5.9 ± 0.6 3.3 ± 1.0 1.8 ± 0.2 2 JMG20 I253R L64Y 29 13.4 ± 0.3  11.8 ± 0.4  8.7 ± 0.7 9.5 ± 0.4 3.42 ± 0.17 2 JMG21 I253R R112P 1019 10.67 ± 0.02  — — 6.07 ± 0.05 2.32 ± 0.03 2 JMG22 I253R D143P 860 23.8 ± 0.7  22.4 ± 1.5  15.1 ± 0.7  19.4 ± 0.7  5.5 ± 0.2 9 JMG23 I253R D151E 1113 9.0 ± 0.3 7.65 ± 0.06 6.6 ± 0.8 4.94 ± 0.06 2.21 ± 0.04 2 JMG24 I253R S166T 1348 9.5 ± 0.8 7.9 ± 0.8 6.0 ± 0.3 5.4 ± 0.6 2.31 ± 0.07 2 JMG26 I253R P168Y 25 15.0 ± 1.9  13.7 ± 1.9  11.3 ± 1.1  10.9 ± 1.3  3.67 ± 0.13 2 JMG27 I253R V169R 1203 15.8 ± 1.8  14.2 ± 1.9  10.1 ± 1.5  11.9 ± 1.9  4.0 ± 0.5 2 JMG28 I253R N170W 16 11 ± 5  10 ± 5  9 ± 4 7 ± 5 3.1 ± 1.7 2 JMG1, JMG3, JMG5, JMG6, JMG7, JMG8, JMG10, JMG11, JMG12, JMG13, JMG14, JMG15, JMG18, JMG25, JMG29 and JMG31 showed too low binding in the TSHR260-binding assays so that determination of thermostability was not possible. The thermostability of JMG21 was determined in the same experiment as only TSHR260-I253R, and not TSHR260-WT. The half-life of each mutant is determined by heating aliquots at 50° C. assaying at intervals over a period of two hours (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. In each experiment, the thermostability of TSHR260-WT and TSHR260-I253R were measured and used to determine the difference in half-life (Δt_(1/2)) and half-life ratio compared to the half-life of TSHR260-WT and TSHR260-I253R in the same experiment. The most thermostabilising mutant with a good level of binding in the TSHR260-binding assay is in bold. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± SEM for experiments repeated at least twice. ^(a)Experiments (assayed in duplicate) that have only been performed a single time do not have SEM associated with them.

TABLE 8 Thermostability of the triple and quadruple TSHR260 mutants measured at 50° C. TSHR260- binding Δ t_(1/2) Stability Mutant Foundation Additional levels t_(1/2) (min) ratio name mutant mutation (% WT) (min) Relative to I253R n WT std 100  1.43 ± 0.05 −2.61 + 0.12  0.35 ± 0.02 9 I253R I253R 827  4.18 ± 0.10  0 + 0  1 ± 0 19  Triple JMG30 JMG22 P142I 42 1.52 −2.7 0.36  1^(a) mutants JMG32 JMG22 P28E 8 56 51 13  1^(a) JMG33 JMG22 L59F 587 39 ± 4 35 ± 4  9.4 ± 0.7 2 JMG35 JMG22 H63C 919 60 ± 4 56 ± 5 12.8 ± 1.1 2 JMG37 JMG22 R112P 622 69 ± 3 65 ± 3 16.6 ± 0.5 7 JMG38 JMG22 D151E 468 70.4 ± 1.1 65.5 ± 1.2 14.4 ± 0.6 2 JMG39 JMG22 S166T 490 65 ± 3 60 ± 3 13.6 ± 1.3 2 JMG41 JMG22 V169R 975 74 ± 3 69 ± 3 15.5 ± 1.4 2 Quadruple JMG43 JMG37 L59F 328 88 ± 3 84 ± 3 24.1 ± 1.9 2 mutants JMG44 JMG37 H63C 2333 131 ± 16 128 ± 16 34 ± 3 3 JMG45 JMG37 D151E 323 226 ± 31 222 ± 31 58 ± 6 3 JMG46 JMG37 S166T 400 151 ± 15 147 ± 15 35 ± 4 2 JMG47 JMG37 V169R 462 123 ± 10 119 ± 10 29 ± 3 2 Foundation mutant refers to the double mutant JMG22 (I253R + D143P; Table 5) or triple mutant JMG37 (I253R + D143P + R112P; Table 5) on which the triple and quadruple mutants were based respectively. JMG34, JMG36, JMG40, JMG42 and JMG48 showed too low binding (<16% of TSHR260-WT) in the TSHR260-binding assays so that determination of their thermostability was not possible. The half-life of each mutant is determined by heating aliquots at 50° C. assaying at intervals over a period of three hours (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. In each experiment, the thermostability of TSHR260-I253R was measured and used to determine the difference in half-life (At1/2) and half-life stability ratio compared to the half-life of TSHR260-I253R in the same experiment. The most thermostabilising mutants are in bold. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± SEM for experiments repeated at least twice. ^(a)Experiments that have only been performed a single time (assayed in duplicate) do not have SEM associated with them.

TABLE 9 Thermostability of the quadruple quintuple and hextuple TSHR260 mutants measured at 55° C. TSHR260- binding Δ t_(1/2) Stability Mutant Foundation Additional levels t_(1/2) (min) ratio name mutant mutation (% WT) (min) Relative to I253R n I253R I253R 793 0.54 ± 0.05  0 ± 0  1 ± 0 6 JMG37 JMG22 R112P 659 5.89 ± 0.11  5.4 ± 0.07 12.0 ± 0.9 2 Quadruple JMG43 JMG37 L59F 322 7.5 ± 0.3  6.9 ± 0.4 13.8 ± 1.2  1^(a) Mutants JMG44 JMG37 H63C 2250 10.9 ± 0.3  10.3 ± 0.3 20.1 ± 1.4  1^(a) JMG45 JMG37 D151E 271 27 ± 2  27 ± 2 54 ± 7 4 JMG46 JMG37 S166T 485 12.4 ± 0.9  12.0 ± 1.0 28 ± 4  1^(a) JMG47 JMG37 V169R 454 16.7 ± 1   16.3 ± 1.0 37 ± 5  1^(a) Quintuple JMG49 JMG45 L59F 194 41.8 ± 2.0  41.2 ± 1.9 78 ± 7 2 Mutants JMG50 JMG45 H63C 930 58 ± 5  58 ± 5 110 ± 7  3 JMG51 JMG45 S166T 300 25 ± 7  25 ± 7  49 ± 19 2 JMG52 JMG45 V169R 241 66 ± 12  65 ± 11 125.1 ± 0.6  2 Hextuple JMG54 JMG50 S166T 1235 837 ± 197  836 ± 197 1171 ± 316  1^(a) mutants JMG55 JMG50 V169R 1574 689 ± 147  688 ± 147  964 ± 239  1^(a) Foundation mutant refers to the triple mutant JMG37 (I253R+D143P+R112P; Table 5), quadruple mutant (I253R + D143P + R112P + D151E; Table 5 or quintuple mutant JMG50 (I253R + D143P + R112P + D151E + H62C; Table 5) on which the resulting quadruple, quintuple and hextuple mutants were respectively based. JMG48 had no detectable binding in the TSHR260-binding assays so that determination of thermostability was not possible. The hextuple mutants, JMG54 and JMG55 were too stable to determine the half-life accurately at 55° C. The half-life of each mutant is determined by heating aliquots at 55° C. assaying at intervals over a period of two hours (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. In each experiment, the thermostability of TSHR260-I253R and TSHR260-JMG37 was measured and used to determine the difference in half-life (Δt_(1/2)) and half-life stability ratio compared to the half-life of TSHR260-I253R in the same experiment. The most thermostabilising mutants are in bold. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± SEM for experiments repeated at least twice. ^(a)Experiments that have only been performed a single time (assayed in duplicate) do not have SEM associated with them.

TABLE 10 Thermostability of the quintuple and hextuple TSHR260 mutants measured at 60° C. TSHR260- binding Δ t_(1/2) Stability Mutant Foundation Additional levels t_(1/2) (min) ratio name Mutant Mutation (% WT) (min) Relative to JMG45 n JMG45 JMG37 D151E 500 2.40 ± 0.16 0 ± 0 1 ± 0 3 Quintuple JMG50 JMG45 H63C 1122 4.50 ± 0.07 2.1 ± 0.2 1.90 ± 0.14 3 mutants JMG52 JMG45 V169R 501 7.1 ± 0.6 4.7 ± 0.5 3.0 ± 0.2 3 Hextuple JMG54 JMG50 S166T 899 9.6 ± 1.5 7.2 ± 1.4 4.0 ± 0.4 3 mutants JMG55 JMG50 V169R 1452 13 ± 3  10 ± 3  5.2 ± 0.9 3 Foundation mutant refers to the triple mutant JMG37 (I253R + D143P + R112P; Table 5), quadruple mutant JMG45 (I253R + D143P + R112P + D151E; Table 5) or quintuple mutant JMG50 (I253R + D143P + R112P + D151E + H62C; Table 5) on which the resulting quadruple, quintuple and hextuple mutants were respectively based. The half-life of each mutant is determined by heating aliquots at 60° C. assaying at intervals over a period of two hours (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. In each experiment, the thermostability of TSHR260-JMG45 was measured and used to determine the difference in half-life (Δ t_(1/2)) and half-life stability ratio compared to the half-life of TSHR260-JMG45 in the same experiment. The most thermostabilising mutants are in bold. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± SEM for experiments repeated at least twice.

TABLE 11 Thermostability curves of TSHR260-WT, TSHR260-I253R, JMG22, JMF37, JMG45, JMG52, JMG54 and JMG55 measured at 37°. Mutant name t_(1/2) (h) Δ t_(1/2) (h) Stability ratio n WT  3.5 ± 0.6 0 ± 0 1 ± 0 2 I253R 11.3 ± 0.3 7.8 ± 0.2 3.3 ± 0.4 2 JMG22 38 ± 4 35 ± 5  11 ± 3  2 JMG37 124 ± 32 120 ± 31  35 ± 4  2 JMG45 150 147 48  1^(a) JMG52 249 246 80  1^(a) JMG54 204 201 65  1^(a) JMG55 358 355 115   1^(a) The half-life of each mutant is determined by heating aliquots at 37° C. assaying at intervals over a period of 37 days (FIG. 12b). The amount of active TSHR protein was determined by TSHR260-binding assay and plotted against time. The difference in half-life (Δt_(1/2)) and half-life stability ratio compared to the half-life of TSHR260-WT measured in the same experiment is shown. n is the number of times the half-life was measured in independent experiments for each sample. Results are expressed as mean ± SEM for experiments repeated at least twice. ^(a)Experiments that have only been performed a single time (assayed in duplicate) do not have SEM associated with them.

TABLE 12 Comparison of thermostability ratios of TSHR260 mutants at different temperatures 37° C. 42° C. 50° C. Mutant t_(1/2) Ratio (to t_(1/2) Ratio (to Ratio (to t_(1/2) Ratio (to Ratio (to name (h) WT (min) WT) I253R) (min) WT) I253R) WT  3.5 ± 0.6 1 ± 0 30.7 ± 1.1 1 ± 0 0.321 ± 0.014  1.43 ± 0.05 1 ± 0 0.35 ± 0.02 I253R 11.3 ± 0.3 3.3 ± 0.4 88 ± 7 3.07 ± 0.13 1 ± 0  4.18 ± 0.10 2.85 ± 0.14 1 ± 0 JMG22 38 ± 4 11 ± 3  261 ± 45 9.3 ± 0.5 3.3 ± 0.2 23.8 ± 0.7 15.1 ± 0.7  5.5 ± 0.2 JMG37 124 ± 32 35 ± 4  69 ± 3 16.6 ± 0.5  JMG45 150 48^(a) 226 ± 31 58 ± 6  JMG52 249 80^(a) JMG54 204 65^(a) JMG55 358 115^(a)  Predicted 55° C. 60° C. stability Mutant t_(1/2) Ratio (to Ratio (to ratio to name (min) I253R) t_(1/2) (min) JMG45) WT WT   1 I253R 0.54 ± 0.05  1 ± 0   3.1 JMG22   12 JMG37 5.89 ± 0.11 12.0 ± 0.9   41 JMG45 27 ± 2  54 ± 7 2.40 ± 0.16 1 ± 0  174^(b) JMG52 66 ± 12 125.1 ± 0.6  7.1 ± 0.6 3.0 ± 0.2 ~450^(b) JMG54 9.6 ± 1.5 4.0 ± 0.4 ~700^(b) JMG55 13 ± 3  5.2 ± 0.9 ~900^(b) Summary of results presented in Tables 6-11. Results are expressed as mean ± SEM for experiments repeated at least twice. ^(a)Experiments that have only been performed a single time (assayed in duplicate) do not have SEM associated with them. ^(b)These stability ratios are based on the stability ratios relative to I253R and JMG45 at 50° C.-60° C.

TABLE 13 Thermostability of full-length TSHR mutants at 42° C. on 14C4 plates TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 Time Active Active Active Active heated TSHR (% TSHR (% TSHR (% TSHR (% at 42° C. unheated unheated unheated unheated (min) OD450 sample) OD450 sample) OD450 sample) OD450 sample) 0 1.97 ± 0.07 100 1.87 ± 0.08 100 2.17 ± 0.03 100 1.93 ± 0.10 100 5 2.03 ± 0.07 103 1.87 ± 0.03 100 2.15 ± 0.02 99 1.95 ± 0.05 101 10 1.99 ± 0.02 101 1.85 ± 0.06 99 2.14 ± 0.03 99 1.98 ± 0.01 103 15 2.04 ± 0.04 104 1.84 ± 0.04 98 2.13 ± 0.04 98 1.96 ± 0.03 102 20 1.99 ± 0.03 101 1.74 ± 0.12 93 2.09 ± 0.05 96 1.90 ± 0.11 99 30 1.82 ± 0.10 93 1.78 ± 0.07 95 2.00 ± 0.06 92 1.89 ± 0.03 98 45 1.40 ± 0.16 71 1.72 ± 0.00 92 1.98 ± 0.04 91 1.81 ± 0.04 94 60 1.23 ± 0.08 63 1.66 ± 0.02 89 1.94 ± 0.06 89 1.78 ± 0.03 92 90 0.77 ± 0.08 39 1.51 ± 0.08 81 1.82 ± 0.11 84 1.62 ± 0.09 84 120 0.69 ± 0.07 35 1.45 ± 0.05 77 1.76 ± 0.03 81 1.56 ± 0.05 81 180 0.51 ± 0.04 26 1.14 ± 0.08 61 1.56 ± 0.05 72 1.47 ± 0.08 76 Results are expressed as both absorbance at 450 nm and as a percentage of the unheated sample's absorbance at 450 nm. Mean ± SD for quadruplicate measurements in a single experiment.

TABLE 14 Thermostability of full-length TSHR mutants at 50° C. on 14C4 plates TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 TSHR-JMG55 Time Active Active Active Active Active heated TSHR (% TSHR (% TSHR (% TSHR (% TSHR (% at 50° C. unheated unheated unheated unheated unheated (min) OD450 sample) OD450 sample) OD450 sample) OD450 sample) OD450 sample) 0 2.42 ± 0.09 100 2.42 ± 0.08 100 2.54 ± 0.08 100 2.39 ± 0.18 100 2.42 ± 0.09 100 5 2.43 ± 0.06 100 2.42 ± 0.08 100 2.55 ± 0.06 100 2.36 ± 0.06 99 2.43 ± 0.06 100 10 2.40 ± 0.04 99 2.44 ± 0.06 101 2.57 ± 0.06 101 2.48 ± 0.04 104 2.40 ± 0.04 99 15 2.30 ± 0.11 95 2.51 ± 0.02 103 2.65 ± 0.02 104 2.56 ± 0.06 107 2.30 ± 0.11 95 20 2.17 ± 0.09 90 2.52 ± 0.02 104 2.73 ± 0.05 107 2.51 ± 0.12 105 2.17 ± 0.09 90 30 1.41 ± 0.08 58 1.95 ± 0.04 81 2.50 ± 0.06 98 2.43 ± 0.14 102 1.41 ± 0.08 58 45 1.06 ± 0.06 44 1.98 ± 0.12 82 2.43 ± 0.01 95 2.12 ± 0.18 89 1.06 ± 0.06 44 60 0.40 ± 0.02 16 1.47 ± 0.03 61 1.82 ± 0.01 71 1.96 ± 0.19 82 0.40 ± 0.02 16 90 0.27 ± 0.02 11 1.33 ± 0.09 55 1.70 ± 0.05 67 1.56 ± 0.22 65 0.27 ± 0.02 11 120 0.19 ± 0.03 8 1.07 ± 0.11 44 1.56 ± 0.06 61 1.53 ± 0.17 64 0.19 ± 0.03 8 180 0.15 ± 0.02 6 0.96 ± 0.09 39 1.51 ± 0.06 59 1.34 ± 0.16 56 0.15 ± 0.02 6 240 0.09 ± 0.02 4 0.74 ± 0.09 30 1.25 ± 0.04 49 1.21 ± 0.14 51 0.09 ± 0.02 4 t1/2 33 110 173 175 226 (min) Stability 1.0 3.4 5.3 5.4 6.9 ratio Results are expressed as both absorbance at 450 nm and as a percentage of the unheated sample's absorbance at 450 nm. Mean ± SD for quadruplicate measurements in a single experiment. Half-life at 50° C. and the stability ratio relative to full-length TSHR-WT for each mutant is listed.

TABLE 15 M22-POD binding to TSHR260 mutants. M22-POD TSHR260-WT TSHR260-JMG37 TSHR260-JMG45 (ng/ml) OD450 % Max OD450 % Max OD450 % Max 179.0 2.94 ± 0.05 100.0 ± 1.6  3.13 ± 0.03 100.0 ± 1.0  2.69 ± 0.14 100.0 ± 5.1  89.5 2.34 ± 0.05 79.5 ± 1.7 2.50 ± 0.06 80.1 ± 1.8 1.91 ± 0.11 70.9 ± 3.9 44.8 1.55 ± 0.05 52.5 ± 1.8 1.62 ± 0.00 52.0 ± 0.1 1.18 ± 0.03 43.7 ± 1.1 22.4 0.89 ± 0.07 30.1 ± 2.2 0.87 ± 0.01 27.7 ± 0.2 0.67 ± 0.05 25.1 ± 1.8 11.2 0.50 ± 0.03 17.0 ± 1.0 0.42 ± 0.10 13.4 ± 3.3 0.34 ± 0.09 12.7 ± 3.5 5.6 0.24 ± 0.08  8.3 ± 2.8 0.22 ± 0.11  7.0 ± 3.5 0.15 ± 0.08  5.6 ± 2.8 2.8 0.09 ± 0.08  3.2 ± 2.8 0.07 ± 0.10  2.2 ± 3.1 0.05 ± 0.07  1.8 ± 2.8 0.0 −0.05 ± 0.08  −1.8 ± 2.6 −0.05 ± 0.08  −1.7 ± 2.4 −0.05 ± 0.08  −2.0 ± 2.8 K_(d) (ng/ml) 82.7 93.8 136.6 K_(d) (% WT) 100 113 165 M22-POD TSHR260-JMG52 TSHR260-JMG55 (ng/ml) OD450 % Max OD450 % Max 179.0 2.58 ± 0.06 100.0 ± 2.2  2.44 ± 0.11 100.0 ± 4.4  89.5 1.88 ± 0.11 72.9 ± 4.2 1.73 ± 0.11 70.9 ± 4.4 44.8 1.17 ± 0.13 45.2 ± 5.1 0.98 ± 0.04 40.2 ± 1.8 22.4 0.57 ± 0.05 22.2 ± 1.9 0.48 ± 0.04 19.7 ± 1.7 11.2 0.32 ± 0.06 12.5 ± 2.5 0.24 ± 0.07 10.0 ± 3.0 5.6 0.15 ± 0.07  5.7 ± 2.8 0.10 ± 0.07  4.0 ± 2.8 2.8 0.04 ± 0.07  1.7 ± 2.7 0.02 ± 0.08  1.0 ± 3.3 0.0 −0.06 ± 0.08  −2.1 ± 3.0 −0.06 ± 0.08  −2.3 ± 3.2 K_(d) (ng/ml) 136.8 184.3 K_(d) (% WT) 165 223 Results are expressed as absorbance at 450 nm, with non-specific binding subtracted, and a percentage of the maximum OD450 reading (% Max) for each mutant, Mean ± SD for duplicate measurements in a single experiment. K_(d) was determined by fitting a saturation binding curve to the data with GraphPad Prism.

TABLE 16 K1-18-POD binding to TSHR260 mutants. K1-18- POD TSHR260-WT TSHR260-I253R TSHR260-JMG22 TSHR260-JMG37 (μg/mL) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 10 2.61 ± 0.06 100 ± 2  1.91 ± 0.11 100 ± 6  2.16 ± 0.08 100 ± 4  2.76 ± 0.12 100 ± 4  7.5 2.50 ± 0.02 96 ± 1 1.84 ± 0.30  96 ± 16 2.29 ± 0.09 106 ± 4  2.86 ± 0.02 104 ± 1  5 2.61 ± 0.09 100 ± 3  2.13 ± 0.20 111 ± 10 2.10 ± 0.00 97 ± 0 2.74 ± 0.00 99 ± 0 2.5 2.18 ± 0.19 83 ± 7 1.68 ± 0.09 88 ± 4 1.75 ± 0.06 81 ± 3 2.45 ± 0.10 89 ± 3 1 1.24 ± 0.06 48 ± 2 0.93 ± 0.03 49 ± 2 0.99 ± 0.00 46 ± 0 1.35 ± 0.12 49 ± 4 0.75 0.98 ± 0.03 37 ± 1 0.73 ± 0.06 38 ± 3 0.80 ± 0.06 37 ± 3 1.16 ± 0.01 42 ± 0 0.5 0.72 ± 0.05 28 ± 2 0.21 ± 0.02 11 ± 1 0.54 ± 0.01 25 ± 1 0.87 ± 0.00 32 ± 0 0.25 0.39 ± 0.09 15 ± 3 0.42 ± 0.03 22 ± 2 0.28 ± 0.02 13 ± 1 0.61 ± 0.17 22 ± 6 0.1 0.12 ± 0.02  4 ± 1 0.08 ± 0.00  4 ± 0 0.11 ± 0.00  5 ± 0 0.19 ± 0.00  7 ± 0 0.01 0.02 ± 0.01  1 ± 0 0.01 ± 0.00  0 ± 0 0.01 ± 0.00  0 ± 0 0.03 ± 0.01  1 ± 0 0 0.01 ± 0.01  1 ± 0 0.01 ± 0.00  0 ± 0 0.04 ± 0.01  2 ± 0 0.10 ± 0.02  4 ± 1 K_(d) 1.45 1.58 1.72 1.28 (μg/mL) K_(d) 100 109 119 88.5 (% WT) K1-18- POD TSHR260-JMG45 TSHR260-JMG52 TSHR260-JMG55 (μg/mL) OD450 % Max OD450 % Max OD450 % Max 10 2.36 ± 0.20 100 ± 8  2.29 ± 0.04 100 ± 2  2.79 ± 0.05 100 ± 2  7.5 2.34 ± 0.15 99 ± 6 2.32 ± 0.01 101 ± 0  2.86 ± 0.03 103 ± 1  5 2.30 ± 0.07 97 ± 3 2.43 ± 0.01 106 ± 0  2.68 ± 0.15 96 ± 5 2.5 1.82 ± 0.03 77 ± 1 2.16 ± 0.03 94 ± 2 2.34 ± 0.22 84 ± 8 1 1.13 ± 0.03 48 ± 1 1.28 ± 0.13 56 ± 6 1.24 ± 0.12 45 ± 4 0.75 0.90 ± 0.06 38 ± 3 0.97 ± 0.08 43 ± 4 1.04 ± 0.09 37 ± 3 0.5 0.56 ± 0.05 24 ± 2 0.56 ± 0.10 25 ± 4 0.76 ± 0.01 27 ± 0 0.25 0.33 ± 0.03 14 ± 1 0.36 ± 0.02 16 ± 1 0.40 ± 0.01 14 ± 0 0.1 0.11 ± 0.01  5 ± 0 0.14 ± 0.01  6 ± 0 0.14 ± 0.01  5 ± 0 0.01 0.02 ± 0.01  1 ± 1 0.02 ± 0.01  1 ± 0 0.02 ± 0.00  1 ± 0 0 0.01 ± 0.00  0 ± 0 0.00 ± 0.00  0 ± 0 0.02 ± 0.02  1 ± 1 K_(d) 1.30 1.60 0.936 (μg/mL) K_(d) 89.7 110 64.7 (% WT) Results are expressed as absorbance at 450 nm, with non-specific binding subtracted, and a percentage of the maximum OD450 reading (% Max) for each mutant, Mean ± SD for duplicate measurements in a single experiment. K_(d) was determined by fitting a saturation binding curve to the data with GraphPad Prism.

TABLE 17 K1-70-POD binding to TSHR260 mutants. K1-70- POD TSHR260-WT TSHR260-I253R TSHR260-JMG22 TSHR260-JMG37 (μg/mL) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 10 3.01 ± 0.02 100 ± 1  2.89 ± 0.06 100 ± 2  2.79 ± 0.05 100 ± 2  3.10 ± 0.03 100 ± 1  5 3.29 ± 0.06 110 ± 2  3.14 ± 0.01 109 ± 0  3.03 ± 0.07 108 ± 2  3.31 ± 0.01 107 ± 0  2.5 3.26 ± 0.03 109 ± 1  2.77 ± 0.23 96 ± 8  2.57 ± 0.20 92 ± 7 3.26 ± 0.01 105 ± 0  1 2.32 ± 0.28 77 ± 9 1.92 ± 0.18 66 ± 6  1.62 ± 0.06 58 ± 2 1.99 ± 0.45  64 ± 15 0.75 1.89 ± 0.12 63 ± 4 1.51 ± 0.28 52 ± 10 1.31 ± 0.01 47 ± 0 1.86 ± 0.07 60 ± 2 0.5 1.39 ± 0.02 46 ± 1 1.19 ± 0.02 41 ± 1  0.98 ± 0.03 35 ± 1 1.45 ± 0.04 47 ± 1 0.25 0.77 ± 0.05 25 ± 2 0.67 ± 0.04 23 ± 1  0.51 ± 0.01 18 ± 0 0.87 ± 0.04 28 ± 1 0.1 0.31 ± 0.02 10 ± 1 0.26 ± 0.00 9 ± 0 0.21 ± 0.00  8 ± 0 0.32 ± 0.00 10 ± 0 0.05 0.14 ± 0.02  5 ± 1 0.13 ± 0.00 4 ± 0 0.12 ± 0.01  4 ± 0 0.16 ± 0.01  5 ± 0 0.01 0.09 ± 0.10  3 ± 3 0.06 ± 0.03 2 ± 1 0.04 ± 0.01  1 ± 0 0.05 ± 0.03  2 ± 1 0 0.01 ± 0.00  0 ± 0 0.00 ± 0.01 0 ± 0 0.00 ± 0.02  0 ± 1 0.01 ± 0.01  0 ± 0 K_(d) (μg/mL) 0.69 0.88 1.12 0.74 K_(d) (% WT) 100 128 163 107 K1-70- POD TSHR260-JMG45 TSHR260-JMG52 TSHR260-JMG55 (μg/mL) OD450 % Max OD450 % Max OD450 % Max 10 2.93 ± 0.08 100 ± 3  3.03 ± 0.04 100 ± 1  3.08 ± 0.06 100 ± 2  5 3.17 ± 0.06 108 ± 2  3.29 ± 0.03 109 ± 1  3.34 ± 0.04 109 ± 1  2.5 2.88 ± 0.01 98 ± 1 3.17 ± 0.03 105 ± 1  3.40 ± 0.01 110 ± 0  1 1.85 ± 0.09 63 ± 3 2.25 ± 0.02 74 ± 1 2.67 ± 0.01 87 ± 0 0.75 1.59 ± 0.02 54 ± 1 1.33 ± 0.03 44 ± 1 2.22 ± 0.02 72 ± 0 0.5 1.15 ± 0.07 39 ± 3 1.95 ± 0.06 64 ± 2 1.71 ± 0.01 56 ± 0 0.25 0.53 ± 0.01 18 ± 0 0.67 ± 0.02 22 ± 1 0.85 ± 0.06 28 ± 2 0.1 0.25 ± 0.03  8 ± 1 0.29 ± 0.01 10 ± 0 0.37 ± 0.01 12 ± 0 0.05 0.12 ± 0.00  4 ± 0 0.30 ± 0.00 10 ± 0 0.19 ± 0.00  6 ± 0 0.01 0.02 ± 0.01  1 ± 1 0.04 ± 0.01  1 ± 0 0.04 ± 0.01  1 ± 0 0 0.00 ± 0.01  0 ± 0 −0.01 ± 0.00   0 ± 0 0.00 ± 0.00  0 ± 0 K_(d) (μg/mL) 0.94 0.72 0.54 K_(d) (% WT) 137 104 78 Results are expressed as absorbance at 450 nm, with non-specific binding subtracted, and a percentage of the maximum OD450 reading (% Max) for each mutant, Mean ± SD for duplicate measurements in a single experiment. K_(d) was determined by fitting a saturation binding curve to the data with GraphPad Prism.

TABLE 18 M22-POD binding to full-length TSHR mutants. M22-POD TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 (ng/ml) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 200 3.44 ± 0.03 100 ± 1  2.51 ± 0.07 100 ± 3  2.65 ± 0.14 100 ± 5  2.64 ± 0.06 100 ± 2  100 2.58 ± 0.05 75 ± 1 1.60 ± 0.02 64 ± 1 1.61 ± 0.09 61 ± 3 1.63 ± 0.01 61 ± 1 75 2.11 ± 0.07 62 ± 2 1.18 ± 0.04 47 ± 2 1.18 ± 0.04 45 ± 1 1.21 ± 0.03 46 ± 1 50 1.47 ± 0.06 43 ± 2 0.86 ± 0.06 34 ± 3 0.85 ± 0.02 32 ± 1 0.85 ± 0.05 32 ± 2 25 0.73 ± 0.01 21 ± 0 0.42 ± 0.01 17 ± 0 0.41 ± 0.01 16 ± 0 0.47 ± 0.08 18 ± 3 10 0.29 ± 0.01  8 ± 0 0.16 ± 0.01  6 ± 0 0.16 ± 0.01  6 ± 0 0.18 ± 0.00  7 ± 0 5 0.15 ± 0.01  4 ± 0 0.08 ± 0.00  3 ± 0 0.08 ± 0.00  3 ± 0 0.09 ± 0.01  3 ± 1 1 0.04 ± 0.00  1 ± 0 0.02 ± 0.00  1 ± 0 0.02 ± 0.00  1 ± 0 0.03 ± 0.01  1 ± 0 0 0.00 ± 0.00  0 ± 0 0.00 ± 0.00  0 ± 0 0.00 ± 0.00  0 ± 0 0.00 ± 0.00  0 ± 0 K_(d) (ng/ml) 155 371 499 430 K_(d) (% WT K_(d)) 100 240 323 278 Results are expressed as absorbance at 450 nm, with non-specific binding subtracted, and a percentage of the maximum OD450 reading (% Max) for each mutant, Mean ± SD for duplicate measurements in a single experiment. K_(d) was determined by fitting a saturation binding curve to the data with GraphPad Prism.

TABLE 19 K1-18-POD binding to full-length TSHR mutants. K1-18-POD TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 (μg/mL) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 200 2.59 ± 0.02 100 ± 1  2.84 ± 0.01 100 ± 0  2.82 ± 0.01 100 ± 0  2.93 ± 0.04 100 ± 1  100 2.34 ± 0.09 90 ± 3 2.80 ± 0.02 99 ± 1 2.77 ± 0.00 98 ± 0 3.04 ± 0.02 104 ± 1  75 1.48 ± 0.01 57 ± 0 1.91 ± 0.08 67 ± 3 1.84 ± 0.06 65 ± 2 2.43 ± 0.05 83 ± 2 50 0.70 ± 0.01 27 ± 0 0.95 ± 0.03 34 ± 1 0.66 ± 0.02 24 ± 1 1.27 ± 0.01 43 ± 0 25 0.53 ± 0.02 20 ± 1 0.74 ± 0.01 26 ± 0 0.90 ± 0.05 32 ± 2 0.96 ± 0.02 33 ± 1 10 0.36 ± 0.01 14 ± 0 0.49 ± 0.02 17 ± 1 0.46 ± 0.01 16 ± 0 0.62 ± 0.02 21 ± 1 5 0.17 ± 0.01  6 ± 0 0.24 ± 0.00  9 ± 0 0.22 ± 0.01  8 ± 1 0.32 ± 0.03 11 ± 1 1 0.07 ± 0.01  3 ± 0 0.09 ± 0.00  3 ± 0 0.08 ± 0.00  3 ± 0 0.16 ± 0.00  5 ± 0 0 0.01 ± 0.01  0 ± 1 0.02 ± 0.01  1 ± 0 0.02 ± 0.00  1 ± 0 0.02 ± 0.00  1 ± 0 K_(d) (μg/mL) 5.3 3.4 3.8 2.2 K_(d) (% WT K_(d)) 100 64 72 41 Results are expressed as absorbance at 450 nm, with non-specific binding subtracted, and a percentage of the maximum OD450 reading (% Max) for each mutant, Mean ± SD for duplicate measurements in a single experiment. K_(d) was determined by fitting a saturation binding curve to the data with GraphPad Prism.

TABLE 20 K1-70-POD binding to full-length TSHR mutants. K1-70-POD TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 (μg/mL) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 7.5 1.92 ± 0.17 100 ± 9  2.64 ± 0.02 100 ± 1  2.66 ± 0.08 100 ± 3  2.85 ± 0.02 100 ± 1  5 1.59 ± 0.12 83 ± 7 2.34 ± 0.01 89 ± 0 2.37 ± 0.06 89 ± 2 2.79 ± 0.00 98 ± 0 2.5 0.89 ± 0.09 46 ± 5 1.33 ± 0.04 50 ± 2 1.36 ± 0.06 51 ± 2 1.74 ± 0.01 61 ± 0 1 0.42 ± 0.02 22 ± 1 0.61 ± 0.01 23 ± 1 0.65 ± 0.01 24 ± 0 0.90 ± 0.07 31 ± 3 0.75 0.30 ± 0.03 16 ± 2 0.46 ± 0.01 17 ± 0 0.50 ± 0.03 19 ± 1 0.64 ± 0.04 22 ± 2 0.5 0.21 ± 0.03 11 ± 1 0.30 ± 0.02 11 ± 1 0.33 ± 0.01 12 ± 1 0.45 ± 0.03 16 ± 1 0.25 0.10 ± 0.02  5 ± 1 0.16 ± 0.01  6 ± 1 0.15 ± 0.01  6 ± 0 0.24 ± 0.01  8 ± 0 0.1 0.05 ± 0.00  3 ± 0 0.11 ± 0.00  4 ± 0 0.11 ± 0.00  4 ± 0 0.16 ± 0.02  6 ± 1 0 0.00 ± 0.00  0 ± 0 0.00 ± 0.01  0 ± 0 0.00 ± 0.00  0 ± 0 0.02 ± 0.00  1 ± 0 K_(d) (μg/mL) 9.8 7.4 6.9 4.1 K_(d) (% WT K_(d)) 100 76 70 42 Results are expressed as absorbance at 450 nm, with non-specific binding subtracted, and a percentage of the maximum OD450 reading (% Max) for each mutant, Mean ± SD for duplicate measurements in a single experiment. K_(d) was determined by fitting a saturation binding curve to the data with GraphPad Prism.

TABLE 21 Summary of effects of mutations (relative to TSHR60-WT or full- length TSHR-WT) on binding of M22-POD, K1-18 POD and K1-70 POD. Mutant M22-POD binding K1-18 POD binding K1-70 POD binding TSHR260-I253R n.d. Little change Little change TSHR260-JMG22 n.d. Little change Little change TSHR260-JMG37 Little change Little change Little change TSHR260-JMG45 Little change Little change Little change TSHR260-JMG52 Little change Little change Little change TSHR260-JMG55 Little change Little change Little change TSHR-JMG37 Little change Little change Little change TSHR-JMG45 Little change Little change Little change TSHR-JMG52 Little change Little change Little change n.d. = not determined.

TABLE 22 Inhibition by K1-18 IgG of M22-POD binding to TSHR260 mutants K1-18 IgG TSHR260-WT TSH260-JMG37 TSHR260-JMG45 (ng/mL) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.07 ± 0.00 97 ± 0 0.25 ± 0.03 89 ± 1 0.25 ± 0.01 88 ± 0 300 0.18 ± 0.02 93 ± 1 0.41 ± 0.06 82 ± 3 0.38 ± 0.05 82 ± 2 100 0.62 ± 0.06 75 ± 3 0.87 ± 0.06 62 ± 3 0.78 ± 0.03 62 ± 2 30 1.59 ± 0.17 35 ± 7 1.57 ± 0.14 32 ± 6 1.38 ± 0.15 33 ± 7 10 1.83 ± 0.05 26 ± 2 1.66 ± 0.04 28 ± 1 1.57 ± 0.21  24 ± 10 3 2.03 ± 0.14 18 ± 6 1.93 ± 0.01 16 ± 1 1.84 ± 0.16 11 ± 8 1 2.38 ± 0.28  3 ± 11 2.21 ± 0.20  5 ± 9 2.02 ± 0.02  2 ± 1 0 2.46 ± 0.01  0 ± 0 2.31 ± 0.03  0 ± 1 2.06 ± 0.05  0 ± 2 K1-18 IgG TSHR260-JMG52 TSHR260-JMG55 (ng/mL) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.38 ± 0.02 79 ± 1 0.35 ± 0.02 78 ± 1 300 0.49 ± 0.03 73 ± 2 0.55 ± 0.02 67 ± 1 100 0.78 ± 0.06 57 ± 3 0.83 ± 0.02 49 ± 1 30 1.26 ± 0.23  30 ± 13 1.24 ± 0.05 24 ± 3 10 1.48 ± 0.13 17 ± 7 1.32 ± 0.03 19 ± 2 3 1.56 ± 0.09 13 ± 5 1.65* −1* 1 1.66 ± 0.12  8 ± 7 1.63 ± 0.03  1 ± 2 0 1.80 ± 0.01  0 ± 0 1.64*  0* Results are presented as absorbance at 450 nm and a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment. *From a single measurement.

TABLE 23 Inhibition by K1-70 IgG of M22-POD binding to TSHR260mutants K1-70 IgG TSHR260-WT TSH260-JMG37 TSHR260-JMG45 (ng/ml) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.066 ± 0.014 97.2 ± 0.6 0.047 ± 0.008 97.9 ± 0.4 0.018 ± 0.001 99.04 ± 0.08 300 0.109 ± 0.013 95.4 ± 0.5 0.130 ± 0.001 94.30 ± 0.03 0.069 ± 0.004 96.3 ± 0.2 100 0.34 ± 0.02 85.8 ± 0.9 0.388 ± 0.012 82.9 ± 0.5 0.241 ± 0.008 87.1 ± 0.5 30 1.045 ± 0.011 55.8 ± 0.4 1.069 ± 0.006 52.9 ± 0.2 0.80 ± 0.03 57.4 ± 1.4 10 1.61 ± 0.09 32 ± 4 1.51 ± 0.06 33 ± 3 1.18 ± 0.02 37.1 ± 1.2 1 2.22 ± 0.03  6.1 ± 1.1 2.1 ± 0.3  10 ± 14 1.47 ± 0.06 21 ± 3 0.1 2.38 ± 0.05 −0.6 ± 1.9 1.99 ± 0.08 13 ± 4 1.77 ± 0.10  5 ± 5 0 2.4 ± 0.2  0.0 ± 10 2.27 ± 0.07  0 ± 3 1.87 ± 0.04  0 ± 2 K1-70 IgG TSHR260-JMG52 TSHR260-JMG55 (ng/ml) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.024 ± 0.004 98.7 ± 0.2 0.02* 99.3* 300 0.10 ± 0.04 95 ± 2 0.072 ± 0.012 97.5 ± 0.4 100 0.29 ± 0.03 84.0 ± 1.5 0.38 ± 0.05 87.0 ± 1.7 30 0.86 ± 0.05 53 ± 3 1.5 ± 0.3 48 ± 9 10 1.23 ± 0.02 32.4 ± 1.2 2.14 ± 0.15 26 ± 5 1 1.58 ± 0.11 13 ± 6 2.71 ± 0.05  6.7 ± 1.7 0.1 1.65 ± 0.10  9 ± 6 2.77 ± 0.06  4.6 ± 2.0 0 1.82 ± 0.06  0 ± 3 2.91 ± 0.04  0.0 ± 1.3 Results are presented as absorbance at 450nm and a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment. *From a single measurement.

TABLE 24 Inhibition by K1-18 IgG of M22-POD binding to full-length TSHR mutants K1-18 IgG TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 (ng/ml) OD450 % Inhibition OD450 % Inhibition OD450 % Inhibition OD450 % Inhibition 1000 0.36 ± 0.02 86.0 ± 0.7 0.46 ± 0.00 82.3 ± 0.1 0.45 ± 0.01 81.5 ± 0.6  0.48 ± 0.00 81.4 ± 0.1 300 0.77 ± 0.01 70.3 ± 0.3 0.95 ± 0.00 63.3 ± 0.1 0.91 ± 0.03 62.3 ± 1.3  0.97 ± 0.02 62.5 ± 0.9 100 1.40 ± 0.09 45.9 ± 3.4 1.70 ± 0.01 34.4 ± 0.3 1.48 ± 0.01 38.6 ± 0.6  1.65 ± 0.01 36.2 ± 0.4 30 2.01 ± 0.00 21.9 ± 0.0 2.24 ± 0.01 13.6 ± 0.3 2.05 ± 0.01 15.2 ± 0.5  2.22 ± 0.03 14.1 ± 1.0 10 2.34 ± 0.01  9.3 ± 0.4 2.46 ± 0.04  5.2 ± 1.6 2.28 ± 0.01 5.3 ± 0.6 2.43 ± 0.06  5.8 ± 2.2 3 2.65 ± 0.11 −2.9 ± 4.3 2.60 ± 0.03 −0.3 ± 1.3 2.28 ± 0.09 5.4 ± 3.7 2.52 ± 0.01  2.3 ± 0.6 1 2.45 ± 0.04  4.9 ± 1.6 2.60 ± 0.04 −0.3 ± 1.4 2.34 ± 0.01 3.1 ± 0.6 2.55 ± 0.05  1.4 ± 1.9 0.3 2.39 ± 0.12  7.4 ± 4.6 2.59 ± 0.04  0.1 ± 1.6 2.39 ± 0.04 0.9 ± 1.7 2.63 ± 0.04 −1.6 ± 1.6 0.1 2.50 ± 0.04  3.2 ± 1.7 2.58 ± 0.03  0.6 ± 1.2 2.34 ± 0.09 3.0 ± 3.8 2.63 ± 0.04 −1.8 ± 1.6 Results are presented as absorbance at 450 nm and as a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment.

TABLE 25 Inhibition by K1-70 IgG of M22-POD binding to full-length TSHR mutants. K1-70 IgG TSHR-WT TSHR-JMG37 TSHR-JMG45 TSHR-JMG52 (ng/ml) OD450 % Inhibition OD450 % Inhibition OD450 % Inhibition OD450 % Inhibition 1000 0.13 ± 0.00 94.9 ± 0.1 0.20 ± 0.00 92.3 ± 0.1 0.14 ± 0.00 94.2 ± 0.1 0.15 ± 0.01 94.3 ± 0.2 300 0.28 ± 0.01 89.1 ± 0.5 0.58 ± 0.01 77.6 ± 0.6 0.50 ± 0.00 79.4 ± 0.2 0.56 ± 0.01 78.4 ± 0.4 100 0.76 ± 0.04 70.4 ± 1.6 1.36 ± 0.02 47.8 ± 0.7 1.21 ± 0.02 50.1 ± 0.7 1.34 ± 0.00 48.2 ± 0.1 30 1.61 ± 0.07 37.7 ± 2.8 2.08 ± 0.05 19.8 ± 1.7 1.80 ± 0.03 25.3 ± 1.2 2.10 ± 0.01 18.9 ± 0.5 10 2.07 ± 0.05 19.7 ± 1.8 2.36 ± 0.04  9.1 ± 1.7 2.12 ± 0.01 12.1 ± 0.5 2.48 ± 0.01  4.2 ± 0.4 3 2.32 ± 0.04 10.1 ± 1.5 2.52 ± 0.00  2.8 ± 0.2 2.31 ± 0.03  4.5 ± 1.1 2.55 ± 0.06  1.5 ± 2.4 1 2.44 ± 0.02  5.3 ± 0.7 2.60 ± 0.01 −0.1 ± 0.3 2.41 ± 0.05  0.0 ± 2.2 2.65 ± 0.01 −2.5 ± 0.5 0.3 2.45 ± 0.10  5.0 ± 3.9 2.54 ± 0.01  2.0 ± 0.3 2.32 ± 0.08  3.8 ± 3.5 2.58 ± 0.06  0.2 ± 2.4 0.1 2.48 ± 0.09  3.7 ± 3.3 2.61 ± 0.00 −0.6 ± 0.0 2.39 ± 0.01  0.9 ± 0.4 2.65 ± 0.01 −2.3 ± 0.5 Results are presented as absorbance at 450 nm and as a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment.

TABLE 26 Summary of effects of mutations (relative to TSHR60-WT or full-length TSHR-WT) on K1-18 IgG and K1-70 IgG inhibition of M22-POD binding to TSHR260 or full-length TSHR-WT. Mutant M22-POD binding K1-18 POD binding K1-70 POD binding TSHR260-JMG37 Little change Little change Little change TSHR260-JMG45 Little change Little change Little change TSHR260-JMG52 Little change Little change Little change TSHR260-JMG55 Little change Little change Little change TSHR-JMG37 Little change Little change Little change TSHR-JMG45 Little change Little change Little change TSHR-JMG52 Little change Little change Little change

TABLE 27 Inhibition of M22-POD binding to TSHR260 mutants by patient sera TSHR260-WT TSHR260-JMG52 TSHR260-JMG55 % Inhibition % Inhibition % Inhibition vs mean of vs mean of vs mean of Test sample OD450 normal sera OD450 normal sera OD450 normal sera Normal NT 9916 1.10 ± 0.03 0.7 1.01 ± 0.02 −3.3 1.13 ± 0.04 3.7 sera NT 9918 1.01 ± 0.05 8.5  0.9 ± 0.03 7.5 1.13 ± 0.10 3.8  NT 11746 0.98 ± 0.11 10.7 0.86 ± 0.07 12.2 1.11 ± 0.11 5.9  NT 11748 1.12 ± 0.02 −1.9 1.055 ± 0.011 −8.1 1.20 ± 0.07 −1.9 NT 9924  1.3 ± 0.03 −17.9 1.06 ± 0.03 −8.2 1.31 ± 0.03 −11.6 Mean  1.1 ± 0.12 0.0 0.98 ± 0.09 0.0 1.18 ± 0.08 0.0 TRAb F11/9573 0.000 ± 0.003 100.0 0.026 ± 0.006 97.3 0.025 ± 0.004 97.9 positive F078459 0.086 ± 0.003 92.2 0.302 ± 0.001 69.1 0.361 ± 0.006 69.3 patient 82 0.009 ± 0.000 99.2 0.026 ± 0.002 97.3 0.038 ± 0.005 96.8 sera 92 0.042 ± 0.008 96.2 0.159 ± 0.011 83.7  0.22 ± 0.013 81.3 101 0.135 ± 0.010 87.8 0.229 ± 0.008 76.5 0.327 ± 0.015 72.2 107 0.043 ± 0.004 96.1 0.088 ± 0.008 91.0  0.14 ± 0.004 88.1 20 0.427 ± 0.012 61.3 0.423 ± 0.008 56.7 0.364 ± 0.001 69.0 110 0.147 ± 0.012 86.7 0.312 ± 0.013 68.0 0.341 ± 0.006 71.0 69 0.064 ± 0.001 94.2 0.096 ± 0.009 90.2 0.134 ± 0.004 88.6 Results are presented as absorbance at 450 nm ± SD and a percentage of inhibition of M22-POD binding for duplicate measurements in a single experiment.

TABLE 28 Inhibition of M22-POD binding to full-length TSHR mutants by patient sera. TSHR-WT TSHR-JMG45 TSHR-JMG52 % Inhibition % Inhibition % Inhibition vs mean of vs mean of vs mean of Test sample OD450 normal sera OD450 normal sera OD450 normal sera Normal NT 9916 1.440 ± 0.003 6.1  1.66 ± 0.018 3.3 1.83 ± 0.04 2.4 sera NT 9918 1.375 ± 0.006 10.4 1.614 ± 0.016 6.0 1.78 ± 0.03 5.1  NT 11746 1.68 ± 0.07 −9.4 1.795 ± 0.008 −4.6 2.01 ± 0.04 −7.0  NT 11748 1.69 ± 0.04 −10.1 1.87 ± 0.04 −9.1 1.93 ± 0.05 −3.0 NT 9924 1.49 ± 0.06 2.9 1.64 ± 0.07 4.3 1.83 ± 0.05 2.5 Mean 1.53 ± 0.14 0.0 1.716 ± 0.111 0.0 1.88 ± 0.09 0.0 TRAb 82 0.074 ± 0.003 95.2 0.124 ± 0.014 92.8 0.143 ± 0.004 92.4 positive 92 0.380 ± 0.006 75.2 0.835 ± 0.001 51.4 0.90 ± 0.03 52.1 patient 101 0.498 ± 0.001 67.5 0.58 ± 0.02 66.4 0.598 ± 0.007 68.1 sera 77 0.377 ± 0.011 75.4 0.69 ± 0.09 59.8 0.849 ± 0.002 54.8 105 0.419 ± 0.013 72.7  0.80 ± 0.012 53.4 0.89 ± 0.03 52.6 117 0.149 ± 0.001 90.3 0.234 ± 0.005 86.4 0.262 ± 0.000 86.0 27 0.324 ± 0.011 78.9 0.81 ± 0.03 52.9 0.86 ± 0.03 54.4 15 0.484 ± 0.006 68.5 0.89 ± 0.07 48.1 1.03 ± 0.03 45.3 60 0.094 ± 0.007 93.9 0.253 ± 0.014 85.3 0.288 ± 0.008 84.7 Results are presented as absorbance at 450 nm ± SD and a percentage of inhibition of M22-POD binding for duplicate measurements in a single experiment.

TABLE 29 Summary of effects of mutations (relative to TSHR60-WT or full-length TSHR-WT) on normal sera and TRAb positive patient sera inhibition of M22-POD binding to TSHR260 or full-length TSHR-WT. Mutant Normal Sera TRAb positive patient sera TSHR260-JMG52 Little change Little change TSHR260-JMG55 Little change Little change TSHR-JMG45 Little change Little change TSHR-JMG52 Little change Little change

TABLE 30 Effect of different concentrations of human monoclonal antibody to the TSHR (M22) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG37 (I253R + D143P + D151E). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG37/ Test sample Wild type TSHR TSHR-JMG37 Wild type (%) Experiment 1 Cyclic AMP 8.3 ± 0.5  2.30 ± 0.08 28 buffer M22 0.1 ng/mL 15 ± 2   9 ± 3 60 0.3 ng/mL 28 ± 4  22.9 ± 1.7 81 1 ng/mL 74 ± 11 70.3 ± 1.7 95 3 ng/mL 125 ± 17*  82 ± 23 65 10 ng/mL 150 ± 19*  103 ± 15* 68 30 ng/mL 179 ± 23  105 ± 10 59 TSH 0.01 ng/mL 9 ± 5  2.68 ± 0.16 28 0.03 ng/mL 16 ± 3*  3.9 ± 1.0 24 0.1 ng/mL 17 ± 3  17 ± 4 99 0.3 ng/mL 47 ± 11 46.9 ± 1.6 99 1 ng/mL 110 ± 19  102 ± 14 93 3 ng/mL 116 ± 18   98 ± 18 84 Experiment 2 Cyclic AMP 4.4 ± 0.3  2.9 ± 0.7 66 buffer M22 0.1 ng/mL 6.7 ± 1.6  6.3 ± 0.9 95 0.3 ng/mL 14.1 ± 1.3  13.0 ± 1.1 92 1 ng/mL 44 ± 10 35.4 ± 1.7 81 3 ng/mL 79 ± 6  66 ± 3 84 10 ng/mL 109 ± 3  102 ± 11 94 30 ng/mL 113 ± 14  125 ± 2* 110 TSH 0.01 ng/mL 3.68 ± 0.16  3.5 ± 0.3 96 0.03 ng/mL 5.5 ± 0.7  5.9 ± 1.5 107 0.1 ng/mL 13.2 ± 1.1  13.7 ± 1.6 104 0.3 ng/mL 37 ± 5  42.6 ± 1.2 116 1 ng/mL 78 ± 9   72 ± 12 93 3 ng/mL 104 ± 5  101 ± 7  97 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(M22) = 1.62 ng/mL, EC50(TSH) = 1.02 ng/mL. For TSHR-JMG37: EC50(M22) = 0.94 ng/mL, EC50(TSH) = 0.39 ng/mL. Experiment 2: For TSHR-WT: EC50(M22) = 2.13 ng/mL, EC50(TSH) = 0.77 ng/mL. For TSHR-JMG37: EC50(M22) = 3.10 ng/mL, EC50(TSH) = 0.86 ng/mL.

TABLE 31 Effect of different concentrations of human monoclonal antibody to the TSHR (M22) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG45 (I253R + D143P + R112P + D151E). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG45/ Test sample Wild type TSHR TSHR-JMG45 Wild type (%) Experiment 1 Cyclic AMP  3.8 ± 0.3  1.2 ± 0.4 32 buffer M22 0.1 ng/mL  9 ± 3  2.90 ± 0.05 33 0.3 ng/mL 15.5 ± 1.0  9 ± 4* 59 1 ng/mL 53 ± 7 18.3 ± 1.7 35 3 ng/mL 100 ± 5  42.3 ± 1.6 42 10 ng/mL 117 ± 15 90 ± 4 77 30 ng/mL 121 ± 12 106 ± 5  88 TSH 0.01 ng/mL  4.3 ± 0.3  1.77 ± 0.18 41 0.03 ng/mL  6.2 ± 0.6  3.4 ± 0.5 55 0.1 ng/mL 14.2 ± 0.9  9.6 ± 0.6 67 0.3 ng/mL 38 ± 2 30 ± 4 80 1 ng/mL  77 ± 13 79 ± 6 103 3 ng/mL 107.2 ± 1.4  94 ± 5 88 Experiment 2 Cyclic AMP  7.5 ± 0.6  4.2 ± 0.5 88 buffer M22 0.1 ng/mL   9 ± 0.6  6.6 ± 0.7 73 0.3 ng/mL 16 ± 3 11.7 ± 2.0 74 1 ng/mL 42 ± 4 23.8 ± 1.5 57 3 ng/mL 106 ± 9* 58 ± 4 55 10 ng/mL 127.4 ± 0.0* 93 ± 4 73 30 ng/mL  97 ± 17* 106.7 ± 0.0* 110 TSH 0.01 ng/mL  8.1 ± 1.0  5.3 ± 0.3 66 0.03 ng/mL  8.5 ± 1.6  7.7 ± 1.0 91 0.1 ng/mL 15.3 ± 1.1 14.2 ± 0.3 93 0.3 ng/mL 38.3 ± 1.3 41 ± 4 107 1 ng/mL 94 ± 5  86 ± 15 91 3 ng/mL 122 ± 11 102 ± 11 83 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(M22) = 1.52 ng/mL, EC50(TSH) = 0.82 ng/mL. For TSHR-JMG45: EC50(M22) = 5.37 ng/mL, EC50(TSH) = 0.84 ng/mL. Experiment 2: For TSHR-WT: EC50(M22) = 1.97 ng/mL, EC50(TSH) = 0.64 ng/mL. For TSHR-JMG45: EC50(M22) = 4.03 ng/mL, EC50(TSH) = 0.63 ng/mL.

TABLE 32 Effect of different concentrations of human monoclonal antibody to the TSHR (M22) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG52 (I253R + D143P + R112P + D151E + V169R). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG52/ Test sample Wild type TSHR TSHR-JMG52 Wild type (%) Experiment 1 Cyclic AMP  2.8 ± 0.5  2.4 ± 0.2 84 buffer M22 0.1 ng/mL  9.2 ± 1.0  8.0 ± 0.9 87 0.3 ng/mL 14.3 ± 0.6  9.69 ± 0.13 68 1 ng/mL 39.8 ± 1.8 27 ± 5 69 3 ng/mL 73 ± 3 60 ± 7 82 10 ng/mL  99 ± 10 112 ± 19 113 30 ng/mL 102 ± 7  118 ± 12 115 TSH 0.01 ng/mL 4.24 ± 0   3.81 ± 0.18 90 0.03 ng/mL  7.0 ± 0.7  7.0 ± 0.5 100 0.1 ng/mL 18.5 ± 0.7 25.4 ± 1.7 137 0.3 ng/mL 49 ± 8 66 ± 4 136 1 ng/mL 86 ± 5  91 ± 10 106 3 ng/mL  99 ± 4* 123 ± 11 124 Experiment 2 Cyclic AMP  9.0 ± 0.4  5.6 ± 0.3 87 buffer M22 0.1 ng/mL 12.9 ± 0.4  7.81 ± 0.19 60 0.3 ng/mL 23 ± 3 13.4 ± 1.3 59 1 ng/mL 60 ± 3 35 ± 4 58 3 ng/mL 101 ± 5  66 ± 2 66 10 ng/mL 130 ± 7  95 ± 2 73 30 ng/mL 110 ± 9  118 ± 11 107 TSH 0.01 ng/mL  8.8 ± 1.5  5.1 ± 0.3 58 0.03 ng/mL 11.8 ± 0.2  7.45 ± 0.12 63 0.1 ng/mL 16.94 ± 0.17 14.0 ± 0.6 83 0.3 ng/mL 41 ± 2 37.2 ± 0.8 91 1 ng/mL 90 ± 3 75.5 ± 0.7 84 3 ng/mL 118 ± 10 99 ± 5 83 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(M22) = 1.92 ng/mL, EC50(TSH) = 0.42 ng/mL. For TSHR-JMG52: EC50(M22) = 3.72 ng/mL, EC50(TSH) = 0.43 ng/mL. Experiment 2: For TSHR-WT: EC50(M22) = 1.40 ng/mL, EC50(TSH) = 0.67 ng/mL. For TSHR-JMG52: EC50(M22) = 3.27 ng/mL, EC50(TSH) = 0.99 ng/mL.

TABLE 33 Effect of different concentrations of human monoclonal antibody to the TSHR (M22) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG55 (I253R + D143P + R112P + D151E + V169R + H63C). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG55/ Test sample Wild type TSHR TSHR-JMG55 Wild type (%) Experiment 1 Cyclic AMP  3.8 ± 1.4  2.48 ± 0.05 65 buffer M22 0.1 ng/mL  8.7 ± 0.2  6 ± 3 72 0.3 ng/mL 16.5 ± 1.8 10.3 ± 1.5 63 1 ng/mL 53 ± 8 30.1 ± 1.5 57 3 ng/mL 102 ± 13 54 ± 5 53 10 ng/mL 140 ± 38  80.7 ± 1.6* 58 30 ng/mL 113 ± 8  88 ± 7 78 TSH 0.01 ng/mL  3.3 ± 0.3  2.6 ± 0.9 79 0.03 ng/mL  4.0 ± 0.7  3.6 ± 0.8 90 0.1 ng/mL  7.1 ± 1.0  7.5 ± 1.7 106 0.3 ng/mL 23.9 ± 0.3 25 ± 2 104 1 ng/mL  73 ± 17 51 ± 5 70 3 ng/mL 109 ± 16  92.1 ± 0.0* 85 Experiment 2 Cyclic AMP  2.6 ± 0.5  2.0 ± 0.0* 76 buffer M22 0.1 ng/mL  7.3 ± 0.9  4.1 ± 0.4 55 0.3 ng/mL 20.7 ± 2.0 10.0 ± 2.9 48 1 ng/mL  51.9 ± 11.7 27.5 ± 2.2 53 3 ng/mL 105.2 ± 3.1  66.2 ± 5.1 63 10 ng/mL 117.8 ± 25.0 121.7 ± 8.3  103 30 ng/mL 125.9 ± 10.2 121.5 ± 2.2  97 TSH 0.01 ng/mL  5.3 ± 1.0  3.5 ± 0.1 66 0.03 ng/mL  5.3 ± 0.8  3.9 ± 0.3 73 0.1 ng/mL 30.5 ± 1.7 20.3 ± 1.9 66 0.3 ng/mL 44.7 ± 4.5 36.0 ± 2.0 81 1 ng/mL 110.0 ± 2.4  108.5 ± 6.6  99 3 ng/mL 102.4 ± 8.2  120.1 ± 16.9 117 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(M22) = 1.53 ng/mL, EC50(TSH) = 1.11 ng/mL. For TSHR-JMG52: EC50(M22) = 2.87 ng/mL, EC50(TSH) = 0.934 ng/mL. Experiment 2: For TSHR-WT: EC50(M22) = 1.30 ng/mL, EC50(TSH) = 0.445 ng/mL. For TSHR-JMG52: EC50(M22) = 3.90 ng/mL, EC50(TSH) = 0.609 ng/mL.

TABLE 34 Effect of different concentrations of human monoclonal antibody to the TSHR (K1-18) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG37 (I253R + D143P + D151E). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG37/ Test sample Wild type TSHR TSHR-JMG37 Wild type (%) Experiment 1 Cyclic AMP  6.6 ± 0.7  4.8 ± 0.3 102 buffer K1-18 0.3 ng/mL  7.8 ± 0.6  6.7 ± 0.2 86 1 ng/mL 12.9 ± 0.7  12.7± 1.2 99 3 ng/mL 29 ± 3 31.4 ± 1.0 107 10 ng/mL 68.3 ± 2   71.8 ± 1.4 105 30 ng/mL 113 ± 4  114 ± 11 100 100 ng/mL 128 ± 10 128 ± 7  100 TSH 0.01 ng/mL  6.7 ± 0.4  4.94 ± 0.09 74 0.03 ng/mL  9.3 ± 0.5  8.08 ± 0.07 87 0.1 ng/mL 23 ± 2 22.7 ± 1.6 101 0.3 ng/mL 48 ± 8 58 ± 3 121 1 ng/mL 102 ± 5  100 ± 12 98 3 ng/mL 123.6 ± 1.7  124 ± 13 101 Experiment 2 Cyclic AMP  7.4 ± 0.5  4.5 ± 0.6 85 buffer K1-18 0.3 ng/mL  9.8 ± 0.4  6.4 ± 0.5 65 1 ng/mL 16.6 ± 0.5 10.9 ± 0.6 66 3 ng/mL 29.9 ± 0.9 23.2 ± 2.0 77 10 ng/mL 71 ± 5 65.7 ± 1.3 92 30 ng/mL 112 ± 3  80 ± 4 72 100 ng/mL 121 ± 13 107 ± 13 88 TSH 0.01 ng/mL  8.0 ± 1.2  4.1 ± 0.3 51 0.03 ng/mL 10.8 ± 1.4  5.8 ± 0.4 53 0.1 ng/mL 18 ± 2 14.4 ± 1.1 79 0.3 ng/mL 40.1 ± 0.8 39.6 ± 0.0 99 1 ng/mL 97 ± 3 85 ± 5 88 3 ng/mL 127 ± 10 93 ± 8 73 Results shown are mean ± SD of triplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(K1-18) = 13.3 ng/mL, EC50(TSH) = 0.64 ng/mL. For TSHR-JMG37: EC50(K1-18) = 11.3 ng/mL, EC50(TSH) = 0.53 ng/mL. Experiment 2: For TSHR-WT: EC50(K1-18) = 12.8 ng/mL, EC50(TSH) = 0.71 ng/mL. For TSHR-JMG37: EC50(K1-18) = 11.1 ng/mL, EC50(TSH) = 0.58 ng/mL.

TABLE 35 Effect of different concentrations of human monoclonal antibody to the TSHR (K1-18) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG45 (I253R + D143P + R112P + D151E). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG45/ Test sample Wild type TSHR TSHR-JMG45 Wild type (%) Experiment 1 Cyclic AMP  6.5 ± 0.4   5 ± 0.3 84 buffer K1-18 0.3 ng/mL  9.7 ± 0.9  5.5 ± 0.15 57 1 ng/mL 15.2 ± 0.6  9.0 ± 0.7 59 3 ng/mL 29 ± 3 27 ± 5 94 10 ng/mL 79 ± 3 65 ± 4 82 30 ng/mL 129 ± 18 108 ± 12 84 100 ng/mL 142 ± 11 150 ± 11 106 TSH 0.01 ng/mL  8.3 ± 0.6  3.6 ± 1.0 43 0.03 ng/mL 10.5 ± 0.7  5.8 ± 0.6 55 0.1 ng/mL 24 ± 3 18 ± 2 75 0.3 ng/mL 60 ± 4 58 ± 4 98 1 ng/mL 117 ± 6  131 ± 18 112 3 ng/mL 141 ± 13 151 ± 45 107 Experiment 2 Cyclic AMP  5.3 ± 0.5  4.3 ± 0.8 105 buffer K1-18 0.3 ng/mL  9 ± 3  5.6 ± 0.4 64 1 ng/mL 10.9 ± 1.0 10.3 ± 0.7 94 3 ng/mL  25 ± 2* 23.2 ± 1.1 93 10 ng/mL 61 ± 5 59.9 ± 0.0 98 30 ng/mL 99.9 ± 1.5 107 ± 11 107 100 ng/mL 126 ± 10 125.6 ± 0.0  100 TSH 0.01 ng/mL  6.7 ± 1.7  4.3 ± 0.4 64 0.03 ng/mL  8.1 ± 0.3  6.2 ± 0.4 77 0.1 ng/mL 16 ± 3 15.4 ± 0.5 97 0.3 ng/mL 38 ± 2 42.0 ± 0.5 110 1 ng/mL 93 ± 3 94 ± 3 101 3 ng/mL 124 ± 14 120 ± 5  97 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1; For TSHR-WT: EC50(K1-18) = 12.9 ng/mL, EC50(TSH) = 0.57 ng/mL. For TSHR-JMG45: EC50(K1-18) = 22.5 ng/mL, EC50(TSH) = 0.63 ng/mL. Experiment 2; For TSHR-WT: EC50(K1-18) = 17.8 ng/mL, EC50(TSH) = 0.82 ng/mL. For TSHR-JMG45: EC50(K1-18) = 16.0 ng/mL, EC50(TSH) = 0.77 ng/mL.

TABLE 36 Effect of different concentrations of human monoclonal antibody to the TSHR (K1-18) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR-JMG52 (I253R + D143P + R112P + D151E + V169R). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG52/ Test sample Wild type TSHR TSHR-JMG52 Wild type (%) Experiment 1 Cyclic AMP  6.7 ± 1.2  5.05 ± 0.19 96 buffer K1-18 0.3 ng/mL  9.5 ± 1.2  6.47 ± 0.07 68 1 ng/mL 13.7 ± 0.7 10.1 ± 1.2 74 3 ng/mL 27.6 ± 0.9 22.3 ± 0.7 81 10 ng/mL 67 ± 5 53.3 ± 1.0 79 30 ng/mL 115 ± 10 79 ± 3 69 100 ng/mL 140 ± 17 106 ± 9  76 TSH 0.01 ng/mL  7.0 ± 0.6  5.3 ± 0.8 76 0.03 ng/mL  9.8 ± 0.2  7.9 ± 0.4 81 0.1 ng/mL 19 ± 2  17.7 ± 0.9* 92 0.3 ng/mL 53 ± 7 47.9 ± 1.4 91 1 ng/mL 116 ± 9* 85 ± 6 74 3 ng/mL 142 ± 11 98 ± 9 69 Experiment 2 Cyclic AMP  6.0 ± 0.4  4.4 ± 0.4 81 buffer K1-18 0.3 ng/mL  8.1 ± 0.7  4.9 ± 0.3 60 1 ng/mL 13 ± 3  8.5 ± 0.6 64 3 ng/mL 30 ± 7 16.4 ± 0.8 55 10 ng/mL 52 ± 5 37 ± 2 70 30 ng/mL 94 ± 7  64 ± 11 68 100 ng/mL 109 ± 9  87 ± 6 80 TSH 0.01 ng/mL  6.8 ± 0.3  3.91 ± 0.07 58 0.03 ng/mL  8.2 ± 0.6  4.1 ± 1.2 50 0.1 ng/mL 14 ± 3 13 ± 3 87 0.3 ng/mL 31 ± 6 25.5 ± 0.0 81 1 ng/mL  70.3 ± 0.0* 58 ± 5 83 3 ng/mL  101 ± 17* 74 ± 5 74 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(K1-18) = 17.9 ng/mL, EC50(TSH) = 0.69 ng/mL. For TSHR-JMG52: EC50(K1-18) = 14.9 ng/mL, EC50(TSH) = 0.51 ng/mL. Experiment 2: For TSHR-WT: EC50(K1-18) = 14.3 ng/mL, EC50(TSH) = 1.00 ng/mL. For TSHR-JMG52: EC50(K1-18) = 19.7 ng/mL, EC50(TSH) = 0.99 ng/mL.

TABLE 37 Effect of different concentrations of human monoclonal antibody to the TSHR (K1-18) and TSH on stimulation of cyclic AMP production in CHO cells expressing wild type TSHR and TSHR- JMG55 (I253R + D143P + R112P + D151E + V169R + H63C). Cyclic AMP produced (pmol/mL; mean ± SD; n = 3) TSHR-JMG55/ Test sample Wild type TSHR TSHR-JMG55 Wild type (%) Experiment 1 Cyclic AMP 3.7 ± 0.3 1.44 ± 0.11 104 buffer K1-18 0.3 ng/mL 5.3 ± 0.9 3.9 ± 0.7 74 1 ng/mL 9.90 ± 0.12 7.9 ± 0.5 80 3 ng/mL 19 ± 2  15.1 ± 1.0  78 10 ng/mL 67.8 ± 1.6  50 ± 3  74 30 ng/mL 99 ± 15 73 ± 8  74 100 ng/mL 111 ± 10  98 ± 10 88 TSH 0.01 ng/mL 4.9 ± 1.4 2.68 ± 0.07 55 0.03 ng/mL 7.7 ± 0.9 5.7 ± 0.6 74 0.1 ng/mL 19 ± 3  14.7 ± 0.6  77 0.3 ng/mL 49 ± 5  45.0 ± 1.8  93 1 ng/mL 93 ± 8  79 ± 11 84 3 ng/mL 104 ± 19  91 ± 11 88 Experiment 2 Cyclic AMP 3.4 ± 0.4  1.8 ± 0.1* 53 buffer K1-18 0.3 ng/mL 4.9 ± 0.5 1.9 ± 0.2 40 1 ng/mL 8.0 ± 1.4 3.7 ± 0.4 47 3 ng/mL 18.9 ± 1.0  8.6 ± 0.7 45 10 ng/mL 54.2 ± 13.8 26.8 ± 3.1  50 30 ng/mL 82.6 ± 5.9  45.9 ± 3.3  55 100 ng/mL 90.2 ± 13.1 66.1 ± 4.2  73 TSH 0.01 ng/mL 3.6 ± 1.3 2.6 ± 0.7 71 0.03 ng/mL 4.9 ± 0.7 2.9 ± 0.8 60 0.1 ng/mL 12.0 ± 0.7  6.6 ± 0.7 55 0.3 ng/mL 33.3 ± 2.2  22.1 ± 4.0  66 1 ng/mL 75.6 ± 8.7  53.2 ± 2.1  70 3 ng/mL 89.8 ± 9.0  69.2 ± 2.5  77 Results shown are mean ± SD of triplicate determinations. *duplicate determinations. Samples diluted in cyclic AMP buffer. Experiment 1: For TSHR-WT: EC50(K1-18) = 11.1 ng/mL, EC50(TSH) = 0.50 ng/mL. For TSHR-JMG55: EC50(K1-18) = 14.3 ng/mL, EC50(TSH) = 0.48 ng/mL. Experiment 2: For TSHR-WT: EC50(K1-18) = 12.0 ng/mL, EC50(TSH) = 0.62 ng/mL. For TSHR-JMG55: EC50(K1-18) = 28.2 ng/mL, EC50(TSH) = 0.81 ng/mL.

TABLE 38 Summary of effects of mutations (relative to TSHR-WT) on stimulation of CHO cells expressing mutated full length TSHR by TSH, M22-Fab and K1-18 IgG. Mutant TSH stimulation M22-Fab stimulation K1-18 IgG Stimulation TSHR-JMG37 Little change Little change Little change TSHR-JMG45 Little change Small increase in EC50 (3-fold) Little change TSHR-JMG52 Little change Small increase in EC50 (2-fold) Little change TSHR-JMG55 Little change Small increase in EC50 (2-fold) Little change

TABLE 39a Summary of the effects of mutations (relative to TSHR-WT) on the EC50 of M22- Fab and TSH stimulation of CHO cells expressing the mutated full length TSHR. M22 Fab TSH Number of Sample LogEC50 EC50 (ng/mL) LogEC50 EC50 (ng/mL) assay repeats WT 0.21 ± 0.07 1.6 −0.16 ± 0.14 0.69 10 JMG37 0.23 ± 0.37 1.7 −0.25 ± 0.26 0.56 2 JMG45 0.67 ± 0.09 4.7 −0.14 ± 0.09 0.73 2 JMG52 0.54 ± 0.04 3.5 −0.19 ± 0.26 0.65 2 JMG55 0.52 ± 0.09 3.3 −0.12 ± 0.13 0.75 2 EC50 is the concentration of ligand required to give half the maximum signalling response. LogEC50 is shown as the mean ± SD from between 2 and 10 independent experiments.

TABLE 39b Summary of the effects of mutations (relative to TSHR-WT) on the EC50 of K1-18 IgG and TSH stimulation of CHO cells expressing the mutated full length TSHR. K1-18 IgG TSH Number of Sample LogEC50 EC50 (ng/mL) LogEC50 EC50 (ng/mL) assay repeats WT 1.13 ± 0.08 13.3 −0.17 ± 0.09 0.68 10 JMG37 1.045 ± 0.007 11.1 −0.26 ± 0.03 0.55 2 JMG45 1.28 ± 0.11 18.8 −0.16 ± 0.06 0.70 2 JMG52 1.23 ± 0.08 17.0 −0.1 ± 0.2 0.71 2 JMG55 1.31 ± 0.21 20.2 −0.20 ± 0.16 0.62 2 EC50 is the concentration of ligand required to give half the maximum signalling response. LogEC50 is shown as the mean ± SD from between 2 and 10 independent experiments.

TABLE 40 Cyclic AMP levels in CHO cells expressing wild type TSHR and TSHR-JMG45 (I253R + D143P + R112P + D151E). Effect of normal sera and patient sera on stimulation of cyclic AMP production. Stimulation (ratio to basal TSHR-JMG45/ stimulation (NPS); mean ± SD; n = 3) Wild type Sample Wild type TSHR TSHR-JMG45 (%) cyclic AMP Buffer 0.72 ± 0.15 0.56 ± 0.08 78 NPS 1.00 ± 0.14 1.00 ± 0.12 100 Normal Sera NT 9916 0.95 ± 0.12 0.82 ± 0.06 86 NT 9918 1.00 ± 0.10 0.78 ± 0.07 78 NT 9924 0.87 ± 0.12 0.84 ± 0.07 97 NT 11746 1.02 ± 0.07 0.98 ± 0.07 96 TRAb F11/9573 12.9 ± 1.8  12.5 ± 0.8  97 positive F07/5459 4.2 ± 0.6  2.1 ± 0.06 50 patient sera 82 18 ± 3  29 ± 4  158 92 11 ± 3  9.2 ± 0.9 83 101 10.1 ± 1.0  6.8 ± 0.6 67 107 15.7 ± 0.5  8.1 ± 0.4 52 111 11.8 ± 0.9  10 ± 3  83 Results are expressed as a ratio to basal stimulation by NPS and are the mean ± SD of triplicate determinations.

TABLE 41 Cyclic AMP levels in CHO cells expressing wild type TSHR and TSHR- JMG52 (I253R + D143P + R112P + D151E + V169R). Effect of normal sera and patient sera on stimulation of cyclic AMP production. Stimulation (ratio to basal TSHR-JMG52/ stimulation (NPS); mean ± SD; n = 3) Wild type Sample Wild type TSHR TSHR-JMG52 (%) cyclic AMP Buffer 0.63 ± 0.07 0.63 ± 0.02 101 NPS 1.00 ± 0.08 1.00 ± 0.05 100 Normal Sera NT 9916 0.83 ± 0.11 0.7 ± 0.2 86 NT 9918 0.96 ± 0.09  0.81 ± 0.009 85 NT 9924  0.84 ± 0.018 0.91 ± 0.11 109 NT 11746 0.96 ± 0.09 0.96 ± 0.05 100 TRAb F11/9573 14.5 ± 1.5  16.3 ± 0.4  112 positive F07/5459 5.1 ± 0.4 2.51 ± 0.08 49 patient sera 82 15.8 ± 1.3  30 ± 3  191 92 11.9 ± 1.6  12.8 ± 0.9  108 101 12.2 ± 1.5  10.3 ± 0.2  84 107 15.3 ± 0.8   13 ± 0.3 85 111 13.5 ± 1.1  11.5 ± 0.7  85 Results are expressed as a ratio to basal stimulation by NPS and are the mean ± SD of triplicate determinations.

TABLE 44 Inhibition of M22-POD binding to TSHR260 mutants by patient sera TSHR260-WT TSHR260-JMG57 TSHR260-JMG58 % % % Test sample OD450 Inhibition OD450 Inhibition OD450 Inhibition Healthy NT 9916 1.962 ± 0.156 12.7 1.523 ± 0.023 10.8 1.722 ± 0.117 8.0 blood NT 9918 2.359 ± 0.084 −5.0 1.606 ± 0.093 5.9 1.890 ± 0.088 −1.0 donor  NT 11748 2.386 ± 0.302 −6.2 1.868 ± 0.115 −9.4 1.871 ± 0.090 0.0 sera NT 9924 2.280 ± 0.040 −1.5 1.832 ± 0.077 −7.3 2.003 ± 0.057 −7.0 Mean 2.247 ± 0.071 0.0 1.707 ± 0.037 0.0 1.872 ± 0.054 0.0 TRAb 77 0.165 ± 0.007 92.7 0.490 ± 0.013 71.3 0.638 ± 0.010 65.9 positive 105 0.225 ± 0.035 90.0 0.334 ± 0.019 80.4 0.437 ± 0.040 76.6 patient 117 0.069 ± 0.009 96.9 0.108 ± 0.001 93.7 0.110 ± 0.006 94.1 sera 27 0.085 ± 0.003 96.2 0.587 ± 0.004 65.6 0.650 ± 0.001 65.3 15 0.621 ± 0.003 72.4 0.724 ± 0.023 57.6 0.851 ± 0.067 54.5 60 0.092 ± 0.012 95.9 0.090 ± 0.010 94.7 0.088 ± 0.002 95.3 70 0.078 ± 0.001 96.5 0.154 ± 0.006 91.0 0.163 ± 0.016 91.3 80 0.166 ± 0.004 92.6 0.422 ± 0.002 75.3 0.503 ± 0.033 73.1 100 0.382 ± 0.021 83.0 0.563 ± 0.021 67.0 0.603 ± 0.029 67.8 Results are shown as absorbance at 450 nm (mean ± SD; n = 2) and percent inhibition of M22-POD binding.

TABLE 45a Binding of human monoclonal TSHR autoantibody M22 (diluted in a pool of healthy blood donor sera) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405 nm M22 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP 1253R JMG22 JMG37 JMG45 100 μg/ml 0.913 ± 0.004 0.940 ± 0.042 1.006 ± 0.030 0.788 ± 0.057 0.992 ± 0.029 10 μg/ml 0.823 ± 0.008 0.895 ± 0.013 0.887 ± 0.031 0.744 ± 0.016 0.919 ± 0.028 1 μg/ml 0.723 ± 0.005 0.790 ± 0.016 0.790 ± 0.009 0.701 ± 0.018 0.843 ± 0.016 0.1 μg/ml 0.359 ± 0.001 0.404 ± 0.016 0.410 ± 0.005 0.388 ± 0.004 0.423 ± 0.027 0.01 μg/ml 0.056 ± 0.013 0.111 ± 0.021 0.126 ± 0.072 0.061 ± 0.015 0.133 ± 0.035 0 μg/ml 0.003 ± 0.003 0.003 ± 0.001 0.003 ± 0.000 0.007 ± 0.001 0.008 ± 0.000 ABSORBANCE 405 nm M22 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 1.067 ± 0.004 0.856 ± 0.119 0.758 ± 0.004 0.790 ± 0.016 10 μg/ml 0.922 ± 0.058 0.809 ± 0.034 0.668 ± 0.009 0.710 ± 0.004 1 μg/ml 0.731 ± 0.008 0.666 ± 0.020 0.590 ± 0.015 0.622 ± 0.001 0.1 μg/ml 0.410 ± 0.006 0.348 ± 0.019 0.317 ± 0.005 0.323 ± 0.001 0.01 μg/ml 0.084 ± 0.035 0.165 ± 0.050 0.097 ± 0.007 0.070 ± 0.016 0 μg/ml 0.003 ± 0.001 0.017 ± 0.000 0.007 ± 0.002 0.004 ± 0.001 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 45b Binding of human monoclonal TSHR autoantibody K1-70 (diluted in a pool of healthy blood donor sera) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405 nm K1-70 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP 1253R JMG22 JMG37 JMG45 100 μg/ml 0.718 ± 0.016 0.799 ± 0.023 1.001 ± 0.001 0.671 ± 0.006 1.037 ± 0.086 10 μg/ml 0.716 ± 0.021 0.786 ± 0.016 0.903 ± 0.015 0.641 ± 0.006 0.901 ± 0.020 1 μg/ml 0.619 ± 0.001 0.667 ± 0.016 0.770 ± 0.046 0.568 ± 0.018 0.802 ± 0.078 0.1 μg/ml 0.251 ± 0.025 0.296 ± 0.038 0.321 ± 0.016 0.261 ± 0.000 0.339 ± 0.017 0.01 μg/ml 0.041 ± 0.016 0.117 ± 0.025 0.115 ± 0.014 0.061 ± 0.033 0.155 ± 0.065 0 μg/ml 0.003 ± 0.003 0.003 ± 0.001 0.003 ± 0.000 0.007 ± 0.001 0.008 ± 0.000 ABSORBANCE 405 nm K1-70 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 0.920 ± 0.007 0.984 ± 0.031 0.729 ± 0.030 0.759 ± 0.018 10 μg/ml 1.035 ± 0.006 0.873 ± 0.027 0.678 ± 0.068 0.705 ± 0.004 1 μg/ml 0.840 ± 0.080 0.809 ± 0.068 0.592 ± 0.006 0.602 ± 0.005 0.1 μg/ml 0.329 ± 0.059 0.330 ± 0.048 0.299 ± 0.005 0.299 ± 0.001 0.01 μg/ml 0.062 ± 0.015 0.148 ± 0.067 0.063 ± 0.006 0.054 ± 0.002 0 μg/ml 0.003 ± 0.001 0.017 ± 0.000 0.007 ± 0.002 0.004 ± 0.001 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 45c Binding of human monoclonal TSHR autoantibody K1-18 (diluted in a pool of healthy blood donor sera) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405 nm K1-18 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP 1253R JMG22 JMG37 JMG45 100 μg/ml 0.663 ± 0.022 0.637 ± 0.085 0.881 ± 0.005 0.691 ± 0.029 1.000 ± 0.027 10 μg/ml 0.587 ± 0.016 0.672 ± 0.020 0.816 ± 0.025 0.600 ± 0.014 0.929 ± 0.028 1 μg/ml 0.490 ± 0.001 0.531 ± 0.006 0.628 ± 0.023 0.512 ± 0.011 0.657 ± 0.004 0.1 μg/ml 0.184 ± 0.008 0.230 ± 0.012 0.258 ± 0.007 0.221 ± 0.003 0.306 ± 0.023 0.01 μg/ml 0.035 ± 0.008 0.042 ± 0.016 0.060 ± 0.025 0.037 ± 0.003 0.106 ± 0.031 0 μg/ml 0.003 ± 0.003 0.003 ± 0.001 0.003 ± 0.000 0.007 ± 0.001 0.008 ± 0.000 ABSORBANCE 405 nm K1-18 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 0.962 ± 0.147 0.966 ± 0.002 0.747 ± 0.000 0.758 ± 0.003 10 μg/ml 0.881 ± 0.086 0.860 ± 0.018 0.668 ± 0.006 0.689 ± 0.013 1 μg/ml 0.645 ± 0.110 0.626 ± 0.045 0.551 ± 0.003 0.575 ± 0.006 0.1 μg/ml 0.247 ± 0.003 0.260 ± 0.047 0.215 ± 0.001 0.229 ± 0.006 0.01 μg/ml 0.046 ± 0.009 0.064 ± 0.003 0.039 ± 0.008 0.038 ± 0.001 0 μg/ml 0.003 ± 0.001 0.017 ± 0.000 0.007 ± 0.002 0.004 ± 0.001 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 45d Binding of human monoclonal GAD autoantibody 5B3 (negative control) (diluted in a pool of healthy blood donor sera), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405 nm WILD TYPE 5B3 TSHR260-AP TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration (?) I235R JMG22 JMG37 JMG45 100 μg/ml 0.008 ± 0.008 0.016 ± 0.001 0.011 ± 0.004 0.005 ± 0.001 0.033 ± 0.01  10 μg/ml 0.01 ± 0.01 0.017 ± 0.009 0.005 ± 0.001 0.003 ± 0.001 0.032 ± 0.006 0.01 μg/ml 0.005 ± 0.005 0.006 0.005 0.004 0.013 0 μg/ml 0.003 ± 0.003 0.003 ± 0.001 0.003 ± 0.000 0.007 ± 0.001 0.008 ± 0.000 ABSORBANCE 405 nm 5B3 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG56 JMG57 100 μg/ml 0.009 ± 0.008 0.013 ± 0.006 0.012 ± 0.004 0.011 ± 0.002 10 μg/ml 0.003 ± 0.0  0.014 ± 0.004 0.009 ± 0.001 0.005 ± 0.002 0.01 μg/ml 0.005 0.0016 0.008 0.005 0 μg/ml 0.003 ± 0.001 0.017 ± 0.000 0.007 ± 0.002 0.004 ± 0.001 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 45e Relative binding of M22 (diluted in a pool of healthy blood donor sera) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a). Relative binding (%) M22 WILD TYPE TSHR260-AP- TSRH260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 100 ± 0.4  100 ± 4.5  100 ± 3.0  100 ± 7.2  100 ± 2.9  10 μg/ml 90 ± 0.9 95 ± 1.4 88 ± 3.1 94 ± 2.0 93 ± 2.8 1 μg/ml 79 ± 0.5 84 ± 1.7 79 ± 0.9 89 ± 2.3 85 ± 1.6 0.1 μg/ml 39 ± 0.1 43 ± 1.7 41 ± 0.5 49 ± 0.5 43 ± 2.7 0.01 μg/ml  6 ± 1.4 12 ± 2.2 13 ± 7.2  8 ± 1.9 11 ± 3.5 0 μg/ml  0 ± 0.3  0 ± 0.1  0 ± 0.0  1 ± 0.1  1 ± 0.0 Relative binding (%) M22 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 100 ± 0.4  100 ± 14  100 ± 0.5  100 ± 2.0  10 μg/ml 86 ± 5.4 95 ± 4.0 88 ± 1.2 90 ± 0.5 1 μg/ml 69 ± 0.7 78 ± 2.3 78 ± 2.0 79 ± 0.1 0.1 μg/ml 38 ± 0.6 41 ± 2.2 42 ± 0.7 41 ± 0.1 0.01 μg/ml  8 ± 3.3 19 ± 5.8 13 ± 0.9  9 ± 2.0 0 μg/ml  0 ± 0.1  2 ± 0.0  1 ± 0.3  1 ± 0.1 Results are shown as the absorbances observed with each particular TSHR260-AP construct with different concentration of M22 expressed as a percentage of the absorbances observed with 100 μg/mL M22 (Relative binding; mean ± SD, n = 2).

TABLE 45f Relative binding of K1-70 (diluted in a pool of healthy blood donor sera) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) Relative binding (%) K1-70 WILD TYPE TSHR260-AP- TSRH260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 100 ± 2.2 100 ± 2.9  100 ± 0.1  100 ± 0.9  100 ± 8.3  10 μg/ml 100 ± 2.9 98 ± 2  90 ± 1.5 96 ± 0.9 87 ± 1.9 1 μg/ml  86 ± 0.1 83 ± 2  77 ± 4.6 85 ± 2.7 77 ± 7.5 0.1 μg/ml  35 ± 3.5 37 ± 4.8 32 ± 1.6 39 ± 0  33 ± 1.6 0.01 μg/ml  6 ± 2.2 15 ± 3.1 11 ± 1.4  9 ± 4.9 15 ± 6.3 0 μg/ml  0 ± 0.4  0 ± 0.1  0 ± 0.0  1 ± 0.1  1 ± 0.0 Relative binding (%) K1-70 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 89 ± 0.7 100 ± 3.2  100 ± 4.1  100 ± 2.4  10 μg/ml 100 ± 0.6  89 ± 2.7 93 ± 0.8 93 ± 0.5 1 μg/ml 81 ± 7.7 82 ± 6.9 81 ± 0.8 79 ± 0.7 0.1 μg/ml 32 ± 5.7 34 ± 4.9 41 ± 0.7 39 ± 0.1 0.01 μg/ml  6 ± 1.4 15 ± 6.8  9 ± 0.8  7 ± 0.3 0 μg/ml  0 ± 0.1  2 ± 0.0  1 ± 0.3  1 ± 0.1 Results are shown as the absorbances observed with each particular TSHR260-AP construct with different concentration of K1-70 expressed as a percentage of the absorbances observed with 100 μg/mL K1-70 (Relative binding; mean ± SD, n = 2).

TABLE 45g Relative binding of K1-18 (diluted in a pool of healthy blood donor sera) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) Relative binding (%) K1-18 WILD TYPE TSHR260-AP- TSRH260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 100 ± 3.3  100 ± 13  100 ± 0.6  100 ± 4.2  100 ± 2.7  10 μg/ml 89 ± 2.4 105 ± 3.1  93 ± 2.8 87 ± 1 2 93 ± 2.8 1 μg/ml 74 ± 0.2 83 ± 0.9 71 ± 2.6 74 ± 1.6 66 ± 0.4 0.1 μg/ml 28 ± 1.2 36 ± 1.9 29 ± 0.8 32 ± 0.4 31 ± 2.3 0.01 μg/ml  5 ± 1.2  7 ± 2.5  7 ± 2.8  5 ± 0.4 11 ± 3.1 0 μg/ml  0 ± 0.5  0 ± 0.2  0 ± 0.0  1 ± 0.1  1 ± 0.1 Relative binding (%) K1-18 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 100 ± 15  100 ± 0.2  100 ± 0   100 ± 0.4  10 μg/ml 92 ± 8.9 89 ± 1.9 89 ± 0.8 91 ± 1.7 1 μg/ml 67 ± 11  65 ± 4.7 74 ± 0.4 76 ± 0.8 0.1 μg/ml 26 ± 0.3 27 ± 4.9 29 ± 0.1 30 ± 0.8 0.01 μg/ml  5 ± 0.9  7 ± 0.3  5 ± 1.1  5 ± 0.1 0 μg/ml  0 ± 0.1  2 ± 0.0  1 ± 0.3  1 ± 0.1 Results are shown as the absorbances observed with each particular TSHR260-AP construct with different concentration of K1-18 expressed as a percentage of the absorbances observed with 100 μg/mL K1-18 (Relative binding; mean ± SD, n = 2).

TABLE 46a Binding of human monoclonal TSHR autoantibody M22 (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405 nm M22 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 0.915 ± 0.698 0.883 ± 0.028 0.977 ± 0.018 0.715 ± 0.025 1.205 ± 0.138 10 μg/ml 0.779 ± 0.073 0.848 ± 0.005 0.862 ± 0.074 0.703 ± 0.004 1.043 ± 0.012 1 μg/ml 0.660 ± 0.055 0.766 ± 0.052 0.792 ± 0.026 0.740 ± 0.022 0.928 ± 0.018 0.1 μg/ml 0.436 ± 0.053 0.522 ± 0.019 0.536 ± 0.006 0.516 ± 0.002 0.603 ± 0.007 0.01 μg/ml 0.105 ± 0.018 0.114 ± 0.08  0.135 ± 0.066 0.143 ± 0.004 0.098 ± 0.024 0 μg/ml 0.003 ± 0.002 0.003 ± 0.001 0.005 ± 0.002 0.003 ± 0.001 0.012 ± 0.001 ABSORBANCE 405 nm M22 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 1.136 ± 0.016 0.977 ± 0.034 1.052 ± 0.011 1.086 ± 0.014 10 μg/ml 1.003 ± 0.056 0.872 ± 0.037 0.851 ± 0.004 0.897 ± 0.001 1 μg/ml 0.925 ± 0.01  0.786 ± 0.016 0.748 ± 0.012 0.777 ± 0.001 0.1 μg/ml 0.619 ± 0.001 0.510 ± 0.013 0.488 ± 0.002 0.509 ± 0.006 0.01 μg/ml 0.082 ± 0.001 0.133 ± 0.029 0.105 ± 0.059 0.110 ± 0.056 0 μg/ml 0.009 ± 0.004 0.021 ± 0.000 0.006 ± 0.001 0.005 ± 0.002 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 46b Binding of human monoclonal TSHR autoantibody K1-70 (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405 nm K1-70 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 0.843 ± 0.0435 0.908 ± 0.057 1.266 ± 0.017 0.672 ± 0.008 1.709 ± 0.037 10 μg/ml 0.710 ± 0.0565 0.834 ± 0.021 0.980 ± 0.029 0.671 ± 0.052 1.159 ± 0.00  1 μg/ml 0.613 ± 0.0266 0.732 ± 0.011 0.849 ± 0.006 0.651 ± 0.013 0.945 ± 0.002 0.1 μg/ml 0.382 ± 0.0317 0.392 ± 0.002 0.468 ± 0.016 0.373 ± 0.003 0.561 ± 0.023 0.01 μg/ml 0.081 ± 0.0286 0.109 ± 0.021 0.168 ± 0.037 0.082 ± 0.042 0.079 ± 0.005 0 μg/ml 0.003 ± 0.002  0.003 ± 0.001 0.005 ± 0.002 0.003 ± 0.001 0.012 ± 0.001 ABSORBANCE 405 nm K1-70 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 1.703 ± 0.092 1.544 ± 0.011 1.146 ± 0.001 1.206 ± 0.020 10 μg/ml 1.255 ± 0.059 1.123 ± 0.007 0.920 ± 0.001 0.953 ± 0.008 1 μg/ml 1.084 ± 0.003 0.872 ± 0.072 0.756 ± 0.006 0.780 ± 0.018 0.1 μg/ml 0.640 ± 0.053 0.598 ± 0.017 0.513 ± 0.007 0.542 ± 0.001 0.01 μg/ml 0.088 ± 0.021 0.156 ± 0.013 0.101 ± 0.004 0.097 ± 0.002 0 μg/ml 0.009 ± 0.004 0.021 ± 0.00  0.006 ± 0.001 0.005 ± 0.002 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 46c Binding of human monoclonal TSHR autoantibody K1-18 (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405nm K1-18 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 0.748 ± 0.0675 0.757 ± 0.036 1.061 ± 0.004 0.739 ± 0.028 1.474 ± 0.021 10 μg/ml 0.618 ± 0.0107 0.718 ± 0.02  0.856 ± 0.022 0.673 ± 0.023 1.030 ± 0.007 1 μg/ml 0.494 ± 0.0122 0.581 ± 0.038 0.637 ± 0.024 0.552 ± 0.043 0.810 ± 0.011 0.1 μg/ml 0.265 ± 0.004  0.305 ± 0.023 0.325 ± 0.00  0.346 ± 0.00  0.447 ± 0.015 0.01 μg/ml 0.0428 ± 0.012  0.079 ± 0.028 0.058 ± 0.011 0.065 ± 0.012 0.108 ± 0.040 0 μg/ml 0.003 ± 0.002  0.003 ± 0.001 0.005 ± 0.002 0.003 ± 0.001 0.012 ± 0.001 ABSORBANCE 405nm K1-18 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 1.422 ± 0.021 1.335 ± 0.103 1.040 ± 0.007 1.074 ± 0.011 10 μg/ml 1.085 ± 0.025 0.970 ± 0.073 0.843 ± 0.002 0.862 ± 0.015 1 μg/ml 0.820 ± 0.001 0.778 ± 0.067 0.709 ± 0.006 0.746 ± 0.005 0.1 μg/ml 0.445 ± 0.006 0.380 ± 0.035 0.378 ± 0.001 0.401 ± 0.001 0.01 μg/ml 0.067 ± 0.006 0.072 ± 0.01  0.074 ± 0.007 0.094 ± 0.025 0 μg/ml 0.009 ± 0.004 0.021 ± 0.000 0.006 ± 0.001 0.005 ± 0.002 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 46d Binding of human monoclonal GAD autoantibody 5B3 IgG (negative control) (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) ABSORBANCE 405nm 5B3 WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 0.008 ± 0.005 0.023 ± 0.001 0.016 ± 0.001 0.005 ± 0.001 0.034 ± 0.001 10 μg/ml 0.003 ± 0.005 0.014 ± 0.001 0.006 ± 0.001 0.001 ± 0.00  0.017 ± 0.001 0.01 μg/ml 0.004 0.01 0.004 0.001 0.012 0 μg/ml 0.003 ± 0.002 0.003 ± 0.001 0.005 ± 0.002 0.003 ± 0.001 0.012 ± 0.001 ABSORBANCE 405nm 5B3 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 0.013 ± 0.007 0.018 ± 0.001 0.014 ± 0.002 0.011 ± 0.001 10 μg/ml 0.007 ± 0.001 0.019 ± 0.001 0.013 ± 0.004 0.009 ± 0.003 0.01 μg/ml 0.004 0.026 0.006 0.006 0 μg/ml 0.009 ± 0.004 0.021 ± 0.000 0.006 ± 0.001 0.005 ± 0.002 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 46e Relative binding of M22 (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) Relative binding (%) M22 WILD TYPE TSHR260-AP- TSRH260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 100 ± 7.6  100 ± 3.2  100 ± 1.8  97 ± 3.5 100 ± 12  10 μg/ml 85 ± 8.1 96 ± 0.6 88 ± 7.6 95 ± 0.6 87 ± 1  1 μg/ml 72 ± 6.1 87 ± 5.9 81 ± 2.7 100 ± 3.1  77 ± 1.5 0.1 μg/ml 48 ± 5.8 59 ± 2.2 55 ± 0.6 70 ± 0.3 50 ± 0.6 0.01 μg/ml 11 ± 2  13 ± 9.1 14 ± 6.8 19 ± 0.6 8 ± 2  0 μg/ml  0 ± 0.3  0 ± 0.1  1 ± 0.2  0 ± 0.1  1 ± 0.1 Relative binding (%) M22 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 100 ± 1.4  100 ± 3.5  100 ± 1   100 ± 1.3  10 μg/ml 88 ± 4.9 89 ± 3.8 81 ± 0.4 83 ± 0.1 1 μg/ml 81 ± 0.9 80 ± 1.6 71 ± 1.1 72 ± 0.1 0.1 μg/ml 54 ± 0.1 52 ± 1.3 46 ± 0.2 47 ± 0.6 0.01 μg/ml  7 ± 0.1 14 ± 3  10 ± 5.6 10 ± 5.2 0 μg/ml  1 ± 0.4  2 ± 0.0  1 ± 0.1  0 ± 0.2 Results are shown as the absorbances observed with each particular TSHR260-AP construct with different concentration of M22 expressed as a percentage of the absorbances observed with 100 μg/mL M22 (Relative binding; mean ± SD, n = 2).

TABLE 46f Relative binding of K1-70 (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) Relative binding (%) K1-70 WILD TYPE TSHR260-AP- TSRH260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 100 ± 5.2  100 ± 6.3  100 ± 1.3  100 ± 1.2  100 ± 2.2  10 μg/ml 84 ± 6.7 92 ± 2.3 77 ± 2.3 100 ± 7.7  68 ± 0  1 μg/ml 73 ± 3.2 81 ± 1.2 67 ± 0.5 97 ± 1.9 55 ± 0.1 0.1 μg/ml 45 ± 3.8 43 ± 0.2 37 ± 1.3 56 ± 0.4 33 ± 1.3 0.01 μg/ml 10 ± 3.4 12 ± 2.3 13 ± 2.9 12 ± 6.3  5 ± 0.3 0 μg/ml  0 ± 0.3  0 ± 0.1  0 ± 0.2  0 ± 0.1  1 ± 0.1 Relative binding (%) K1-70 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 100 ± 5.4  100 ± 0.7  100 ± 0.1  100 ± 1.7  10 μg/ml 74 ± 3.5 73 ± 0.5 80 ± 0.1 79 ± 0.7 1 μg/ml 64 ± 0.2 56 ± 4.7 66 ± 0.5 65 ± 1.5 0.1 μg/ml 38 ± 3.1 39 ± 1.1 45 ± 0.6 45 ± 0.1 0.01 μg/ml  5 ± 1.2 10 ± 0.8  9 ± 0.3  8 ± 0.2 0 μg/ml  1 ± 0.2  1 ± 0.0  1 ± 0.1  0 ± 0.2 Results are shown as the absorbances observed with each particular TSHR260-AP construct with different concentration of K1-70 expressed as a percentage of the absorbances observed with 100 μg/mL K1-70 (Relative binding; mean ± SD, n = 2).

TABLE 46g Relative binding of K1-18 (diluted in assay buffer), to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) Relative binding (%) K1-18 WILD TYPE TSHR260-AP- TSRH260-AP- TSHR260-AP- TSHR260-AP- concentration TSHR260-AP I235R JMG22 JMG37 JMG45 100 μg/ml 100 ± 9   100 ± 4.8  100 ± 0.4  100 ± 3.8  100 ± 1.4  10 μg/ml 83 ± 1.4 95 ± 2.6 81 ± 2.1 91 ± 3.1 70 ± 0.5 1 μg/ml 66 ± 1.6 77 ± 5  60 ± 2.3 75 ± 5.8 55 ± 0.7 0.1 μg/ml 35 ± 0.5 40 ± 3  31 ± 0  47 ± 0  30 ± 1  0.01 μg/ml  6 ± 1.5 10 ± 3.7 5 ± 1   9 ± 1.6  7 ± 2.7 0 μg/ml  0 ± 0.3  0 ± 0.1  0 ± 0.2  0 ± 0.1  1 ± 0.1 Relative binding (%) K1-18 TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- concentration JMG52 JMG55 JMG57 JMG58 100 μg/ml 100 ± 1.5  100 ± 7.7  100 ± 0.7  100 ± 1   10 μg/ml 76 ± 1.8 99 ± 7.5 81 ± 0.2 80 ± 1.3 1 μg/ml 58 ± 0.1 80 ± 6.9 68 ± 0.6 69 ± 0.5 0.1 μg/ml 32 ± 0.4 39 ± 3.6 36 ± 0.1 37 ± 0.1 0.01 μg/ml  5 ± 0.4 7 ± 1   7 ± 0.7  9 ± 2.3 0 μg/ml  1 ± 0.3  2 ± 0.0  1 ± 0.1  0 ± 0.2 Results are shown as the absorbances observed with each particular TSHR260-AP construct with different concentration of K1-18 expressed as a percentage of the absorbances observed with 100 μg/mL K1-18 (Relative binding; mean ± SD, n = 2).

TABLE 47a Binding of TRAb positive patient sera (G1-G12) and healthy blood donor sera (N1 - N11) to wild type and mutated TSHR260-AP in a bridge ELISA (FIG. 13a) Absorbance 405 nm WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- Test Sample TSHR260-AP I235R JMG22 JMG37 JMG45 Healthy 0.007 ± 0.001 0.007 ± 0.003 0.007 ± 0.001 0.002 ± 0.001 0.009 ± 0.002 blood donor sera pool K1-70 IgG 0.017 ± 0.002 0.016 ± 0.004 0.019 ± 0.003 0.019 ± 0.003 0.019 ± 0.001 0.003 μg/ml K1-70 IgG 0.038 ± 0.007 0.041 ± 0.003 0.045 ± 0.001 0.051 ± 0.004 0.041 ± 0.00  0.01 μg/ml K1-70 IgG 0.108 ± 0.021 0.097 ± 0.021 0.122 ± 0.01  0.147 ± 0.001 0.105 ± 0.014 0.03 μg/ml K1-70 IgG 0.320 ± 0.077 0.354 ± 0.005 0.391 ± 0.018 0.464 ± 0.003 0.282 ± 0.006 0.01 μg/ml K1-70 IgG 0.587 ± 0.063 0.641 ± 0.002 0.663 ± 0.018 0.792 ± 0.021 0.572 ± 0.003 0.3 μg/ml K1-70 IgG 0.779 ± 0.011 0.768 ± 0.011 0.798 ± 0.024 0.943 ± 0.016 0.867 ± 0.005 1 μg/ml G1 0.291 ± 0.005 0.327 ± 0.016 0.356 ± 0.001 0.378 ± 0.013 0.322 ± 0.018 G2 0.265 ± 0.003 0.265 ± 0.0  0.333 ± 0.013 0.373 ± 0.013 0.354 ± 0.014 G3 0.281 ± 0.014 0.249 ± 0.021 0.310 ± 0.012 0.363 ± 0.013 0.323 ± 0.021 G4 0.095 ± 0.011 0.105 ± 0.009 0.127 ± 0.006 0.145 ± 0.002 0.123 ± 0.005 G5 0.072 ± 0.006 0.075 ± 0.006 0.090 ± 0.008 0.096 ± 0.004 0.085 ± 0.001 G6 0.179 ± 0.006 0.192 ± 0.004 0.209 ± 0.002 0.249 ± 0.001 0.213 ± 0.013 G7 0.064 ± 0.007 0.054 ± 0.009 0.066 ± 0.012 0.070 ± 0.003 0.063 ± 0.00  G8 0.149 ± 0.009 0.137 ± 0.005 0.153 ± 0.009 0.183 ± 0.004 0.150 ± 0.006 G9 0.181 ± 0.006 0.203 ± 0.013 0.219 ± 0.007 0.220 ± 0.018 0.198 ± 0.011 G10 0.372 ± 0.007 0.366 ± 0.034 0.408 ± 0.021 0.477 ± 0.019 0.439 ± 0.002 G11 0.170 ± 0.001 — — — — G12 0.339 ± 0.004 — — — — N1 0.015 ± 0.003 0.01 ± 0.0  0.012 ± 0.005 0.005 ± 0.0  0.009 ± 0.001 N2 0.009 ± 0.002 0.007 ± 0.001  0.01 ± 0.004 0.004 ± 0.007 0.008 ± 0.002 N3 0.008 ± 0.002 0.007 ± 0.004 0.008 ± 0.001 0.003 ± 0.003 0.005 ± 0.00  N4 0.006 ± 0.001 0.006 ± 0.001 0.007 ± 0.007 0.00 ± 0.00 0.007 ± 0.001 N5 0.024 ± 0.005 0.006 ± 0.002 0.006 ± 0.001  0.01 ± 0.001 0.013 ± 0.001 N6 0.007 ± 0.001 0.004 ± 0.001 0.005 ± 0.0  0.002 ± 0.004 0.006 ± 0.0  N7 0.005 ± 0.000 — — — — N8 0.007 ± 0.001 — — — — N9 0.004 ± 0.001 — — — — N10 0.011 ± 0.002 — — — — N11 0.014 ± 0.001 — — — — Absorbance 405 nm TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- Test Sample JMG52 JMG55 JMG57 JMG58 Healthy 0.005 ± 0.00  0.015 ± 0.001 0.002 ± 0.003 0.005 ± 0.001 blood donor sera pool K1-70 IgG 0.014 ± 0.004 0.025 ± 0.003 0.019 ± 0.005 0.018 ± 0.001 0.003 μg/ml K1-70 IgG 0.036 ± 0.004 0.049 ± 0.009 0.050 ± 0.002 0.046 ± 0.001 0.01 μg/ml K1-70 IgG 0.110 ± 0.004 0.105 ± 0.012 0.123 ± 0.001 0.122 ± 0.003 0.03 μg/ml K1-70 IgG 0.316 ± 0.001 0.317 ± 0.004 0.319 ± 0.002 0.318 ± 0.004 0.01 μg/ml K1-70 IgG 0.662 ± 0.02  0.623 ± 0.011 0.496 ± 0.004 0.499 ± 0.004 0.3 μg/ml K1-70 IgG 0.940 ± 0.01  0.979 ± 0.009 0.576 ± 0.020 0.570 ± 0.011 1 μg/ml G1 0.363 ± 0.023 0.288 ± 0.026 0.266 ± 0.005 0.274 ± 0.003 G2 0.363 ± 0.029 0.358 ± 0.001 G3 0.351 ± 0.008 0.311 ± 0.006 0.247 ± 0.000 0.255 ± 0.003 G4 0.129 ± 0.006 0.117 ± 0.008 — — G5 0.088 ± 0.004 0.075 ± 0.001 — — G6 0.228 ± 0.009 0.184 ± 0.025 — — G7 0.070 ± 0.004 0.077 ± 0.011 — — G8 0.167 ± 0.008 0.161 ± 0.009 0.137 ± 0.000 0.137 ± 0.004 G9 0.207 ± 0.0  0.184 ± 0.016 0.151 ± 0.004 0.154 ± 0.003 G10 0.465 ± 0.035 0.418 ± 0.012 0.371 ± 0.000 0.326 ± 0.001 G11 — — 0.160 ± 0.002 0.169 ± 0.005 G12 — — 0.371 ± 0.000 0.378 ± 0.001 N1 0.014 ± 0.001 0.017 ± 0.004 — — N2 0.009 ± 0.004 0.015 ± 0.003 — — N3 0.009 ± 0.003 0.016 ± 0.003 — — N4 0.005 ± 0.001 0.013 ± 0.001 — — N5 0.008 ± 0.001 0.013 ± 0.001 — — N6 0.005 ± 0.001 0.014 ± 0.005 0.003 ± 0.002 0.006 ± 0.005 N7 — — 0.003 ± 0.002 0.005 ± 0.0  N8 — — 0.006 ± 0.004 0.007 ± 0.001 N9 — — 0.003 ± 0.001 0.004 ± 0.001 N10 — — 0.008 ± 0.004 0.011 ± 0.002 N11 — — 0.005 ± 0.001 0.014 ± 0.001 Results shown are mean absorbances at 405 nm ± SD of duplicate determinations

TABLE 47b TRAb concentration of sera shown in Table 47a (G1-G17 and N1-N11) calculated from the K1-70 calibration curve for wild type and mutated TSHR260-AP in the bridge ELISA (FIG. 13a) TRAb concentration (μg/mL mean ± SD; n=2) calculated from the K1-70 standard curve WILD TYPE TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- Test Sample TSHR260-AP I235R JMG22 JMG37 JMG45 Healthy blood <0.003 <0.003 <0.003 <0.003 <0.003 donor serum pool G1 0.093 ± 0.029 0.091 ± 0.005 0.088 ± 0.0  0.076 ± 0.003 0.118 ± 0.009 G2 0.083 ± 0.025 0.071 ± 0.0  0.081 ± 0.004 0.075 ± 0.003 0.135 ± 0.007 G3 0.088 ± 0.023 0.067 ± 0.006 0.074 ± 0.003 0.073 ± 0.003 0.119 ± 0.006 G4 0.027 ± 0.002 0.032 ± 0.002 0.031 ± 0.001 0.030 ± 0.0  0.036 ± 0.002 G5 0.020 ± 0.002 0.024 ± 0.002 0.023 ± 0.002 0.020 ± 0.001 0.024 ± 0.0  G6 0.053 ± 0.014 0.052 ± 0.001 0.048 ± 0.0  0.048 ± 0.0  0.070 ± 0.005 G7 0.018 ± 0.001 0.017 ± 0.004 0.017 ± 0.003 0.015 ± 0.001 0.017 ± 0.0  G8 0.044 ± 0.008 0.039 ± 0.001 0.036 ± 0.002 0.036 ± 0.001 0.046 ± 0.002 G9 0.054 ± 0.014 0.055 ± 0.003 0.051 ± 0.002 0.043 ± 0.003 0.064 ± 0.004 G10 0.129 ± 0.041 0.105 ± 0.013 0.106 ± 0.008 0.104 ± 0.006 0.185 ± 0.001 G11 0.036 ± 0.00  — — — — G12 0.085 ± 0.001 — — — — N1 <0.003 <0.003 <0.003 <0.003 <0.003 N2 <0.003 <0.003 <0.003 <0.003 <0.003 N3 <0.003 <0.003 <0.003 <0.003 <0.003 N4 <0.003 <0.003 <0.003 <0.003 <0.003 N5 0.006 ± 0.001 <0.003 <0.003 <0.003 <0.003 N6 <0.003 <0.003 <0.003 <0.003 <0.003 N7 <0.003 — — — — N8 <0.003 — — — — N9 <0.003 — — — — N10 <0.003 — — — — N11 <0.003 — — — — TRAb concentration (μg/mL mean ± SD; n=2) calculated from the K1-70 standard curve TSHR260-AP- TSHR260-AP- TSHR260-AP- TSHR260-AP- Test Sample JMG52 JMG55 JMG57 JMG58 Healthy blood <0.003 <0.003 <0.003 <0.003 donor serum pool G1 0.118 ± 0.009 0.089 ± 0.01 0.075 ± 0.002 0.079 ± 0.001 G2 0.118 ± 0.012 0.118 ± 0.001 — — G3 0.113 ± 0.003 0.098 ± 0.003 0.068 ± 0.000 0.071 ± 0.001 G4 0.036 ± 0.002 0.033 ± 0.002 — — G5 0.024 ± 0.001 0.021 ± 0.0  — — G6 0.068 ± 0.003 0.053 ± 0.008 — — G7 0.019 ± 0.001 0.021 ± 0.004 — — G8 0.048 ± 0.003 0.046 ± 0.003 0.034 ± 0.000 0.034 ± 0.001 G9 0.061 ± 0.0  0.053 ± 0.005 0.038 ± 0.001 0.038 ± 0.001 G10 0.163 ± 0.018 0.148 ± 0.006 0.110 ± 0.005 0.104 ± 0.001 G11 — — 0.040 ± 0.001 0.043 ± 0.001 G12 — — 0.133 ± 0.000 0.137 ± 0.001 N1 <0.003 <0.003 — — N2 <0.003 <0.003 — — N3 <0.003 <0.003 — — N4 <0.003 <0.003 — — N5 <0.003 <0.003 — — N6 <0.003 <0.003 <0.003 <0.003 N7 — — <0.003 <0.003 N8 — — <0.003 <0.003 N9 — — <0.003 <0.003 N10 — — <0.003 <0.003 N11 — — <0.003 <0.003 Results below the lowest K1-70 standard (0.003 μg/ml) are not attributed a value and are shown as <0.003 ug/ml.

TABLE 47c Pearson correlation (r-value) of calculated TRAb IgG concentration for TRAb positive (G1-G11) and TRAb negative (N1-N11) sera tested in TSHR260-AP mutants compared to the average concentration of the sera determined using wild type TSHR260-AP r-value of sera tested in TSHR260-AP mutant bridge ELISA compared to average wild type TSHR260-AP TSHR260-AP- TSHR260- TSHR260-AP- TSHR260-AP- TSHR260- TSHR260- TSHR260- TSHR260-AP- I235R AP-JMG22 JMG37 JMG45 AP-JMG52 AP-JMG55 AP-JMG57 JMG58 ALL SERA 0.988 0.993 0.996 0.992 0.996 0.985 0.970 0.990 TRAb POSITIVE 0.980 0.989 0.994 0.987 0.994 0.971 0.952 0.986 SERA ONLY

TABLE 48 Thermostability of TSHR260-AP mutants at different temperatures and predicted stability ratio compared to wild type TSHR260-AP (FIG. 13b) Predicted 50° C. 60° C. 65° C. stability RATIO TO RATIO TO RATIO TO ratio to t_(1/2) WILD t_(1/2) TSHR260-AP- t_(1/2) TSHR260-AP- TSHR260-AP- Mutant name (min) TYPE (min) JMG22 (min) JMG45 WT TSHR260-AP WILD TYPE 4.13 1.0 — — — — 1 TSHR260-AP-JMG22 44.55 10.8 1.28 1.0 — — ~11 TSHR260-AP-JMG45 — — 7.76 6.1 1.72 1.0 ~66 TSHR260-AP-JMG55 — — 20.06 15.7 4.34 2.5 ~165 Half lives (t_(1/2)) were calculated by fitting an exponential curve to the time course data (0 h-3 h) for each TSHR260-AP construct at each temperature, (duplicate measurements). Predicted stability ratios were determined by comparing t_(1/2) to either TSHR260-AP-JMGH45 (650 C.), TSHR260-AP-JMG22 (600 C.) or TSHR260-AP-WT (500 C.). The half-life of TSHR260-AP-WT at 500C was 2.9x greater than for TSHR260 wild type (without alkaline phosphatase). Similarly, at 600 C. TSHR260-AP-JMG45 and TSHR260-AP-JMG55 gave half lives of 3.2x and 1.5x greater, respectively, than the equivalent TSHR260 constructs without alkaline phosphatase.

TABLE 49 Summary of the purification and specific activities of the two different forms of TSHR260-JMG55 TSHR260 Total TSHR260 specific OD protein activity activity Purification Sample Volume 280 nM (mg) (U/mL) (U/mg) level Streamline 36 Litres 13.9 500,400 422 30 1 Loads (1-3) Streamline 600 mL 0.164 141 3,730 15,872 529 elution/ 14C4 affinity column load Purification of high specific activity TSHR260-JMG55-4.5 14C4 pH 4.5 50 mL 0.061 4.36 99,787 1,144,346 38,145 elution/ Nickel column load Nickel 5.6 mL 0.083 0.665 761,333 6,414,000 213,708 column elution Purification of low specific activity TSHR260-JMG55-5.0 14C4 pH 5.0 10 mL 0.062 0.887 1,068 12,041 401 elution/ Nickel column load Nickel 9.4 mL 0.069 0.927 2,008 20,361 679 column elution TSHR260 activity is the activity of the sample in the TSHR260-binding assay (FIG. 12a). Specific activity is the activity of the sample in the TSHR260-binding assay (U/mL), divided by the protein concentration of the sample (mg/mL) to give the activity of one milligram of protein. Purification level is the specific activity of the purified material at each step divided by the specific activity of the starting material (Streamline Loads).

TABLE 50a Activity of purified TSHR260-JMG55-4.5 (high specific activity): Elution from nickel-affinity column at pH 4.5 Total Average TSHR260 protein TSHR260 TSHR260 Specific yield OD activity activity activity Sample (mg) Dilution 450 nM (U/mL) (U/mL) (U/mg) TSHR260-WT 3.590 20 standard 3.414 10 2.553 5 1.418 2.5 0.661 1.25 0.272 0.625 0.127 0.3125 0.000 0 TSHR260- 0.665 1/10000 3.689 738,400 761,333 6,414,000 JMG55-4.5 1/40000 3.633 715,520 1/80000 3.380 830,080 1/160000 2.448 1/320000 1.297 1/640000 0.654 1/12800000 0.282 1/25600000 0.171

TABLE 50b Activity of purified TSHR260-JMG55-5.0 (low specific activity): Elution from nickel-affinity column at pH 5.0 Total Average protein TSHR260 TSHR260 Specific yield OD activity activity activity Sample (mg) Dilution 450 nM (U/mL) (U/mL) (U/mg) TSHR260-WT 3.620 20 standard 3.442 10 2.405 5 1.330 2.5 0.606 1.25 0.267 0.625 0.128 0.3125 0.000 0 TSHR260- 0.927 1/50 3.705 1,972 2,008 20,361 JMG55-5.0 1/100 3.604 1,923 1/200 3.327 2,130 1/400 2.444 1/800 1.292 1/1600 0.619 1/3200 0.316 1/6400 0.163

TABLE 51 Binding of TSHR monoclonal autoantibodies (K1-70, K1-18 and M22) to purified TSHR260-JMG55-4.5 coated ELISA plate wells Antibody-Peroxidase TSHR260-JMG55-4.5 coated TSHR260-JMG55-4.5 coated Concentration (μg/mL) plates (4 μg/mL). OD₄₅₀ plates (0.4 μg/mL). OD₄₅₀ K1-70-POD 7.5 3.542 1.421 5.0 3.129 1.067 2.5 2.035 0.679 1.0 0.904 0.302 0.75 0.750 0.238 0.50 0.488 0.159 0.25 0.263 0.070 K1-18-POD 7.5 3.301 1.535 5.0 2.945 1.203 2.5 1.946 0.782 1.0 0.871 0.369 0.75 0.659 0.266 0.50 0.458 0.178 0.25 0.188 0.070 M22-POD 7.5 2.645 0.941 5.0 2.319 0.770 2.5 1.809 0.528 1.0 1.160 0.309 0.75 0.951 0.258 0.50 0.748 1.192 0.25 0.479 0.120

TABLE 52 Analysis of TSHR260-JMG55-4.5 activity in the TSHR260 binding assay following deglycosylation with Endoglycosidase F3 Endo F3 (mU of EndoF3 TSHR260-JMGG55-4.5 activity per mg of TSHR260- Incubation TSHR260 (% of untreated TSHR260- JMG55-4.5) time (hours) activity (U/mL) JMG55-4.5 control) 0 (untreated 0 362,880 100 control)  0 120 401,280 111 40 120 361,200 100 60 120 377,840 104 80 120 378,960 104 TSHR260 activity is the activity of the sample in the TSHR260-binding assay compared to the TSHR260 standard as defined “TSHR260-binding assay” and “Transient transfections of TSHR260 mutants into CHO-K1 cells using Freestyle Max reagent” (FIG. 12a).

TABLE 53 Deglycosylation of TSHR260-JMG55-4.5 after nickel-affinity purification Endo F3 (mU of EndoF3 Reduction in Molecular per mg of TSHR260- Incubation Calculated Molecular Weight By JMG55-4.5) time (h) Weight of Band (kDa) Deglycosylation (kDa) 0 24 34.3 0.0 72 34.5 0.0 120 34.4 0.0 40 24 32.9 1.1 72 32.3 1.7 120 32.0 2.0 60 24 32.7 1.3 72 31.9 2.1 120 31.7 2.3 80 24 32.1 1.9 72 31.8 2.2 120 31.6 2.4

TABLE 54 Equivalent residues of hTSHR-JMG55 mutations in mouse and porcine TSHR Amino acid Position hTSHR mutation Mouse TSHR Porcine TSHR LRR2 H63C H63 H63 LRR4 R112P R112 R112 LRR5 D143P D143 D143 LRR5 D151E D151 D151 LRR6 V169R E169 A169 LRR10 I253R I253 I253 Most of the thermostabilising mutated residues of hTSHR-JMG55 are well-conserved across TSHR from mouse and porcine. Only the residue at position 169 differs across species. Residue 169 is Valine in human, Glutamic acid in mouse and Alanine in porcine.

TABLE 55 Thermostability of full-length wild type and mutated mouse, porcine and human TSHR at 45° C. Half-life ratio Species TSHR Half-life (min) (mutant/wild type) Mouse TSHR-Wild-type  2.15 ± 0.07 6.3 ± 0.3 TSHR-mutant 13.60 ± 0.14 Porcine TSHR-Wild-type  3.6 ± 0.3 3.34 ± 0.15 TSHR-mutant 12.1 ± 1.5 Human TSHR-Wild-type  4.8 ± 1.0 39 ± 6  TSHR-mutant (JMG55) 184 ± 12 The half-life of each construct was measured in stability assay B by binding TSHR preparations to a 4E31-coated plate and then heating the plate for up to three hours at 45° C. in a water-bath. The amount of active TSHR protein was determined by the TSHR-binding assay (FIG. 14c). Results were plotted against time and fitted to a two-phase exponential decay curve. The half-life is the time at which the TSHR has lost half of its activity. Results shown are means ± SD, n = 2.

TABLE 56 Effect of different concentrations M22 IgG and TSH on stimulation of cAMP production in CHO cells expressing either wild type or mutated mouse TSHR cyclic AMP produced (pmol/ml; mean ± SD; n = 3) Wild type Mutated Mutated mTSHR/ Test sample mouse TSHR mouse TSHR wild type mTSHR (%) CAMP assay 4.8 ± 0.2  2.9 ± 0.9 60 buffer M22 100 ng/ml 71.4 ± 5.1  80.6 ± 3.1 113 30 ng/ml 55.4 ± 5.3  58.4 ± 6.4 105 10 ng/ml 38.6 ± 3.1  29.4 ± 1.4 76 3 ng/ml 18.6 ± 4.1  12.3 ± 0.9 66 1 ng/ml 8.7 ± 0.3  6.3 ± 0.7 72 0.3 ng/ml 5.9 ± 0.5  4.0 ± 0.4 67 TSH 10 ng/ml 78.3 ± 17.0  75.7 ± 12.5 97 3 ng/ml 65.4 ± 11.2 60.5 ± 5.8 92 1 ng/ml 49.1 ± 4.0  33.1 ± 3.6 67 0.3 ng/ml 16.4 ± 0.6  12.7 ± 0.6 77 0.1 ng/ml 7.4 ± 0.6  5.1 ± 0.4 69 0.03 ng/ml 4.6 ± 0.5  3.1 ± 0.3 67 Results shown are mean ± SD of triplicate determinations. Samples were diluted in cyclic AMP assay buffer. For mTSHR-WT: EC50 (M22) = 13.09 ng/ml; EC50 (TSH) = 0.81 ng/ml. For mTSHR-mutated; EC50 (M22) = 20.36 ng/ml; EC50 (TSH) = 1.41 ng/ml. Mutated mTSHR was based on the human TSHR mutant JMG55, Mutated amino acids in the mouse TSHR were analogous to amino acids mutated in the human TSHR-JMG55 construct and comprised H63C; R112P; D143P; D151E; E169R (analogous to hTSHR V169R) and I253R.

TABLE 57 Effect of different concentrations of M22 IgG and TSH on stimulation of cAMP production in CHO cells expressing either wild type or mutated porcine TSHR cyclic AMP produced Mutated (pmol/ml; mean ± SD; n = 3) pTSHR/ Wild type Mutated wild type Test sample porcine TSHR porcine TSHR pTSHR (%) CAMP assay buffer 2.9 ± 1.0 1.9 ± 0.2 66 M22 100 ng/ml 84.9 ± 9.4 65.4 ± 0.8 77 30 ng/ml 81.9 ± 4.9 68.3 ± 2.2 83 10 ng/ml 60.8 ± 8.0 44.0 ± 2.4 72 3 ng/ml 23.5 ± 2.3 21.2 ± 1.4 90 1 ng/ml 10.7 ± 0.7 9.0 ± 1.4 84 0.3 ng/ml 4.5 ± 0.8 3.7 ± 0.3 82 TSH 10 ng/ml 96.0 ± 6.8 91.2 ± 6.3 95 3 ng/ml 86.7 ± 11.7 81.2 ± 3.0 94 1 ng/ml 58.4 ± 4.1 46.0 ± 3.8 79 0.3 ng/ml 19.8 ± 0.8 13.4 ± 2.3 67 0.1 ng/ml 6.3 ± 0.5 5.4 ± 0.3 86 0.03 ng/ml 2.5 ± 0.0 2.4 ± 0.1 96 Results shown are mean ± SD of triplicate determinations. Samples were diluted in cyclic AMP assay buffer. For pTSHR-WT: EC50 (M22) = 6.23 ng/ml; EC50 (TSH) = 0.79 ng/ml. For mTSHR-mutated; EC50 (M22) = 6.53 ng/ml; EC50 (TSH) = 1.04 ng/ml. Mutated pTSHR was based on the human TSHR mutant JMG55, Mutated amino acids in the porcine TSHR were analogous to amino acids mutated in the human TSHR-JMG55 construct and comprised H63C; R112P; D143P; D151E; A169R (analogous to hTSHR V169R) and I253R.

TABLE 58 Association constants for TSH binding to full-length wild type and mutated TSHR from different species (human, mouse and porcine) ¹²⁵I-TSH binding to full-length wild type and mutated TSHRs:association constant (×109 L/mol) Mutant TSHR species Wild Type (equivalent to JMG55) Human 1.80 0.98 Mouse 1.58 0.87 Porcine 1.99 1.25 Association constants calculated from single experiments with duplicate determinations.

TABLE 59 Single amino acid mutations made in the TMD of TSHR-JMG55 Mutation Mutation E409K T588L D410K I591A D410N V595I H443N V597A N447T C599S L452Y C600R N455A Y601F D460A Y601A M463V K603Q Y466F I604A L467P Y605A T477I I606A Q489H V608A N495K I622A S505A I622D R519L L629M I523A D633K T524A I635M T524R I648L F525L L649M L529H K660D C539Y Y667A L557A Y667V K565A S671A K565L C672S V584I N674A V584L Y678L F585L Y678A

TABLE 60 Stability of TSHR-JMG55 mutants having a single mutation in the TMD Stability Assay C^(d) Stability Assay A and B^(c) Survival at 14C4^(a) 4E31^(b) Half-life at Half-life 33° C. (%) Half-life Mutant of Activity Activity 55° C. (min) Ratio 10 30 120 at 33° C. Half-life TSHR-JMG55 (U/ml) (U/ml) A B A B min min min (min) Ratio TSHR-JMG55 100 100 12 13 1.0 1.0 55 39 21 14 ± 5 1.0 E409K 392 499 21 12 2.2 0.9 60 49 32 28 2.2 D410K 57 159 29 17 3.1 1.2 82 68 47 95 7.7 D410N 130 206 14 12 1.5 0.9 59 51 39 34 2.1 H443N 243 158 25 19 1.1 1.0 74 64 46 99 15.4 N447T 476 252 21 20 1.0 1.0 59 53 37 44 6.9 L452Y 71 155 32 20 1.4 1.0 65 61 46 93 4.7 N455A 42 102 35 15 2.1 1.2 68 63 46 96 15.1 D460A 20 76 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. M463V 90 183 23 15 1.4 1.2 78 70 45 99 5.0 Y466F 47 90 26 12 1.6 0.9 61 58 48 78 12.2 L467P 113 428 28 15 3.4 1.3 66 53 41 49 3.9 T477I 48 187 35 16 4.2 1.3 80 72 50 120 6.4 Q489H 39 150 30 13 3.6 1.1 70 58 45 81 3.6 N495K 861 1749 10 10 0.9 1.1 63 44 26 20 0.9 S505A 26 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. R519L 150 259 14 12 1.3 1.2 78 62 40 67 6.0 I523A 150 228 24 13 2.2 1.4 61 49 28 26 2.2 T524A 210 339 21 16 1.1 1.1 61 52 31 38 3.2 T524R 736 661 21 11 1.1 0.8 68 55 37 52 4.3 F525L 109 252 13 17 0.7 1.1 58 49 32 27 2.3 L529H 1266 1611 6 9 0.7 1.2 67 51 32 34 2.0 C539Y 376 518 16 10 2.0 1.3 66 56 38 54 3.1 L557A 345 906 11 9 1.3 1.2 67 53 36 41 2.4 KS65A 215 219 16 17 0.8 1.2 56 50 34 30 5.7 K565L 70 150 19 15 1.0 1.1 68 56 44 46 8.6 V584I 326 172 15 16 0.7 1.1 63 55 36 49 9.3 V584L 399 1121 11 21 1.3 0.9 69 55 40 54 2.8 F585L 188 108 10 21 1.2 0.9 58 48 28 23 4.4 T588L 79 111 8 23 1.0 1.0 62 53 34 42 1.9 I591A 207 421 21 8 2.9 0.7 61 49 31 27 1.4 V595I 570 672 12 14 1.6 1.3 77 58 44 60 3.8 V597A 136 253 17 9 2.3 0.9 74 50 32 31 1.9 C599S 250 344 18 11 1.0 0.8 37 29 17 5 0.3 C600R 35 104 n.d. 10 n.d. 0.7 79 64 38 72 8.4 Y601F 194 108 20 13 1.1 0.9 63 54 32 44 3.7 Y601A 177 244 14 11 0.9 0.8 63 53 31 40 3.4 K603Q 1085 820 14 16 1.4 1.4 61 52 29 36 3.1 1604A 223 282 14 10 1.4 0.9 68 53 36 43 3.6 Y605A 164 284 13 9 1.3 0.8 63 45 27 21 1.6 I606A 214 469 5 9 0.8 0.8 53 43 27 14 1.0 V608A 243 210 7 13 1.0 1.2 50 40 20 11 0.8 I622A 319 497 5 8 0.8 0.8 57 38 16 13 1.0 I622D 440 479 16 8 1.2 1.4 50 36 13 10 1.0 L629M 217 447 18 7 1.4 1.2 68 59 39 65 3.5 D633K 145 445 12 14 0.9 2.3 67 48 35 36 3.9 I635M 205 568 8 11 0.7 1.2 60 45 30 31 3.4 I648L 611 767 18 15 1.6 1.6 64 51 50 118 12.8 L649M 231 276 15 8 1.3 0.8 74 58 38 58 3.3 K660D 179 573 24 9 2.5 1.0 68 59 48 101 5.5 Y667A 91 227 12 5 1.2 0.5 65 51 37 40 2.1 Y667V 119 477 28 10 3.0 1.1 82 68 48 109 5.9 S671A 178 267 5 13 0.6 0.9 74 57 43 114 13.2 C672S 55 130 8 21 1.0 1.4 68 54 42 51 4.3 N674A 86 121 5 15 0.6 1.0 62 52 37 41 3.5 Y678L 38 129 31 17 2.1 1.2 76 65 45 114 9.6 Y678A 58 130 27 22 1.9 1.5 71 61 44 83 7.1 All of these TSHR mutants also contain the six mutations of JMG55: 1253R, D143P, R112P, D151E, H63C and V169R. ^(a)14C4 activity is the activity of the unheated sample when bound to a 14C4-coated ELISA plate well, as detected in the TSHR binding assay. For use in stability assay A, the samples were diluted to 10 U/mL 14C4 activity. See section Transient transfections of full-length TSHR mutants into CHO-K1 cells using Freestyle Max reagent for definition of U/ml. ^(b)4E31 activity is the activity of the unheated sample when bound to a 4E31-coated ELISA plate well as detected in the TSHR binding assay. For use in stability assay B, the samples were diluted to 10 U/mL 4E31 activity and for use in stability assay C, the samples were diluted to a final concentration of 12.5 U/ml. See Transient transfections of full-length TSHR mutants into CHO-KI cells using Freestyle Max reagent for definition of U/ml. ^(c)In stability assays A and B the half-life of each mutant is determined by coating a 14C4-plate (stability assay A, FIG. 14b) or 4E31-coated ELISA plate well (stability assay B, FIG. 14c) with the TSHR mutants. Strips of the plates with TSHR bound were heated at 55° C. for a period of up to two hours. The amount of active TSHR protein was determined by the TSHR-binding assay, plotted against time and fitted to an exponential decay curve. In each experiment, the thermostability (half-life, t1/2) of TSHR-JMG55 was measured and used to determine the half-life ratio compared to the half-life of TSHR-JMG55 mutants in the same experiment. ^(d)In stability assay C (FIG. 14d), solubilised aliquots of each TSHR-JMG55 mutant were heated at 33° C. in solution for up to two hours. The amount of active TSHR protein was determined by the TSHR-binding assay, plotted against time and fitted to a two-phase exponential decay curve. The percentage of active TSHR-JMG55 mutant remaining after heating for 10, 30 and 120 min was calculated and compared to TSHR-JMG55. The apparent half-life is the time point at which the TSHR-JMG55 mutant has lost half of its activity. This is used to calculate the half-life ratio is by dividing it by the apparent half-life of TSHR-JMG55 measured in the same experiment. In bold are the 20 most thermostabilising mutants, which were used to make double mutants. Experiments were performed once for each mutant in each assay, assayed in duplicate. “n.d.” = determined.

TABLE 61 Combination of single mutations in the TSHR-JMG55 TMD to produce double, triple and TSHR-JMG55 mutants. Mutant Name Base mutant Mutation 1 Mutation 2 Mutation 3 JMG59 JMG55 T477I H443N JMG60 JMG55 T477I L452Y JMG61 JMG55 T477I N455A JMG62 JMG55 T477I M463V JMG63 JMG55 T477I Y466F JMG64 JMG55 T477I Q489H JMG65 JMG55 T477I K565L JMG66 = 82 JMG55 T477I V595I JMG67 JMG55 T477I C600R JMG68 = 101 JMG55 T477I I648L JMG69 JMG55 T477I K660D JMG70 JMG55 T477I Y667V JMG71 JMG55 T477I S671A JMG72 JMG55 T477I Y678L JMG73 JMG55 T477I Y678A JMG74 JMG55 V595I E409K JMG75 JMG55 V595I D410K JMG76 JMG55 V595I H443N JMG77 JMG55 V595I L452Y JMG78 JMG55 V595I N455A JMG79 JMG55 V595I M463V JMG80 JMG55 V595I Y466F JMG81 JMG55 V595I L467P JMG82 = 66 JMG55 V595I T477I JMG83 JMG55 V595I Q489H JMG84 JMG55 V595I K565L JMG85 JMG55 V595I C600R JMG86 JMG55 V595I Y601F JMG87 = 104 JMG55 V595I I648L JMG88 JMG55 V595I K660D JMG89 JMG55 V595I Y667V JMG90 JMG55 V595I S671A JMG91 JMG55 V595I Y678L JMG92 JMG55 V595I Y678A JMG93 JMG55 I648L E409K JMG94 JMG55 I648L D410K JMG95 JMG55 I648L H443N JMG96 JMG55 I648L L452Y JMG97 JMG55 I648L N455A JMG98 JMG55 I648L M463V JMG99 JMG55 I648L Y466F JMG100 JMG55 I648L L467P JMG101 = 68 JMG55 I648L T477I JMG102 JMG55 I648L Q489H JMG103 JMG55 I648L K565L JMG104 = 87 JMG55 I648L V595I JMG105 JMG55 I648L C600R JMG106 JMG55 I648L Y601F JMG107 JMG55 I648L K660D JMG108 JMG55 I648L Y667V JMG109 JMG55 I648L S671A JMG110 JMG55 I648L Y678L JMG111 JMG55 I648L Y678A JMG112 JMG55 V595I Y678L E409K JMG113 JMG55 V595I Y678L D410K JMG114 JMG55 V595I Y678L H443N JMG115 JMG55 V595I Y678L L452Y JMG116 JMG55 V595I Y678L N455A JMG117 JMG55 V595I Y678L Y466F JMG118 JMG55 V595I Y678L L467P JMG119 JMG55 V595I Y678L T4771 JMG120 JMG55 V595I Y678L Q498H JMG121 JMG55 V595I Y678L K565L JMG122 JMG55 V595I Y678L Y601F JMG123 JMG55 V595I Y678L 1648L JMG124 JMG55 V595I Y678L K660D JMG125 JMG55 V595I Y678L Y667V JMG126 JMG55 V595I Y678L S671A All TSHR mutants listed contain the six mutations of JMG55: I253R, D143P, R112P, D151E, H63C and V169R. JMG66 is identical to JMG82, JMG68 is identical to JMG101 and JMG87 is identical to JMG104. JMG85 construct was not made as the mutations V595I and C600R are too close together and are likely to interfere with each other.

TABLE 62 Thermostability of TSHR-JMG55 mutants having a double mutation in the TMD: Stability assay C Stability Assay C^(c) 14C4^(a) 4E31^(b) Survival at 33° C. (%) Survival ratio at 33° C. Half-life Activity Activity 10 30 120 10 30 120 at 33° C. Half-life Mutant name (U/ml) (U/ml) min min min min min min (min) Ratio JMG55-T477I 48 187 78 63 44 1.0 1.0 1.0 84 ± 20 1.0 JMG55-V595I 570 672 66 55 37 1.0 1.0 1.0 58 ± 7 1.0 JMG55-I1648L 611 767 74 60 43 1.0 1.0 1.0 86 ± 52 1.0 JMG59 51 367 79 66 42 1.0 1.0 0.8 84 0.8 JMG60 31 246 79 66 50 1.0 1.0 1.0 123 1.1 JMG61 24 194 74 65 50 0.9 1.0 1.1 122 1.3 JMG62 32 282 75 68 48 0.9 1.0 0.9 114 1.0 JMG63 10 70 85 63 31 1.1 1.0 0.7 48 0.5 JMG64 29 248 71 64 45 1.0 1.1 1.1 94 1.0 JMG65 25 199 70 60 42 0.9 1.0 1.0 75 0.8 JMG66 29 184 71 58 44 0.9 0.9 1.0 63 0.8 JMG67 84 352 85 69 46 1.0 1.0 1.0 97 1.1 JMG68 42 52 75 68 52 1.0 1.1 1.2 75 0.9 JMG69 57 311 77 62 43 0.9 0.9 0.9 80 0.9 JMG70 54 305 74 60 42 0.9 0.8 0.9 74 0.9 JMG71 118 599 75 65 47 1.0 1.1 1.2 104 1.6 JMG72 52 278 74 60 36 1.1 1.1 0.9 62 1.1 JMG73 41 249 85 64 41 1.2 1.1 1.1 59 1.0 JMG74 230 432 68 56 37 1.2 1.1 1.2 55 0.9 JMG75 121 289 77 60 44 1.1 1.1 1.1 77 1.6 JMG76 389 705 70 55 38 1.2 1.1 1.2 48 0.8 JMG77 78 248 77 64 46 1.3 1.2 1.4 94 1.5 JMG78 42 257 73 62 38 1.0 1.0 0.9 69 1.1 JMG79 149 329 70 54 37 1.2 1.1 1.2 47 0.8 JMG80 54 257 64 55 36 0.9 1.0 1.1 51 0.8 JMG81 32 81 59 46 29 0.9 0.9 0.7 20 0.4 JMG82 = 66 30 151 76 62 47 1.1 1.1 1.4 98 1.6 JMG83 61 300 68 63 46 1.0 1.1 1.4 93 1.5 JMG84 232 718 72 60 48 1.1 1.1 1.4 102 1.6 JMG85 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. JMG86 197 448 70 56 41 1.0 1.0 1.1 62 1.3 JMG87 = 104 333 742 79 64 54 1.2 1.2 1.5 164 3.2 JMG88 85 198 72 62 41 1.1 1.1 1.1 76 1.6 JMG89 159 299 77 53 31 1.0 0.9 0.7 34 0.5 JMG90 366 851 79 64 54 1.3 1.1 1.5 134 2.6 JMG91 102 245 80 64 49 1.3 1.1 1.3 108 2.1 JMG92 136 558 84 66 47 1.1 1.1 1.0 95 1.5 JMG93 144 336 69 61 44 0.9 0.9 0.9 85 0.6 JMG94 123 476 79 67 50 1.1 1.3 1.5 117 2.9 JMG95 161 276 64 51 27 0.9 1.0 0.8 33 0.8 JMG96 41 224 83 67 47 1.2 1.3 1.4 85 2.1 JMG97 81 189 73 60 45 0.9 0.9 0.9 85 0.6 JMG98 58 507 73 66 48 1.1 1.3 1.4 108 3.0 JMG99 29 134 71 56 43 1.0 1.1 1.3 64 1.6 JMG100 44 105 70 56 34 0.9 0.8 0.7 45 0.3 JMG101 = 68 52 628 75 68 52 1.1 1.3 1.5 132 3.7 JMG102 36 216 72 58 45 1.1 1.1 1.3 82 2.3 JMG103 24 66 76 64 50 1.2 1.2 1.5 122 3.4 JMG104 = 87 333 742 79 64 54 1.0 0.9 1.0 164 1.2 JMG105 35 206 74 60 44 1.2 1.1 1.3 81 2.1 JMG106 36 443 76 62 49 1.2 1.2 1.5 113 2.9 JMG107 49 124 76 59 39 1.0 0.9 0.8 62 0.5 JMG108 66 339 76 60 45 1.2 1.1 1.4 82 2.1 JMG109 161 757 81 64 47 1.3 1.2 1.4 94 2.4 JMG110 77 182 76 61 42 1.0 0.9 0.8 72 0.6 JMG111 47 4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. TSHR mutants as defined in Table 61. ^(a)14C4 activity is the activity of the unheated sample when bound to a 14C4-coated ELISA plate well, as detected in the TSHR binding assay. See Transient transfections of full-length TSHR mutants into CHO-K1 cells using Freestyle Max reagent for definition of U/ml. ^(b)4E31 activity is the activity of the unheated sample when bound to a 4E31-coated ELISA plate well as detected in the TSHR binding assay. For use in stability assay C, the samples were diluted to a final concentration of 12.5 U/ml. See Transient transfections of full-length TSHR mutants into CHO-K1 cells using Freestyle Max reagent for definition of U/ml. ^(c)In stability assay C, solubilised aliquots of each TSHR mutant were heated at 33° C. in solution for up to two hours. The amount of active TSHR protein remaining was determined by TSHR-binding assay and plotted against time (FIG. 14d). The percentage of active TSHR mutant remaining after heating for 10, 30 and 120 min was calculated and compared to TSHR-JMG55-T477I for JMG59 to JMG73, TSHR-JMG55-V595I in the case of JMG74 to JMG92 or TSHR-JMG55-1648L for JMG93 to JMG111. Additionally, the apparent half-life is the time point at which the TSHR-JMG55 mutant has lost half of its activity. This is used to calculate the half-life ratio is by dividing it by the apparent half-life of TSHR-JMG55-T4771, TSHR-JMG55-V595I or TSHR-JMG55-1648L measured in the same experiment. Experiments were performed once for each mutant in each assay (assayed in duplicate). “n.d.” = not determined.

TABLE 63 Thermostability of mutants having a double mutation in the TMD of TSHR-JMG55 (JMG74 to JMG92): Stability assays A, B and C Stability Assay A and B^(a) Stability Assay C^(b) Half-life at Half-life Survival at 33° C. (%) Survival ratio at 33° C. Half-life 55° C. (min) ratio at 55° C. 10 30 120 10 30 120 at 33° C. Half-life Mutant name A B A B min min min min min min (min) Ratio JMG55-V5951 27 18 1.0 1.0 66 55 37 1.0 1.0 1.0 58 ± 7 1.0 JMG74 38 37 1.4 1.7 68 56 37 1.2 1.1 1.2 55 0.9 JMG75 45 25 1.6 1.2 77 60 44 1.1 1.1 1.1 77 1.6 JMG76 38 32 1.4 1.5 70 55 38 1.2 1.1 1.2 48 0.8 JMG77 38 21 1.3 1.3 77 64 46 1.3 1.2 1.4 94 1.5 JMG78 44 19 1.6 0.9 73 62 38 1.0 1.0 0.9 69 1.1 JMG79 26 15 1.1 0.9 70 54 37 1.2 1.1 1.2 47 0.8 JMG80 48 19 1.8 1.0 64 55 36 0.9 1.0 1.1 51 0.8 JMG81 53 20 2.0 1.1 59 46 29 0.9 0.9 0.7 20 0.4 JMG82 = 66 59 19 2.4 1.2 76 62 47 1.1 1.1 1.4 98 1.6 JMG83 39 24 1.4 1.5 68 63 46 1.0 1.1 1.4 93 1.5 JMG84 44 38 1.6 2.4 72 60 48 1.1 1.1 1.4 102 1.6 JMG85 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. JMG86 35 33 1.2 1.7 70 56 41 1.0 1.0 1.1 62 1.3 JMG87 = 104 33 33 1.2 1.7 79 64 54 1.2 1.2 1.5 164 3.2 JMG88 47 29 1.6 1.5 72 62 41 1.1 1.1 1.1 76 1.6 JMG89 45 31 2.0 2.1 77 53 31 1.0 0.9 0.7 34 0.5 JMG90 27 25 1.0 1.4 79 64 54 1.3 1.1 1.5 134 2.6 JMG91 48 30 1.8 1.7 80 64 49 1.3 1.1 1.3 108 2.1 JMG92 40 36 1.4 1.7 84 66 47 1.1 1.1 1.0 95 1.5 TSHR mutants as defined in Table 61. ^(a)In stability assays A and B the half-life of each mutant was determined by first binding the mutant to a 14C4-coated ELISA plate well (stability assay A, FIG. 14b) or 4E31-coated ELISA plate well (stability assay B, FIG. 14c). Strips of the plate wells with mutant TSHR bound were heated at 55° C. for periods of up to two hours. The amount of active mutant TSHR protein remaining was determined by the TSHR-binding assay and plotted against time. In each experiment, the thermostability (half-life, t1/2) of TSHR-JMG55-V595I was measured and used to determine the half-life ratio for each mutant compared to the half-life of TSHR-JMG55-V595I in the same experiment. ^(b)In stability assay C (FIG. 14d), solubilised aliquots of TSHR mutant were heated at 33° C. in solution for up to two hours. The amount of active TSHR protein was determined by TSHR-binding assay and plotted against time. The percentage of active TSHR mutant remaining after heating for 10, 30 and 120 min was calculated and compared to TSHR-JMG55-V595I. The apparent half-life is the time point at which the TSHR-JMG55 mutant has lost half of its activity. This is used to calculate the half-life ratio is by dividing it by the apparent half-life of TSHR-JMG55-V595I measured in the same experiment. The most thermostabilising mutants overall, JMG91 and JMG84, are shown in bold and these were used as a basis for making triple mutants. Experiments were performed once for each mutant in each assay (assayed in duplicate). “n.d.” = determined.

TABLE 64 Thermostability of mutants having a triple mutation in the TMD of TSHR-JMG55 (JMG112 to JMG142): Stability assays A, B and C. Stability Assay A and B^(a) Stability Assay C^(b) Half-life at Half-life Survival at 40° C. (%) Survival ratio at 40° C. Half-life Half-life 55° C. (min) ratio at 55° C. 10 30 120 10 30 120 at 40° C. ratio at TSHR mutant A B A B min min min min min min (min) 40° C. JMG91 34 ± 8 23 ± 2 1.0 1.0 57 48 29 1.0 1.0 1.0 24 ± 9 1.0 JMG84 38 ± 4 23 ± 7 1.0 1.0 57 42 24 1.0 1.0 1.0 14 ± 3 1.0 JMG112 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. JMG113 46 23 1.1 1.2 46 34 19 0.8 0.7 0.6 8 0.4 JMG114 36 16 1.1 0.7 49 41 24 0.9 0.9 0.8 9 0.4 JMG115 44 22 1.1 1.1 36 25 8 0.6 0.5 0.3 5 0.2 JMG116 57 21 1.7 1.0 51 43 25 0.9 0.9 0.8 11 0.5 JMG117 41 21 1.0 1.1 37 29 12 0.7 0.6 0.4 5 0.3 JMG118 n.d. 32 n.d. 1.4 45 31 9 0.8 0.6 0.3 8 0.2 JMG119 n.d. 34 n.d. 1.5 57 32 14 1.0 0.6 0.5 13 0.4 JMG120 38 25 1.3 1.1 71 48 27 1.2 0.9 0.9 27 0.8 JMG121 45 24 1.5 1.0 44 35 16 0.7 0.7 0.6 6 0.2 JMG122 44 19 1.5 0.8 40 30 12 0.7 0.7 0.4 5 0.4 JMG123 40 20 1.2 0.9 49 41 21 0.9 0.9 0.7 9 0.7 JMG124 66 22 1.8 0.9 47 38 19 0.9 0.9 0.7 8 0.6 JMG125 32 19 0.9 0.8 48 38 17 0.8 0.8 0.6 8 0.3 JMG126 29 33 1.3 1.4 52 39 23 0.9 0.8 0.9 11 0.4 JMG127 61 31 1.6 1.4 55 43 26 1.0 1.0 1.1 19 1.3 JMG128 73 26 2.0 1.7 55 43 28 0.9 1.0 1.1 14 0.9 JMG129 39 19 1.1 1.2 47 41 23 0.8 0.9 0.9 8 0.4 JMG130 56 28 1.6 0.9 47 39 24 0.8 0.9 0.9 10 0.6 JMG131 60 32 1.5 1.1 63 50 32 1.2 1.2 1.4 47 3.5 JMG132 54 28 1.5 0.9 47 39 25 0.8 1.0 1.0 8 0.6 JMG133 49 28 1.4 0.9 41 34 22 0.7 0.8 0.9 7 0.5 JMG134 64 30 1.8 1.6 50 42 24 0.9 1.0 1.0 11 0.8 JMG135 63 23 1.8 1.3 52 43 24 0.9 1.0 1.0 19 1.3 JMG136 59 24 1.7 1.3 52 40 24 0.9 1.0 1.0 11 0.8 JMG137 52 22 1.5 1.2 56 49 31 1.0 1.2 1.3 35 2.4 JMG138 55 35 1.3 1.2 60 48 26 1.1 1.2 1.1 30 2.2 JMG139 65 29 1.5 1.4 56 43 23 1.0 1.0 1.0 15 1.1 JMG140 57 24 1.3 1.1 48 41 21 0.9 1.0 0.9 17 1.3 JMG141 46 23 1.3 1.2 47 38 19 0.8 0.9 0.8 8 0.6 JMG142 73 29 1.6 1.3 43 35 20 0.8 0.9 0.9 7 0.5 TSHR mutants as defined in Table 61. ^(a)In stability assay A (FIG. 14b) and stability assay B (FIG. 14c) the half-life of each mutant was determined by first binding the mutant to a 14C4-coated ELISA plate well (stability assay A) or 4E31-coated ELISA plate well (stability assay B). Strips of the plate wells with mutant TSHR bound were heated at 55° C. for periods of up to two hours. The amount of active mutant TSHR protein remaining was determined by the TSHR-binding assay and plotted against time. In each experiment, the thermostability (half-life, t1/2) of TSHR-JMG91 or TSHR-JMG84 was measured and used to determine the half-life ratio for each mutant compared to the half-life of TSHR-JMG91 or TSHR-JMG84 in the same experiment. ^(c)In stability assay C (FIG. 14d), solubilised aliquots of TSHR mutant were heated at 40° C. in solution for up to two hours. The amount of active TSHR protein remaining was determined by TSHR-binding assay, plotted against time and fitted to a two-phase exponential decay curve. The percentage of active TSHR mutant remaining after heating for 10, 30 and 120 min was calculated and compared to TSHR-JMG91 or TSHR-JMG84 (JMG112 to JMG126 compared to TSHR-JMG91 and JMG127 to JMG142 compared to TSHR-JMG84). The apparent half-life was also determined as the time point at which the TSHR-JMG55 mutant has lost half of its activity. This is used to calculate the half-life ratio is by dividing it by the apparent half-life of TSHR-JMG91 or TSHR-JMG84 measured in the same experiment. Experiments were performed once for each mutant in each assay (assayed in duplicate). “n.d.” = not determined.

TABLE 65 M22-POD binding to TSHR-JMG55 with mutants in the TMD (FIG. 14a) M22-POD TSHR-JMG55 TSHR-JMG55-V5951 TSHR-JMG84 TSHR-JMG91 (ng/ml) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 500 3.21 ± 0.07 100.0 ± 2.5  3.20 ± 0.07 100.0 ± 2.4  3.16 ± 0.03 100.0 ± 0.1  3.15 ± 0.05 100.0 ± 1.1  200 2.51 ± 0.04 77.0 ± 1.0 2.62 ± 0.03 80.6 ± 0.7 2.56 ± 0.09 88.7 ± 0.2 2.23 ± 0.02 69.9 ± 0.8 100 1.65 ± 0.05 50.5 ± 1.7 1.77 ± 0.04 54.2 ± 1.4 1.65 ± 0.02 59.7 ± 1.6 1.38 ± 0.01 43.2 ± 0.4 75 1.29 ± 0.02 39.4 ± 0.5 1.41 ± 0.03 43.3 ± 0.9 1.30 ± 0.13 48.5 ± 0.3 1.13 ± 0.00 35.3 ± 0.1 50 0.89 ± 0.02 27.1 ± 0.7 0.98 ± 0.02 30.0 ± 0.7 0.91 ± 0.03 33.9 ± 0.1 0.64 ± 0.02 19.9 ± 0.6 25 0.47 ± 0.00 14.4 ± 0.0 0.51 ± 0.01 15.8 ± 0.4 0.41 ± 0.01 17.5 ± 0.2 0.35 ± 0.00 11.0 ± 0.1 10 0.19 ± 0.00  5.9 ± 0.1 0.18 ± 0.02  5.6 ± 0.4 0.11 ± 0.09  7.1 ± 0.2 0.14 ± 0.00  4.5 ± 0.0 5 0.10 ± 0.01  3.2 ± 0.2 0.10 ± 0.00  3.2 ± 0.0 0.06 ± 0.04  3.8 ± 0.1 0.07 ± 0.00  2.3 ± 0.1 1 0.01 ± 0.01  0.4 ± 0.2 0.02 ± 0.00  0.7 ± 0.0 −0.02 ± 0.03   0.8 ± 0.1 0.02 ± 0.00  0.5 ± 0.0 0 0.00 ± 0.00  0.0 ± 0.0 0.00 ± 0.00  0.0 ± 0.0 −0.05 ± 0.04   0.1 ± 0.1 0.00 ± 0.00  0.0 ± 0.0 K_(d) (ng/ml) 176.9 149.4 121.5 255.9 K_(d) (% JMG55) 100 84 69 145 Results are expressed as absorbance at 450 nm, with non-specific binding (i.e. absorbance of well with no TSHR bound, at the M22-POD concentrations listed) subtracted. Also the percentage of the OD450 reading obtained with 500 ng/ml M22-POD (% Max) is shown, Kd was determined by fitting a saturation binding curve to the data with GraphPad Prism. Values shown are means ± SD; n = 2, for single experiments.

TABLE 66 K1-70-POD binding to TSHR-JMG55 with mutants in the TMD (FIG. 14a) K1-70-POD TSHR-JMG55 TSHR-JMG55-V5951 TSHR-JMG84 TSHR-JMG91 (μg/ml) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 10 2.83 ± 0.07 100.0 ± 2.4  2.86 ± 0.05 100.0 ± 0.7  2.34 ± 0.31 100.0 ± 0.1  2.82 ± 0.04 100.0 ± 0.5  7.5 2.95 ± 0.08 98.3 ± 3.2 2.97 ± 0.04 97.9 ± 0.3 2.59 ± 0.22 98.3 ± 1.1 2.85 ± 0.06 96.1 ± 0.8 5 2.59 ± 0.21 83.2 ± 7.0 2.76 ± 0.02 87.3 ± 0.6 2.50 ± 0.01 89.0 ± 7.7 2.57 ± 0.07 83.0 ± 0.8 2.5 1.66 ± 0.01 52.4 ± 1.6 1.86 ± 0.03 57.5 ± 0.5 1.88 ± 0.23 71.1 ± 1.8 1.70 ± 0.03 53.8 ± 0.6 1 0.67 ± 0.05 21.8 ± 0.2 0.80 ± 0.05 25.2 ± 0.2 0.88 ± 0.04 35.8 ± 1.7 0.62 ± 0.00 20.6 ± 1.4 0.75 0.52 ± 0.02 17.2 ± 1.0 0.62 ± 0.06 19.7 ± 0.2 0.66 ± 0.04 19.5 ± 0.4 0.59 ± 0.14 19.3 ± 2.4 0.5 0.35 ± 0.05 12.0 ± 0.2 0.40 ± 0.11 13.2 ± 1.5 0.43 ± 0.01 30.7 ± 2.1 0.40 ± 0.09 13.4 ± 1.0 0.25 0.16 ± 0.04  6.1 ± 0.4 0.21 ± 0.07  7.4 ± 0.5 0.21 ± 0.00  9.4 ± 1.3 0.20 ± 0.04  7.4 ± 0.5 0.1 0.04 ± 0.07  2.5 ± 0.3 0.07 ± 0.06  3.4 ± 0.1 0.08 ± 0.00  4.8 ± 0.3 0.02 ± 0.02  3.4 ± 0.2 0 −0.05 ± 0.06  −0.2 ± 0.0 −0.04 ± 0.06   0.2 ± 0.1 −0.02 ± 0.00   0.0 ± 0.0 −0.04 ± 0.06   0.0 ± 0.0 K_(d) (μg/mL) 4.5 3.5 2.3 4.1 K_(d) (% JMG55) 100 79 52 92 Results are expressed as absorbance at 450 nm, with non-specific binding (i.e. absorbance of well with no TSHR bound, at the K1-70-POD concentrations listed) subtracted. Also the percentage of the OD450 reading obtained with 10 μg/mL K1-70-POD (% Max) is shown, Kd was determined by fitting a saturation binding curve to the data with GraphPad Prism. Values shown are means ± SD; n = 2, for single experiments.

TABLE 67 K1-18-POD binding to TSHR-JMG55 with mutants in the TMD (FIG. 14a) K1-18-POD TSHR-JMG55 TSHR-JMG55-V5951 TSHR-JMG84 TSHR-JMG91 (ug/ml) OD450 % Max OD450 % Max OD450 % Max OD450 % Max 10 2.76 ± 0.11 100.0 ± 0.4  2.69 ± 0.07 100.0 ± 0.8  2.34 ± 0.27 100.0 ± 1.4  2.77 ± 0.13 100.0 ± 0.9  7.5 2.88 ± 0.14 97.4 ± 2.0 2.72 ± 0.05 94.8 ± 0.5 2.45 ± 0.21 99.1 ± 0.2 2.86 ± 0.03 96.7 ± 1.0 5 2.76 ± 0.06 88.1 ± 0.6 2.34 ± 0.08 78.2 ± 1.3 2.40 ± 0.11 97.2 ± 1.0 2.68 ± 0.03 85.7 ± 1.8 2.5 1.84 ± 0.11 56.8 ± 2.9 1.61 ± 0.13 51.5 ± 3.5 1.66 ± 0.03 82.5 ± 0.5 1.76 ± 0.18 54.6 ± 5.0 1 0.79 ± 0.03 24.3 ± 1.3 0.70 ± 0.02 22.2 ± 0.2 0.80 ± 0.04 43.1 ± 3.3 0.80 ± 0.11 24.6 ± 3.5 0.75 0.55 ± 0.03 17.1 ± 0.4 0.47 ± 0.06 15.1 ± 1.2 0.60 ± 0.06 32.7 ± 0.8 0.59 ± 0.02 18.1 ±1.2  0.5 0.37 ± 0.01 11.6 ± 0.3 0.34 ± 0.03 10.8 ± 0.1 0.43 ± 0.01 26.7 ± 0.5 0.34 ± 0.02 10.6 ± 0.1 0.25 0.16 ± 0.01  5.3 ± 0.5 0.12 ± 0.02  4.3 ± 0.2 0.22 ± 0.04 13.5 ± 0.5 0.15 ± 0.04  4.8 ± 0.3 0.1 0.06 ± 0.02  2.0 ± 0.1 0.06 ± 0.03  2.1 ± 0.0 0.06 ± 0.01  5.5 ± 0.4 0.07 ± 0.03  2.3 ± 0.1 0 −0.02 ± 0.03  −0.4 ± 0.1 −0.01 ± 0.02  −0.2 ± 0.2 −0.02 ± 0.01   0.2 ± 0.2 0.00 ± 0.06  0.1 ± 0.7 K_(d) (μg/mL) 3.5 4.3 1.7 3.6 K_(d) (% JMG55) 100 124 49 104 Results are expressed as absorbance at 450 nm, with non-specific binding (i.e. absorbance of well with no TSHR bound, at the K1-18-POD concentrations listed) subtracted. Also the percentage of the OD450 reading obtained with 10 μg/mL K1-18-POD (% Max) is shown, Kd was determined by fitting a saturation binding curve to the data with GraphPad Prism. Values shown are means ± SD; n = 2, for single experiments.

TABLE 68 Inhibition by M22 IgG of M22-POD binding to TSHR mutants (FIG. 14e). M22 IgG TSHR-JMG55 TSHR-JMG55 + V5951 TSHR-JMG84 TSHR-JMG91 (ng/ml) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.80 ± 0.02 75.7 ± 0.5 0.61 ± 0.01 78.7 ± 0.3 0.55 ± 0.02 80.9 ± 0.8 0.52 ± 0.00 82.3 ± 0.1 300 1.08 ± 0.01 67.3 ± 0.3 0.81 ± 0.00 71.5 ± 0.1 0.82 ± 0.00 71.8 ± 0.1 0.83 ± 0.04 72.2 ± 1.4 100 1.78 ± 0.01 45.8 ± 0.4 1.36 ± 0.01 52.1 ± 0.2 1.54 ± 0.03 46.9 ± 0.9 1.59 ± 0.03 46.4 ± 1.1 30 2.65 ± 0.07 19.4 ± 2.2 2.08 ± 0.01 26.7 ± 0.2 2.44 ± 0.02 16.0 ± 0.8 2.50 ± 0.02 15.6 ± 0.6 10 2.94 ± 0.02 10.7 ± 0.6 2.43 ± 0.03 14.3 ± 1.1 2.68 ± 0.04  7.6 ± 1.4 2.64 ± 0.07 11.1 ± 2.5 3 3.24 ± 0.01  1.6 ± 0.4 2.69 ± 0.04  5.3 ± 1.5 2.99 ± 0.00 −3.1 ± 0.1 2.91 ± 0.00  1.9 ± 0.0 1 3.27 ± 0.01  0.8 ± 0.4 2.77 ± 0.01  2.3 ± 1.5 2.96 ± 0.03 −1.8 ± 1.0 2.98 ± 0.05 −0.6 ± 1.8 0 3.29 ± 0.02  0.0 ± 0.5 2.84 ± 0.03  0.0 ± 0.9 2.90 ± 0.10  0.0 ± 3.3 2.97 ± 0.09  0.0 ± 3.1 Results are presented as absorbance at 450 nm and a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment.

TABLE 69 Inhibition by K1-18 IgG of M22-POD binding to TSHR mutants (FIG. 14e). K1-18 IgG TSHR-JMG55 TSHR-JMG55 + V5951 TSHR-JMG84 TSHR-JMG91 (ng/ml) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.43 ± 0.01 86.9 ± 0.4 0.36 ± 0.01 87.4 ± 0.2 0.29 ± 0.02 89.9 ± 0.8 0.30 ± 0.01 90.0 ± 0.3 300 1.05 ± 0.05 68.1 ± 1.6 0.89 ± 0.03 68.7 ± 1.1 0.88 ± 0.05 69.6 ± 1.8 0.98 ± 0.04 67.1 ± 1.5 100 2.11 ± 0.02 35.8 ± 0.6 1.72 ± 0.02 39.5 ± 0.5 1.91 ± 0.03 34.1 ± 1.0 1.83 ± 0.00 38.2 ± 0.1 30 2.95 ± 0.03 10.4 ± 0.8 2.47 ± 0.01 13.0 ± 0.3 2.52 ± 0.04 13.3 ± 1.2 2.54 ± 0.04 14.5 ± 1.4 10 3.16 ± 0.05  4.1 ± 1.6 2.65 ± 0.05  6.5 ± 1.9 2.84 ± 0.04  2.2 ± 1.5 2.83 ± 0.01  4.8 ± 0.3 3 3.29 ± 0.03  0.2 ± 0.9 2.80 ± 0.00  1.3 ± 0.1 3.03 ± 0.07 −4.3 ± 2.4 2.90 ± 0.00  2.1 ± 0.1 1 3.26 ± 0.03  1.1 ± 0.9 2.84 ± 0.01 −0.3 ± 0.4 3.00 ± 0.01 −3.3 ± 0.2 2.89 ± 0.03  2.5 ± 0.9 0 3.29 ± 0.02  0.0 ± 0.5 2.84 ± 0.03  0.0 ± 0.9 2.90 ± 0.10  0.0 ± 3.3 2.97 ± 0.09  0.0 ± 3.1 Results are presented as absorbance at 450 nm and a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment.

TABLE 70 Inhibition by K1-70 IgG of M22-POD binding to TSHR mutants (FIG. 14e). K1-70 IgG TSHR-JMG55 TSHR-JMG55 + V5951 TSHR-JMG84 TSHR-JMG91 (ng/ml) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) OD450 Inhibition (%) 1000 0.23 ± 0.00 93.0 ± 0.1 0.20 ± 0.01 93.1 ± 0.4 0.19 ± 0.00 93.5 ± 0.0 0.19 ± 0.00 93.8 ± 0.1 300 0.88 ± 0.02 73.4 ± 0.7 0.70 ± 0.01 75.5 ± 0.2 0.79 ± 0.02 72.8 ± 0.8 0.83 ± 0.04 72.1 ± 1.4 100 2.11 ± 0.07 35.8 ± 2.0 1.64 ± 0.10 42.1 ± 3.5 1.81 ± 0.01 37.6 ± 0.3 2.02 ± 0.00 32.0 ± 0.1 30 2.86 ± 0.00 13.0 ± 0.0 2.29 ± 0.05 19.3 ± 1.6 2.55 ± 0.01 12.3 ± 0.3 2.54 ± 0.10 14.3 ± 3.3 10 3.16 ± 0.06  3.9 ± 1.8 2.61 ± 0.04  8.1 ± 1.2 2.85 ± 0.00  1.8 ± 0.0 2.82 ± 0.09  4.9 ± 3.1 3 3.20 ± 0.02  2.8 ± 0.5 2.74 ± 0.04  3.5 ± 1.2 2.94 ± 0.09 −1.2 ± 3.0 2.96 ± 0.12  0.2 ± 3.9 1 3.28 ± 0.08  0.3 ± 2.5 2.80 ± 0.06  1.4 ± 2.0 2.97 ± 0.01 −2.2 ± 0.5 3.04 ± 0.03 −2.6 ± 1.1 0 3.29 ± 0.02  0.0 ± 0.5 2.84 ± 0.03  0.0 ± 0.9 2.90 ± 0.10  0.0 ± 3.3 2.97 ± 0.09  0.0 ± 3.1 Results are presented as absorbance at 450 nm and a percentage of inhibition of M22-POD binding ± SD for duplicate measurements in a single experiment.

TABLE 71 Inhibition of M22-POD binding to TSHR mutants by patient sera (FIG. 14e). TSHR-JMG55 TSHR-JMG55 + V5951 TSHR-JMG84 TSHR-JMG91 % % % % Test sample OD450 Inhibition OD450 Inhibition OD450 Inhibition OD450 Inhibition Normal 9924 1.43 ± 0.00 13.2 2.108 ± 0.05 7.1 2.585 ± 0.04 4.9 1.231 ± 0.01 8.3 sera 18284 1.67 ± 0.00 −1.2 2.223 ± 0.00 2.1 2.635 ± 0.04 3.1 1.275 ± 0.04 5.0 18288 1.70 ± 0.10 −3.3 2.319 ± 0.06 −2.2 2.783 ± 0.01 −2.4 1.354 ± 0.07 −0.9 18289 1.72 ± 0.05 −4.4 2.292 ± 0.02 −1.0 2.787 ± 0.03 −2.5 1.419 ± 0.06 −5.7 18290 1.70 ± 0.01 −3.0 2.436 ± —  −7.3 2.796 ± 0.03 −2.8 1.405 ± 0.05 −4.7 18296 1.67 ± 0.01 −1.3  2.24 ± 0.07 1.3 2.726 ± 0.01 −0.3  1.37 ± 0.05 −2.1 Mean 1.647 ± 0.05  0.0 2.270 ± 0.05 0.0 2.719 ± 0.03 0.0 1.342 ± 0.05 0.0 TRAb 52 0.80 ± 0.01 51.7 1.107 ± 0.01 51.2 1.504 ± 0.03 44.7 0.699 ± 0.05 47.9 positive 57 0.33 ± 0.00 80.1 0.448 ± 0.00 80.3 0.704 ± 0.02 74.1 0.353 ± 0.03 73.7 patient 69 0.51 ± 0.05 69.3 0.715 ± 0.01 68.5  1.05 ± 0.03 61.4 0.516 ± 0.01 61.5 sera 73 0.16 ± 0.00 90.5 0.164 ± 0.00 92.8 0.192 ± 0.01 92.9 0.141 ± 0.00 89.5 98 0.15 ± 0.00 90.9 0.174 ± 0.01 92.3 0.231 ± 0.00 91.5 0.122 ± 0.01 90.9 102 0.65 ± 0.02 60.8 0.923 ± 0.06 59.3 1.297 ± 0.01 52.3 0.544 ± 0.06 59.5 104 0.62 ± 0.05 62.7 0.876 ± 0.01 61.4 1.244 ± 0.00 54.2 0.549 ± 0.01 59.1 112 0.66 ± 0.01 59.9 1.014 ± 0.06 55.3 1.283 ± 0.01 52.8 0.602 ± 0.04 55.1 113 0.51 ± 0.02 69.2 0.714 ± 0.03 68.5 1.048 ± 0.02 61.5 0.471 ± 0.00 64.9 Results are shown as absorbance at 450 nm (mean ± SD; n = 2) and percent inhibition of M22-POD binding.

TABLE 72 Equivalent residues of hTSHR-JMG55 mutations in mouse and porcine TSHR Equivalent Equivalent hTSHR mouse TSHR porcine TSHR mutation residue residue E409K E409 E409 D410K D410 D410 H443N H443 H443 L452Y L452 L452 N455A N455 N455 M463V M463 M463 Y466F Y466 Y466 L467P L467 L467 T477I T477 T477 Q489H Q489 Q489 K565L K565 K565 V595I V595 T595 C600R C600 C600 Y601F Y601 Y601 I648L L648 L648 K660D K660 K660 Y667V Y667 Y667 S671A S671 S671 Y678L Y678 Y678 Y678A Y678 Y678 Most of the thermostabilising mutated residues of hTSHR-JMG55 are well-conserved across TSHR from mouse and porcine. Only the residues at positions 595 and 648 differ across species. Residue 595 is Valine in human and mouse, but Threonine in porcine. Residue 648 is Isoleucine in human but Leucine in mouse and porcine.

TABLE 73 Analysis of the thermostabilising amino acid residues in the TMD of the human TSHR compared to the equivalent amino acid residues in human FSHR and human LHR hTSHR Equivalent Equivalent mutation hFSHR residue hLHR residue E409K E357 E354 D410K D358 D355 H443N Q391 R388 L452Y L400 L397 N455A N403 N400 M463V I411 M408 Y466F Y414 Y411 L467P L415 L412 T477I T425 T422 Q489H Q437 Q434 K565L K513 K510 V595I V543 V540 C600R C548 C545 Y601F Y549 Y546 I648L S596 A593 K660D K608 K605 Y667V H615 Y612 S671A S619 S616 Y678L Y626 Y623 Y678A Y626 Y623 The residues in hFSHR (SEQ ID No 57) and hLHR (SEQ ID No 58) that are identical in hTSHR (SEQ ID No 2) are in bold. In addition to these, many of the residue differences between the receptors are limited to amino acids with similar properties, e.g. basic, acidic, aliphatic or aromatic. Transferring the analogous thermostabilising mutations from hTSHR to hFSHR and hLHR is likely to improve the thermostability of these receptors. 

1. A mutant thyroid stimulating hormone receptor (TSHR) which is a mutated form of human wild type TSHR as shown in SEQ ID NO 2 or fragment thereof, which mutant or fragment thereof is able to bind TSHR autoantibodies, wherein the mutant or fragment thereof comprises at least 80% or more of SEQ ID No 2, or wherein the fragment comprises residues 22-260 of the TSHR as shown in SEQ ID NO 4 or a sequence having 80% sequence identity therewith, and wherein the mutant or fragment thereof comprises one, two, three, four, five or six mutation(s) within said residues 22 to 260 of the TSHR selected from: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, I167F, P168Y, V169R, N170W, T179C, I253R and R255Y, wherein the mutant TSHR or fragment thereof has increased thermostability with respect to the equivalent wild type TSHR or fragment thereof, wherein thermostability refers to the half-life of the mutant TSHR or fragment thereof, as compared to the half-life of the equivalent wild type TSHR or fragment thereof, as measured under identical conditions in a binding assay which determines the amount of mutant TSHR or fragment thereof that retains the ability to bind, at the test temperature, an autoantibody selected from the group consisting of: M22, K1-70; and K1-18, wherein the half-life of the mutant or fragment at 42° C. is 1.5 times greater or more than the half-life of the equivalent wild type TSHR or fragment.
 2. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant comprises two point mutations, one of which is I253R and the second of which is selected from: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D143P, D151E, S166T, 1167F, P168Y, V169R, N170W, T179C, and R255Y.
 3. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant comprises three point mutations, one of which is I253R, the second of which is D143P, and the third of which is selected from: P28E, L59F, T62V, H63C, L64Y, R112P, P142I, D151E, S166T, P168Y, V169R and N170W.
 4. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant comprises four point mutations, one of which is I253R, the second of which is D143P, the third of which is R112P, and a fourth of which is selected from: L59F, H63C, D151E, S166T, V169R and N170W.
 5. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant comprises five point mutations, one of which is I253R, the second of which is D143P, the third of which is R112P, a fourth of which is D151E or H63C, and a fifth of which is selected from: L59F, H63C, D151E, S166T and V169R.
 6. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant comprises six point mutations, one of which is I253R, the second of which is D143P, the third of which is R112P, a fourth of which is D151E, a fifth of which is H63C, and a sixth of which is either S166T or V169R.
 7. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant comprises a set of mutations selected from the group consisting of: 1) I253R 2) D143P+I253R 3) R112P+D143P+I253R 4) R112P+D143P+D151E+I253R 5) R112P+D143P+D151E+V169R+I253R 6) H63C+R112P+D143P+D151E+V169R+I253R 7) H63C+R112P+D143P+V169R+I253R 8) H63C+R112P+D143P+S166T+I253R.
 8. The mutant TSHR or fragment thereof according to claim 1, which binds a TSHR autoantibody selected from the group consisting of: M22, K1-70; and K1-18.
 9. The mutant TSHR or fragment thereof according to claim 1, further comprising one or more mutation(s) in the transmembrane domain of the TSHR (TMD).
 10. The mutant TSHR or fragment thereof according to claim 9 wherein the one or more mutations within the transmembrane domain (TMD) are selected from the group consisting of: E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, V595I, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L, Y678A, which mutations are as shown with reference to the said wild type TSHR in SEQ ID Nos 89-108.
 11. The mutant TSHR or fragment thereof according to claim 9, wherein the one or more mutations within the transmembrane domain (TMD) contains two point mutations, one of which is T477I or V595I or I648L, and the second of which is a different mutation selected from the group consisting of: E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, V595I, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L, Y678A.
 12. The mutant TSHR or fragment thereof according to claim 9, wherein the one or more mutation(s) within the transmembrane domain (TMD) contains three point mutations, one of which is V595I, the second of which is Y678L or K565L, and the third of which is selected from the group consisting of: E409K, D410K, H443N, L452Y, N455A, M463V, Y466F, L467P, T477I, Q489H, K565L, C600R, Y601F, I648L, K660D, Y667V, S671A, Y678L, Y678A.
 13. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant further comprises a detectable label selected from the group consisting of: enzymatic labels, isotopic labels, chemiluminescent labels, fluorescent labels, dyes, alkaline phosphatase (AP) labels and biotin labels.
 14. The mutant TSHR or fragment thereof according to claim 13, wherein the mutant further comprises an alkaline phosphatase (AP) label.
 15. The mutant TSHR or fragment thereof according to claim 14, selected from the group consisting of: TSHR260-AP-I253R=TSHR260-AP+I253R TSHR260-AP-JMG22=TSHR260-AP+D143P+I253R TSHR260-AP-JMG37=TSHR260-AP+R112P+D143P+I253R TSHR260-AP-JMG45=TSHR260-AP+R112P+D143P+D151E+I253R TSHR260-AP-JMG52=TSHR260-AP+R112P+D143P+D151E+V169R+I253R TSHR260-AP-JMG55=TSHR260-AP+H63C+R112P+D143P+D151E+V169R+I253R TSHR260-AP-JMG57=TSHR260-AP+H63C+R112P+D143P+V169R+I253R TSHR260-AP-JMG58=TSHR260-AP+H63C+R112P+D143P+S166T+I253R, wherein TSHR260 consists of residues 22-260 of the TSHR as shown in SEQ ID NO 4, and AP indicates an alkaline phosphatase label.
 16. A method of purifying a mutant TSHR or fragment thereof as defined in claim 1, which method comprises: i) purifying a composition, which composition comprises the mutant TSHR or fragment thereof and optionally culture supernatant, wherein the purifying is by column chromatography using cation or anion exchange chromatography; optionally wherein the method further comprises, either before or after step (i), purifying the said composition by affinity chromatography, optionally wherein the affinity chromatography comprises antibody affinity chromatography and/or metal ion affinity chromatography; and ii) collecting the purified mutant TSHR or fragment thereof.
 17. The method according to claim 16, wherein the method comprises: i) purifying a composition comprising the mutant or fragment thereof and optionally culture supernatant, wherein the purifying is by cation-exchange or anion-exchange column chromatography ii) further purifying the mutant or fragment thereof by antibody affinity chromatography; optionally wherein the antibody is a monoclonal antibody which binds a conformational epitope within the TSHR extracellular domain; iii) optionally further purifying the mutant or fragment thereof by metal-ion affinity chromatography, which optionally comprises nickel-affinity chromatography; iv) collecting the purified mutant TSHR or fragment thereof.
 18. The method according to claim 16, wherein the mutant consists of, or consists essentially of, the subdomain TSHR260 of the TSHR as shown in SEQ ID NO 4 and wherein the mutant consists of one of the following set of mutations: 1) I253R 2) D143P+I253R 3) R112P+D143P+I253R 4) R112P+D143P+D151E+I253R 5) R112P+D143P+D151E+V169R+I253R 6) H63C+R112P+D143P+D151E+V169R+I253R 7) H63C+R112P+D143P+V169R+I253R 8) H63C+R112P+D143P+S166T+I253R.
 19. Purified mutant TSHR or fragment thereof as defined in claim 1, which purified mutant or fragment is produced by a method comprising: i) purifying a composition, which composition comprises the mutant TSHR or fragment thereof and optionally culture supernatant, wherein the purifying is by column chromatography using cation or anion exchange chromatography; optionally wherein the method further comprises, either before or after step (i), purifying the said composition by affinity chromatography, optionally wherein the affinity chromatography comprises antibody affinity chromatography and/or metal ion affinity chromatography; and ii) collecting the purified mutant TSHR or fragment thereof.
 20. The mutant TSHR or fragment thereof according to claim 1, wherein the mutant TSHR or fragment thereof is deglycosylated. 